CA2267634A1 - Methods and compounds for inhibiting .beta.-amyloid peptide release and/or synthesis - Google Patents

Abstract

Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease.
Also disclosed pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

Description

DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEIV(ANDE OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST LE TOME ~ DE Z
NOTE: Pour les tomes additionels, veuillez contacter le Bureau canadien des brevets JUMBO APPLlCATiONS/P.ATENTS
THIS SECTION OF THE APPLICATION/PATIENT CONTAINS MORE
THAN ONE VOLUME
THIS !S VOLUME
NOTE. For additional volumes-please cantact'the ~~anadian Patent Office ~ -- METHODS AND COMPOUNDS FOR INHIBITING ,B-AMYLOID PEPTIDE
RELEASE AND/OR ITS SYNTHESIS
CROSS-REFERENCE TO RELATED APPLICATIONS
This application claims the benefit of the: following U.S. Provisional Applications:
1. U.S. Provisional Application No. 60/ , , which was converted pursuant to 37 C.F.R. ~1.53(b)(2)(ii) from U.S. Patent Application No.
08/755,442, filed November 22, 1996;

2. U.S. Provisional Application No. 60/ , , which was converted pursuant to 37 C.F.R. ~1.53(b)(2)(ii) from U.S. Patent Application No.
08/808,528, filed February 28, 1997;

3. U.S. Provisional Application No. 60/ , , which was converted pursuant to 37 C.F.R. ~1.53(b)(2)(ii) from U.S. Patent Application No.
08/807,528, filed February 28, 1997; and 4. U.S. Provisional Application No. 60/ , , which was converted pursuant to 37 C.F.R. ~1.53(b)(2)(ii) from U.S. Patent Application No.
08/807,427, filed February 28, 1997.
Each of these applications are incorporated herein by reference in their entirety .
BACKGROUND OF Tf~ INVENTION
Field of the Invention This invention relates to methods which inhibit cellular (i-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. This invention also relates to pharmaceutical compositions comprising such compounds as well as methods for inhibiting release of (3-amyloid peptide.

-_2__ BACKGROUND OF THE INVENTION
Field of the Invention This invention relates to methods which inhibit cellular ~-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. This invention also relates to pharmaceutical compositions comprising such compounds as well as methods for inhibiting release of a-amyloid peptide.
References The following publications, patents and patent applications are cited in this application as superscript numbers:
' Glenner, et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein", Biochem. Biophys. Res. Commun., 120:885-890 (1984).
Glenner, et al., "Polypeptide Marker for Alzheimer's Disease and its Use for Diagnosis", U. S. Patent No. 4,666,829 issued May 19, 1987.
Selkoe, "The Molecular Pathology of Alzheimer's Disease", Neuron, 6:487-498 (1991}.
4 Goate, et al., "Segregation of a Missense Mutation in the Amyloid Precursor Protein Gene with Familial Alzheimer's Disease", Nature, 349:704-706 (1990).
Chartier-Harlan, et al., "Early-Onset Alzheimer's Disease Caused by Mutations at Codon 7I7 of the ~3-Amyloid Precursor Proteing Gene", Nature, 353:844-846 (1989).
Murrell, et al., "A Mutation in the Amyloid Precursor Protein Associated with Hereditary Alzheimer's Disease", Science, 254: 97-99 ( 1991 ).
Mullan, et al., "A Pathogenic Mutation for Probable Alzheimer's Disease in the APP Gene at the N-Terminus of ~3-Amyloid, Nature Genet., 1:345-347 (1992).

__ 3 __ Schenk, et al. , "Methods and Compositions for the Detection of Soluble ~-Amyloid Peptide", Iruernational Patent Application Publication No. WO 94/IOS~i9, published 11 May 1994.
9 Selkoe, "Amyloid Protein and Alzheimer's Disease", Scientific American, pp. 2-8, November, 1991.
'o L.osse, et al., Tetrahedron, 27:1423-1434 (1971).
" Citron, et al. , "Mutation of the ~i-Amyloid Precursor Protein in Familial Alzheimer's Disease. Increases ~i-Protein Production, Nature, 360:672-674 {1992).
'2 Hansen, et al., "Reexamination and Further Development of a Precise and Rapid Dye Method for Measuring Cell Growth/Cell Kill", J. Immun. Meth. , 1 I9: 203-210 ( 1989).
'3 P. Seubert, Nature (1992) 35'9:325-327 '4 3ohnson-Wood et al., PNAS 'USA (1997) 94:150-1555 's Tetrahedron Letters, 34(48), 7685 (1993)) All of the above publications, patents and patent applications are herein incorporated by reference in their entirety b~ the same extent as if each individual publication, patent or patent application was specifically and individually indicated to be incorporated by reference in its entirety.
State of the Art Alzheimer's Disease (AD) is a degenerative brain disorder characterized clinically by progressive loss of memory, cognition, reasoning, judgment and emotional stability that gradually leads to profound mental deterioration and ultimately death. AD is a very common cause of progressive mental failure (dementia) in aged humans and is believed 1:o represent the fourth most common medical cause of death in the United States. AD has been observed in races and ethnic groups worldwide and presents a major present and future public health problem. The disease is currently estimated to affect about two to three __ 4 __ million individuals in the United States alone. AD is at present incurable. No treatment that effectively prevents AD or reverses its symptoms and course is currently known.
The brains of individuals with AD exhibit characteristic lesions termed senile (or amyloid) plaques, amyloid angiopathy (amyloid deposits in blood vessels) and neurofibrillary tangles. Large numbers of these lesions, particularly amyloid plaques and neurofibrillary tangles, are generally found in several areas of the human brain important for memory and cognitive function in patients with AD. Smaller numbers of these lesions in a more restrictive anatomical distribution are also found in the brains of most aged humans who do not have clinical AD. Amyloid plaques and amyloid angiopathy also characterize the brains of individuals with Trisomy 21 (Down's Syndrome) and Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch Type (HCHWA-D). At present, a definitive diagnosis of AD usually requires observing the aforementioned lesions in the brain tissue of patients who have died with the disease or, rarely, in small biopsied samples of brain tissue taken during an invasive neurosurgical procedure.
The principal chemical constituent of the amyloid plaques and vascular amyloid deposits (amyloid angiopathy) characteristic of AD and the other disorders mentioned above is an approximately 4.2 kilodalton (kD) protein of about 39-43 amino acids designated the (3-amyloid peptide ((3AP) or sometimes A~3, A(3P or ~i/A4. /3-Amyloid peptide was first purified and a partial amino acid sequence was provided by Glenner, et al.' The isolation procedure and the --- sequence data for the first 28 amino acids are described in U.S. Patent No.
4,666,8292.
Molecular biological and protein chemical analyses have shown that the /3-amyloid peptide is a small fragment of a much larger precursor protein (APP), that is normally produced by cells in many tissues of various animals, WO 98/22494 PCT/US97l20804 __ 5 __ including humans. Knowledge of the structure of the gene encoding the APP
has demonstrated that ~-amyloid peptide arises as a peptide fragment that is cleaved from APP by protease enzyme(s). The precise biochemical mechanism by which the Q-amyloid peptide fragment is cleaved from APP and subsequently deposited as amyloid plaques in the cerebral tissue and in the walls of the cerebral and meningeal blood vessels is currently unknown.
Several lines of evidence indicate that progressive cerebral deposition of J3-amyloid peptide plays a seminal role in the pathogenesis of AD and can precede cognitive symptoms by years or decades. See, for example, Selkoe3.
The most important line of evidence is the. discovery that missense DNA
mutations at amino acid 717 of the 770-amino acid isoform of APP can be found in affected members but not unaffecaed members of several families with a genetically determined (familial) form of AD (Goate, et al.'; Cha.rtier-Harlan, et al.s; and Murrell, et al.b) and is referred to as the Swedish variant. A
double mutation changing lysine595-methionine59e to asparagine59s-leucine596 (with reference to the 695 isoform) found in a Swedish family was reported in 1992 (Mullan, et al.'). Genetic linkage analyser have demonstrated that these mutations, as well as certain other mutations in the APP gene, are the specific molecular cause of AD in the affected members of such families. In addition, a mutation at amino acid 693 of the 770-amiino acid isoform of APP has been identified as the cause of the j3-amyloid peptide deposition disease, HCHWA-D, and a change from alanine to glycine at amino acid 692 appears to cause a phenotype that resembles AD is some patients but HCHWA-D in others. The discovery of these and other mutations in .APP in genetically based cases of AD
prove that alteration of APP and subsequent deposition of its /3-amyloid peptide fragment can cause AD.
Despite the progress which has been made in understanding the underlying mechanisms of AD and other ~'-amyloid peptide related diseases, there remains a need to develop methods and compositions for treatment of the __6__ disease(s). Ideally, the treatment methods would advantageously be based on drugs which are capable of inhibiting ~-amyloid peptide release and/or its synthesis in vivo.
S><fMMARY OF THE INVENTION
This invention is directed to the discovery of a class of compounds which inhibit ~i-amyloid peptide release and/or its synthesis and, therefore, are useful in the prevention of AD in patients susceptable to AD and/or in the treatment of patients with AD in order to inhibit furt~rer deterioration in their condition. The class of compounds having the described properties are defined by formula I below:
X, X" ~ Ra RS
H
N _ z R Z O ~ ~ X
RZ Rs wherein R' is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkenyl, substituted alkynyl, aryl, heteroaryl and heterocyclic;
RZ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclic;
each R3 is independently selected from the group consisting of hydrogen and methyl and R3 together with R4 can be fused to form a cyclic structure of from 3 to 8 atoms which is optionally fused with an aryl or heteroaryl group;

each R" is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, c,ycloalkenyl, heteroaryl, heterocyclic, substituted alkyl, substituted alkenyl and substituted alkynyl;
each RS is selected from hydrogen and methyl or together with R' forms a cycloalkyl group of from 3 to 6 carbon atoms;
X is selected from the group consisting of -C(O)Y and -C(S)Y where Y
is selected from the group consisting of (a) alkyl or cycloalkyl, (b) substituted alkyl with the proviso that the substitution on said substituted alkyl do not include a-haloalkyl, a-diazoalkyl, a-OC(O)alkyl, or a-OC(O)aryl groups, (c) alkoxy or thioalkoxy, (d) substituted alkoxy or substituted thioalkoxy, (e) hydroxy, (f) aryl, (g) heteroaryl, (h) heterocyclic, (i) -NR'R" where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, where one of R' or R" is hydroxy or aIkoxy, and where R' and R" ~~re joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl, alkoxy or carboxylalkyl groups, (j) -NHSOZ-R8 where R8 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic, (k) -NR9NR'°R'° where R9 is hydrogen or alkyl, and each R'° is independently selected from hydrogen, alk~~l, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and (1) -ONR9[C(O)O]ZR'° where z is zero or one, R9 and R'° are as defined above;

__ g __ X can also be -CR6R6Y' where each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, alkoxy, substituted alkoxy, thioalkoxy, substituted thioalkoxy, -OC(O)R', -SSR', -SSC(O)R' where R' is selected from the group consisting of alkyl, substituted alkyl, cycloalkyi, aryl, heteroaryl and heterocyclic, X' is hydrogen, hydroxy, or fluoro;
X" is hydrogen, hydroxy or fluoro, or X' and X" together form an oxo group, Z is selected from the group consisting of a bond covalently linking R' to -CX'X"-, oxygen and sulfur;
n is an integer equal to 1 or 2; and pharmaceutically acceptable salts thereof with the provisos that:
A. when R' is phenyl or 3-nitrophenyl, Rz is methyl, R3 is hydrogen, R' is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH;
B. when R' is phenyl, RZ is methyl, R3 is hydrogen, R° is -CH(OH)CH3 derived from D-threonine, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH or -C(O)OCH3;
C. when R' is phenyl, Rz is methyl, R4 is benzyI, RS is hydrogen, X is methoxycarbonyl, X' and X" are hydrogen, Z is a bond, and n is 1, then R3 is not methyl;
D. when R' is iso-propyl, RZ is -CHZC(O)NH2, R3 is hydrogen, R' is iso-butyl, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
E. when R' is phenyl, RZ is methyl, RS is hydrogen, X is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R3, the nitrogen atom attached to R3, and R4 do not form 1,2,3,4-tetrahydroiso-quinolin-2-yl or pyrrolidin-2-yl;

__9_-F. when R' is phenyl, RZ is meth~~l, R3 is hydrogen, RS is hydrogen, X
is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not 4-amino-n-butyl;
G. when R' is 3-nitrophenyl, RZ is. methyl, R3 is hydrogen, R' is -CH(OH)CH3, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH2 or -CHZOH;
H. when R' is phenyl, RZ is methyl, R3 is hydrogen, R5 is hydrogen, X
is -CHzOCH3, X' and X" are hydrogen, ~~ is a bond, and n is 1, then R' is not benzyl or ethyl;
I. when R' is 3,5-difluorophenyl, l(t2 is methyl, R' is methyl, R4 is methyl, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~;
J. when R' is 3,5-difluorophenyl, RZ is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X' is not -CHOH~ or -CHZOH;
K. when R, is N (2-pyrroIidinonyl;~, RZ is methyl, R3 is hydrogen, Ra is benzyl, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
L. when R' is 3,5-difluorophenyl, Rz is methyl derived from D-alanine, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH-benzyl;
M. when R' is 3,5-difluorophenyl, R'- is methyl, R3 is hydrogen, R'' is hydrogen, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHZOH;
N. when R' is .~,5-difluorophenyl, RZ is methyl, R3 is hydrogen, R4 is 4-phenylphenyl, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHC(CH3)3; and O. when R' is 3,5-difluorophenyl, :RZ is methyl, R3 is hydrogen, R° is phenyl derived from D-phenylglycine, RS is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHCH(CH3)~.

Preferably, the compounds of this invention are derived from L-amino acids and, accordingly, are represented by formula IA:
O Ra Rs X' X"
IA
R,Z ~ ~ X
~ R2 R3 Accordingly, in one of its method aspects, this invention is directed to a method for inhibiting /3-amyloid peptide release and/or its synthesis in a cell which method comprises administering to such a cell an amount of a compound or a mixture of compounds of formula I above effective in inhibiting the cellular release and/or synthesis of /3-amyloid peptide.
Because the in vivo generation of (3-amyloid peptide is associated with the pathogenesis of AD8~9, the compounds of formula I can also be employed in conjunction with a pharmaceutical composition to prophylactically andlor therapeutically prevent and/or treat AD. Accordingly, in another of its method aspects, this invention is directed to a prophylactic method for preventing the onset of AD in a patient at risk for developing AD which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically inert carrier and an effective amount of a compound or a mixture of compounds of formula I above.
In yet another of its method aspects, this invention is directed to a therapeutic method for treating a patient with AD in order to inhibit further deterioration in the condition of that patient which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically inert carrier and an effective amount of a compound or a mixture of compounds of formula I above.
Compounds suitable for use in the claimed methods include, by way of example only, the following:

N [N (3,5-difluorophenylacetyl)-L-a.laninyl]-(S)-2-aminohexanoate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-histidine methyl ester N benzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N 2-(N,N dimethylamino)ethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N (2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N 2-(N,N dimethylamino)ethyl-N'-[i'V (3,5-difluorophenylacetyl)-L-ala.ninyl]-L-phenylalaninamide N (4-pyridyl)methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N (3-pyridyl)methyl-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-L-phenylalaninamide N (4-pyridyl)methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N [N (3,5-difluorophenylacetyl)-L-a:laninyl]-(S)-2-aminohexanoate tert-butyl ester N [N (pent-4-enoyl)-L-alaninyl]-L-plhenylalanine methyl ester N [N (dec-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[3-(N,N
dimethylamino)propoxy]phenylalanine methyl ester __ 12 __ N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[(tert-butyloxycarbonyl)methoxy]phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester N [N {3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(carboxymethoxy)phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4.-(2-morpholinoethoxy)phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-6-(N,N
dimethylamino)hexanoate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-pyridyl)propionate methyl ester N [N (3,5-difluorophenylacetyI)-L-alaninyl]-(S)-2-amino-3-(3-pyridyl)propionate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-proIine methyl ester 1-[N {3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-pyridyl)propionate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-morpholinopropionate methyl ester N (2-methoxyethyl}-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalaninamide N (2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-2-amino-3-methoxypropionamide N [N (3,5-difluorophenyiacetyl)-L-alaninyl]glycine methyl ester N (2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(4-pyridyl)propionamide N (2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(2-pyridyl)propionamide N [N {3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-{thiazol-4-yl)propionate methyl ester 2-[N (3,5-difluorophenylacetyl)-L-alaninyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylate methyl ester N (3-methoxybenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanina.mide N [N (3,5-difluorophenylacetyl)-L-aaninyl]-(S)-2-amino-3-(1-naphthyl)propionate methyl ester N-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-naphthyl)propionate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-thienyl)propionate methyl ester N [N-(3,S-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine benzyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-bromo-propyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-iodopropyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine tent-butyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetamide N'-[N (3,5-difluorophenylacetyl)-L-,~laninyl]-2-amino-2-(3-pyridyl)acetamide __ _ N [N (3,5-difluorophenylacetyl)-L-alaninyl]-Nf-(tent-butoxycarbonyl)-L-lysine methyl ester methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-4-phenylbutanoate N [N (3,5-difluorophenylacetyl)-L-alaninyl]glycine 2-phenylethyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]glycine 3-phenylpropyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-pyridyl)acetamide N [N (phenylacetyl)-L-alaninyl]-L-threonine methyl ester N'-[N (phenylacetyl)-L-alaninyl]-L-leucinamide N'-[N (phenylacetyl)-L-alaninyl]-L-alaninamide N'-[N (phenylacetyl)-L-alaninyl]-L-phenylalaninamide N'-[N (phenylacetyl)-L-alaninyl)-L-valinamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetate ethyl ester N methyl-N'-[N (phenylacetyl)-L-alaninyl]-L-leucinamide N,N dimethyl-N'-[N (phenylacetyl}-L-alaninyl]-L-phenylalaninamide N,N dimethyl-N'-[N (phenylacetyl)-L-alaninyl]-L-leucinamide N,N dimethyl-N'-[N (phenylacetyl)-L-alaninyl]-L-valinamide N methyl-N'-[N (phenylacetyl)-L-alaninyl]-L-phenylalaninamide N methyl-N'-[N (phenylacetyl)-L-alaninyl]-L-valinamide N-methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N,N dimethyl-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-(S)-2-aminohexanamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-methoxyphenyl)acetate methyl ester N [N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-methoxyphenyl)acetate methyl ester N [N (3,S-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetate ethyl ester N [N (3,5-difluorophenylacetyl)-L-;~laninyl]-2-amino-2-(4-pyridyl)acetate ethyl ester N [N (cyciohexylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (cyclopentylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (cyclohex-1-enylacetyl)-L-alminyl]-L-phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-aaninyl]-1-aminocyclopropane-1-- - _ carboxylate methyl ester N 2-(N,N dimethylamino)ethyl-N methyl-N'-(N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N [N (cyclopropylacetyl}-L-alaninyl]-L-phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]glycine benzyl ester N-[N (isovaleryl)-L-phenylglycinyl]-L-alanine ethyl ester N [N (3-nitrophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester lV (N (3-nitrophenylacetyl)-L-alanin,yl]-L-alanine ethyl ester N [N (3-nitrophenyiacetyl)-L-alanin.yl]glycine ethyl ester N hydroxy-N'-[N (3-nitrophenylacetyl)-L-alaninyl]-D,L-threoninamide N [N (isovaleryl)-L-phenylglycinyl]~-L-alanine iso-butyl ester N (N (3-nitrophenylacetyl)-L-alanin.yl]-2-amino-3-(3-hydroxyphenyl)propionate methyl ester N [N (3-nitrophenylacetyl)-L-alaninyl]-L-tyrosine ethyl ester N [N (isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N [N (N (isovaleryl)-L-valinyl]-L-phenylglycinyl]-L-alanine iso-butyl ester N [N (isovaleryl)-L-phenylalaninyl]-L-alanine iso-butyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester 1-[N (3-nitrophenylacetyl)-L-alaninyl]-indoline-(S)-2-carboxylate ethyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N methoxy-N methyl-N'-[N (isovaleryl)-L-phenylglycinyl]-L-alaninamide N iso-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N,N di-n-propyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-valinamide N (4-nitrophenyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N [N (isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-phenylalaninamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N iso-butyl-N'-[N (isovaleryl}-L-phenylglycinyl]-L-alaninamide N-(2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N (4-nitrobenzyl)-N'-(N-(3,5-difluorophenylacetyl}-L-alaninyl]-L-alaninamide N (4-nitrophenyl)-N'-[N [N (isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-alaninamide N (4-nitrophenyl}-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-L-phenylalaninamide N-benzyl-N methyl-N'-[N=(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N (3,5-difluorobenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N (3-nitrobenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide __ 1 ~ __ N benzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N (4-nitrobenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophan methyl ester N (4-methoxybenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-ataninyl]-L-alaninamide N [N (phenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N [N [N (3,5-difluorophenylacetyl;l-L-alaninyl]-L-phenylalaninyl]-L-phenylglycine methyl ester N [N (cyclohexylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N [N (3,5-difluorophenylacetyl)-L-~alaninyl]-L-phenylglycine methyl ester N [N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]-L-phenylglycine methyl ester N (2-phenylethyl)-N'-[N (3,S-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophanamide N [N (3,5-difluorophenylacetyl}-L-alaninyl]-(S)-2-amino-3-cyclohexylpropionate methyl ester N (2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-nitrophenyl)propionamide N [N-(3-nitrophenylacetyl)-L-alaninyl]-L-serine ethyl ester N [(R)-a-methylbenzyl]-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N [(S}-a-methylbenzyl]-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N (4-fluorobenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N (4-pyridylmethyl)-N'-[N (3,5-difl.uorophenylacetyl)-L-alaninyl]-L-alaninamide -_ 1 g __ N (4-trifluoromethylbenzyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-phenylpropionate ethyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine tent-butyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-methylpropionate methyl ester N [N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-cyclohexylacetate ethyl ester N (2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide IV [N (isovaleryl)-2-amino-2-cyclohexylacetyl]-L-alanine ethyl ester N 2-(N,N dimethylamino)ethyl-N'-[N (3,5-difluorophenyiacetyl)-L-alaninyl]-L-phenylglycinamide N (2-pyridylmethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyi]-L-phenylglycinamide N [N (3-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (2-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (4-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-{4-fluorophenyl)acetate ethyl ester N [N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-fluorophenyl)acetate ethyl ester N-[N (3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-phthalimidopropionate ethyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine neopentyl ester N tent-butyl-N'-[N (3,5-difluorophenylacetyI)-L-alaninyl]-L-phenylglycinamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine ten-butyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide 4-[N [N (3-nitrophenylacetyl)-L-alac~inyl]-L-valinyl]morpholine N [N (3-nitrophenylacetyl)-L-alaninyl]-L-valine ethyl ester N [N (3-nitrophenylacetyl)-L-alanimyl]-L-threonine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S}-2-aminopentanoate methyl ester 4-[N [N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-amino-3-tert-butoxybutyryl]morpholine 4-[N [N (3-nitrophenylacetyl)-L-alaninyl]-L-isoleucinyl]morpholine N [N (3-nitrophenylacetyl}-L-alaninyl]-L-isoleucine methyl ester N [N (3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine N [N [N (3-nitrophenylacetyl)-L-alaninyl)-L-threoninyl]-L-valine ethyl ester N [N (3-nitrophenyiacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester N [N (3-nitrophenylacetyl)-L-alaninyl]-L-leucine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine methyl ester N 2-methoxyethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N 2-(N,N dimethylamino)ethyl-N'-[.'V (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N cyclohexyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N neopentyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-tetrahydrofurfuryl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl)-L-alaninamide N 2-pyridylmethyl-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-L-alaninamide 3-[N (N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl)thiazolidine N [N (3,5-difluorophenylacetyl)-L-alaninyl)-(S)-2-aminobutanoate methyl ester N [N (3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N (R)-sec-butyl-N'-[N (3,5-difluorophenylace~l)-L-alaninyl]-L-alaninamide 1-[N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]pyrrolidine N (S)-sec-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N (N (3,5-difluorophenylacetyl)-L-alaninyl]-L-valine methyl ester N 2-fluoroethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl)-L-alaninamide N [(S)-6-methyl-3-oxohept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-aianinamide N 4-nitrobenzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutyramide N 4-nitrobenzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-fluorophenyl)acetate methyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(5-chlorobenzothiophen-2-yl)acetate methyl ester N [lV (3,5-difluorophenylacetyl)-L-alaninyl)-2-amino-2-(benzothiophen-2-yl)acetate ethyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-3-yl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-thienyl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-5-yl)acetate ethyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate methyl ester N (N (3,5-difluorophenylacetyl)-L-afaninyl]-(S)-2-amino-2-(2-thienyl)acetate ten-butyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetic acid N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(IH-tetrazol-5-yl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(6-methoxy-2-naphthyl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3 trifluoromethylphenyl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4,5,6,7-tetrahydrobenzothiophen-2-yl)acetate methyl ester N (N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(thieno[2,3-b]thiophen-2-yl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-methylthiazol-4-yl)acetate methyl ester (3S,4S)-N [N (3,5-difluorophenylacetyl)-L-alaninyl]-4-amino-3-hydroxy-5-phenylpentanoate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohex-4-enoate methyl ester N (N (cyclopropylacetyl)-L-alaninyl]~-L-phenylglycine tent-butyl ester N-ten-butyl-N'-[N (3,5-Difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(4-phenylphenyl)acetamide N [N (3,5-difluorophenylacetyl)-(S)-2-aminobutanoyl]-L-phenylglycine tent-Butyl Ester N [N (3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine ten-butyl ester N [N (3,S-difluorophenylacetyl)-L-methioninyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-leucinyl]-L-phenylglycine methyl ester N [N-(3,5-difluorophenylacetyl}-L-phenylalaninyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)glycinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-phenylgIycinyl]-L-phenylglycine methyl ester N [N (phenylacetyl)-L-alaninyl]-L-alanine methyl ester N [N (phenylacetyl)-L-alaninyl]-L-leucine methyl ester N [N (phenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N [N (phenylacetyl)-L-alaninyl]-L-proline methyl ester N [N-(phenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N [N (phenylacetyl)-L-alaninyl]-NE-(tent-butoxycarbonyl)-L-lysine methyl ester N [N (phenylacetyl)-L-alaninyl]-glycine methyl ester N [N (phenylacetyl}-L-alaninyl]-L-valine methyl ester N [N {phenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N [N (phenylacetyl)-L-alaninyl]-{S)-2-aminopentanoate methyl ester N [N (3-nitrophenyiacetyl)-L-alaninyl]-L-valine N (N (phenylacetyl)-L-alaninyl]-L-i'V methylaianine methyl ester N [N (isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N [N (isovaleryl)-L-isoleucinyl]-L-canine iso-butyl ester N Cyclohexyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-hydroxyproline ethyl ester N [N (3,5-difluorophenylacetyl)-L-:~laninyl]-L-lysine methyl ester N (N (3,5-difluorophenylacetyl}-L-alaninyl]-L-glutamide 1-[N (3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N ((S)-3-hydroxy-6-methylhept-2-yu]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(S)-2-hydroxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [N (3,5-difluorophenyl-a-fluoroacetyl)-L-alaniny]-L-phenylgIycine tent-butyl ester N [N (3,5-difluorophenylacetyl)-2-(S}-aminocyclohexylacetyl]-L-phenylglycine methyl ester N [(1R,2S}-1-hydroxy-1-phenylprop-2-yl)-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(1R,2S)-1-hydroxy-1,2-diphenyleth-2-yl]-N'-(3,5 difluorophenylacetyl)-L-alaninamidf:
N [(1S,2R)-1-hydroxy-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N 2-methoxyethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N [(S)-a-hydroxy-a-phenyl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(S)-2-hydroxy-1,2-diphenylethyI)-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(S)-1-hydroxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [a-hydroxy-a'-(4-hydroxyphenyl)-iso-propyl)-N'-(3,5-difluorophenylacetyl)-L-alaninamide N 2-pyridylmethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N [a-hydroxy-«'-pyrid-2-yl-iso-propyl)-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [a-hydroxy-«'-pyrid-4-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-((S)-1-hydroxy-4-methylpent-2-y1]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [a-methoxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-hydroxy-3-methyl-but-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [N (3,5-difluorophenylacetyl)-L-alaninyl)-2-amino-2-(6-aminopyrid-2-yl)acetate methyl ester N (I-hydroxy-prop-2-yl]-N'-(3,S-difluorophenylacetyl)-L-alaninamide N [(S)-2-methoxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(S)-1-methoxy-2-phenyl-prop-2-yl}-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(S)-1-acetoxyhex-2-yl]-N'-(3,5-difluorophenyIacetyl)-L-alaninamide N [(S)-1-(tent-butylcarbonyloxy)-hex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N (2-hydroxy-1-{thien-2-yl)ethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [(S)-2-hydroxy-2-methyl-1-phenylprop-1-yl]-N'-(3,5-difluorophenylacetyl}-L-alaninamide N [N (3,S-difluorophenylacetyl)-L-(thien-2-yl)glycinyl]-L-phenylalanine ten-butyl ester N [N (3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinol S
N [N (cyclopropaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N (N (cyclopentaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N [N (3,5-difluorophenylacetyl)-D,,L-phenylglycinyl]-D,L-phenylglycinamide N [N (3,5-difluorophenylacetyl)-D,L-valinyl]-D,L-phenylglycinamide N [N (2-thienylacetyl)-L-alaninyl]-L-phenylglycinamide N (N (n-caprotyl)-L-alaninyl]-L-phenylglycinamide N (N (3,5-difluorophenylacetyl)-L-norleucinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-norvalinyl]-L-phenylglycine methyl ester N (N (3,5-difluorophenylacetyl)-L-tert-leucinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-isoleucinyl]-L-phenylglycine methyl ester N [N {3,5-difluorophenylacetyl)-L-c:yclohexylalaninyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-(S)-2-amino-2-(cyclopropyl)acetyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-3-yl)acetyl]-L-__ phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-2-yl)acetyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-D-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-(4-methoxyphenyl)glycinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N [N (cyclopropylacetyl)-L-phenylglycinyl]-L-phenylglycine ten-butyl ester N [N (cyclopentylacetyl)-L-phenylglycinyl]-L-phenylglycine tent-butyl ester N [N (tent-butylacetyl)-L-alaninyl]-L-phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-(5-bromothien-2-yl)glycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D-(5-bromothien-2-yl)glycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-(4-bromothien-2-yl)glycinamide N ten-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-2-yl)glycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N ten-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-3-yl)glycinamide N tert-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide - -- N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N ten-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-{5-chiorothien-2-yl)glycinamide __ 2~ __ N Cyclohexyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D-4-(phenyl)phenylglycinamide N ten-butyl-N'-[N {3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenoxy)phenylglycinamide N {S)-{-)-a-methylbenzyl-N'-[N (3,;5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenyl)phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(ethyl)phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(phenyl)phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(benzyl)phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-bromophenyIglycinamide N tert-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(cyclohexyl)phenyIglycinamide N ten-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(4-ethylphenyl)phenylglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(tert-butyl)phenyiglycinamide N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-3-(4-chlorophenoxy)phenylglycinamide N cyclohexyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(phenyl)phenylglycinamide N [N (3,5-difluorophenyl-a-hydroxyacetyl)-L-aianinyl)-L-phenylglycine ten-butyl ester N ten-butyl-N'-[N (3,5-difluorophenyl-a,a-difluoroacetyl)-L-alaninyl]-L-phenylglycinamide __2g-_ N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine ten-butyl ester lV [(S)-1-oxo-l-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(pyrid-3-yl)glycine tert-butyl ester [N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]morpholine N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(2-methoxy)phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N ten-butoxycarbonyl(hydroxyl amine) ester N neopentyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N tetrahydrofurfuryl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N methoxy-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide [N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]azetidine N iso-butyl-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-D,L-phenylglycinamide N cyclopropanemethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N methoxy-N methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N 2-methylprop-2-enyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N (pyrid-3-yl)methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N (pyrid-4-yl)methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N furfuryl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide 1V cyclopentyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N 1-benzylpiperidin-4-yl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N,N dimethyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N 2,2,6,6-tetramethylpiperidin-4-yl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N 2-methylcyclohexyl-N'-(N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N 4-meihylcyclohexyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N 1-ethoxycarbonylpiperidin-4-yl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N ten-butoxy-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N tert-butyl(hydroxylamine) ester N [N (3,S-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N {1-ethoxyethen-1-yl)-[N'-(3,S-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N [N (phenylacetyl)-L-alaninyl]-L-phenylglycine tent-butyl ester N 4-(phenyl)butyl-N'-[N {3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N 3-(4-iodophenoxy)propyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N 6-(amino)hexyl-N'-jN (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide Hydrochloride N 1-(phthalimido)pent-2-yl-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [N (3,5-difluorophenylacetyl)-L-(3,5-difluorophenyl)glycinyl]-L-(3,5-difluorophenyl)glycine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-norleucine N [N (cyclopentaneacetyl)-L-alaninyl]-L-phenylglycine tent-butyl ester N [N (3,S-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine iso-propyl ester N (isopropyl) N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylgiycinamide N [N (cyclopentylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N [N (cyclopropylacetyl)-L-alaninyl]-L-phenylalanine tent-butyl ester N [N {3,5-Difluorophenylacetyl)-L-alaninyl]-L-phenylglycine iso-butyl ester N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-D-phenylglycine methyl ester N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-L-(3-a-phenyl)proline methyl ester N [N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-azetidine methyl ester N-[N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(5-chlorobenzothiophen-2-yl)acetate methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl)propionate ten-butyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide tert-butyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N [N (3,4-dichlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (3-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (3-bromophenylacetyl)-L-alaninyl]-D-phenylgiycinamide N [N (3-fluorophenylacetyl)-L-alatlinyl]-D-phenylglycinamide N (N (4-fluorophenylacetyl)-L-alarlinyl]-D-phenylglycinamide N [N (3-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (4-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (3-trifluoromethylphenylacet:yl)-L-alaninyl]-D-phenylglycinamide N [N (3-methoxyphenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (2-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (1-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (2-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (phenylacetyl)-L-alaninyl]-D-phenylglycinamide N [N (3,5-difluorophenylacetyl)-L-~alaninyl]-D-phenylglycine N [N (3,5-difluorophenylacetyl)-L-~alaninyl]-D-phenylglycinamide N'-[N (3,5-difluorophenylacetyl)-L,-alaninyl]-(S)-2-amino-2-(2-furanyl)acetamide N'-[1V-(3,5-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N (3,4-difluorophenylacetyl)-L)-alaninyl]-D-phenylglycinamide N'-[N (3,5-difluorophenylacetyl)-L,-alaninyl]-L-phenyla.lanin-N-methylsulfonamide N"-methyl-N"-phenyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-methyl-N"-phenyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N (3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycinamide N"-methyl-N"-benzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-4-fluorobenzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-{4-fluoro)phenylglycine neopentyl ester N [N (2,3,4,5,6-pentafluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl)glycine methyl ester N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl)glycine tert-butyl ester N [N (3,5-difluorophenylacetyl)-L-(O-benzyl)serinyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-(O-benzyl)threoninyI]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-threoninyl]-L-phenylglycine methyl ester N [N (3,5-difluorophenylacetyl)-L-serinyl]-L-phenylglycine methyl ester N"-4-methylphenyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenyiglycinamide N"-tetrahydrofurfuryl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenyl-glycinamide N'-[N-(3,5-difluorophenylacetyl)-L-methionyl]-L-phenylglycinamide N [N-(3;5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycinamide N'-[N (3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinamide N [N (3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycinamide N [(R)-a-methylbenzyl]-N'-[N (3,5-~difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N [1-phenyl-2-oxo-3-methylbutan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-phenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-phenyl-2-oxo-pentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-phenyl-2-oxo-2-phenyl-ethan-l-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[ 1-phenyl-2-oxo-butan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N [1-phenyl-2-oxo-4-methylpentan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-a-hydroxyphenylalanine methyl ester N"-[4-((2-hydroxy-4-azido)-phenyl)-NHC(O)-)butyl] N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N [(S)-1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-aIaninamide N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine ten-butyl ester N'-[N (3,S-difluorophenylacetyl)-L-alaninyl]-L-4-phenylphenylglycine tent-butyl ester -[N (3,5-difluorophenylacetyl)-L-ala~~inyl]-L-(2,3-benzo[b]proline) methyl ester N"-tert-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-n-butylphenylglycinamide N"-ten-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(phenylacetenyl)phenylglycinamide N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-D,L-phenylglycinthioamide N [1,3-Biphenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-phenyl-2-oxo-2-cyclopentylethan-1-yI]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-phenyl-2-oxo-hexan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N [1-phenyl-2-oxo-3-methylpentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N"-n-hexyl-6-biotinamidyI-N'-[N (3,S-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N'-[N (3,5-difluorophenylacetyl)-L-methioninyl]-L-methionine N'-[N (2-tert-BOC-amino)propionyl)-L-alaninyl]-L-phenylglycine methyl ester N"-tert-butyl N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-2-fluorophenylglycinamide N'-[N (3,5-difluorophenylacetyl)-L-aIaninyl]-D,L-2-phenylglycine methyl ester N=((S)=1-phenyl-2-oxo-3-phenylpropan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N'-[N (3,5-difluorophenylacetyl)-D,L-thien-3-yIglycinyl]-D,L-2-phenylglycine N'-[N (3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl]-D,L-2-phenylglycine tent-butyl ester N'-[N (3,5-difluorophenylacetyI)-L-thien-3-ylglycinyl]-L-2-phenylglycine N'-[N (3,S-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine tent-butyl ester N [2-hydroxy-1-(S)phenyleth-1-yI]-N'-[(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alaninamide N [2-hydroxyeth-1-yl]-N'-[(3,5-difluorophenylacetyi)-L-alaninyl]-L-phenylglycinamide N'-[N (3,5-difluorophenyl-2-oxo-acetyl)-L-alaninyl]-L-2-phenylglycine tent-butyl ester [N (2,5-dichlorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N (3,5-difluorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N (3,4-dichlorothiophenoxyacetyl;l-L-alaninyl]-L-phenylglycine methyl ester [N (3-aminoproprionyl)-L-alaninyl]-L-phenylglycine tent-butyl ester (N (3-tent-butoxycarbonylamino)propionyl)-L-alaninyl]-L-phenylglycine tert-butyl ester The pharmaceutical compositions described above comprise a pharmaceutically inert carrier and a compound of the formula I above.
In formula I above, X" is preferably hydrogen and X' is preferably hydrogen or fluoro.
In formula I above, Z is preferably a covalent bond linking R' to -CX'X"-In formula I above, preferred R' unsubstituted aryl groups include, for example, phenyl, 1-naphthyl, 2-naphthyl, and the like.
Preferred R' substituted aryl groups include, for example, monosubsti-tuted phenyls (preferably 3 or 5 substituents); disubstituted phenyls (preferably _ 3,5 substituents); and trisubstituted phenyls (preferably 3,4,5 substituents).
Preferably, the substituted phenyl groups do not include more than 3 substituents.

I

WO 98/22494 . PCT/US97/20804 Examples of substituted phenyls include, for instance, 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-nitrophenyl, 4-methylphenyl, 3-methoxy-phenyl, 3-nitrophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-bromophenyl, 3-thiomethoxyphenyl, 3-methylphenyl, 3-trifluoromethylphenyl, 2-hydroxy-phenyl, 2-methylphenyl, 2-fluorophenyl, 2-chlorophenyl, 3,4-difluorophenyl, 2,3,4,5,6-pentafluorophenyl, 3,4-dibromophenyl, 3,4-dichlorophenyl, 3,4-methylene-dioxyphenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 2,4-dichlorophenyl, and 2,S-difluorophenyl.
Preferred R' alkaryl groups include, by way of example, benzyl, 2-phenylethyl, 3-phenyl-n-propyl, and the like.
Preferred R' alkyl, substituted alkyl, alkenyl, cycloalkyl and cycloalkenyl groups include, by way of example, iso-propyl, n-propyl, n-butyl, iso-butyl, sec-butyl, tent-butyl, -CHZCH=CH2, -CHZCH=CH(CHZ)QCH3, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclohex-1-enyl, -CHZ-cyclopropyl, -CHZ-cyclobutyl, -CHz-cyclohexyl, -CHZ-cyclopentyl, -CHZCHZ-cyclopropyl, -CHzCH2-cyclobutyl, -CHZCHZ-cyclohexyl, -CHZCHZ-cyclopentyl, aminomethyl, N-tent-butoxycarbonylaminomethyl, and the like.
Preferred R' heteroaryls and substituted heteroaryls include, by way of example, pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, fluoropyridyls (including 5-fluoropyrid-3-yl), chloropyridyls (including 5-chloropyrid-3-yl), thien-2-yl, thien-3-yl, benzothiazol-4-yl, 2-phenylbenzoxazol-S-yl, furan-2-yl, benzofuran-2-yl, thionaphthen-2-yl, 2-chlorothiophen-5-yl, 3-methylisoxazol-5-yl, 2-(thiophenyl)thiophen-5-yl, 6-methoxythionaphthen-2-yl, 3-phenyl-1,2,4-thiooxadiazol-5-yl, 2-phenyloxazol- 4-yl, and the like.
Preferably RZ is selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic. Particularly preferred R'- substituents include, by way of example, methyl, ethyl, n-propyl, __ 37 __ iso-propyl, n-butyl, iso-butyl, sec-butyl, phenyl, 4-fluorophenyl, 3,5-difluoro-phenyl, 4-methoxyphenyl, benzyl, cyclopropyl, cyclohexyl, cyclopentyl, cycloheptyl, thien-2-yl, thien-3-yl, -CHzCH2SCH3, -CHZOCH2~, -CH(CH3)OCH2~, -CH(OH)CH3, -CHZOH and the like. As noted below, RZ
(as well as R4) is preferably the side chain of an L-amino acid.
Preferably, R3 is hydrogen, methyl or together with R° and the nitrogen to which R3 is attached forms pyrrolidin ~!-yl, 2,3-dihydroindol-2-yl, piperidin-2-yl, 4-hydroxy-pyrrolidin-2-yl, 1,2,3,4-tetrahydroisoquinolin-3-yl, and the like.
Preferred R' substituents include, ;for example, hydrogen, methyl, ethyl, iso-propyl, n-propyl, n-butyl, sec-butyl, iso-butyl, cyclopentyl, cyclohexyl, allyl, iso-but-2-enyl, 3-methylpentyl, -CHz-cyclopropyl, -CH2-cyclohexyl, -CHZ-indoi-3-yl, phenyl, p-(phenyl)phenyl, m-(phenyl)phenyl o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, p-bromophenyl, m-methoxyphenyl, p-methoxyphenyl, phenethyl, benzyl, m-hydroxybenzyl, p-hydroxybenzyl, p-nitrobenzyl, m-trifluoromethylphenyl, p-(CH3)zNCHzCH2CHz0-benzyl, p-(CH3)3COC(O)CH20-benzyl, p-phenylphenyl, 3,5-difluorophenyl, p-(HOOCCH~O)-benzyl, 2-aminopyrid-6-;yl, 4-(N-morpholino-CHZCHzO)-benzyl, -CHZCHzC(O)NHZ, -CHZ-imidazol-4-yl, -CHz-(3-tetrahydrofuranyl), -CHZ-thien-2-yl, -CHZ-thiazol-4-yl, -CHz( l-methyl)cyclopropyl, -CHZ-thien-3-yl, thien-3-yl, thien-2-yl, -CHz-C(O)O-t-buty:l, -CHZ-C(CH3}3, -CHZCH(CH~CH3)z, 2-methylcyclopentyl, -cyclohex-2-enyl, -C'.H[CH(CH3)2]COOCH3, -(CHZ)zSCH3, -CHZCHzN(CH3)Z, -CHzC(CH3)=CH2, -CHZCH=CHCH3 (cis and trans), -CH20H, -CH(OH)CH3, -CH(O-t-butyl)CH3, -CHZOCH3, -(CH~4NH-Boc, ___ -(CHZ}4NH2, -(CHZ)QN(CH3)2, -CHZ-pyridyl (e.g., 2-pyridyl, 3-pyridyl and 4-pyridyl), pyridyl (2-pyridyl, 3-pyridyl and 4-pyridyl), -CHZ-naphthyl (e.g., 1-naphthyl and 2-naphthyl), -CHZ-(N-morpholino), p-(N-morpholino-CHZCHzO}-benzyl, benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, 5-chlorobenzo[b]thiophen-2-yl, 4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl, I

__ 3g __ benzo[b)thiophen-3-yl, tetrazol-5-yl, 5-chlorobenzo[b]thiophen-3-yl, benzo(b]thiophen-5-yl, 6-methoxynaphth-2-yl, -CHZ-N-phthalimidyl, 2-methylthiazol-4-yl, and thieno[2,3-b]thiophen-2-yl, 5-bromothien-2-yl, 4-bromothien-2-yl, 5-chlorothien-2-yl, 3-phenoxyphenyl, 2-phenoxyphenyl, 4-ethylphenyl, 2-benzylphenyl, (4-ethylphenyl)phenyl, 4-ten-butylphenyl, 4-n-butylphenyl, o-(4-chlorophenoxy)phenyl, furan-2-yl, 4-phenylacetylenylphenyl and the like.
Preferably, RS is hydrogen. However, in another embodiment, R° and RS are fused to form a cycloalkyl group including, for example, cyclopropyl, cyclobutyl, and the like.
One preferred X substituent is -C(O)Y. Preferably Y is hydroxy, alkoxy or substituted alkoxy such as methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tent-butoxy, neo-pentoxy, benzyloxy, 2-phenylethoxy, 3-phenyl-n-propoxy, 3-iodo-n-propoxy, 4-bromo-n-butoxy, -ONHC(O)OC(CH3~, -ONHC(CH3)3 and the like. Another preferred Y group is -NR'R" where R' and R" are as defined above. Such preferred Y groups include, by way of example, amino (-NHZ), -NH(iso-butyl), -NH(sec-butyl), N-methylamino, N,N-dimethylamino, N-benzylamino, N-morpholino, azetidino, N-thiomorpholino, N-piperidinyl, N-hexamethyleneimino, N-heptamethylene-imino, N-pyrrolidinyl, -NH-methallyl, -NHCHz-(furan-2-yl), -NHCHz-cyclopropyl, -NH(tert-butyl), -NH(p-methylphenyl), -NHOCH3, -NHCHz(p-fluorophenyl), -NHCH,CHZOCH3, -NH-cyclopentyl, -NH-cyclohexyl, -NHCHZCHZN(CH3)Z, -NHCHzC(CH3)3, -NHCH2-(pyrid-2-yl), -NHCH2-(pyrid-3-yl), -NHCHz-(PYnd-4-yl), N-thiazolindinyl, -N(CHzCH2CH3)Z, -N[CHzCH(CH3)2]z, -NHOH, -NH(p-NOZ-~), -NHCHZ(p-NOZ-~), -NHCHz(m-NOZ-~), -N(CH3)OCH3, -N(CH3)CHZ-~, -NHCHZ-(3,5-di-fluorophenyl), -NHCHzCH2F, -NHCHZ(p-CH30-~), -NHCHz(m-CH30-~), -NHCHZ(p-CF3-~), -N(CH3)CHZCHZOCH3, -NHCHzCH2~, -NHCH(CH3)~, -NHCHZ-(p-F-~), -N(CH3)CHZCHzN(CH3)z, -NHCHZ-(tetrahydrofuran-2-yl), -NHCHZ(p-trifluoromethylphenyl), -NHCHZC(CH3)=CH2, -NH-[(p-benzyl)pyrid-4-yl], -NH-[(2,6-dimethyl)pyrid-4-yl], -NH-(2-methylcyclohexyl), -NH-(4-methylcyclohexyl), -NH-[N-ethoxycarbonyl]-piperidin-4-yl, -~NHOC(CH3)3, -NHCH2CHZCHZCH2-ø~, -C(O)NH(CH~30-(p-CH3)~, -C(O)NH(C'.H~NHZ, -NH-(tetrahydrofuran-2-yl), -N(CH3)~, -NH(CH~4NHC(O)-(2-hydroxy-4-azido)-phenyl, -NH(CH~6-(biotinamidyl), and the like.
-- w Another preferred Y group is an alkyl group such as methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, sec-butyl, tert-butyl, -CHZCHzCH(CH3)2, -CHz-pyridy-2-yl, -C:HZ-pyridy-3-yl, -CHz-pyridy-4-yl, -CHZ-fur-2-yl, and the like; a substituted alkyl group such as benzyl; a cycloaIkyl group such as cyclopentyl; and an aryl group such as phenyl.
Still another preferred Y group is -NHSOZ-R where R is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic. Such groups are exemplified by NH-SOz-CH3.
Preferred Y' groups include a substituted alkyl group such as -CHZOH, -CH(OH)CHzCHzCH(CH3)2, -(:H(OH)~, -CH(OH)CHzC(O)OCH3, -C(OH)(CH3)z, -CHZOCH3, -CHZOC(O)OCH3, -CHzOC(O)C(CH3)3, and the like.
Preferred compounds for use in the methods of this invention include those set forth in the tables below:

~ ..
T T 7~

tTM

J 'O 7 I T T
v - ~-U U U U U U U U U U U U

..:(;~O_C_ O_ O O O O C O O O

_ _ _ U U V O C O O C O O O C C O O

O U U U U U U U U U U U

Z Z Z U
.

O O C

U U V

r r r ~, r W'-'~..,~ r O

V V N ~ N ~ >,~., $ -6 ~j"" .9-9 U C
=

..;_; U ,.:= ~ U ~ -~c Z
c N ~

U U '= ~ U U U o U ",., c c a ~

.: _ J U _ _~ ~, O Z ~ ~_..;
~

U U ~ ~ 4~ U U

U

y a ->., z x .:i = U L U U U U U C~ J U U U U U U

U

-a-e -~~ V U -e. r s -a~9. s ~aW s ~) _ C. C. _ L:. Cr G L:. L..

U
~~

h h h ~n h h 4i h ~i h ~ h h ~-i~; ~i " "' ~i ~~ M ~i~i ~i ~-i~i ~i U U

U

U U U ~j O

O O O C -"

_~ ~ _~ .,_., V ..;..:

O p U C U U U :>U ~ U U U '""
U U

_ C _ O _ O

O C O O U U O U U p p ~ ~ ~ ~

U U U U Z Z U Z Z _ (~ Z U U U
U

O O p p _ U U J U C

U

N ~ r ~ -r >' ~ y,T ~' ?, T
N

.

J ~ ~ U ~ ~ N .6.c " ~ .g ~

T p ~ O > ' ~ _ a O

, > .
G , C.

.-.
U

Z
U

U U
U " '~ ~ ~ U U U V
~

U yU

II II
T

ZN Z

a~
V ~
r .-.

T
'1 ~

V
~

v ~ _ C

G~
N
__ U U V U U U U U U U U U L U U U

$ -6 -W9 ~ -~ -0..8, .g~. y 9. -9 e.c:. c ':: c:,c:, c:. c:.c:.c::.
., h h h Yi ~i~n ~%,h h h h h h h h r.i~i _.
I V
I

I $

U : y e U ..: .r ~

V _ U .,.
k U V U Z_ Z C ~ ~ U Z ~,Z_ Z_Z_ Z U U
O O_ O C C ~ "'O C'O O O C p Z Z
O_ O V U V ~j~ p U L;U U U U p O_O
O U U U
~ 0 O U
~j V

U

a _ U
$ $ T ?~~'r~ T ~ ~ $ ~ ~, .T.
-, ~~ U V ,r ~ U
~ O_ - q ~ ..:U r., U U '~-'~ J J "' U ...
G -- w CiU U w U

c c'~._ U c " ~ U
U Z Ci~; ' ' ~j Ci ., ~ ~ ~ ~ ~ ., ., = U J J U U U U U U U U U J U U U U U

9 -3~6 ~96 -68 -6$ -6.

_ ~:.c:. c_c:.c::.c: c:_ ~J~. ~ ~J ~J.-~~~$ $ $ '.4.=

h h h 41 v'1h h h v1h v'1 ~'1~'~~1~1 ~ ~' W1~'1"'7~'''1 U

.-~. Z

V U U ~ ~ ~ ' _VU = ......~~ = .,'9 U Z _ _ _ ~ ""-:
Z_ Z U Z_ z ~ O ~ U U C_O O_O U p U
O O C Z O p V O O ~ O O O O O V p U U U_C U ~;' V U ~ ~ U U U U , U , z U

N

U U U

~ ~ c ~ U $ ~ ' ' ... N .~ $ ~3 -e. $
~; V U V C C .:
~ = - ... ~
~'U ~j U ..:..:_ .. ~, J V ' U U V U ~>, ~ U U U
' V ~ ~ I
!

' U C)U :.
, , G

..: _ U :: U U J U U U U U U U U U U G U U

c 9 $ $ $ $ $ $ C v $ $ G $
$ $ $ $ '_~, ~ a_~v ~ Li.G:.O G:"
~ '7~ 7 ~ ~ : O ~ ~ ~ ~ G , ~ O
h h h h h vi T v p ~1 ~i;~h ~'1~'1~ t'"1~'1~"fh U U U ~~i~i~ ~'i rv1 T

U

r U U

U , U U O -= U V U U
_ ...

U

U O U U z V O U U V U U " ..;V Z

O p C O C V p C U 0 0 O U ~j V p V _ O U % ~ V C U C O O O O V Z z U

U z U U U p p p U U

v U U U

U
U

i~
I

N

N

~ ~ ~ U ~

X ~ ...~..:..~ ~
, ' U
J V J J U ~ c U U U J CiU U

V T ~. U

z C

II
Z
~
i, >, N

~

n N
~

U

$

_:= ~ ~ ~ ~ U ~ ., ~ ~ ~ ~
-. - ....~ .. ..

_ ~ ......
U .: U U U U - U U U ~ U U U

V

U

W.~ -~-~ C -~ .AL .~
9 .y A. -~.~9 -6-A

(.. ~ : V tx, tr.U

.. C _ O C ~ ~ p _ ' Z Z Z Z - Z Z ~~ = ? Z

y ,:~ ~i~~ U ~ hiU U ~ hi ~ U ~

, ., ~;~.i .;

.~ -s _.
S p Z ~ o z o -e.~ z $ z U U U U U
U o S S V ~ V V g g ~ C V U ~ ...U =_ ~ .~O ~ U U O U
~j U " U Z U O O O ~ ...
Z _ Z GZ~,~ U Z O Z U V O C V Z
Z Z U ~ Z U U O
~ V V U V j U O O C U
V U V

_ _ _ w -y ~.y y V r ,r r M 11 n $ $ T ~ n n n $
~,qn i ~~ n ~ ~ n n n U U U V V ~ V V vi U Cj -~? . ....- ~ U
V CJU U

U

I
i U U U $ J U U U U J U U U Ci~ ~ U U

$ $ $ ,_.:$ $ $ $ $ $ $ $ $ $ T $ $
$ c h h ~ V h h h ~,h h ~-,h ~, ~''h ~ ~ h ~'1~,,1~"f'r~~ ry~'1~ ~'1~'7~1 ~'ff'''1 U tv1n"1 __ ., _ ..
n U U $ $ -a ~ U U _ -pU U C, U
" ~ U U g ~i,~'... ~ ~ z ~, w 7G U = .,: L~._.: ..:
U ~ = ~ v S U ~j "',c.U
O C U (, U ,.;."= U U O U ~ U V " O
V O _ U U V O O O O V O U U
V U p z Z Z ~ O C O O O ._..~_ U
Z (~O O 0 z Z U U ~jU z U Z_Z
U U U C O ' ' ~ O O O
U ~jU U V U

U U

T T
X T ~r n n ,~"~ri.~ $ .~iC "~ $
O
U r:~ ~ $ ~ v ~ ...$ $
>. r~ U U ", U V
~ U U ~ U
~ U U ' ' V ~
' O ' ' " " z , U U C

M
N

T

'..

U U U U U U U U U U U U U U o U U U

U

T

U

n $ $ $ ~ $ $ $ $ $ $ -9 $ $ $ .=.$ $ i, L. ~ L..L:.4:.G:.L. 4:.L:. U C:.. cn ' w 7 ~ z ~ ~ ~ ~ ~ ~ ~ '7 h h h h h h h Y1 h h h h h ~ h h ?v ~'1~1M ~ M ~''1~1 ~'1'~ ~'1~'1h1~1 ~T1r ~1~.~4 __ 4g __ _ _ 0 _ ., _~U U U U V U V U z - U U
U U - ~ = ~_=U U U o = o 0 O O U U U U ~ -~z U U O ~ CjO
p p O_ O_O_ C_~ ~ O_O_ O c U U O O O O j j ~ O O U Z ~ z O
C ~ O
U U U U V U U O ~j O
~ O U V C;
U V

CY w ,.", I
T

I

U

$ $ .3 ~ .~, $ .~ .~U U
.n ",.,~t..t..V ~ C. -~-a $ a. $ U U ' v U
U C " -U :" o ~'a, .: ~ p ""., O

w U U

U U
I

U U U U $ U U U U U U U U U U U U
, , , ?. T $ $ $ '~$ $ $ $ $ $ ~ $ $ $ 'A.
_ N etL:.L.CL L.L. L:.i:.~~.L:.L:.~ ~ ~ , n 'a ~ O O O O O
T '?.v1 v1U1 h 41 ~1h ~1V1 V~z z z z z C G e.j~ ~,~~'iM ~O~'1~.7~,~~,j~'1~'f,'"1~~ ~'1 WO 98!22494 PCT/US97/20804 T U ~ U

U x ~ ~ ~'T ~; c ."
~ .. S

Z ~ _ ~ 3 ? U ~ U
U a, _ _ V

U p V U U U V ~ _ ~ ~ ~ U U U "' ~ .T.
c O O O O -: v ~ O C O U a,U
j ~

C ~ _ _ _ U V '"V ~ U ~ C _ _ _ .-.
O C O O C

U U ~ a z z _ Z' .. U U U U Z V
z v ' 'z o ~ o~, z ' ' z o : o o z _ _ C U U U O U O U O
.

U V V U U

N "~ "~"","

U U '" _ '~ J U
U

U U V U

a V V U U U U U U U ~~U ~~C) U U

U U ~ U ~ U

v U U U

U U ' ' ..

U U U U U U U U L U U U U U U U :.TU
, ~ ~ ~ , , , ~ ~ , -s.-a-a ~ 9 s s ', -a.9 a -a~e ~ .g G:..G:..L:,L L '.~.j C_,G:.~ '.~L:.LL
::. ~

z z z z ~ '~~ ~ ~ ~ ~ '_ ~ ~ Z ~ ~ ' h ~ h h WO 98!22494 PCTlUS97/20804 ~

z z " _:= : ~ ' V '"'" ~
U U U U U

_ ..::: O z z O (VV ..O ~ U O
U O

C U U C~ ,>=,O O p O O O p C p ~ p O
z v _ _ _ p-U Z Z U V O O O U U O U p U
V

U ~ O O V V V V U

V U U

~., M

C
v T T ?,j, j., p ~ON N M V1 "'[~ a.>, ~ ~ ~ v c~
d T = >.>. >, .: U ... N N C 'JGG G N ~ N N N
c : ~ T
' ~ U . - N ~ :_.:.
r ~ .7 .. ~ J C
N

U

U o 0 N_0 0 0 N
N_ N_~

41'U L N y U I~ .G

M
w ~~ U U U U U U U U U .UU C.iU U U U U U
i I
I 8 -6~ -8.-8 3 -E~$ ~9 -8.t~ -6-~ W 9 $ 9 9 _ L..L:.L..C:.t_ L..G C. 4:. L, G:..v. 's.

h h h h h h h h h h h ~1h h h h h h ~i ~'7~'1~'ir"1~'1~'i~"i~'1 ~ ~'i"'1~~i''~7~~i'ri~1 M

U U C:U U U U U U V U U V (j U U U

O_C_ O O_ O_ O_O_ O_ U U rJU O O O O O

C O C O O O O O O Z 'OO O _ O _ O
O O

C~U L U U U U U U p 'JU U U U U U

U ~,, -~

T

T , N
T

N

?vV'~ T . U
v '~.

$ a _ O U
~ .~~

O G, T ~-.ao " _ L $ $ $ $ $ $ $
'- s ~ 'J'' U
~

N _ N

C = U
N

L

,-.n ~ M

U U J ..:U U U U , U ~ V "' "'U U

U ~y V U

U , U

, $ $ ~ ~ $ ~ 'S $ ~'$ '~$ $ $ $ $ $
$

_ L. C. L ' C. f.:..C. f.:.L. ::.C..Lt., ~ '~7 ~ ~ ~ ~ ~ 7 G 'O '~~ ~ 7 7 'O

h h h ~n h h h h h h v1 41h h h Y1 ~'1H1 ~'f'~7~'7 N1H1 ~'1 :J~1 h'1~7 ~'1~"'1 .:
_ U T
U

U U U U U _ U V U U U U _ U U V
O U O O O C U O U C O O C p O
O O

O C O_C C _ _ O _ _ _ _ C ~ ~ ..., O O O O O C

U O _t~U U U U U U U U U U V U O O

U O O

U U

...

O
U ~ _ ..;_ .~ U -g U -: "' ~ U ~~ T J .... ...~..:.,:

N -9S 3 ~ '~ _ V U -' ~ Z ~ ,~U U U U U
~
:

~ ;~ ,= V U U U
V .

V U ' ., I
I
Z

"

a U
'-N
r.s U

.:.
-s -a- U U U ..;...~...:..:..r..:..:..:
U U U U U U U U U ....~

U
T

U

$ ~3 $ ' .:
_ Ci. C. e~ ~"
U U

"' ~ ~ ~ ~ -'~-e.-6 -6 ~ a ~ e.~ Q ~

h h h ".,".,"~ .:~ U U

i '>, ~j cr O
. ~ ., ~

, ~" ~ ~ ., o U --~"~, ......T '""",~._.:~ ..~~ ......
a U -- U U c V U U U
U Z Z

v U O Z'O -: 0 ..:(JZ_ Z_ O O O

_ _ O C O p U p V O O_ O O O p p O

V U V z ~j O U U U U U U U

z U
..

O

U U U

oC = = ...

z ..
z o .s. . U -e..= 3 -d.-s.-e.-6-s 9 -9 U

U U ' U

II II
y~ T
T

Z ~ Z
N N

.

V
~' \
G

\ ~ .
G

v r:, -' U U

U U U U U U U v ~9'V U U ~ ~ V

v U U U U

~

-6.-6 ~ 9 -g 9 9 -9 -8.9 ~. ~ 6 -9.-6 c. c: d,cr c_,' c:, ~,~ '"a: c:,cL
c_. ~'- ~_..: ' , , , , , ~ , 3 ~ ~ ~ ~ ~ ~ ~ V

h h ~i h ~i h h h ~nh h ~ '~'~n h h ~-i~i~~i ~ ~i~~ ni~i ~i U ~'i~~~i k U U U U U U U U U U " U U U U U U

O O O O O O O U U U z U L U U U U

o c o c o 0 0 0 0 0 o z z z z z z U U U -L U U U ~ O O V

p p p O O O
U U U

~j ~jU ~jU V O

U

4. ...
"' ~, >, N N

J CJ~' T N $
' w $ $ ~~$ $ $ '8$ '~$ $ = N ~

$
i i i O :. ~ ' $
~

v U

N rrr.., w M

w U c >, a. $

_ U -" ~ tn N $ ~ ~ ~ ~ ~
:

~' ~'C c Gi.V -9 $ $ ...r ..:..:..;

V ~ ~ " 4 O ~ V U U U U U U U
: .

U J ._.~. C

U

'~ W e ~ $ ~ .:$ ~ -e.-A.~ 9 -0.
,:

_ G:;.:~.t ~"~ ...~,~_. c:::: i i , o o U , . c t , %,~i h ~n h h ~n~i ~ ~' U Yi ~ i i , v ~ ~i h h ~"1n1 ev1i'7~7~'1~ ~'1U J

~ ~1M ~'1~1 _ ~ ~ ~ .: ~ _ ~ U
U U U U U U U U U U ~ V .e V . V O
~t U U U U U U U U U ~~ V ~ V E' O O
~ ._.._ Z Z Z Z Z Z Z Z Z O (j O ~ O T

p z , O O O O O O O O Z O O O U Z
U ~ O V U U U U U U U V Q V U
U

U

.,.

-e.

-g .e. $ ~ l3 T 9 'A '~'S ~9' r >, >, - y 6 ~ -'~- ~ ~ C $ M '~ Q -9 U -~=' ~ A. U .? " 9 C ? -c. ~ j a ' U ~ S g' U y U g .c''.
S " g S

w ~

..
n ...n n n n n n n U U U U U U U U U U U U U U U U U U

9 -e . 3 -e-a -a~a ~ss ~e. ~a~a ~e. ~a-a ~ 9 ~

c_c: . . . ~_.~ . ~ ~.~:;.c:.c:,. c ~_c: c~ ~. ~

Wv ~% , h ~ih ~,~i ~ Y , ~i h h h h ~. ~ i j i j j ~ ~ 1 M rot i 1 1 j ~ ev ~'et evM ~r M f'"~'~ n ; , q -...
U ~

a a .. O n I' j>>, ~ ~ >, n U o U '''~ '' a, a o 0 (~ -'U >,"" a O ~" ~ ~ ' G ~ ~ '~'-'>, . ' n v v... O ~ ~ U U
a U ~ ~' v c ~

z' c a v a ~ ~ _ _ s ~

z U U V v ~'~w:,T: ;~ N z ~ U ~
z ~ v i, CJ

o .v o 0 3 V c c ~..z z o 0 ~ ......

o ~ U v a 0 , U
O O O

U U U

N

N 'S 'A~ $ T~ "A~$ '.~'aT~'.~'g $ '~ ~A -e.-A

N

U U v U U U U U U U U U U U U U U

.8,.g .g9 -e.-9.~ .e.6a .9 .e.a .6 -6.
: ' r crc: c_r:.r:.~.~i.~ c:u. c:. ~.a.

h h ~%,h h h h h :

h , ~i h ~ih h h h ~'i";"i ~;~'i~'i~.i,~i~;~ ~i .
~-i ~ ~.i~i ~i ~iM
.~

__ y o ~ ~ cj -aU :' b _ ~

o ~ U U Z V U O U O U V U U
~

Z O - Z U U , ~~ U O U U O O
- ' a _ ~ _ O p O
. _ ' O Z O ~ CIp Z V ;~" U O D
U

~ ~V _ _ V Z ~ ~ U V
O

-: ~ U O U U
c:

Z V V Z V ~ U

O O ~j U U ' ...
.r ... ...

U

~3 9 y 6.-9 -93 h U

U

il 11 ~ N
~

Z ~ Z

. 'O
~ .C

a.w ~

a d ~, d , N

, d :a d~ .

T

N

U U U U U U U U U U ~ U U ~ U U

, J ~ ~J ~ -9 ~A 9 -8.''~9 9 w9~.

L: L..f:..4:.L L:. C...i:..L:.C:.L:.G L:.LL 4L

_ 7 ~ ~ ~ ~ $ 7 7 ~ 7 7 ~ 7 ~ b ' h h h V1h 41 h h v1h h j ~ h 41 h ~'1 ~'1~~ ~"1~'7"r~ ~1~'1~'1~'1~'~V ~'1~''~ ~'f __ $g __ i i .:
O V ..:._.:~_ ..:_~ ._..~...~;_ ~__~ ~_._..~~ ..:"' U
V U Z Z Z Z Z Z Z Z Z Z Z Z Z Z

O O ~ O O O O O O O O O O O O O O

U-_ p ~ U U U U U U U U U U U U U U

U
i U

p T

>, $ '~'~ !~$
n n v U

'' U

U

rH rr U U U U U U U
U U U U U U U U U U U

>, -6 . v 6 ~ ~' ' ' L L C ~ - $ .~; ~ ~ ~ - _ 4.
.

U c ~. c:.,~jJ U
~

, h h ~ a ~i ~i"' e'~i~ ~iU N ~
' ~1 ~1"1 ~ ~rj ~1 fV ~~
~ i .,_ $ $ ~e ~ o x Z Z ~ U Z '_'"~-U U U U U U Z z U U g v =' o o '- z z ~ ~ a =_ 0 0 0 0 o E 4 O

" U O O O O O v a O O
U U O O O U O O O U U U U ...,cSU V
U U V U ~ Z_ V O
U .r ' U

G Z Z

?, $ a $

C $ $ $
' U ~' $,~ $ $ '9~$ O $
U o C

' r 'et V

~r $ ~

_ U ' U
~=U U U .r ~nU U U U .. O ~ O U ~ U v~
U U tj O U U' " U V
= C U ' ..
U

V V V V U

I -~ $ -9.~ -~ -~-6.$ -a W e. $ -W a $ ~e~a c crt _.c. ~~.,~ c.~:.~ ~. c,c~.c c~ c:.c. Gi.
h v r, h h h h ~%,h ".~~ h h h h h h h ~i ~i~i ~,~~ ~ ~ ~,Mi Q:~i ~-i~i ~i~i Mi~i ~~i lV

,:
$ ~ ~ O

~ ~ V
~ U w o ~

U = ? , .:
. . ' ~ U ' "'-6 U V "' Z - ,....,~...~ w ~ "; eNa ".~

Z Z Z V ..~U U -: "' p ""'c U U V

O O O U O ""~ V U 2 U U O V
>, v ~ ~ U U p """O U O O p Z
U U U p , o.~
c o O U O V ... . U
Q ~ O

V U V ~ U U
s ~

v U

o: .,.. w w w ""' ""~ w w w T
-9, C

i _ y 9 $ ~ $ $ $ $ $ -A'9 $ ~ ~' G

~ $ ~, C

'V

~I
>, Z ~
o V ~

Gi v..v r ~ ~
N ~
"

w .n cC w ;~
v T

~

fV

J

U U U U U U U U U
U U U j ( 9. W 9 -a-9 ~ W e. ~..e. .g c,.c:,,~.rr ~.:.ci.ci.~: c c::c:,c:. :: ctcr , .

h h h h h h ~iVi h h h h h h h h rri~7 ~ie~i~i~'1evi~.inriMy ~-ievj ''h ~

~

E

.: ~ U c .:

-6 c >, ~ . _ ?G x Z ~ o ~ U ~" U ~ V ~ x V Z Z Z
p U
Z v~~ T ~ U " O O x 4 ~ O O
Z .~ O
Q V U p ~ O ~ U U p V ~ 0 U U U

U O
v U

x x x x x x x x x x x x x x x c s :

c x U

a v~
T -69 -9-~ -A-6 U -9 y 6 -6.-9 $ -9 -e.
U
N
c U

a a v i x x x x x x x x T x x ~- ~-x x V T T

x x T ~- ,y U U U U U U U V U U U ~ ~ U U U

x s U

O p p ~ -6-9 -6-6 -9~-A 6 U -6~6 ~ -6 ~ ~ e, _ L. Gi.L. u.4. a. L.' C.Gi.LLLt.

n y :9:D :9 y 'v ~ Z ~ y vv U ~' V

h h ~n~, ~nU h ~n h h ~ ? z?
~~i~.i~.i~-i~-i~i~O ~~~i ~iM '~"? ~r v v WO 98!22494 PCT/US97/20804 ..
,r n--i "" ~~4 ~ ~e Nr r~4 ~ w r..r r~~r N
n fy1 C1 M
w U U
O
w w w r.:r I~r r.~r $ $ w ~ r.~'.~ r~.rr w U
r.1 N
U w ' U
i I
v >, a r.~ rr -S- ~"~ w ~ /W N Cr ~ L ~ it U V ' (~ U U ~ w w ~t ~ a, O ' U U o ~ , c~ v ' ~, =Z
O ~ .., ...
r" w w w ~ ryr ~ ' ~r ,~'., r.., r.,r w w U U U ''''"" w U U U x x x , U U U U U
'0- $ $ -E~ -0- -8. -g -8.
G . u.. u.
T T T
Gi. L. G:. u, Gi, ' , ._,:.,:..~ ~~~w c:.,c..
h ~ h ' ~; h ~; h M "~ ~'i M h'i ~'ri ~'ri ~'ri ni M

x w w ~ .~

1.nw U Fr1w r.~

H

r.wr,~r.vr~.rw hr r.r ~...~

,.:.,m -. md.r~ w W .:r N

M

_ U

w d U ~ -9-U

U x s .-:U

U

LwH1 M IwwM r..r t " W r w ~ w r~.~w .ir . e1 n c~ e~ e~

__ U U U U U

LtrGL G:.L~ G:,u, _ ' ' : ~ .'..' G C.

. . . 'O 'flb O O
,. . 'O
'O

h h h h h h n~1n1 M ~'~1M M U V

__ (~ __ I.~YL.qw ~ r...nr..q w w w w .~ .~
U U

a , >- O O O U p ~

~ c, CJ

...:..r;
w U U ~~
w O .,.N U
w .r.N
w U U .--U U ...,....

N

U

"~~U
=Z

U
O

'~ ~ m ....nr.-n, w w w r:rr.r,.~., n rn M n r1 ~
r_.~w r.-~w ...rw_ U U

. ..
U U U U

_ u. ti.u, G:.:~:, fn ~
w w~.m W
~.

-- 65 --.
N
/'1 ~1 M
~

I
N

V ~ O
-. .:.U

...._., U U

~"
V O O

O ~ O O U ~ :

U ~ x O O p ..,.,..
..~.

U Z ~ U U

O U U

p I , U

>C V U ' =Z N

n O ~ x ~ w -a 'e.U 'a ~t V ~ U , mr , w x ' U

Z=

O

w Hw1H.4 I 1.11- I

N r1 N w r. ~ w ~

=Z ~ ' U U U U O U I

O U

x U
: : ; ~
.

$ ~ _. .. _,.~ U
U

U U

, I , , U

, , I I , , x x w _ U U U Ci,t-:.~N G:.Li, N N ~ _I , c~ ~, ~, ~ O

x x .~ ~ z , ,~ ,~
U U V

I

.:.

U U

U

O

z z ., U U U

X
Z=
M H
f1 U U U
N
=Z

X
w X
II
>C O ~ x II
k t~ u. Gi.

-_ 6~ -_ DETAILED DESCRIPTION OF THE INVENTION
As above, this invention relates to methods for inhibiting ,B-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. However, prior to describing this invention in further detail, the following terms will first be defined.
Definitions The term "(3-amyloid peptide" refers to a 39-43 amino acid peptide having a molecular weight of about 4.2 kI?, which peptide is substantially homologous to the form of the protein described by _~lenner, et al.' including mutations and post-translational modifications of the normal (3-amyloid peptide.
In whatever form, the /3-amyloid peptide is an approximate 39-43 amino acid fragment of a large membrane-spanning glycoprotein, referred to as the /3-amyloid precursor protein (APP). Its 43-amino acid sequence is:
_l Asp Ala Glu Phe Arg His Asp Ser Gly Tyr _11 Glu Val His His Gln Lys Leu Val Phe Phe _21 Ala Glu Asp Val Gly Ser Asn Lys Gly Ala _31 Ile Ile Gly Leu Met Val Gly Gly Val Val _41 Ile Ala Thr (SEQ ID NO: 1 ) or a sequence which is substantially homologous thereto.
"Alkyl" refers to monovalent alkyl groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, n-hexyl, and the like.

__ 6g __ "Substituted alkyl" refers to an alkyl group, preferably of from 1 to 10 carbon atoms, having from I to 3 substituents selected from the group consisting of alkoxy, substituted alkoxy, aryloxy, heteroaryloxy, heterocyclyloxy, acyl, acylamino, amino, aminoacyl, aminocarboxy esters, cyano, cycloalkyl, halogen, hydroxyl, carboxyl, carboxylalkyl, oxyacyl, oxyacyIamino, thiol, thioalkoxy, substituted thioalkoxy, aryl, heteroaryl, heterocyclic, nitro, and mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono-and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic.
"Alkylene" refers to divalent alkylene groups preferably having from 1 to 10 carbon atoms and more preferably 1 to 6 carbon atoms. This term is exemplified by groups such as methylene (-CHZ-), ethylene (-CHZCHZ-), the propylene isomers (e.g., -CHzCH2CH2- and -CH(CH3)CHz-), and the like.
"Alkaryl" refers to -alkylene-aryl groups preferably having from 1 to 10 carbon atoms in the alkylene moiety and from 6 to 10 carbon atoms in the aryl moiety. Such alkaryl groups are exemplified by benzyl, phenethyl and the like.
"Alkoxy" refers to the group "alkyl-O-". Preferred alkoxy groups include, by way of example, methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tent-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, 1,2-dimethylbutoxy, and the like.
"Substituted aIkoxy" refers to the group "substituted alkyl-O-" where substituted alkyl is as defined above.

_ __ 69 __ "Alkylalkoxy" refers to the group "'-alkylene-O-alkyl" where alkylene and alkyl are as defined above. Such groups include, by way of example, methylenemethoxy (-CHzOCH3), ethylenemethoxy (-CHZCHZOCH3), n-propylene-iso-propoxy (-CHzCHZCH20CH(CH3)Z), methylene-t-butoxy (-CHZ-O-C(CH3)3) and the like.
"Alkylthioalkoxy" refers to the group "-alkylene-S-alkyl" wherein alkylene and alkyl are as defined above. Such groups include, by way of example, methylthiomethoxy (-CHZSCH3), ethylthiomethoxy (-CHZCHZSCH3), n-propyl-iso-thiopropoxy (-CHZCHZCHZSCH(CH3)2), methylthio-t-butoxy (-CHZSC(CH3)3) and the like.
"Alkenyl" refers to alkenyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of aikenyl unsaturation. Preferred alkenyl groups include ethenyl (-CH=CH2), n-propenyl (-CHZCH=CHZ), iso-propenyl (-C(CH3)=CHz), but-2-enyl (-CHZCH=CHCH3), and the like.
"Substituted alkenyl" refers to an alkenyl group as defined above having from 1 to 3 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, amino, aminoacyl; aminocarboxy esters, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, cycloalkyl, oxyacyl, oxyacylamino, thiol, thioalkoxy, substituted thioalkoxy, aryl, heteroaryl, heterocyclic, vitro, and mono- and di-~lkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroaryIamino, mono-and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic.
"Alkynyl" refers to alkynyl groups preferably having from 2 to 10 carbon atoms and more preferably 2 to 6 carbon atoms and having at least 1 and preferably from 1-2 sites of alkynyl unsaturation. Preferred alkynyl groups include ethynyl (-CH ~ CHI, propargyl (-CHZC = CH) and the like.
"Substituted alkynyl" refers to an alkynyl group as defined above having from 1 to 3 substituents selected from the group consisting of alkoxy, substituted alkoxy, acyl, acylamino, amino, aminoacyl, aminocarboxy esters, cyano, halogen, hydroxyl, carboxyl, carboxylalkyl, cycloalkyl, oxyacyl, oxyacylamino, thiol, thioalkoxy, substituted thioalkyoxy, aryl, heteroaryl, heterocyclic, nitro, and mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono-and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic.
"Acyl" refers to the groups alkyl-C(O)-, substituted alkyl-C(O)-, cycloalkyl-C{O)-, aryl-C(O)-, heteroaryl-C(O)- and heterocyclic-C(O)- where alkyl, substituted alkyl, cycloalkyI, aryl, heteroaryl and heterocyclic are as defined herein.
"Acylamino" refers to the group -C(O)NRR where each R is independently hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
"Aminoacyl" refers to the group -NRC(O)R where each R is independently hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.

WO 98122494 PCT/L1S97l20804 __ ~ 1 __ "Oxyacyl" refers to the groups -OC(O)-alkyl, -OC(O)-aryl, -C(O)O-heteroaryl-, and -C(O)O-heterocyclic where alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
"Oxyacylamino" refers to the groups -OC(O)NR-alkyl, -OC(O)NR-substituted alkyl, -OC(O)NR-aryl, -OC(O)NR-heteroaryl-, and -OC(O)NR-heterocyclic where R is hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
"Aminocarboxy esters" refers to the groups -NRC(O)O-alkyl, -NRC(O)O-substituted alkyl, -NRC(O)O-aryl, -NRC(O)O-heteroaryl, and -NRC(O)O-heterocyclic where R is hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl, and heterocyelic and where each of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic are as defined herein.
"Aryl" refers to an unsaturated aromatic carbocyclic group of from 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). Preferred aryls include phenyl, naphthyl and the like.
Unless otherwise constrained by the definition for the aryl substituent, such aryl groups can optionally be substituted with from 1 to 5 and preferably to 3 substituents selected from the group consisting of hydroxy, biotinamidyl, acyl, alkyl, aIkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, amino, aminoacyl, aminocarboxy esters, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylalkyl, acylamino, cyano, halo, nitro, heteroaryl, heterocyclic, oxyacyl, oxyacylamino, thioalkoxy, substituted thioaIkoxy, trihalomethyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-__ heteroarylamino, mono- and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic, and the like. Preferred substituents include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy.
"Aryloxy" refers to the group aryl-O- wherein the aryl group is as defined above including optionally substituted aryl groups as also defined above.
The term "carboxy terminal R~ group" refers to that R° group in compounds of formula I which, when n is two, is closest to the X group.
"Carboxyalkyl" refers to the groups -C(O)O-alkyl and -C(O)O-substituted alkyl where alkyl and substituted alkyl are as defined above.
"Cycloalkyl" refers to cyclic alkyl groups of from 3 to 10 carbon atoms having a single cyclic ring or multiple condensed rings which can be optionally substituted with from 1 to 3 alkyl groups. Such cycloalkyl groups include, by way of example, single ring structures such as cyclopropyl, cyclobutyl, cyclopentyl, cyclooctyl, 1-methylcyclopropyl, 2-methylcyclopentyl, 2-methylcyclooctyl, and the like, or multiple ring structures such as adamantanyl, and the like.
"Cycloalkenyl" refers to cyclic alkenyl groups of from 4 to 8 carbon atoms having a single cyclic ring and at least one point of internal unsaturation which can be optionally substituted with from 1 to 3 alkyl groups. Examples of suitable cycloalkenyl groups include, for instance, cyclobut-2-enyl, cyclopent-enyl, cyclooct-3-enyl and the like.
"Halo" or "halogen" refers to fluoro, chloro, bromo and iodo and preferably is either chloro or bromo.

__ "Heteroaryl" refers to a monovalent aromatic group of from 2 to 10 carbon atoms and 1 to 4 heteroatoms selected from oxygen, nitrogen and sulfur within the ring.
Unless otherwise constrained by the definition for the heteroaryl substituent, such heteroaryl groups can be optionally substituted with 1 to 3 substituents selected from the group consisting of hydroxy, aryl, alkyl, alkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyi, substituted alkynyl, amino, aminoacyl, aminocarboxy esters, alkaryl, aryl, aryloxy, carboxyl, carboxylalkyl, aminoacyl, cyano, halo, nitro, heteroaryl, heterocyclic, oxyacyl, oxyacylamino, thioalkoxy, substituted thioalkoxy, trihalomethyl, mono- and di-alkylamino, mono- and di-{substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono- and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, heteroaryl and heterocyciic, and the like. Preferred substituents include alkyl, alkoxy, halo, cyano, nitro, trihalomethyl, and thioalkoxy.
Such heteroaryl groups can have a single ring (e.g., pyridyl or furyl) or multiple condensed rings (e.g., indolizinyl or benzothienyl). Preferred heteroaryls include pyridyl, pyrrolyl and furyl.
"Heteroaryloxy" refers to the group heteroaryl-O- wherein the heteroaryl group is as defined above including optionally substituted heteroaryl groups as also defined above.
"Heterocycle" or "heterocyclic" refers to a monovalent (i.e., one point of attachment) saturated or unsaturated group having a single ring or multiple condensed rings, from 1 to 8 carbon atoms and from 1 to 4 hetero atoms selected from nitrogen, sulfur or oxygen within the ring.

i I

__ 74 __ Unless otherwise constrained by the definition for the heterocyclic substituent, such heterocyclic groups can be optionally substituted with 1 to substituents selected from the group consisting of hydroxy, acyl, alkyl, alkoxy, alkenyl, alkynyl, substituted alkyl, substituted alkoxy, substituted alkenyl, substituted alkynyl, amino, aminoacyl, aminocarboxy esters, alkaryl, aryl, aryloxy, carboxyl, carboxylalkyl, aminoacyl, cyano, halo, nitro, heteroaryl, heterocyclic, oxyacyl, oxyacylamino, thioalkoxy, substituted thioalkoxy, trihalomethyl, mono- and di-alkylamino, mono- and di-(substituted alkyl)amino, mono- and di-arylamino, mono- and di-heteroarylamino, mono- and di-heterocyclic amino, and unsymmetric di-substituted amines having different substituents selected from alkyl, substituted alkyl, aryl, heteroaryl and heterocyclic, and the like. Such heterocyclic groups can have a single ring or multiple condensed rings. Preferred heteroaryls include morpholino, piperidinyl, and the like.
Examples of heterocycles and heteroaryls include, but are not limited to, furan, thiophene, thiazole, oxazole, pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine, pyridazine, indolizine, isoindole, indole, indazole, purine, quinolizine, isoquinoline, quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline, cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine, phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine, phenothiazine, imidazolidine, imidazoline, piperidine, piperazine, indoline, phthalimide, 1,2,3,4-tetrahydroisoquinoline, 4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiazolidine, thiophene, benzo[b)thiophene, morpholino, piperidinyl, pyrrolidine, tetrahydrofuranyl, and the like.
"Heterocyclyloxy" refers to the group heterocyclyl-O- wherein the heterocyclic group is as defined above including optionally substituted heterocyclic groups as also defined above.

"Oxyacyl" refers to the groups -OC(O)-alkyl, -OC(O)-aryl, -C(O)O-heteroaryl-, and -C(O)O-heterocyclic where alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
"Oxyacylamino" refers to the groups -OC(O)NH-alkyl, -OC(O)NH-substituted alkyl, -OC(O)NH-aryl, -OC(O)Nl~i-heteroaryl-, and -OC(O)NH-heterocyclic where alkyl, aryl, heteroaryl and heterocyclic are as defined herein.
"Thiol" refers to the group -SI-I.
"Thioalkoxy" refers to the group -S-alkyl.
"Substituted thioalkoxy" refers to the group -S-substituted alkyl.
"Thioaryloxy" refers to the group aryl-S- wherein the aryl group is as defined above including optionally substituted aryl groups also defined above.
"Thioheteroaryloxy" refers to the group heteroaryl-S- wherein the heteroaryl group is as defined above including optionally substituted aryl groups as also defined above.
"Pharmaceutically acceptable salt" refers to pharmaceutically acceptable salts of a compound of Formula I which salts are derived from a variety of organic and inorganic counter ions well known in the art and include, by way ___ of example only, sodium, potassium, calcium, magnesium, ammonium, tetraalkylammonium, and the like; and when the molecule contains a basic functionality, salts of organic or inorganic acids, such as hydrochloride, hydrobromide, tartrate, mesylate, acetate, maleate, oxalate and the like.

i I

__ compound Preparation The compounds of formula I are readily prepared via several divergent synthetic routes with the particular route selected relative to the ease of compound preparation, commercial availability of starting materials, etc.
A first synthetic method involves conventional coupling of an acetic acid derivative with a primary amine of an esterified amino acid as shown in reaction (1) below:
X. O 0 X" QH + ZN XR3 ----.
R~ RZ

(1) X' X" 0 H
N
R XRs wherein R', Rz, R3, X' and X" are as defined above, and X is either oxygen or _.
Reaction (1) merely involves coupling of a suitable acid derivative _1 with the primary amine of amino acid ester 2_ under conditions which provide for the N-acetyl derivative 3_. This reaction is conventionally conducted for -- ~7 __ peptide synthesis and synthetic methods used therein can also be employed to prepare the N-acetyl amino acid esters ~ of this invention. For example, well known coupling reagents such as carbodiirnides with or without the use of well known additives such as N-hydroxysuccinimide, 1-hydroxybenzotriazole, etc.
can be used to facilitate coupling. The reaction is conventionally conducted in an inert aprotic diluent such as dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like. Alternatively, the acid halide of compound 1 can be employed in reaction ( 1 ) and, when so employed, it is typically employed in the presence of a suitable base to scavenge the acid generated during the reaction. Suitable bases include, by way of example, triethylamine, diisopropylethylamine, N-methylmorpholine and the like.
Reaction (I) is preferably conducted at from about 0°C to about 60°C
until reaction completion which typically occurs within 1 to about 24 hours.
Upon reaction completion, N-acetyl amino acid ester 3 is recovered by conventional methods including precipitation, chromatography, filtration and the like or alternatively is hydrolyzed to the corresponding acid without purification and/or isolation other than conventional work-up (e.g., aqueous extraction, etc.). Alternatively, the synthesis described above in reaction (1) can be conducted on the amino acid (XR' = OH) and subsequent to N-acetyl formation as described above.
In any event, if an N-acetyl amino acid ester is formed, it is converted to the corresponding acid prior to the coupling step with another amino acid ester/amide, HNR3CR'RSC(O)Y. Coupling is accomplished using well known peptide coupling chemistry with well known coupling reagents such as carbodiimides with or without the use of well known additives such as N-hydroxysuccinimide, 1-hydroxybenzotriazole, etc. which can be used to facilitate coupling. The reaction is conventionally conducted in an inert aprotic polar diluent such as dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like.

__ ~g __ Such coupling yields compounds of formula I where n is 1. The synthesis of compounds of formula I where n is 2 is accomplished via a second coupling reaction. Specifically, in the first coupling reaction, HNR'CR°RSC(O)Y is selected to be an amino acid ester. That is to say that Y
is -O-alkyl. After coupling, the ester is hydrolyzed via conventional conditions well known in the art to provide for the corresponding carboxylic acid which can now be used to couple a second amino acid ester/amide.
In reaction (1), each of the reagents (compound 1 and amino acid ester 2) are well known in the art with a plurality of each being commercially available.
Alternatively, the compounds of formula I can be prepared by first forming the dipeptide ester and then N-acylating these esters. That is to say that the amino acid ester or amide HNR3CR'RSC(O)Y is coupled to the N-blocked amino acid BlockNHCHRzCOOH via conventional coupling conditions to provide for the dipeptide BlockNHCHRZC(O)N(R3)CR°RSC(O)Y.
The blocking group is then removed via conventional conditions to provide for the free amine which is then N-acylated in the manner described above to provide for the compounds of formula I.
After coupling and N-acylation (in whatever order) is complete, the resulting esters and amides can be derivatized via conventional chemistry to provide for derivatives of the synthesized compounds. For example, conventional reduction of a terminal ester group with lithium borohydride leads --- to the terminal -CHZOH group. Alternatively, an ester group can be converted to a primary amide [-C(O)NHZ) by reaction with ammonia in methanol with a catalytic amount of sodium cyanide while heating.
Similarly, reactive functionality which is blocked on either RZ and/or R3 groups can be deblocked and then derivatized. For example, the a BOC

__ protected amino group on R3 (e.g., lysine side chain) can be deblocked after synthesis and the amino group acylated or otherwised derivatized.
Additionally, a terminal ester can be subjected to transesterification techniques to provide for other esters. Numerous techniques are known in the art to effect transesterification and each technique merely replaces one ester group with a different ester group derived from the corresponding alcohol or thioalcohol and, in some cases, a catalyst such as titanium (IV) iso-propoxide is used to facilitate reaction completion. In one technique, the alcohol or thioalcohol is first treated with sodium hydride in a suitable diluent such as toluene to form the corresponding sodium alkoxide or thioalkoxide which is then employed to effect transesterification. The efficiency of this technique makes it particularly useful with high boiling and/or expensive alcohols or thioalcohols.
In another transesterification technique, the ester to be transesterified is placed in a large excess of the alcohol or thioalcohol which effects trans-esterification. A catalytic amount of sodium hydride is then added and the reaction proceeds quickly under conventional conditions to provide the desired transesterified product. Because this protocol requires the use of a large excess of alcohol or thioalcohol, this procedure is particularly useful when the alcohol or thioalcohol is inexpensive.
Transesterification provides a facile means to provide for a multiplicity of different ester substituents on the compounds of formula I above. In all cases, the alcohols and thioalcohols employed to effect transesterification are well known. in the art with a significant number being commercially available.
ZS Other methods for preparing the esters of this invention include, by way of example, first hydrolyzing the ester to the free acid followed by O-alkylation with a halo-R3 group in the presence of a base such as potassium carbonate.

Alternatively, for esterification procedures for alcohols containing an ester group can be achieved by using the methods of Losse, et aL"
The compounds described herein can also be prepared by use of polymer supported forms of carbodiimide peptide coupling reagents. A polymer supported form of EDC, for example, has been described (Tetrahedron Letters, 34(48), 7685 (1993))'°. Additionally, a new carbodiimide coupling reagent, - PEPC, and its corresponding polymer supported forms have been discovered and are very useful for the preparation of the compounds of the present invention.
Polymers suitable for use in making a polymer supported coupling reagent are either commercially available or may be prepared by methods well known to the artisan skilled in the polymer arts. A suitable polymer must possess pendant sidechains bearing moieties reactive with the terminal amine of the carbodiimide. Such reactive moieties include chloro, bromo, iodo and methanesulfonyl. Preferably, the reactive moiety is a chloromethyl group.
Additionally, the polymer's backbone must be inert to both the carbodiimide and reaction conditions under which the ultimate polymer bound coupling reagents will be used.
Certain hydroxymethylated resins may be converted into chloromethylated resins useful for the preparation of polymer supported coupling reagents. Examples of these hydroxylated resins include the 4-hydroxymethyl-phenylacetamidomethyl resin (Pam Resin) and 4-benzyloxybenzyl alcohol resin (Wang Resin) available from Advanced Chemtech of Louisville, Kentucky, USA (see Advanced Chemtech 1993-1994 catalog, page 115). The hydroxymethyl groups of these resins may be converted into the desired chloromethyl groups by any of a number of methods well known to the skilled artisan.

__ 81 __ Preferred resins are the chloromethylated styrene/divinylbenzene resins because of their ready commercial availability. As the name suggests,-these resins are already chloromethylated and require no chemical modification prior to use. These resins are commercially known as Merrifield's resins and are available from Aldrich Chemical Company of Milwaukee, Wisconsin, USA (see Aldrich 1994-1995 catalog, page 899). Methods for the preparation of PEPC
and its polymer supported forms are outlined in the following scheme.
NCO o/~
IizN~N
----~ ~IN,I~H~\/~N
O
~~CI
/ ~ ~O
~N=C -N
LG
Functionalized Resin where ~ = an inert polymer and LG = Ci, Br, I or OSOiCH~
N+' ~ 'N-C -N~
PO~ Clv V' Such methods are described more fully in U.S. Patent Application Serial No. 60/019,790 filed June 14, 1996 which application is incorporated herein by reference in its entirety. Briefly, PEPC is prepared by first reacting ethyl isocyanate with 1-(3-aminopropyl)pyrrolidine. The resulting urea is treated with 4-toluenesulfonyl chloride to provide PEPC. The polymer supported form is prepared by reaction of PEPC with an appropriate resin under standard conditions to give the desired reagent.

WO 98!22494 PCTlUS97/20804 __ g2 __ The carboxylic acid coupling reactions employing these reagents are performed at about ambient temperature to about 45°C, for from about 3 to 120 hours. Typically, the product may be isolated by washing the reaction with CHC13 and concentrating the remaining organics under reduced pressure. As discussed supra, isolation of products from reactions where a polymer bound reagent has been user! is greatly simplified, requiring only filtration of the reaction mixture and then concentration of the filtrate under reduced pressure.
Still other methods for the preparation of esters are provided in the examples below.
Compounds where X is -CR6R6Y' are readily prepared by coupling, e.g., an amino alcohol H2NCR'~RSCR6R°OH, to the carboxyl group of R'ZCX'X"C(O)NHCHRZC(O)OH under standard coupling conditions well known in peptide coupling chemistry which can use well known coupling reagents such as carbodiimides with or without the use of well known additives such as N-hydroxysuccinimide, 1-hydroxybenzotriazole, etc. If necessary, well known blocking groups on Y' can be employed to protect the group during coupling. Such blocking groups are particularly desirable when Y' is an amino group.
The reaction is conventionally conducted in an inert aprotic polar diluent such as dimethylformamide, dichloromethane, chloroform, acetonitrile, tetrahydrofuran and the like. Upon reaction completion, any blocking groups on Y' are selectively removed to provide for the desired compound.
When Y' is -OH or -SH, post-synthetic conversion of these groups to the corresponding esters (i.e., -OC(O)R'), disulfides (i.e., -SSR') and -SSC(O)R' groups is accomplished using well known chemistry. For example, ester synthesis requires only reaction with a suitable acid such as acetic acid (R' -_ g3 __ = methyl), acid halide (e.g., acid chloride) or acid anhydride under suitable esterification conditions.
When one of R6 is hydrogen, post-synthetic oxidation of the -CHR60H group leads to the ketone derivatives. Alternatively, such ketones S can be prepared by coupling the suitable aminoketone HCl salt with the terminal carboxyl group of the amino acid as illustrated in Example 168 below.
In these synthetic methods, the starting materials can contain a chiral center (e.g., alanine) and, when a racemic starting material is employed, the resulting product is a mixture of R,S enatiamers. Alternatively, a chiral isomer of the starting material can be employed and, if the reaction protocol employed does not racemize this starting material, a chiral product is obtained. Such reaction protocols can involve inversion of the chiral center during synthesis.
Accordingly, unless otherwise indicated, the products of this invention are a mixture of R,S enatiomers or diasteriomers. Preferably, however, when a chiral product is desired, the chiral product corresponds to the L-amino acid derivative. Alternatively, chiral products c;an be obtained via purification techniques which separate enatiomers from a R,S mixture to provide for one or the other stereoisomer. Such techniques are well known in the art.
Pharmaceutical Formulations When employed as pharmaceut~caIs, the compounds of formula I are usually administered in the form of pharmaceutical compositions. These compounds can be administered by a variety of routes including oral, rectal, transdermal, subcutaneous, intravenous, intramuscular, and intranasal. These compounds are effective as both injectable and oral compositions. Such compositions are prepared in a manner well known in the pharmaceutical art and comprise at least one active compound.

__ g4 __ This invention also includes pharmaceutical compositions which contain, as the active ingredient, one or more of the compounds of formula I above associated with pharmaceutically acceptable carriers. In making the compositions of this invention, the active ingredient is usually mixed with an excipient, diluted by an excipient or enclosed within such a carrier which can be in the form of a capsule, sachet, paper or other container. When the excipient serves as a diluent, it can be a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, suppositories, sterile injectable solutions, and sterile packaged powders.
In preparing a formulation, it may be necessary to mill the active compound to provide the appropriate particle size prior to combining with the other ingredients. If the active compound is substantially insoluble, it ordinarily is milled to a particle size of less than 200 mesh. If the active compound is substantially water soluble, the particle size is normally adjusted by milling to provide a substantially uniform distribution in the formulation, e.g. about 40 mesh.
Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose.
The formulations can additionally include: lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl- and propylhydroxy-benzoates; sweetening agents; and flavoring agents. The compositions of the invention can be formulated so as to provide quick, sustained or delayed release __ 85 __ of the active ingredient after administration to the patient by employing procedures known in the art.
The compositions are preferably formulated in a unit dosage form, each dosage containing from about 5 to about 100 mg, more usually about 10 to about 30 mg, of the active ingredient. The term "unit dosage forms" refers to physically discrete units suitable as unitary dosages for human subjects and other mammals, each unit containing a predetermined quantity of active material calculated to produce the desired therapeutic effect, in association with a suitable pharmaceutical excipient. Preferably, the compound of formula I
above is employed at no more than about ~0 weight percent of the pharmaceutical composition, more preferably no more than about 15 weight percent, with the balance being pharmaceutically inert carrier(s).
The active compound is effective over a wide dosage range and is generally administered in a pharmaceutically effective amount. It, will be understood, however, that the amount of the compound actually administered will be determined by a physician, in the light of the relevant circumstances, including the condition to be treated, the chosen route of administration, the actual compound administered, the age, weight, and response of the individual patient, the severity of the patient's symptoms, and the like.
For preparing solid compositions such as tablets, the principal active ingredient is mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of the present invention. When referring to these preformulation compositions as homogeneous, it is meant that the active ingredient is dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.
This solid preformulation is then subdivided into unit dosage forms of the type I

__ g6 __ described above containing from, for example, 0.1 to about S00 mg of the active ingredient of the present invention.
The tablets or pills of the present invention may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action. For example, the tablet or pill can comprise an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can separated by enteric layer which serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.
The liquid forms in which the novel compositions of the present invention may be incorporated for administration orally or by injection include aqueous solutions suitably flavored syrups, aqueous or oil suspensions, and flavored emulsions with edible oils such as cottonseed oil, sesame oil, coconut oil, or peanut oil, as well as elixirs and similar pharmaceutical vehicles.
Compositions for inhalation or insufflation include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. Preferably the compositions are administered by the oral or nasal respiratory route for local or systemic effect. Compositions in preferably pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be breathed directly from the nebulizing device or the nebulizing device may be attached to a face masks tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder compositions may be administered, __ g~ __ preferably orally or nasally, from device:~ which deliver the formulation in an appropriate manner.
The following formulation examples illustrate the pharmaceutical compositions of the present invention.
Formulation 'Example 1 Hard gelatin capsules containing the following ingredients are prepared:
Quantity In rg edient (m /g-capsule) Active Ingredient 30.0 Starch 305.0 Magnesium stearate 5.0 The above ingredients are mixed and filled into hard gelatin capsules in 340 mg quantities.
Formulation E,xamnle 2 A tablet formula is prepared using l:he ingredients below:
Quantity Ingredient m /tablet Active Ingredient 25.0 Cellulose, microcrystalline 200.0 Colloidal silicon dioxide 10.0 Stearic acid 5.0 The components are blended and compressed to form tablets, each weighing 240 mg.
Formulation Example 3 A dry powder inhaler formulation is prepared containing the following components:

__ gg __ Ingredient Weight Active Ingredient 5 Lactose 95 The active ingredient is mixed with the lactose and the mixture is added to a dry powder inhaling appliance.
Formulation Example 4 Tablets, each containing 30 mg of active ingredient, are prepared as follows:
Quantity Ingredient . (m /g tablet) Active Ingredient 30.0 mg Starch 45.0 mg Microcrystalline cellulose 35.0 mg Polyvinylpyrrolidone I5 (as 10 % solution in sterile water) 4.0 mg Sodium carboxymethyl starch 4.5 mg Magnesium stearate 0.5 mg Talc 1.0 m~

Total 120 mg The active ingredient, starch and cellulose are passed through a No. 20 mesh U.S. sieve and mixers thoroughly. The solution of polyvinyl-pyrrolidone is mixed with the resultant powders, which are then passed through a 16 mesh U.S. sieve. The granules so produced are dried at 50° to 60°C and passed through a 16 mesh U.S. sieve. The sodium carboxymethyl starch, magnesium stearate, and talc, previously passed through a No. 30 mesh U.S. sieve, are then adders to the granules which, after mixing, are compressed on a tablet machine to yield tablets each weighing 150 mg.
Formulation Example 5 Capsules, each containing 40 mg of medicament are made as follows:

__ g9 __ n redien (mg/cansul_el Active Ingredient 40.0 mg Starch 109.0 mg Magnesium stearate 1~
Total 150.0 mg The active ingredient, starch, and magnesium stearate are blended, passed w through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in mg quantities.
Formulation Example 6 Suppositories, each containing 25 mg of active ingredient are made as follows:
Ingredient Am unt Active Ingredient 25 mg Saturated fatty acid glycerides to 2,000 mg The active ingredient is passed through a No. 60 mesh U.S. sieve and suspended in the saturated fatty acid glycendes previously melted using the minimum heat necessary. The mixture is then poured into a suppository mold of nominal 2.0 g capacity and allowed to cool.
Formulation Example 7 Suspensions, each containing 50 mg of medicament per 5.0 ml dose are made as follows:

i Ineredient Amoun Active Ingredient 50.0 mg Xanthan gum 4.0 mg Sodium carboxymethyl cellulose (11 ~) Microcrystalline cellulose (89%) 50.0 mg Sucrose 1.75 g Sodium benzoate 10.0 mg Flavor and Color q.v.

Purified water to 5.0 ml The active ingredient, sucrose and xanthan gum are blended, passed through a No. 10 mesh U.S. sieve, and then mixed with a previously made solution of the microcrystalline cellulose and sodium carboxymethyl cellulose in water. The sodium benzoate, flavor, and color are diluted with some of the water and added with stirring. Sufficient water is then added to produce the required volume.
Formulation Example 8 Quantity In reg diem (mg_/capsule) Active Ingredient 15.0 mg Starch 407.0 mg Magnesium stearate 3.0 m~
Total 425.0 mg The active ingredient, starch, and magnesium stearate are blended, passed through a No. 20 mesh U.S. sieve, and filled into hard gelatin capsules in 560 25mg quantities.
Formulation Example 9 A subcutaneous formulation may be prepared as follows:
Ingredient uantit Active Ingredient 5.0 mg corn oil 1 ml Formulation Eixample 10 A topical formulation may be ;prepared as follows:
n r ien a ti Active Ingredient 1-10 g Emulsifying Wax 30 g Liquid Paraffin 20 g White Soft Paraffin to 100 g The white soft paraffin is heated until molten. The liquid paraffin and emulsifying wax are incorporated and stirred until dissolved. The active ingredient is added and stirring is continued until dispersed. The mixture is then cooled until solid.
Another preferred formulation employed in the methods of the present invention employs transdermal delivery de~rices ("patches"). Such transdermal patches may be used to provide continuous or discontinuous infusion of the compounds of the present invention in conorolled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. See. e.~., U.S. Patent 5,023,252, issued June 11, 1991, herein incorporated by reference. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.
Frequently, it will be desirable or necessary to introduce the pharmaceutical composition to the brain, either directly or indirectly. Direct techniques usually involve placement of a drug delivery catheter into the host's ventricular system to bypass the blood-brain barrier. (ire such implantable delivery system used for the transport of biological factors to specific anatomical regions of the body is described in U.S. Patent 5,011,472 which is herein incorporated by reference.
Indirect techniques, which are generally preferred, usually involve formulating the compositions to provide for drug latentiation by the conversion __ 92 __ of hydrophilic drugs into lipid-soluble drugs. Latentiation is generally achieved through blocking of the hydroxy, carbonyl, sulfate, and primary amine groups present on the drug to render the drug more lipid soluble and amenable to transportation across the blood-brain barrier. Alternatively, the delivery of hydrophilic drugs may be enhanced by infra-arterial infusion of hypertonic solutions which can transiently open the blood-brain barrier.
-_ _ Other suitable formulations for use in the present invention can be found in Remington's Pharmaceutical Sciences, Mace Publishing Company, Philadelphia, PA, 17th ed. (1985).
Ut~ ilitv The compounds and pharmaceutical compositions of the invention are useful in inhibiting /3-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease in mammals including humans.
As noted above, the compounds described herein are suitable for use in a variety of drug delivery systems described above. Additionally, in order to enhance the in vivo serum half-life of the administered compound, the compounds may be encapsulated, introduced into the lumen of liposomes, prepared as a colloid, or other conventional techniques may be employed which provide an extended serum half-life of the compounds. A variety of methods are available for preparing tiposomes, as described in, e.g., Szoka, et al., U.S.
Patent Nos. 4,235,871, 4,501,728 and 4,837,028 each of which is incorporated herein by reference.
The amount of compound administered to the patient will vary depending upon what is being administered, the purpose of the administration, such as prophylaxis or therapy, the state of the patient, the manner of administration, and the Like. In therapeutic applications, compositions are administered to a patient already suffering from AD in an amount sufficient to at least partially arrest further onset of the symptoms of the disease and its complications. An amount adequate to accomplish this is defined as "therapeutically effective dose." Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the degree or severity of AD
in the patient, the age, weight and general condition of the patient, and the like.
Preferably, for use as therapeutics, the compounds described herein are administered at dosages ranging from about 1 to about S00 mg/kg/day.
In prophylactic applications, compositions are administered to a patient at risk of developing AD (determined for example by genetic screening or familial trait) in an amount sufficient to inhibit the onset of symptoms of the disease.
An amount adequate to accomplish this is defined as "prophylactically effective dose." Amounts effective for this use will depend on the judgment of the attending clinician depending upon factors such as the age, weight and general condition of the patient, and the like. Preferably, for use as prophylactics, the compounds described herein are administered at dosages ranging from about 1 to about S00 mg/kg/day.
As noted above, the compounds administered to a patient are in the form of pharmaceutical compositions described above. These compositions may be sterilized by conventional sterilization techniques, or may be sterile filtered.
The resulting aqueous solutions may be packaged for use as is, or lyophilized, the lyophilized preparation being combined with a sterile aqueous carrier prior to administration. The pH of the compound preparations typically will be between 3 and 11, more preferably from S to 9 and most preferably from 7 and 8. It will be understood that use of certain of the foregoing excipients, carriers, or stabilizers will result in the formation of pharmaceutical salts.
The following synthetic and biological examples are offered to illustrate this invention and are not to be construed i;n any way as limiting the scope of !I

this invention. Unless otherwise stated, all temperatures are in degrees Celsius.
EXAMPLES
In the examples below, the following abbreviations have the following meanings. If an abbreviation is not defined, it has its generally accepted meaning.

BOC - ten-butoxycarbonyl BOP - benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate bd - broad doublet bs - broad singlet c - concentration (g/mL) CDI - l , l'-carbonyldiimidazole d - doublet dd - doublet of doublets DCM - dichloromethane DEAD - diethyl azodicarboxylate DMF - dimethylformamide DMSO - dimethylsulfoxide EDC - 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride EEDQ - 2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline eq. - equivalents EtOAc - ethyl acetate EtOH - ethanol g - grams L - liter m - multiplet max - maximum MeOH - methanol meq - milliequivalent mg - milligram mL - milliliter mm - millimeter mmol - millimole N/A - not available N - normal ng - nanogram nm - nanometers OD - optical density ~ - phenyl PEPC - 1-(3-( 1-pyrrolidinyl)propyl)-3-ethylcarbodiimide psi - pounds per square inch q - quartet _ __ g5 __ quint. - quintet rpm - rotations per minute s - singlet t - triplet TFA - trifluoroacetic acid THF - tetrahydrofuran tlc - thin layer chromatography ~cL - microliter UV - ultraviolet In the examples below, all temperatures are in degrees Celcius (unless otherwise indicated) and each of the compounds set forth in these examples was prepared by one of the following general procedures, unless otherwise indicated.
Additionally, the term "Aldrich" indicates that the compound or reagent used in the following procedures is commercially available from Aldrich Chemical Company, Inc., 1001 West Saint Paul Avenue, Milwaukee, WI 53233 USA; the term "Fluka" indicates that the compound or reagent is commercially available from Fluka Chemical Corp., 98(1 South 2nd Street, Ronkonkoma NY
11779 USA; the term "Lancaster" indicates that the compound or reagent is commercially available from Lancaster Synthesis, Inc., P.O. Box 100 Windham, NH 03087 USA; the term "Sigma" indicates that the compound or reagent is commercially available from Sil;ma, P.O. Box 14508, St. Louis MO
63178 USA; the term "Chemservice" indicates that the compound or reagent is commercially available from Chemservice Inc., Westchester, PA; the term "Bachem" indicates that the compoued or :reagent is commercially available from Bachem Biosciences Inc., 3700 Hori;~on Drive, Renaissance at Gulph Mills, King of Prussia, PA 19406 USA; the term "Maybridge" indicates that the compound or reagent is commercially available from Maybridge Chemical Co. Trevillett, Tintagel, Cornwall PL34 OHW United Kingdom; and the term "TCI" indicates that the compound or reagent is commercially available from TCI America, 9211 North Harborgate Street, Portland OR 97203; the term "Alfa" indicates that the compound or reagent is commercially available from WO 98!22494 PCT/US97/20804 Johnson Matthey Catalog Company, Inc. 30 Bond Street, Ward Hill, MA
01835-0747; the term "Novabiochem" indicates that the compound or reagent is commercially available from Calbiochem-Novabiochem Corp. 10933 North Torrey Pines Road, P.O. Box 12087, La Jolla CA 92039-2087; the term "Oakwood" indicates that the compound or reagent is commercially available from Oakwood, Columbia, South Carolina; the term "Advanced Chemtech"
indicates that the compound or reagent is commercially available-from Advanced Chemtech, Louisville, KY; and the term "Pfaltz & Bauer" indicates that the compound or reagent is commercially available from Pfaltz & Bauer, Waterbury, CT, USA.
The following General Procedures A'-P' and Examples A1-A74 illustrate the synthesis of N (aryl/heteroarylacetyi)amino acid esters which can be hydrolyzed to provide for N (aryl/heteroarylacetyl)amino acid starting materials of this invention. Other N (aryl/heteroarylacetyl)amino acid esters can be prepared using these procedures from commerically available or known starting material s .
GENERAL PROCEDURE A' Couplin~~of R'ClX')(X")Cf0)Cl with H~NCHIR~nC(OZXR3 To a stirred solution of (D,L)-alanine iso-butyl ester hydrochloride (from Example B below) (4.6 mmol) in 5 mL of pyridine was added 4.6 mmol of an acid chloride. Precipitation occurred immediately. The mixture was stirred for 3.5 h, diluted with 100 mL of diethyl ether, washed with 10% HCl three times, brine once, 20% potassium carbonate once and brine once. The solution was dried over magnesium sulfate, filtered, and evaporated at reduced pressure to yield the product. Other amino acid esters may also be employed in this procedure.

_- 97 __ GENERAL PROCEDURE B' Coupling of R' '?fX"~~H with H~NCHlR2)CfC))XR' A solution of the acid (3.3 mmol) and CDI in 20 mL THF was stirred for 2 h. L-alanine iso-butyl ester hydrochloride (from Example B below) (3.6 mmol) was added, followed by 1.5 mL ( 10. 8 mmol) of triethylamine. The reaction mixture was stirred overnight. 7ifie reaction mixture was diluted with 100 mL of diethyl ether, washed with 10% HCl three times, brine once, 20%
potassium carbonate once and brine once. The solution was dried over magnesium sulfate, filtered, and evaporated at reduced pressure to yield the product. Other amino acid esters may also be employed in this procedure.
GENERAL PRCICEDURE C' Esterification of R'C(X')(X"~NHCHlR2)C(O)OH With HORS
To a stirred solution of phenylacetylvaline (1.6470 g, 7.0 mmol) in 20 mL
THF was added CDI (1.05 g, 6.5 mmol) and the mixture was stirred for 1.5 h.
2-Methylbutanol (0.53 g, 6 mmol) was added the mixture, followed by addition of NaH (0.16 g, 6.5 mmol). Bubbling occurred immediately. The reaction mixture was stirred overnight. The reacti~~n mixture was diluted with 100 mL
of diethyl ether, washed with 10% HCl three times, brine once, 20°l potassium carbonate once and brine once. The solution was dried over magnesium sulfate, filtered, and evaporated at reduced pressure to yield the product.
Other N-acyl amino acids and alcohols may also be employed in this procedure.
GENERAL PROCEDURE D' Ester Hydrol sy is to the Free Acid Ester hydrolysis to the free acid was conducted by conventional methods.
Below are two examples of such conventional de-esterification methods.
To the ester in a 1:1 mixture of CH,OH/Hz0 was added 2-5 equivalents of KZCO,. The mixture was heated to about ~i0°C for about 0.5 to 1.5 hours until tlc showed complete reaction. The reaction was cooled to room temperature __ 9g __ and the methanol was removed at reduced pressure. The pH of the remaining aqueous solution was adjusted to about 2, and ethyl acetate was added to extract the product. The organic phase was then washed with saturated aqueous NaCI
and dried over MgSO,. The solution was stripped free of solvent at reduced pressure to yield the product.
The amino acid ester was dissolved in dioxane/water (4:1) to which was added LiOH (-2 eq.) that was dissolved in water such that the total solvent after addition was about 2:1 dioxane: water. The reaction mixture was stirred until reaction completion and the dioxane was removed under reduced pressure.
The residue was diluted with EtOAc, the layers were separated and the aqueous layer acidified to pH 2. The aqueous layer was back extracted with EtOAc, the combined organics were dried over Na2S04 and the solvent was removed under reduced pressure after filtration. The residue was purified by conventional methods {e.g., recrystallization).
The following exemplifies this later example. The methyl ester of 3-NOz phenylacetyl alanine 9.27 g (0.0348 mots) was dissolved in 60 mL dioxane and 15 mL of H,O and adding LiOH (3.06 g, 0.0731 moI) that has been dissolved in 15 mL of HZO. After stirring for 4 hours, the dioxane was removed under reduced pressure and the residue diluted with EtOAc, the layers were separated and the aqueous layer acidified to pH 2. The aqueous layer was back extracted with EtOAc (4 X 100 mL), the combined organics were dried over Na2S04 and the solvent was removed under reduced pressure after filtration. The residue was recrystallized from EtOAc/isooctane giving 7.5 g (85%) of 3-nitrophenylacetyl alanine. C"H,zN205 requires C = 52.38, H = 4.80, and N
- 11.11. Analysis found C = 52.54, H = 4.85, and N = 11.08. [a]23 =
- 29.9 Qa 589 nm.

GENERAL PROCEDURE E' I.ow Temperature BOP nur,linQ of Acid aid Alcohol A solution of methylene chloride containing the carboxylic acid (100Mh) and N-methyl morpholine (150 M % ) was cooled to -20 ° C under nitrogen.
S BOP ( 105 M % ) was added in one portion and the reaction mixture was maintained at -20°C for 15 minutes. The corresponding alcohol (120 M%) was added and the reaction mixture was allowed to warm to room temperature and stirred for 12 hours. The reaction mixture was then poured into water and extracted with ethyl acetate (3x). The combined ethyl acetate portions were backwashed with saturated aqueous citric acid (2x), saturated aqueous sodium bicarbonate (2x), brine (lx), dried over anhydrous magnesium sulfate or sodium sulfate and the solvent removed under reduced pressure to yield the crude product.
GENERAL PROCEDURE F' EDC Coupling of Acid and Amine The acid derivative was dissolved in m~ethylene chloride. The amine {1 eq.), N-methylmorpholine (5 eq.), and hydroxybenzotriazole monohydrate (1.2 eq.) were added in sequence. The reacaion was cooled to about 0°C
and then 1.2 eq. of 1-(3-dimethylaminopropyl}-:3-ethylcarbodiimide hydrochloride was added. The solution was allowed to stir overnight and come to room temperature under N, pressure. The reaction mix was worked up by washing the solution with saturated, aqueous Na2C0" O.1M citric acid, and brine before drying with Na:SO, and removal of solvents to yield crude product. Pure products were obtained by flash chromatography in an appropriate solvent.
GENERAL PROCIEDURE G' EDC Coup og f Acid and Amine A round bottom flask was charged with carboxylic acid (1.0 eq.), hydroxy-benzotriazole hydrate (1.1 eq.) and amine (I.0 eq.) in THF under nitrogen atmosphere. An appropriate amount (1.1 eq, for free amines and 2.2 eq. for __ lpp __ hydrochloride amine salts) of base, such as Hunig's base was added to the well stirred mixture followed by EDC (1.1 eq.). After stirring from 4 to 17 hours at room temperature the solvent was removed at reduced pressure, the residue taken up in EtOAc (or similar solvent)/water. The organic layer was washed with saturated aqueous sodium bicarbonate solution, 1N HCI, brine and dried over anhydrous sodium sulfate. In some cases, the isolated product was analytically pure at this stage while, in other cases, purification via chromatography and/or recrystallization was required prior to biological evaluation.
GENERAL PROCEDURE H' CouQling of R'ClX'~X"lCfO)C1 with H~NCHfRz)CfO
An excess of oxalyl chloride in dichloromethane was added to the acid derivative together with one drop of DMF. The resulting mixture was stirred for about 2 hours or until bubbling ceases. The solvent was then removed under reduced pressure and rediluted with dry methylene chloride. To the resulting solution was added about 1.1 eq. of the appropriate amino acid ester and triethylamine (1.1 eq. in methylene chloride). The system was stirred at room temperature for 2 hours and then the solvent was removed under reduced pressure. The residue was dissolved in ethyl acetate, washed with 1N HCl followed by 1N NaOH. The organic layer was dried over anhydrous soldium sulfate, filtered and the solvent removed under reduced pressure to provide for the desired product.
GENERAL PROCEDURE I' P-EPC coupling P-EPC coupling employs an amino acid ester and a substituted acetic acid compound. The acetic acid derivative is well known in the art and is typically commercially available. The amino acid ester is prepared by conventional methods from the known and typically commercially available N-BOC amino acid as described in GENERAL PROCEDURE 1' below.

Specifically, the appropriate amino ester free base (0.0346 mmols) and substituted phenylacetic acid (0.069 mmols) were dissolved in 2.0 mL CHCl3 (EtOH free), treated with 150 mg of P-EPC (0.87 meq./g) and the reaction was mixed for 4 days at 23°C. The reaction was filtered through a plug of cotton, rinsed with 2.0 mL of CHCl3 and the filb~te evaporated under a stream of nitrogen. The purity of each sample was determined by 'H NMR and ranged from 50 % to > 95 % . Between 8.0 and 15.0 mg of final product was obtained from each reaction and was tested without additional purification.
GENERAL PRt)CEDURE J' S_Ynthesis of Amino Acid Esters From th~~ Corresponding N-BOC Amino Acid A. Esterification of the Acid.
The N-BOC amino acid was dissolved in dioxane and treated with an excess of alcohol (-1.5 eq.) and catalytic DMAP (100 mg) at 0°C.
Stirring was continued until reaction completion whereupon the product was recovered by conventional methods.
B. Removal of N-BOC Group.
The N-BOC protected amino acid was dissolved in methylene chloride (O.OSM) and treated with 10 eq. of TFA at room temperature under a nitrogen atmosphere. The reaction was monitored by tlc until starting material was consumed usually within 1-5 hours. An additional 10 eq. of TFA was added to the reaction if the starting material was still present after 5 hours. The reaction was carefully neutralized with NazC03, separated, the organic layer washed with brine and dried over anhydrous Na,SO4. The crude amine was then used without purification.
Specific exemplification of these proce~3ures are as follows:
1. Racemic (+/-)-N-BOC-a-amino butyric acid (Aldrich) (9.29 g, 0.0457 mol) was dissolved in 100 mL of dioxane and treated with iso-butyl alcohol (6.26 mL, 0.0686 mol), EDC (8.72 g, 0.0457) and catalytic DMAP
(100 mg) at 0°C. After stirring for 17 hours, the organics were evaporated at reduced pressure, the residue diluted with EtOAc washed with NaHC03, brine and dried over NazSO,. Evaporation yields 8.42 g (71 % ) of an oil. C,3HuN04 requires: C = 60.21, H = 9.72, and N = 5.40. Anal found: C = 59.91, H=9.89,andN=5.67.
The above N-BOC amino acid ester (8.00 g, 0.032 mol) was deprotected as above giving 3.12 g (61 %) of the free base as a colorless oil which solidifies upon standing.
2. L-N-BOC-alanine (Aldrich) (8.97 g, 0.047 mol) was dissolved in 100 mL of CHZCIz, iso-butyl alcohol (21.9 mL, 0.238 mol) and treated with DMAP (100 mg) and EDC (10.0 g, 0.52 mol) at O°C. The mixture was stirred for 17 hours, diluted with HzO, washed with 1.0 N HCI, NaHC03, then brine and the organics were dried over Na2S04. Filtration and evaporation yields 11.8 g (quantitative) of L-N-BOC alanine iso-butyl ester which is contaminated with a small amount of solvent. A sample was vacuum dried for analytical analysis. C,ZHZ3N0,~ requires: C = 58.79, H = 9.38, and N =
5.71. Anal found: C = 58.73, H = 9.55, and N = 5.96.
The above N-BOC amino acid ester ( 11. 8 g, 0.0481 mol) was deprotected as above. The free base was converted to the corresponding HCl salt using saturated HC1 (g)/EtOAc to give L-N-alanine iso-butyl ester hydrochloride.
Obtained 4.2 g (48%) of a colorless solid. C~H,5N02. HCl requires:
--- C = 46.28, H = 8.88, and N = 7.71. Anal found: C = 46.01, H = 8.85, and N = 7.68.

GENERAL PROCEDURE K' Methyl ester formation from amino acids The amino acid (amino acid or amino acid hydrochloride) is suspended in methanol and chilled to 0°C. HCl gas is bubbled through this solution for 5 minutes. The reaction is allowed to warm to room temperature then stirred for 4 hours. The solvents are then removed pit reduced pressure to afford the desired amino acid methyl ester hydrochloride. This product is usually used without further purification.
Example A' Synthesis of free and polymer bound PEPC
N-ethyl-N'-3-(1-pvrrolidinyl)Qro~vlurea To a solution of 27.7 g (0.39 moI) ethyl isocyanate in 250 mL chloroform was added 50 g (0.39 mol) 3-(1-pyrrolidinyl)propylamine dropwise with cooling. Once the addition was complete, the cooling bath was removed and the reaction mixture stirred at room temperature for 4 hours. The reaction mixture was then concentrated under reduced pressure to give 74.5 g (96.4 % ) of the desired urea as a clear oil.
1-(3-(1-pyrrolidin~~prop5r11-3-ethylcarbodiimide (P-EPC~
To a solution of 31.0 g (0.156 mol) N~-ethyl-N'-3-(1-pyrrolidinyl)propyl-urea in 500 mL dichloromethane was added 62.6 g (0.62 mol) triethylamine and the solution was cooled to 0°C. To this solution were then added 59.17 g (0.31 mot) 4-toluenesulfonyl chloride in 4CI0 mL dichloromethane dropwise at such a rate as to maintain the reaction at 0-5°C. After the addition was complete, the reaction mixture was warme~j to room temperature and then heated to -reflex for 4 hours. After cooling to room temperature, the reaction mixture was washed with saturated aqueous potassium carbonate (3 x 150 mL).
- The aqueous phases were combined and extracted with dichloromethane. All organic phases were combined and concentrated under reduced pressure. The resultant orange slurry was suspended in 250 mL diethyl ether and the solution __ 1 p4 __ decanted off from the solid. The slurry/decantation process was repeated 3 more times. The ether solutions were combined and concentrated under reduc:d pressure to give 18.9 g (67%) of the desired product as a crude orange oil. A portion of the oiI was distilled under vacuum to give a colorless oil distilling at 78-82°C (0.4 mm Hg).
PreRaration of a polymer supported form of 1-l~-~(l~yrrolidinyl~propyl_)-3--.__ ethylcarbodiimide fP-EPC) A suspension of 8.75 g (48.3 mmol) 1-(3-(1-pyrrolidin-yl)propyl)-3-ethylcarbodiimide and 24.17 g (24.17 mmol) Merrifleld's resin (2 % cross-linked, 200-400 mesh, chloromethylated styrene/divinylbenzene copolymer, 1 meq. Cl/g) in dimethylformamide was heated at 100°C for 2 days. The reaction was cooled and filtered and the resulting resin washed sequentially with 1L DMF, 1L THF and 1L diethyl ether. The remaining resin was then dried under vacuum for 18 hours.
Example B' Preparation of alanine iso-butyl ester hydrochloride A mixture of 35.64 g (0.4 mol) of (D,L)-alanine (Aldrich) (or L-alanine (Aldrich)); 44 mL (0.6 mol) of thionyl chloride (Aldrich) and 200 mL of isobutanol was refluxed for 1.5 hours and the volatiles were removed completely on a rotavapor of 90°C under reduced pressure to give (D,L)-alanine iso-butyl ester hydrochloride (or L-alanine iso-butyl ester hydrochloride), which was pure enough to be used for further transformations.
Example C' Preparation of 3,5-dichlorophenylacetic acid To a solution of 3.5 g of 3,5-dichlorobenzyl alcohol (Aldrich) in 75 mL of dichloromethane at 0°C was added 1.8 mL of methane sulfonylchloride followed by 3.5 mL of triethylamine added dropwise. After 2 hours the solution was diluted to 150 mL with dichloromethane, washed with 3N HCI, saturated aqueous NaHC03 dried with Na2S04 and the solvents removed to yield the desired 3,5-dichlorobenzyl metlhanesulfonate as a yellow oiI that was used without purification.
The crude sulfonate was dissolved ire 50 mL of DMF at 0°C and then 3 g of KCN was added. After 2 hours an adfditional 50 mL of DMF was added and the solution was stirred for lb hours. The red solution was diluted with 1 L
of H20 and acidified to pH 3 with 3N HCI. The aqueous solution was extracted with dichloromethane. The combined orl;anics were washed with 3N HCI, dried with Na2S04 and the solvents removed at reduced pressure to yield crude 3,5-dichlorophenylacetonitrile which was used without purification.
The nitrile was added to a mixture of 40 mL of concentrated sulfuric acid and 50 mL HZO and heated to reflux for ~t8 hours, cooled to room temperature and stirred for 48 hours. The reaction was diluted into 1 L of crushed ice, warmed to toom temperature and extractea3 with 2 x 200 mL of dichloromethane and 2 x 200 mL of ethyhacetate. Both sets of organics were combined and washed with saturated aqueous NaHC03. The NaHC03 fractions were combined and acidified to pH 1 with 3N HCI. The white solid was too fine to filter and was extracted out with 2 X 200 mL of dichloromethane. The combined organics were dried with Na2S0~4 and the solvents removed at reduced presure to yield crude 3,5-dichlorophenylacetic acid as a white solid. The solid was slurried with hexane and filtered to gea 1.75g of white solid.
NMR (CDCl3): (in ppm) 3.61 (s, 2H)., 7.19 (s,lH), 7.30 (s, 1H) Example D' Synthesis of N-(3-chlorohhenylacetyl)alanine The title compound was prepared using L-alanine (Nova Biochem) and 3-chlorophenyl acetic acid (Aldrich) by following General Procedures F' or G', followed by hydrolysis using General Procedure D'.

Example A 1 Synthesis of N-(phenylacetyl)-D,Iralanine iso-butyl ester Following General Procedure A' above and using phenylacetyl chloride (Aldrich) and D,L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by extraction with Et~O followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.23-7.36 (m, SH), 6.18 (d, 1H), 4.58 {t, J = 7.3 Hz, 1H), 3.87 (m, 2H), 3.57 (s, 2H), 1.90 (m, 1H), ,I.34 (d, J = 7.2 Hz, 3H), 0.89 (d, J = 6.8 Hz, 6H).
'3C-nmr (CDCI,): 8 = 172.7, 170.3, 134.5, 129.2, 128.8, 127.2, 71.3, 48.1, 43.4, 27.5, 18.8, 18.3.
C,SHZ,N03 (MW = 263.34; Mass Spectroscopy (MH+ = 264)) Example A2 Synthesis of N (3-phenylpropionyl)-D,Iralanine iso-butyl ester Following General Procedure A' above and using 3-phenylpropionyl chloride (Aldrich) and D,L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of from 51 °-54°C. The reaction was monitored by tlc on silica gel and purification was by extraction with Et,O followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.25 (m, 2H), 7.19 (m, 3H), 6.28 (d, J = 7.2 Hz, 1H), 4.58 (quint., J = 7.2 Hz, 1H), 3.89 (m, 2H), 2.95 (t, J = 7.7 Hz, 2H), 2.50 (m, 2H), 1.92 (m, 1H), 1.33 (d, J = 7.1 Hz, 3H), 0.91 (d, J = b.7 Hz, 6H) .
'3C-nmr (CDC13): 8 = 173.0, 171.5, 140.6, 128.3, 128.1, 126.0, 71.2, 47.8, 37.9, 31.4, 27.5, 18.79, 18.77, 18.3.
C,6Hz3N03 (MW = 277.37, Mass Spectroscopy (MH+ 278)) __ 107 _-Example: A3 Synthesis of N (3-methylpentanoyl)-Iralanine iso-butyl ester Following General Procedure B' and using 3-met:'~ylpentanoic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as an oil. The reaction was monitored by tlc on silica gel and purification was by extraction with EtzO followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): b = 6.08 (d, J = 5.~~ Hz, 1H), 4.62 (quint., J = 7.3 Hz, 1H), 3.92 (m, 2H), 2.22 (m, 1H), 1.84-2.1~ (m, 3H), 1.40 (d, J = 7.2 Hz, 3H), 1.35 (m, 1H), 1.20 (m, IH), 0.85-0.16 (m, 12H).
'3C-nmr (CDCl3): b = 173.3, 172.1, 71.4, 47.9, 43.9, 32.3, 29.38, 29.35, 27.6, 19.10, 19.06, 18.93, 18.91, 18.72, 18.67, 11.3.
C,jH25NO3 (MW = 243.35, Mass Spectroscopy (MH+ 244)) Example A4 Synthesis of N-[(4-chlarophenyl)aaetyl]-Iralanine iso-butyl ester Following General Procedure B' and using 4-chlorophenylacetic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 111 °-113°C. The reaction was monitored by tlc on silica gel and purification was by extraction with Et20 followed by washes with aqueous KzC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.30 (d, J = 8.2 Hz, 2H), 7.21 (d, J = 8.3 Hz, 2H), 6.18 (d, J = 5.5 Hz, 1H), 4.57 (quint., J = 7.2 Hz, 1H), 3.88 (m, 2H), 3.53 (s, 2H), 1.91 (m, 1H), 1.36 (d, J = T.1 Hz, 3H), 0.90 (d, J = 6.8 Hz, 6H) .
'3C-nmr (CDCl3): b = 172.8, 169.8, 1:33.1, 133.0, 130.6, 128.9, 71.4, 48.2, 42.6, 27.6, 18.85, 18.82, 18.4.
3O C,SHZOlVO3Cl (MW = 297.78, Mass Spectroscopy (MH+ 298)) Example A5 Synthesis of N [(3,4-dichlorophenyl)acetyl]-I~alanine iso-butyl ester Following General Procedure B' and using 3,4-dichlorophenylacetic acid {Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 81 °-83 °C.
The reaction was monitored by tlc on silica gel and purification was by extraction with EtzO followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 0.90 (d, J = 6.8 Hz, 6H), 1.38 (d, J = 7.1 Hz, 3H), 1.91 (m, 1H), 3.50 (s, 2H}, 3.90 (m, 2H), 4.57 (quint., J = 7.1 Hz, 1H), 6.31 (d, J = 4.9 Hz, IH),7.12 (m, 1H), 7.38 (m, 2H).
'3C-nmr (CDC13): 8 = 18.4, 18.8, 18.9, 27.6, 42.2, 48.3, 71.5, 128.6, 130.6, 131.2, 131.3, 132.6, 134.7, 169.2, 172.8.
C,SH,9N03CIz (MW = 332.23, Mass Spectroscopy (MH+ 332)) Example A6 Synthesis of N [(4-methylphenyl)acetyl]-D,I~-alanine iso-butyl ester Following General Procedure B' and using 4-methylphenylacetic acid (Aldrich) and D,L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 102°-104°C. The reaction was monitored by tlc on silica gel (Rf =0.6 in 33%
ethyl acetate/hexanes) and purification was by extraction with Et20 followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 0.90 (d, J = 6.7 Hz, 6H), 1.35 (d, J = 7.2 Hz, 3H), 1.91 (m, 1H), 2.34 (s, 3H), 3.55 (s, 2H), 3.88 (m, 2H), 4.58 (m, iH), 6.05 (bd, 1H}, 7.16 (s, 4H).
'3C-nmr (CDC13): b = 18.5, 18.85, 18.87, 21.0, 27.6, 43.1, 48.1, 71.3, 129.2, 129.6, 131.3, 136.9, 170.6, 172.8.
3O C16H23N~3 (M~ = 277.37, Mass Spectroscopy (MH+ 278)) ExamFde A7 Synthesis of N [(3-pyridyl)acetyl]-D,Iralanine iso-butyl ester Following General Procedure F' and. using 3-pyridylacetic acid hydrochloride (Aldrich) and D,L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound vvas prepared as a solid having a melting point of 62°-b4°C. The reaction. was monitored by tlc on silica gel (Rf = 0.48 10 % methanol/dichloromethane} and purification was by silica gel chromatography.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 8.40 (d, J = 2,.8, 2H); 7.6 (m, 1H): 7.16 (m, 2H);
4.5 (quint., J = 7.2, 7.2, IH); 3.8 (m, 2H); 3.48 (s, 2H); 1.8 (m, 1H); 1.30 (d, J = 7.2, 3H); 0.81 (d, J = 6.7, 6H).
'3C-nmr (CDCI3): 8 = 173.4, 170.1, 150.6, 148.8, 137.4, 131.4, 124.1, 71.9, 48.9, 40.6, 28.1, 19.5, I9.4, 18.6.
IS C~4HZONZO3 (MW = 264, Mass Spec~:roscopy (MH+ 265)) Example A8 Synthesis of N [(1-naphthyl)acetyl]-I~alanine iso-butyl ester Following General Procedure B' and using 1-naphthylacetic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 69°-73°C. The reaction was monitored by tlc on silica gel and purification was by extraction with EtzO followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,}: b = 0.83 (m, 6H), l~ .25 (d, J = 7.1 Hz, 3H), 1.8I (m, 1H), 3.79 (m, 2H), 4.04 (2s, 2H), 4.57 (quint., J = 7.3 Hz, 1H), 5.99 (d, J
= 7.1 Hz, 1H), 7.44 (m, 2H), 7.53 (m, 2H), 7.85 (m, 2H), 7.98 (m, 1H).
'3C-nmr (CDCI3): 8 = 18.2, 18.81, 18.83, 27.5, 41.5, 48.2, 71.3, 123.7, 125.6, 126.1, 126.6, 128.2, 128.5, 128.7, 130.7, 132.0, 133.9, 170.3, 172.5.
C,9H23N03 (MW = 313.40, Mass Spectroscopy (MH+ 314)) Example A9 Synthesis of N ((2-naphthy!)acetyl]-I~alanine iso-butyl ester Following General Procedure B' and using 2-naphthylacetic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 128°-129°C. The reaction was monitored by tlc on silica gel and purification was by extraction with Et20 followed by washes with aqueous K2C03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 0.86 (m, 6H), 1.35 (d, J = 7.1 Hz, 3H), 1.7$ (m, 1H), 3.76 (s, 2H), 3.87 (m, 2H), 4.62 (quint., J = 7.2 Hz, 1H), 6.13 (d, J =

7.1 Hz, 1H), 7.41 (m, 1H), 7.48 (m, 2H), 7.74 (s, 1H), 7.83 (m, 3H).
'3C-nmr (CDCl3): 8 = 18.4, 18.82, 18.85, 27.6, 43.7, 48.2, 71.4, 125.9, 126.3, 127.2, 127.6, 127.7, 128.2, 128.7, 132.0, 132.5, 133.5, 170.3, 172.8.
C19H23N03 (MW = 313.40, Mass Spectroscopy (MH+ 314)).
Example A 10 Synthesis of N-(4-phenylbutanoyl)-L-alanine iso-butyl ester Following General Procedure B' and using 4-phenylbutanoic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as an oil. The reaction was monitored by tlc on silica gel and purification was by extraction with Et20 followed by washes with aqueous KzC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 0.92 (d, J-=~ 6.7 Hz, 6H), 1.38 (d, J = 7.1 Hz, 3H), 1.96 (m, 3H), 2.21 (t, J = 7.1 Hz, 2H), 2.64 (t, J = 7.3 Hz, 2H), 3.90 (m, 2H), 4.59 (quint., J = 7.2 Hz, 1H), 6.31 (d, 1H), 7.16 (m, 3H), 7.24 (m, 2H).
'3C-nmr (CDC13): 8 = 18.3, 18.75, 18.78, 26.8, 27.5, 34.9, 35.3, 47.8, 71.2, 125.7, 128.2, 128.3, 141.3, 172.1, 173Ø
C,~HZSN03 (MW = 291.39, Mass Spectroscopy (MH+ 292)).

Example: A 11 Synthesis of N (S-phenylpentanoyl)-L-alanine iso-butyl ester Following General Procedure B' and using 5-phenylpentanoic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as an oil. The reaction was monitored by tlc on silica gel and purification was by extraction with Et~O followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.23 (m, 2H), '7.17 (m, 3H), 6.30 (d, 1H), 4.59 (quint., J = 7.3 Hz, 1H), 3.91 (m, 2H), 2.61 (t, J = 7.2 Hz, 2H), 2.22 (t, J
= 7.2 Hz, 2H), 1.93 (m, 1H), 1.66 (m, f.H), 1.38 (d, J = 7.2 Hz, 3H), 0.92 (d, J = 6.7 Hz, 6H).
'3C-nmr (CDCl3): b = 173.1, 172.3, 142.0, 128.2, 128.1, 125.6, 71.2, 47.8, 36.1, 35.5, 30. 8, 27.5, 25.0, 18.80., 18.77, 18.4.
C,BHZ,N03 (MW = 305.39, Mass Spectroscopy (MH+ 306)).
Example A 12 Synthesis of N [(4-pyridyl)acetyl]-D,L-alanine iso-butyl ester Following General Procedure F' and using 4-pyridylacetic acid hydrochloride (Aldrich) and (D,L)-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound wa.s prepared as a solid having a melting point of 64°-66°C. The reaction was monitored by tlc on silica gel (Rf = 0.43 10 % methanol/dichloromethane) a~~d purification was by silica gel chromatography.
NMR data was as follows:
, . 'H-nmr (CDCI,): b = 8.51 (dd, J = 1.6, 2.8, 1.6, 2H); 7.23 (dd, J = 4.3, 1.6, 4.4, 2H); 6.71 (d, J = 6.8, 1H); 4.Sfi (quint., J = 7.3, 7.2, 1H); 3.88 (m, 2H); 3.53 (s, 2H); 1.89 (m, 1H); 1.36~ (d, J = 7.2, 3H); 0.88 (d, J = 6.7, 6H).
'3C-nmr (CDCl3): b = 173.5, 169.3, 150.5, 144.4, 125.1, 72.1, 48.9, 43.0, 28.2, 19.5, 19.5, 18:9.

C14H2~2~3 (Mw = 2~~ Mass Spectroscopy (MH+ 265)) Example A 13 Synthesis of N-(phenylacetyl)-Iralanine iso-butyl ester Following General Procedure B' and using phenylacetyl chloride (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the tide compound was prepared as a solid having a melting point of 45 °-47°C. The reaction was monitored by tlc on silica gel and purification was by extraction with EtzO followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.24-7.39 (m, 5H), 6.14 (d, 1H), 4.58 (t, J = 7.3 Hz, 1H), 3.88 (m, 2H), 3.58 (s, 2H), 1.90 (m, 1H), 1.35 (d, J = 7.2 Hz, 3H), 0.89 (d, J = 6.7 Hz, 6H).
'3C-nmr (CDC13): b = 172.8, 170.4, 134.5, 129.3, 128.9, 127.2, 71.3, 48.1, 43.5, 27.5, 18.9, 18.8, 18.4.
C,SH2,N03 (MW = 263.34, Mass Spectroscopy (MH+ 264)).
Example A 14 Synthesis of 2-[(3,4-dichiorophenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 3,4-dichlorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above) the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.36 (m, 3H), 6.03 (bd, 1H), 4.54 (m, 1H), 3.87 (m, 2H), 3.49 (s, 2H), 1.93 (m, 2H), 1.72 (m, 1H), 0.88 (d, 6H), 0.80 (t, 3H) .

Example A 15 Synthesis of 2-((3-methoxyphenyl)acetamidojbutyric acid iso-butyl ester Following General Procedure I' above and using 3-methoxyphenylacetic acid (Aldrich) and iso-butyl 2-aminobutyate (prepared frollowing General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purifimtion was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 6.75 (m, 4H), .5.93 (bd, 1H), 4.51 (m, 1H), 3.83 (m, 2H), 3.75 (s, 2H), 3.52 (s, 2H}, 1.82 (m; 2H), 1.60 (m, 1H), 0.84 (d, 6H), 0.74 (t, 3H).
C"Hz5N04 (MW = 307.39, Mass SpE:ctroscopy (MH+ 309)).
Example A 16 Synthesis of 2-[(4-nitrophenyl)acetamidojbutyric acid iso-butyl ester Following General Procedure I' above; and using 4-nitrophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 8.16 (d, 2H), 7.44 (d, 2H), 6.04 (bd, 1H), 4.55 (m, 1H), 3.86 (m, 2H}, 3.66 (s, 2H), 1.86 (m, 2H), 1.67 {m, IH), 0.85 (d, 6H), 0.81 (t, 3H).
C,6HzzN20s (MW = 322.36, Mass Spectroscopy (MH+ 323)).
Example ,A 17 Synthesis of 2-j(3,4-methylenedioxyphenyl)acetamidojbutyric acid . iso-butyl Ester Following General Procedure I' above and using 3,4-(methylenedioxy)-phenyl acetic acid (Aldrich) and iso-butyl 2~-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 6.72 (m, 3H), 5.92 (bd, 1H), 4.54 (m, 1H), 3.86 (m, 2H), 3.66 (s, 2H), 1.86 (m, 2H), 1.66 (m, 1H), 0.89 (d, 6H), 0.79 (t, 3H).
Example A 18 Synthesis of 2-[(thien-3-yl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 3-thiopheneacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.37 (m, 1H), 7.16 (m, 1H), 7.04 (m, 1H), 6.05 (bd, 1H), 4.57 (m, 1H), 3.66 (s, 2H), 1.93 (m, 2H), 1.67 (m, 1H), 0.91 (d, 6H), 0.86 (t, 3H).
Example A 19 Synthesis of 2-[(4-chlorophenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 4-chlorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.22 (m, 2H), 7.11 (m, 2H), 5.80 (m, 1H), 4.44 (m, 1H), 3.78 (m, 2H), 3.43 (s, 2H), 1.77 (m, 2H), 1.56 (m, iH), 0.83 (d, 6H) 0.71 (t, 3H).

Example A20 Synthesis of 2-[(3-nitrophenyl)acet~~mido]butyric acid iso-butyl ester Following General Procedure I' above and using 3-nitrophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was preparExi. The reaction was monitored by tlc on silica gel and purification was by filtraidon as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 8.15 (m, 2H), 7.65 (m, 1H), 6.08 (m, 1H), 4.46 (m, 1H), 3.92 (m, 2H), 3.68 (s, 2H), 1.91 (m, 2H), 1.75 (m, 1H), 0.98 (d, 6H) 0.71 (t, 3H).
Example A21 Synthesis of 2-[(2-hydroxyphenyl)acet:amido]butyric acid iso-butyl ester Following General Procedure I' above; and using 2-hydroxyphenylacetic acid (Aldrich) and iso-butyl 2-aminobutyra.te (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.14 (m, 1H), 7.01 (m, 1H), 6.93 (m, 1H), 6.79 (m, 1H), 6.46 (m, 1H), 4.51 (m, 1H), 3.87 (m, 2H), 3.57 (s, 2H), 2.01 (m, 2H), 1.75 (m, 1H), 0.89 (d, 6H), 0.85 (t, 3H).
Example A22 Synthesis of 2-[(2-naphthyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 2-naphthylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure _ J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.

NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.83 (m, 7H), 5.95 (m, 1H), 4.58 (m, 1H), 3.84 (m, 2H), 3.75 (s, 2H), 1.89 (m, 2H), 1.63 (m, 1H}, 0.91 (d, 6H), 0.81 (t, 3H).
CZflHuN03 (MW = 327.42, Mass Spectroscopy (MH+ 328)).
Example A23 Synthesis of 2-[(2,4-dichlorophenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 2,4-dichlorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was IO monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.49 (m, 1H), 7.22 (m, 2H) 5.98 (m, 1H), 4.52 (m, 1H), 3.86 (m, 2H), 3.61 (s, 2H), 1.84 (m, 2H), 1.62 (m, 1H) 0.87 (d, 6H), 15 0.80 (t, 3H).
Example A24 Synthesis of 2-((4-bromophenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 4-bromophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure 20 J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
---- 'H-nmr (CDCI,): b = 7.43 (d, 2H), 7.19 (d, 2H) 5.85 (m, 1H), 4.51 (m, 25 1H), 3.81 (m, 2H), 3.47 (s, 2H), 1.84 (m, 2H), 1.61 (m, 1H) 0.84 (d, 6H), 0.76 (t, 3H).
C,6HZZN03Br (MW = 356.26, Mass Spectroscopy (MH+ 358)).

Example A25 Synthesis of 2-[(3-chlorophenyl)acetamido])butyric acid iso-butyLester Following General Procedure I' above and using 3-chlorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepare. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.25 (m, 3H), 7.12 (m, 1H) 5.80 (m, 1H), 4.52 (m, 1H), 3.86 (m, 2H}, 3.50 (s, 2H), 1.87 (rn, 2H), 1.67 (m, 1H) 0.88 {d, 6H), 0.77 (t, 3H).
C,6HZZN03C1 (MW = 311.81 Mass Spectroscopy (MH+ 313)).
Example A26 Synthesis of 2-[(3-fluorophenyl)acetaunidoJbutyric acid iso-butyl ester Following General Procedure I' above: and using 3-fluorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepa~reli. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.31 (m, 1H), T.OI (m, 3H) 5.95 {m, 1H), 4.54 (m, 1H), 3.84 (m, 2H), 3.54 (s, 2H), 1.88 (m, 2H), 1.65 (m, 1H) 0.87 (d, 6H), 0.81 (t, 3H).
C,6HZZN03F (MW = 295.35 Mass Spectroscopy (MH+ 296)).
Example A27 Synthesis of 2-[(benzothiazol-4-yl)acetamido]butyric acid iso-butyl ester Following Generaa Procedure I' above and using 4-benzothiazol-4-yl acetic acid (Chemservice) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound ways prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.82 (m, IH), 7.51-7.21 (m, 4H) 5.84 (m, 1H), 4.51 (m, 1H), 3.90 (s, 2H), 3.79 (m, 2H), I.78 (m, 2H), 1.58 (m, 1H) 0.80 (d, 6H), 0.66 (t, 3H).
Example A28 Synthesis of 2-((2-methylphenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using-2-methyiphenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,}: 8 = 7.18 (m, 4H), 5.79 (m, 1H), 4.54 (m, 1H), 3.85 (m, 2H), 3.59 (s, 2H), 3.29 (s, 3H), 1.81 (m, 2H), 1.59 (m, 1H) 0.87 (d, 6H), 0.77 (t, 3H).
C"HZSNO3 (MW = 291.39 Mass Spectroscopy (M+ 29I)).
Example A29 Synthesis of 2-[(2-fluorophenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 2-fluorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.,_ NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.28 (m, 1H), 7.09 (m, 3H) 6.03 (m, 1H), 4.54 (m, 1H), 3.87 (m, 2H), 3.57 (s, 2H), 1.89 (m, 2H), 1.64 (m, 1H) 0.88 (d, 6H), 0.80 (t, 3H).

Example; A30 Synthesis of 2-[(4-fluorophenyl)acet;~mido]butyric acid iso-butyl ester Following General Procedure I' above and using 4-fluorophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.20 (m, 2H), ti.97 (m, 2H) 5.87 (m, 1H), 4.492 (m, 1H), 3.83 (m, 2H), 3.48 (s, 2H), 1.86 (m, 2H), 1.60 (m, 1H) 0.87 (d, 6H), 0.78 (t, 3H).
C16H2zN03F (MW = 295.35 Mass Sp~:ctroscopy (MH+ 296)).
Example A31 Synthesis of 2-[(3-bromophenyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 3-bromophenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.45 (m, 2H), 7.23 (m, 2H) 5.95 (m, 1H), 4.55 (m, 1H) 3.84 (m, 2H) 3.55 (s, 2H), 1.89 (m, ~!H), 1.68 (m, 1H) 0.91 (d, 6H), 0.81 (t, 3H). -C,6HZZN03Br (MW = 356.26 Mass Spectroscopy (M+ 357)).
Example A32 Synthesis of 2-[(3-trifluoromethylp~henyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 3-trifluoromethyl phenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title comFround was prepared. The reaction WO 98!22494 PCT/US97l20804 was monitored by tlc on silica gel and purification was by filtration as described in the general procedure. _,-NMR data was as follows:
'H-nmr (CDCI,): b = 7.52 (m, 1H), 7.47 (m, 2H) 6.01 (m, 1H), 4.56 (m, 1H), 3.86 (m, 2H), 3.61 (s, 2H), 1.84 (m, 2H), 1.62 (m, 1H) 0.87 (d, 6H), 0.80 (t, 3H).
C1~HZZNO3F3 (MW = 345.36 Mass Spectroscopy (MH+ 345)).
Example A33 Synthesis of 2-[(2-thienyl)acetamido]butyric acid iso-butyl ester Following General Procedure I' above and using 2-thiopheneacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 6.89 (m, 3H), 6.07 (bd, 1H), 4.50 (m, 1H), 3.82 (m, 2H), 3.71 (s, 2H), 1.85 (m, 2H), 1.62 (m, 1H), 0.81 (d, 6H), 0.75 (t, 3H).
C,4Hz,N03S (MW = 283.39, Mass Spectroscopy (MH+ 284)).
Example A34 Synthesis of 2-(phenyiacetamido)butyric acid iso-butyl ester Following General Procedure H' above and using phenylacetic acid (Aldrich) and iso-butyl 2-aminobutyrate (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by chromatography on silica gel using 9:1 toluene:EtOAc as the eluant.
NMR data was as follows:

'H-nmr (CDCI,): 8 = 7.17-7.28 (m, SH), 6.23 (bd, 1H), 4.51 (m, 1H), 3.86 (m, 2H), 3.54 (s, 2H), 1.87 (m, 2ii), 1.62 (m, IH), 0.87 (d, 6H), 0.78 (t, 3H).
C,6H~N03 (MW = 277.36, Mass Spectroscopy (MH+ 277)).
Example A35 Synthesis of N (phenylacetyl)valine 2-methylbutyl ester Step A. Preparation of N-(phenylacetyl) praline To a stirred solution of 5.15 g (44 mmol) of valine (Bachem) in 50 mL
(100 mmol) of 2N NaOH cooled to 0°C was added dropwise 5.3 mL (40 mmol) of phenylacetyl chloride (Atdrich),. A colorless oil precipitated. The reaction mixture was allowed to warm to room temperature and stirred for 18 hours, washed with 50 mL diethyl ether, acidified to pH 2-3 with aqueous HCI.
The white precipitate formed was filtered off, washed thoroughly with water, followed by diethyl ether to give 7.1 g (30 mmol, 69 % yield) of the title compound.
NMR data was as follows:
'H-nmr (DMSO-db): b = 12.63 (s, 1H), 8.25 (d, J = 8.6 Hz, 1H), 7.27 (m, SH), 4.15 (m, 1H), 3.56 (d, J = 13.F~ Hz, 1H), 3.47 (d, J = 13.8 Hz, 1H), 2.05 (m, 1H), 0.87 (d, J = 6.8, Hz, 3H), 0.84 (d, J = 6.8 Hz, 3) '3C-nmr (DMSO-db): b = 173.2, 170.4, 136.6, 129.0, 128.2, 126.3, 57.1, 41.9, 30.0, 19.2, 18.0 C,3H"N03 (MW=235.29; Mass Spectroscopy (MH+ = 236)) Step B. Synthesis of N (phenylacetyl)valinE; 2-methylbutyl ester Following General Procedure C' and using the N-(phenylacetyl) valine prepared in Step A above and 2-methylbuti~n-1-of (Aldrich), the title compound was prepared as a diastereomeric mixture. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:

__ -- 122 -_ 'H-nmr (CDCI,): b = 7.25-7.40 (m, 5H), 5.95 (d, 1H), 4.56 (m, 1H), 3.84-4.00 (m, 2H), 3.61 (s, 2H), 2.10 (m, 1H), 1.68 (m, 1H), 1.38 (m, 1H), 1.15 (m 1H), 0.82-0.94 (m, 9H), 0.76 (d, 3H).
'3C-nmr (CDCl3): 8 = 171.84, 171.81, 170.7, 134.6, 129.31, 129.27, 128.9, 127.3, 69.8, 57.0, 43.7, 33.9, 31.3, 25.9, 25.8" 18.9, 17.4, 16.34, 16.27, 11.12, 11.07.
C,gH~,NO3 (MW = 305.42, Mass Spectroscopy (MH 306)).
Example A36 Synthesis of N (phenytacetyt)-Irmethionine iso-butyl ester i0 L-Methionine (0.129g, 0.869 mmols) (Aldrich) was taken-up in dioxane (5.0 mL) and treated with a saturated solution of sodium bicarbonate (5.0 mL) followed by phenylacetyl chloride (Aldrich) (0.114 mL, 0.822 mmols). After stirring for 17 hours at room temperature the mixture was diluted with ethyl acetate, the layers separated and the aqueous layer acidified to pH 2 with 5N
HCI. The crude product was extracted into ethyl acetate, dried over sodium sulfate, vacuum dried and used without further purification.
N-phenylacetyl-L-methionine (0.1285 g, 0.447 mmol) was dissolved in 3.0 mL dioxane and iso-butyl alcohol (0.2 mL) and treated with EDC (0.094 g, 0.492 mmol), and catalytic DMAP (0.015g). After stirring for 17 hours at 23°C, the mixture was evaporated at reduced pressure to an oil, the residue was diluted in EtOAc and washed with 0.1 N HCl and saturated sodium bicarbonate. Chromatography on silica gel using 98:2 CHCI3/MeOH as eluant provided the pure product. -NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.4-7.23 (m, 5H), 6.14 (bd, 1H), 4.70 (m, 1H), 3.89 (d, 2H), 3.62 (s, 2H), 2.43 (m, 2H), 2.12 (m, 1H), 1.93 (m, 2H), 0.94 (d, 6H) .
C,~H,SN03S (MW = 323.17, Mass Spectroscopy (M+ 323) Example A37 Synthesis of N (phenylacetyl)-Irleucine iso-butyl ester L-Leucine (Aldrich) (0.114g, 0.869 mmols) Evas taken-up in dioxane (5.0 mL) and treated with a saturated solution of sodium bicarbonate (5.0 mL) followed by phenylacetyl chloride (Aldrich) (0.114 mL, 0.822 mmols). After stirring for 17 hours at room temperature the mixture was diluted with ethyl acetate, the layers separated and the aqueous layer acidified to pH 2 with SN
HCI. The crude product was extracted into ethyl acetate, dried over sodium sulfate, vacuum dried and used without further purification.
N-Phenylacetyl-L-leucine (0.0081 g, 0,038 mmol) was dissolved in 2.0 mL
CHCI3 (EtOH free) and iso-butyl alcohol (0.055 mL) and treated with P-EPC
(100 mg, 0.87 milliequivalents). The mixture was rotated for 4 days, filtered through a plug of cotton and the filtrate evaporated at reduced pressure to an oil which was sufficiently pure for testing.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.22 (m, SH), 5.57 (d, 1H), 4.35 (m, 1H), 3.35 (m, 3H), 1.35 (m, 4H), 0.68 (m, 9H).
C,gH2,N03 (MW = 305.40, Mass Spectroscopy (M+ 305)).
Example A38 Synthesis of N [(3-chlorophenyl)acetyl]alanine 3-methylbut-2-enyl ester Following General Procedure C' above and using N-(3-chlorophenylacetyl alanine (from Example D' above) and 3-methylbut-2-en-1-of (Aldrich), the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatograF~hy using 30% EtOAc/hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.39-7.16 (m, 4H.), 6.06 (bd, 1H), 5.38-5.29 (m, 1H), 4.63 (d, J = 9Hz, 2H), 3.56 (s, 2H), 1.79 (s, 3H), 1.7 (s, 3H), 1.39 (d, J = 9Hz, 3H).

WO 98!22494 PCT/US97/20804 Example A39 Synthesis of N [(3-chlorophenyl)acetyl]alanine cyclopropylmethyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and cyclopropylmethanol (Aldrich), the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.2-7.1 (m, 4H), 6.09 (bs, 1H), 4.6 (dq, J = 9 Hz, 1H), 3.96 (dd, J = 9Hz, 2H), 3.59 (s, 2H), 1.2 (d, J = 9Hz, 3H), 1.2-1.0 (m, 1H), 0.603-0.503 (m, 2H), 0.300-0.203 (m, 2H).
Example A40 Synthesis of N [(3-chlorophenyl)acetyl]alanine 2-thienylmethyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and 2-thiophenemethanol (Aldrich) the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCl,): 8 = 7.37-6.97 (m, 7H), 5.97 (q, J = 14 Hz, 2H), 4.6 (dq, J = 9 Hz, 1H), 3.76 (s, 2H), 1.38 (d, J = 9Hz, 3H).
Example A41 Synthesis of N-[(3-chlorophenyl)acetyl]alanine (1-methylcyclopropyl)methyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and (1-methylcyclopropyl)methanol (Aldrich) the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:hexane as the eluant.

NMR data was as follows:
'H-nmr (CDCI,): b = 8.6 (bd, J = 9 Hz, 1H), 3.86 (q, J = 14 Hz, 2H), 3.4 (s, 2H), 2.29 (q, J = 9 Hz, 1H), 1.3 (d, J = 9Hz, 3H), 1.03 (s, 3H), 0.5-0.4 (m, 2H), 0.4-0.28 (m, 2H).
Example: A42 Synthesis of N [(3-chlorophenyl)acetyl]alanine 3-thienylmethyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and 3-triiophenemethanol (Aldrich) the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 8.03 (bd, J = 9~ Hz, 1H), 7.56-7.5 (m, 1H), 7.47 (bs, IH), 7.4-7.17 (m, 4H), 7.06 (d, J = 9 Hz, 1H), 5.1 (s, 2H), 4.3 (dq, 1H), 1.3 (d, J = 9 Hz, 3H).
Example A43 Synthesis of N [(3-chlorophenyl)acetyl_[alanine 2-methylcyclopentyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and 2-mEahylcyclopentanol (Aldrich) the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatogravphy using 3:7 EtOAc:hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,}: b = 7.39-7.16 (m, 413), 6.3 (bd, IH), 4.79-4.7 (m, 1H), 4.6-4.25 (m, J = 9 Hz, 1H), 3.577 (s, 2H ), 2.09-I.8 (m, 2H), 1.74-1.6 (m, 2H), 1.39 (dd, J = 9 Hz, 3H), 1.2 (dt, J == 9 Hz, 1H), 0.979 (dd, J = 9 Hz, - 2H) C"HZZN03Cl (MW = 323.82, Mass SF~ectroscopy (MH+ 323).

Example A44 Synthesis of N [(3-chlorophenyl)acetyl]alanine 2-methylprop-2-enyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and 2-methylprop-2-en-1-of (Aldrich) the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.39-7.16 (m, 4H), 6.03 (bs, 1H), 4.77 (s, 2H), 4.7-10- 4.29 (m, 3H), 2.59 (s, 2H), 1.73 (s, 3H), 1.43 (d, J = 9 Hz, 3H) C,SH,gN03C1 (MW = 295.76, Mass Spectroscopy (MH+ 295)).
Example A45 Synthesis of N-[(3-chlorophenyl)acetyl]alanine cyclohex-2-enyl ester Following General Procedure C' above, and using N-(3-chlorophenylacetyl alanine (from Example D' above) and cyclohex-2-en-1-of (Aldrich) the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:hexane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): b = 8.6 (bd, J = 9 Hz, 1H), 7.4-7.2 (m, 4H), 6.0-5.8 (m, 1H), 5.7-5.5 (m, 1H), 5.1 (bs, 1H), 4.13-4.29 (m, 1H), 3.5 (s, 2H), 2.1 1.9 (m, 2H), 1.8-1.69 (m, 1H}, 1.69-1.49 (m, 4H), 1.3 (dd, J = 9 Hz, 3H) C~~HZON03Cl (MW = 321.8, Mass Spectroscopy (MH+ 321.2)).
Example A46 Synthesis of N-[(2-phenylbenzoxazol-5-yl)acetyl]alanine iso-butyl ester Following General Procedure I' above, and using 5-(2-phenylbenzoxazol)-yl-acetic acid (CAS# 62143-69-5) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared.

NMR data was as follows:
'H-nmr {CDCI,): 8 = 8.24 (m, 3H), 7.68 (m, 1H), 7.51 (m, SH), 6.04 (m, 1H), 4.58 (m, 1H), 3.85 (m, 2H), 3.68 (:;, 2H), 1.9 (m, 1H), 1.35 (d, 3H), 0.87 (d, 6H).
CnH~Nz04 (MW = 380, Mass Spectroscopy (MH+ 381)).
Example 47 - - Synthesis of N [(3-methyltbiophen;yl)acetyl)alanine iso-butyl ester Following General Procedure I' above, and using 3-methylthiophenylacetic acid (CAS# 18698-73-2) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.14 (m, 2H), T.01 (m, 1H), 4.56 (m, 1H), 3.88 (m, 2H), 3.54 (s, ZH), 2.46 (s, 3H), 1.89 (m, 1H), 1.35 (d, 3H) 0.85 (d, 6H).
C~6Hz3NO3S (MW = 309, Mass Spectroscopy (MH+ 310)).
Example A48 Synthesis of N 4-[(2-furyl)acetyl]alanine iso-butyl ester Following General Procedure I' above., and using 2-furylacetic acid (CAS#
2745-26-8) and alanine iso-butyl ester {prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.36 (m, 1H), 6.34 (m, 1H), 6.21 (m, 1H), 4.56 (m, 1H), 3.91 (m, 2H), 3.61 (s, 2H), 1.92 (m, 1H), 1.38 (d, 3H) 0.89 (d, 6H).
- C13H19N04 {MW = 253, Mass Spectroscopy (MH+ 254)).

Example A49 Synthesis of N [(benzofuran-2-yl)acetyl]alanine iso-butyl ester Following General Procedure I' above, and using benzofuran-2-ylacetic acid (Maybridge) and alanine iso-butyl ester (prepared following General S Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.51 (m, 1H), 7.44 (m, 1H),7.25 (m, 2H), 6.67 (s, 1H), 4.60 (m, 1H), 3.87 (m, 2H), 3.77 (s, 2H), 1.88 (m, 1H), 1.38 (d, 3H), 0.87 (d, 6H).
C,~H2,N04 (MW = 303, Mass Spectroscopy (MH+ 304)).
Example A50 Synthesis of N [(benzothiophen-3-yl)acetyl]alanine iso-butyl ester Following General Procedure I' above, and using thianaphthen-3-ylacetic acid (Lancaster) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.89 (m, 1H), 7.76 (m, 1H), 7.38 (m, 3H), 6.07 (m, 1H), 4.57 (m, 1H), 3.92 (m, 2H), 3.82 (s, 4H), 1.84 (m, 1H), 1.32 (d, 3H) 0.85 (d, 6H).
___ C'7Hz,N03S (MW = 319, Mass Spectroscopy (MH+ 320)).
Example A51 Synthesis of N [(2-chloro-5-thienyl)acetyl]alanine iso-butyl ester Following General Procedure I' above, and using S-chloro-2-thienyl)acetic acid (CAS# 13669-19-7) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 6.77 (m, 1H), 6.68 (d, 1H), 6.31 (bm, 1H), 4.59 (m, 1H), 3.91 (m, 2H), 3.38 (s, 2H), 1.90 (m, 1H), 1.39 (d, 3H) 0.89 (d, 6H).
C,3H,eN03SCI (MW = 303, Mass Spectroscopy (MH+ 303)).
Example A52 Synthesis of N-[(3-methylisoxazol-,5-yl)acetyl~alanine iso-butyl ester Following General Procedure I' above, and using (3-methyl-isoxazol-5-yI)acetic acid (CAS#f 19668-85-0) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gf;l and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 6.07 (s, 2H), 4..56 (m, 1H), 3.92 (m, 2H), 3.68 (s, 2H), 2.29 (s, 3H), 1.94 (m, 1H), 1.89 (d, 3H) 0.91 (d, 6H).
C13H2~2~4 (MW = 268, Mass Spectroscopy (MH+ 269)).
Example: A53 Synthesis of N-[(2-phenylthiothienyl)acetyl]alanine iso-butyl ester Following General Procedure I' abovE:, and using (2-phenyl-thiothienyl)acetic acid and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purifica~~tion was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.21-7.11 (m, 6~H), 6.92 (d, 1H), 4.56(m, 1H), 3.87 (m, 2H), 3.72 (s, 2H), 1.94 (m, 1H), 1.3f~ (d, 3H) 0.89 (d, 6H).
C,9H23NO3S2 (MW = 377, Mass Spectroscopy (MH+ 378)).

Example A54 Synthesis of N [(6-methoxybenzothiophen-2-yl)acety!]alanine iso-butyl ester Following General Procedure I' above, and using (6-methoxythianaphthen-2-yl)acetic acid and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
- _ _ NMR data was as follows:
'H-nmr (CDCI,): b = 7.59 (d, 1H), 7.33 (d, 1H), 7.16 (s, 1H), 7.03 (dd, 1H), 4.56 (m, 1H), 3.87(s, 3H), 3.84 (m, 2H), 3.76 {s, 2H),1.85 {m, 1H), 1.30 (d, 3H) 0.86 (d, 6H).
C,gH23NO4S (MW = 349, Mass Spectroscopy (MH+ 350)).
Example A55 Synthesis of N [(3-phenyl-1,2,4-thiadiazol-5-yl)acetyl]alanineiso-butyl ester Following General Procedure I' above, and using (3-phenyl-1,2,4-thiadiazol-5-yl)acetic acid (CAS# 90771-06-5) and alanine iso-butyl ester {prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.47 (m, SH), 4.66 (m, 1H), 4.16 (s, 2H), 3.91 (m, 2H), 1.93 (m, 1H), 1.48 (d, 3H) 0.93 (d, 6H).
C"HZ,N303S (MW = 347, Mass Spectroscopy (MH+ 348)).
Example A56 Synthesis of N [2-phenyloxazol-4-yl)acetyl]alanine iso-butyl ester Following General Procedure I' above, and using (2-phenyloxazol-4-yl)acetic acid (CAS# 22086-89-1) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica l;el and purification was by filtration as described in the general procedure. _ NMR data was as follows: __ Example A57 Synthesis of N-j(3-methylphenyl)acetyl]aianine iso-butyl ester Following General Procedure I' above, and using 3-methylphenylacetic acid (Aldrich) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.21 (m, 1H), 7.07 (m, 3H), 4.54 (m, 1H), 3.83 (m, 2H), 3.52 (s, 2H), 2.35 (s, 3H), 1.87 (m, 1H), 1.32 (d, 3H), 0.88 (d, 6H).
C16H23N~3 (~ = 277, Mass Spectroscopy (MH+ 278)).
Example A58 Synthesis of N [(2,5-difluorophen~~l)acetylJalanine iso-butyl ester Following General Procedure I' above:, and using 2,5-difluorophenylacetic acid (Aldrich) and alanine iso-butyl ester (prepared following General Procedure J' above}, the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.08-6.94 (m, 3iH), 4.57 (m, IH), 3.91 (m, 2H), 3.56 (s, 2H), 1.92 (m, 1H}, 1.41 (d, 3H) CL91 (d, 6H).
C,SH,91V03F2 (MW = 299, Mass Spectroscopy (MH+ 300)}.

Example A59 Synthesis of N [(3,5-diflurophenyl)acetyl]alanine iso-butyl ester Following General Procedure I' above, and using 3,5-difluorophenylacetic acid (Aldrich) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. T'he reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 6.81 (m, 2H}, 6.74 (m, 1H), 6.Ob (m, IH), 4.57 (m, 1H), 3.92 (m, 2H), 3.51 (s, 2H), 1.94 (m, 1H), 1.3'6w(d, 3H) 0.87 (d, 6H).
C,SH,9N03F2 (MW = 299, Mass Spectroscopy (MH+ 300)).
Example A60 Synthesis of N [(3-thienyl)acetyl]alanine iso-butyl ester IS Following General Procedure I' above, and using 3-thiopheneacetic acid (Aldrich) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.33 (m, IH), 7.14 (m, IH), 7.01 (m, IH), 6.09 (m, 1H), 4.58 (m, 1H), 3.88 (m, 2H), 3.60 (s, 2H), 1.91 (m, 1H), 1.37 (d, 3H) 0.92 (d, 6H).
Optical Rotation: [a]23 -52 (c 1 MeOH) Q 589 nm.
C13H19N~3S (M~ = 269, Mass Spectroscopy (MH+ 269)).
Example A61 Synthesis of N [(4-methylphenyl)acetyl)-L-alanine iso-butyl ester Following General Procedure I' above, and using 4-methylphenylacetic acid (Aldrich) and L-alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by filtration as described in the general procedure.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.11 (s, 4H), 5.93 (m, 1H), 4.58 (m, IH), 3.88 (m, 2H), 3.54 (s, 2H), 2.33 (s, 3H), 1.89 (m, 1H), 1.32 (d, 3H), 0.89 (d, 6H).
C,bH~N03 (MW = 277.35, Mass Spectroscopy (MH+ 278)).
ExamplE: A62 Synthesis of N (phenylacetyl)-L-alanine S-1-(methoxycarbonyl) iso-butyl ester Following General Procedure K' and using (S)-(+)-2-hydroxy-2-methylbutyric acid (Aldrich) in place of tlhe amino acid, methyl (S)-(+)-2-hydroxy-2-methylbutyrate was prepared.
Methyl (S)-(+)-2-hydroxy-2-methylb~utyrate was then coupled with carbobenzyloxy-L-alanine (Aldrich) using General Procedure E' to provide carbobenzyloxy-L-alanine S-1-(methoxycarbonyl) iso-butyl ester.
Carbobenzyloxy-L-alanine S-1-(methoxycarbonyl) iso-butyl ester (1.0 g) was then dissolved in 20 mL of methanol and 6N HC1 (0.5 mL) and 10%
palladium on carbon (0.1 g) were added. This reaction mixture was hydrogenated at 40 psi of hydrogen on a farr apparatus for 5 hours at room temperature and then filtered through a pad of Celite. The filtrate was concentrated at reduced pressure to provide L-alanine S-1-(methoxycarbonyl) iso-butyl ester hydrochloride (98% yield).
L-Alanine S-I-(methoxycarbonyl) iso-butyl ester hydrochloride was then coupled to phenylacetic acid using General Procedure G' to provide the title compound.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.35 - 7.20 (m, SH), 6.22 (bd, IH), 4.83 (d, 1H), 4.65 (p, 1H), 3.68 (s, 3H), 3.55 (s, 2H), 2.21 (m, 1H), 1.40 (d, 3H), 0.97 (d, 3H), 0.93 (d, 3H).
'3C-nmr (CDCI3): b = 173.25, 171.18, 170.22, 135.11, 129.94, 129.50, 127.88, 52.67, 48.49, 43.98, 30.53, 19.21, 18.75, 17.58.

i Example A63 Synthesis of N [(3-nitrophenyl)acetyl]-Iralanine iso-butyl ester Following General Procedure H' above and using 3-nitrophenylacetic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by recrystallization from butyl chloride.
NMR data was as follows:
'H-nmr (CDCI,): b = 8.17 (m, 2H), 7.68 (d, 1H), 7.52 (t, 1H), 6.18 (m, 1H), 4.48 (m, 1H), 3.94 (m, 2H), 3.67 (s, 2H), 1.93 (m, 1H), 1.42 (d, 3H), 0.91 (d, 3H).
Optical Rotation: [a]z3 -49 (c 5, MeOH).
Example A64 Synthesis of N [(3,5-difluorophenyl)acetyl]alanine ethyl ester Following General Procedure G' and using 3,5-difluorophenylacetic acid (Aldrich) and alanine ethyl ester (Aldrich), the title compound was prepared as a solid with a melting point of 93°-95°C. The reaction was monitored by tlc on silica gel (Rf = 0.8 in EtOAC) and purification was by chromatography on silica gel using EtOAc as the eluant followed by recrystallization from 1-chlorobutane.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.30 (d, 3H); 3.52 (s, 2H).
C,3H,SN03F2 (MW = 271.26, Mass Spectroscopy (MH+ 271)).
Example A65 Synthesis of N [(3-nitrophenyl)acetyl]methionine ethyl ester Following General Procedure G' above and using 3-nitrophenylacetic acid (Aldrich) and methionine ethyl ester hydrochloride (Aldrich), the title compound was prepared. The reaction was monitored by tlc on silica gel and purification was by recrystallization from butyl chloride.
NMR data was as follows:

'H-nmr (CDCI,): 8 = 8.18 (s, 1H), l3.15 (d, 1H) 7.66 (d, 1H), 7.48 (t, 1H), 6.30 (m, 1H), 4.67 (m, IH), 4.21 (t, 2H), 3.67 (s, 2H), 2.47 (t, 2H), 2.12 (m, 2 H), 2.08 (s, 3H), 1.27 (t, 3H;1.
C>Ptical Rotation: [a]~ -30 (c 5, MeOH).
Example; A66 Synthesis of N [(3-chlorophenyl:lacetylJalanine iso-butyl ester Following General Procedure G' abo~re and using 3-chlorophenylacetic acid (Aldrich) and alanine iso-butyl ester (prepared following General Procedure J' above), the title compound was prepared. The reaction was monitored by tlc on silica gel.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 7.29 (m, 3H), 7.18 (m, 1H), 6.0 (m, 1H), 4.56 (m, 1H), 3.89 (m, 2H), 3.53 (s, 2H), 1.91 (m, 1H), 1.39 (d, 3 H), 0.91 (d, 3H).
C~tical Rotation: [a]~ -45 (c 5, MeC>H).
IS ClSHZOIVO3Cl (MW = 297.78, Mass Spectroscopy (MH+ 297)).
Example A67 Synthesis of N [(3-chlorophenyl)acetyl]alanine 2-(N,N dimethylarriino)ethyl ester Following General Procedure C' above, and using N-(3-chlorophenyl-acetyl)alanine (from Example D' above) and 2-(N, N-dimethyl amino) ethanol (Aldrich), the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 0.1:2:0.79 NH40H: EtOH: CHCI3 as the eluant.
NMR data was as follows:
~ ~-iH-nmr (CDCI,): 7.37 (s, IH), 7.33-7.2 (m, 3H), 4.675-4.6 (m, 1H), 4.5-4.37 (m, IH), 4.25-4. i3 (m, 1H), 3.6 (d, .~ = 7 Hz, 2H), 2.86 (bs, 2H), 2.3 (s, 6H), 1.23 (d, J = 9 Hz, 3H).
C,SHZ,N203C1 (MW = 313.799, Mass Spectroscopy (M+ 313)).

WO 98!22494 PCT/LTS97/20804 Example A68 Synthesis of 2-[(3,5-dichlorophenyl)acetamido]hexanoic acid methyl ester Following General Procedure F' above, an using 3,5-dichlorophenylacetic acid (from Example C' above) and L-norleucine methyl ester hydrochloride (Bachem), the title compound was prepared as a solid having a melting point of 77°-78°C. The reaction was monitored by tlc on silica gel (Rf =
0.70 in 40!
EtOAC/hexanes) and purification was by flash chromatography on silica gel using 40% EtOAclhexanes as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.20 (s), 7.18 (s), 6.6 (m), 4.55 (m), 3.7 (s), 3.5 (s), 3.4 (s), 2.0 (s), 1.8 (m), 1.6 (m), 1.2 (m), 0.8 (t).
'3C-nmr (CDCl3): b = 173.54, 169.67, 138.43, 135.72, 128.33, 128.07, 78.04, 77.62, 77.19, 53.04, 52.90, 43.14, 32.57, 27.87, 22.81, 14.41.
Example A69 Synthesis of N [(3,5-diciorophenyl)acetyl]-I~alanine iso-butyl ester Following General Procedure F' above, and using 3,5-dichlorophenylacetic acid (from Example C' above) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 115°-116°C. The reaction was monitored by tlc on silica geI
(Rf = 0.40 in 3 % methanol/dichloromethane) and purification was by flash chromatography on silica gel using 3 % methanol/dichloromethane as the eluant.
NMR data was as follows:
'H-nmr (CDCI,): b = 7.27 (d, J = 2 Hz, 1H), 7.19 (s, 2H), 6.22 (d, J =
6 Hz, 1H), 4.59 (quint., J = 7 Hz, 1H), 3.9 (q, J = 4 Hz, 2H), 3.5 (s, 2H), 1.9 (m, 1H), 1.4 (d, J = 7 Hz, 3H), 0.91 (d, J = 7 Hz, 6H).
'3C-nmr (CDCl3): 8 = 173.45, 169.37, 138.31, 135.75, 128.39, 128.11, 78.04, 77.61, 77.19, 72.19, 54.03, 48.97, 43.12, 28.24, 19.52, 19.49, 19.09.
C'SH'9NO3C12 (MW = 331.9, Mass Spectroscopy (MH+ 332)).

__ 137 -_ Example A70 Synthesis of N (cyclohexylacetyl)-I,-alanine iso-butyl ester Following General Procedure B' above, and using cyclohexylacetic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a soliid having a melting point of 92°C-93 °C. The reaction was monitored by tip: on silica gel (Rf = 0.39 in 1:3 EtOAc: hexane) and purification was by extraction with Et~O followed by washes with aqueous KzC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 0.93 (d, J = 6.7 Hz, 6H), 0.85-1.01 (m, 2H), 1.05-1.35 (m, 3H), 1.40 (d, J = 7.1 Hz, 3H), 1.60-1.85 (m, 6H), 1.95 (m, 1H), 2.06 (d, J = 7.0 Hz, 2H), 3.92 (m, ZH), 4.61 (m, 1H), 6.08 (bd, 1H).
'3C-nmr (CDCl3): b = 18.7, 18.9, 26.0, 26.1, 27.6, 33.0, 35.3, 44.6, 47.9, 71.4, 171.8, 173.3.
C,SHz,N03 (MW = 269.39, Mass SpE:ctroscopy (MH+ 270)).
Example A71 Synthesis of N (cyclopentylacet,yl)-L-alanine iso-butyl ester Following General Procedure B' above, and using cyclopentylacetic acid (Aldrich) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 62°C-64°C. The reaction was monitored by tlc on silica gel (Rf = 0.37 in 1:3 EtOAc:hexane) and purification was by extraction with Et20 followed by washes with aqueous KzC03 and aqueous HCI.
NMR data was as follows:
--w 25 'H-nmr (CDCI,): 8 = 0.87 (d, J = 6.8 Hz, 6H), 1.01-1.17 (m, 2H), 1.34 (d, J = 7.2 Hz, 3H), 1.40-1.62 (m, 4H), :1.70-1.83 (m, 2H), 1.89 (m, 1H), 2.15 (m, 3H), 3.86 (m, 2H), 4.55 (m, 1H), 6.30 (d, J = 7.1 Hz, 1H).
'3C-nmr (CDC13): b = 18.4, 18.78, 18.80, 24.8 (very high), 27.5, 32.27, 32.32, 36.9, 42.5, 47.7, 71.2, 172.2, 173.2.

Elemental Analysis-Calc (%): C, 65.85; H, 9.87; N, 5.49; Found (%): C, 66.01; H, 10.08; N, 5.49.
C,4HuN03 (MW = 255.36, Mass Spectroscopy (MH+ 256)).
Example A72 Synthesis of N [(cyciohex-1-enyl)acetyl]-Iralanine iso-butyl ester Following General Procedure B' above, and using cyclohex-1-enyl acetic acid {Alfa) and L-alanine iso-butyl ester hydrochloride (from Example B' above), the title compound was prepared as a solid having a melting point of 49°C-51 °C. The reaction was monitored by tlc on silica gel (Rf = 0.40 in 1:3 EtOAc:hexane) and purification was by extraction with EtzO followed by washes with aqueous KZC03 and aqueous HCI.
NMR data was as follows:
'H-nmr (CDCI,): 8 = 0.91 (d, J = 4.5 Hz, 3H), 0.93 (d, J = 6.7 Hz, 3H), 1.40 (d, J = 7.2 Hz, 3H), 1.52-1.70 (m, 4H), 1.97 (m, 3H), 2.06 (bs, 2H), 2.89 (s, 2H), 3.92 (m, 2H), 4.59 (m, 1H), 5.65 (s, 1H), 6.33 (d, J = 6.6 Hz, 1H).
'3C-nmr (CDC13): b = 18.7, 18.91, 18.93, 21.9, 22.7, 25.3, 27.6, 28.3, 46.1, 47.9, 71.4, 127.1, 132.5, 170.6, 173.1.
Elemental Analysis-Calc (%): C, 67.38; H, 9.42; N, 5.24; Found (%): C, 67.34; H, 9.54; N, 5.16.
C15HZSN03 (MW = 267.37, Mass Spectroscopy (MH+ 268)).
Example A73 Synthesis of N-[(3-chlorophenyl)acetyl]alanine 3-methylbut-2-enyl thioester Following General Procedure C' above, and using N [(3-clilorophenyl)acetyl] alanine and 3-methyl-2-butene thioester (TCI), the title compound can be prepared. The reaction was monitored by tlc on silica gel and purification was by liquid chromatography using 3:7 EtOAc:Hexane as the eluant.
NMR data was as follows:

'H-nmr (DMSO-db): 8 = 5.2-5.075 (m, 1H), 4.37 (dq, J = 9 Hz, 1H), 3.56 (s), 3.43 (d, J = 12 Hz, 2H), 1.266 (d, J = 12 Hz, 6H) I.3 (d, J = 9 Hz, 3H).
C,6HZOIVO2C1S (MW = 325.86, Mass Spectroscopy (M+ 325)).
Example A74 Synthesis of N [(2-phenyl)-2-fhuoroacetyl]alanine ethyl ester ---- Following General Procedure F' above, and using a-fluorophenyl acetic acid (Aldrich) and alanine ethyl ester (Aldrich), the title compound was prepared. The reaction was monitored by tlc on silica gel (Rf = 0.75 in 1:1 EtOAc:hexane) and purification was by clhromatography on silica gel using 1:2 ethyl acetate/hexanes as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.14 (q, 3H), 1.34 (d, 3H), 4.07 (m, 2H), 4.33 (m, IH), 5.84 (d, IH), 6.01 (d, 1H), 7.41)-7.55 (m, 5H), 8.87 (m, 1H).
C,3H,6N03F (MW = 253.27, Mass Spectroscopy (MH+ 253)).
Example A75 Synthesis of N (3,5-difluorophenylacntyl)-L-phenylglycine methyl ester Following General Procedure F above:, and using 3,5-ditluorophenylacetic acid (Aldrich) and L-phenylglycine methyl ester hydrochloride (Bachem), the title compound was prepared.
NMR data was as follows:
'H-nmr (CDCl3): 8 =7.4-7.3 (m, 5H), 6.9-6.7 (m, 3H}, 6.55 (d 1H, 7.1 Hz), 5.56 (d 1H 7 Hz), 3.72 (s 3H), 3.57 (s 2H) '3C-nmr (CDCl3): b = 197.6, 177.6, :171.8, 169.3, 136.7, 129.6, 129.3, 127.8, 113.0, 112.9, 112.7, 111.4, 103.8, 103.5, 65.1, 57.2, 53.5, 45.1, 43.3, 43.3 C,~H,SN03F2 (MW = 319.31, Mass Spectroscopy (MH +320)).
Example: 76 Synthesis of N (3,5-difluorophenylacetyl)-I~phenylglycine iso-butyl ester The 3,5-difluorophenylacetic acid (Aldrich) was EDC coupled to L-phenylglycine methyl ester hydrochloride (Bachem) via General Procedure F
above.
The resulting compound was placed in a large excess of the desired alcohol. A catalytic amount of dry NaH was added, and the reaction was followed by tlc until the presence of starting material was no longer detected.
The reaction was quenched with a few milliliters of 1N HCI, and after a few minutes of stirring saturated aqueous NaHCO, was added. The volume of the reaction mixture was reduced on a rotary evaporator until the excess alcohol was removed and then the remaining residue was taken up in ethyl acetate and additional water was added. The organic phase was washed with saturated aqueous NaCI and dried over MgSO,. The solution was stripped free of solvent on a rotary evaporator, and the crude product residue was then further purified by chromatography.
NMR data was as follows:
'H-nmr (CDCI3): b = 7.35-7.3 (m 5H), 6.8-6.7 (m 3H) 6.60 (d 1H, 7 Hz), 5.55 (d 1H 7.1 Hz), 3.9 (m 2H), 3.60 (s 2H), 1.85 (m 1H 7 Hz), 0.8 (q 6H 7 Hz) '3C-nmr (CDCl3): b = 171.3, 169.3, 165.4, 138.5, 137.0, 129.5, 129.2, 127.6, 113.1, 113.0, 112.8, 112.7, 103.8, 103.5, 103.2, 75.5, 57.2, 43.4, 43.3, 28.2, 19.3 CZOH2,NO3F2 (MW = 361.39, Mass Spectroscopy (MH +362)).
Example A77 Synthesis of N (cyclopentylacetyl)-Irphenylglycine methyl ester Following General Procedure D' above, and using cyclopentylacetic acid (Aldrich) with L-phenylglycine methyl ester hydrochloride (Bachem) the title compound was prepared.
NMR data was as follows:

'H-nmr (CDC13): b = 7.35 (s, SH), 6.44 (bd, 1H), 5.6 (d, 1H), 3.72 (s, 3H), 2.24 (bs, 3H), I.9-1.4 (m, 6H), 1.2-1.05 (m, 2H) "C-nmr (CDC13): b = 172.3, 171.7,, 136.7, 129.0, 128.6, 127.3, 56.2, 52.7, 42.5, 36.9, 32.40, 32.38, 24.8 Example A78 Synthesis of N (cyclopentylacetyl)-L-alanine methyl ester Following General Procedure D' above, and using cyclopentylacetic acid (Aldrich) with L-alanine methyl ester hydrochloride (Sigma) the title compound was prepared.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 6.38 (d, 1H), ~G.50 (m, 1H), 3.65 (s, 3H), 2.13 (bs, 3H), 1.80-1.00 (m (includes d at 1.30, 3Fi), 11H) '3C-nmr (CDC13): 8 = 173.7, 172.5, 52.1, 47.6, 42.3, 36.8, 32.15, 32.14, 18.0 C,~H,9N03 (MW = 213.28, Mass Spectroscopy (MH+ 214)).
Example A79 Synthesis of N (cyclopropylacetyl)-L-phenylglycine methyl ester Following General Procedure D' above, and using cyciopropylacetic acid (Aldrich) with L-phenylglycine methyl ester hydrochloride (Bachem), the title compound was prepared.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.35 (m, SH) 6.97 (bd, J = 7.2 Hz, 1H) 5.59 (d, J = 7.8 Hz, 1H), 3.71 (s, 3H), 2.17 (m, 2H), 1.05-0.95 (m, 1H), 0.62 (m, 2H), 0.02 (m, 2H) '3C-nmr (CDCl3): 8 = 171.9, 174.6, 136.6, 129.0, 128.5, 127.2, 56.1, 52.7, 41.0, 6.9, 4.37, 4.33 Example A80 Synthesis of N (cyclopropylacetyl)-L-alanine methyl ester Following General Procedure D' above, and using cyclopropylacetic acid (Aldrich) with L-alanine methyl ester hydrochloride (Sigma), the title compound was prepared.
NMR data was as follows:
'H-nmr (CDC13): b = 6.60 (d, 1H), 4.55 (m, 1H), 3.69 (s, 3)E17, 2.10 (m, _ 2H), i.34 (d, 3H), 0.95 (m, 1H), 0.58 (m, 2H) 0.15 (m, 2H) '3C-nmr (CDCl3): 8 = 173.7, 172.3, 52.3, 47.7, 41.0, 18.2, 6.7, 4.27, 4.22 Example A81 Synthesis of N [(3-nitropheny!)acetyl]-Irmethionine iso-butyl ester Following General Procedure H' above, and using nitrophenylacetic acid (Aldrich) and L-methionine (Aldrich), the title compound was prepared as a tan oil. The reaction was monitored by tlc on silica gel.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.16 (m,2H) 7.67 (d,1H) 7.32 (t, 1H), 6.31 (bd, 1H), 4.69 (m, 1H), 3.90 (d, 2H), 3.68 (s, 2H), 2.47 (t, 2H), 2.15 (m, 1H), 2.02 (s, 3H), 1.90 (m, 2H), 0.91 (d, 6H).
2O C,-,H24NZOSS (MW = 368.4, Mass Spectroscopy (MH+ 368)}.
The following General Procedures A"-B" and Examples Bl-B2 illustrate the synthesis of N (aryl/heteroarylacetyl)amino acid starting materials useful in this invention. Other N (aryl/heteroarylacetyl)amino acids can be prepared using these procedures from commerically available or known starting materials.

GENERAL PROCEDURE A"
Acid Chloride Pre arati n 3,5-Difluorophenylacetic acid (30 g, 0.174 mol) (Aldrich) was dissolved in dichloromethane and this solution was cooled to 0°C. DMF (0.5 mL, catalytic) was added followed by the dropwise addition of oxalyl chloride (18 mL, 0.20 mol) over a 5 minute period. The reaction was stirred for 3 h and then rotoevaporated at reduced pressure to a residue which was placed on a high vacuum pump for 1 h to afford 3,5-difluorophenylacetyl chloride as a thin yellow oil. Other acid chlorides can be prepared in a similar manner.
GENERAL PROCEDURE B"
Schotten-Baum;an Procedure 3,5-Difluorophenylacetyl chloride (from General Procedure A") was added dropwise to a 0°C solution of L-alanine (Aldrich) (16.7 g, 0.187 mol) in 2 N
sodium hydroxide (215 mL, 0.43 mol). '.fhe reaction was stirred for 1 h at 0°C
and then overnight at room temperature. The reaction was diluted with water (100 mL), then extracted with ethyl acetate (3 x 150 mL). The organic layer was then washed with brine (200 mL), dried over MgS04, and rotoevaporated at reduced pressure to a residue. Recryst;~llization of the residue from ethyl acetate/hexanes afforded the desired product (34.5 g, 82 % yield). Other acid chlorides may be used in this procedure to provide for intermediates useful in this invention.
ExamplE: B 1 Synthesis of N-(Phenylacetyl)-Iralanine Following General Procedure B" above, title compound was prepared from phenylacetyl chloride (Aldrich) and L-alanine (Aldrich) as a solid having a melting point of 102-104°C.
NMR data was as follows:

'H-nmr (CDC13): b = 9.14 (br s, 1H), 7.21-7.40 (m, 5H), 6.20 (d, J =
7.0 Hz, 1H), 4.55 (m, 1H), 3.61 (s, 2H), 1.37 (d, J = 7.1 Hz, 3H).
'3C-nmr (CDCl3): b = 176.0, 171.8, 134.0, 129.4, 127.5, 48.3, 43.2, 17.9.
Example B2 Synthesis of N (3,5-Difluorophenylacetyl)-L-alanine Following General Procedure B" above, the title compound was prepared from 3,5-difluorophenylacetyl chloride (from General Procedure A" above) and L-alanine (Aldrich).
NMR data was as follows:
'H-nmr (CD30D): 8 = 8.32 (br s, 0.3H), 6.71 (m, 2H), 6.60 (m, 1H), 4.74 (br s, 1.7H), 4.16 (m, 1H), 3.36 (s, 2H), 1.19 (d, J = 7.3 Hz, 3H).
'3C-nmr (CD30D): 8 = 175.9, 172.4, 164.4 (dd, J = 13.0, 245.3 Hz), 141.1, 113.1 (dd, J = 7.8, 17.1 Hz), 102.9 (t, J = 25.7 Hz), 49.5, 42.7, 17.5.
The following General Procedures A"'-C"' and Examples C1-C8 illustrate the synthesis of dipeptide ester starting materials useful in this invention.
Other dipeptide esters can be prepared using these procedures from commerically available or known starting materials.
GENERAL PROCEDURE A"' EDC Coupling Procedure A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at 0°C or room temperature was charged with THF, carboxylic acid (1.0 ec~, an amine or amine hydrochloride (1.1 eq.), 1-hydroxybenzotriazole hydrate (1.15-1.2 eq.), N,N-diisopropylethylamine (2.2-2.9 eq.), followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (I.15-1.2 eq.). The cooling bath was removed and the mixture allowed to warm to room temperature with stirring for 10-20 hours. The mixture was diluted with EtOAc and washed with 0.5 N aqueous HCl (2x), dilute aqueous NaHC03 (lx), brine (lx) and dried over either NaZS04 or M;gS04. The drying agent was removed by filtration and the filtrate concentrated in vacuo. The residue was either used without further purification or purified using standard procedures, such as flash chromatography on silica gel and/or remystallization.
GENERAL PROCEDURE B'"
Removal of the N ten-Boc Protecting roun The N ten-Boc-amine was dissolved in a suitable dry solvent (such as 1,4-dioxane or ethyl acetate) and the solution was cooled in an ice bath. Gaseous HCl was introduced into the solution until the mixture was saturated with HCI.
The mixture was then stirred until the re;iction was complete. The resulting mixture was concentrated under reduced pressure to yield the amine hydrochloride. The amine hydrochloride was used without purification or was triturated using, for example, diethyl ether and the resulting solid was collected by filtration.
GENERAL PRCiCEDURE C"' EEDQ Cou~lir~g Procedure A round bottom flask containing a magnetic stir bar under as atmosphere of nitrogen at room temperature was charged with THF, a carboxylic acid (1 eq.), an amine hydrochloride (1.1 eq.), and 2-e.thoxy-1-ethoxycarbonyl-1,2 dihydroquinoline (EEDQ) (1.1 eq). The reaction mixture was allowed to stir for 15 minutes and then 4-methylmorpholiine (1.1 eq) was added and stirring was continued at room temperature for 15-20 hours. The reaction mixture was concentrated in vacuo and the resulting residue was partitioned between ethyl acetate and water. The organic phase was, separated and washed with saturated aqueous NII4Cl (2x), saturated aqueous NaHC03 (2x), followed by brine (lx).
The organic phase was then dried over NaZS04 and the drying agent was removed by filtration and the filtrate concE;ntrated in vacuo. The residue was WO 98!22494 PCT/CTS97120804 either used without further purification or purified using standard procedures, such as flash chromatography on silica gel and/or recrystallization.
Example C 1 Synthesis of N (I~-Methionine)-I~phenylglycine Methl Ester Hydrochloride Following General Procedure A"' and using N (ten-butoxycarbonyl)-L-methionine (Sigma) and L-phenylglycine methyl ester hydrochloride (Bachem), the Boc-protected dipeptide was prepared as a crude solid or foam. The resulting crude dipeptide was deprotected using General Procedure B"' to afford the title compound as a crude solid or foam.
Example C2 Synthesis of N-(2-Aminobutanoyl)-Irphenylglycine Methl Ester Hydrochloride Following General Procedure A"' and using N (tent-butoxycarbonyl)-2-aminobutyric acid (Sigma) and L-phenylglycine methyl ester hydrochloride (Bachem}, the Boc-protected dipeptide was prepared as a crude solid or foam.
The resulting crude dipeptide was deprotected using General Procedure B"' to afford the title compound as a crude solid or foam.
Example C3 Synthesis of N (IrLeucine)-Irphenylglycine Methl Ester Hydrochloride Following General Procedure A"' and using N {tent-butoxycarbonyl}-L-leucine (Sigma) and L-phenylglycine methyl ester hydrochloride (Bachem), the Boc-protected dipeptide was prepared as a crude solid or foam. The resulting crude dipeptide was deprotected using General Procedure B"' to afford the title compound as a crude solid or foam.

__ 147 -_ Example C4 Synthesis of N (L-Phenylalanine)-L-phenylgl,ycine Methl Ester Hydrochloride Following General Procedure A"' arid using N (ten-butoxycarbonyl)-L-S phenylalanine (Sigma) and L-phenylglycine methyl ester hydrochloride (Bachem), the Boc-protected dipeptide was prepared as a crude solid or foam.
The resulting crude dipeptide was deprotected using General Procedure B'" to afford the title compound as a crude solid or foam.
Example CS
IO Synthesis of N (Glycine)-L-phenylglycine Methl Ester Hydrochloride Following General Procedure A"' arnd using N (tent-butoxycarbonyl)glycine (Sigma) and L-phenylglycine methyl ester hydrochloride (Bachem), the Boc-protected dipeptide was prepared as a crude solid or foam. The resulting crude 15 dipeptide was deprotecte;d using General ;Procedure B"' to afford the title compound as a crude solid or foam.
Example C6 Synthe~;is of N (L-Phenylglycine)-L-phenylglycine Methl Ester Hydrochloride 20 Following General Procedure C"' and using N (tert-butoxycarbonyl)-L-phenylalanine (Sigma) and L-phenylglycine methyl ester hydrochloride (Bachem), the Boc-protected dipeptide wa:~ prepared as a crude solid or foam.
The resulting crude dipeptide was deprote~aed using General Procedure B"' to afford the title compound as a crude solid or foam.
25 Example: C7 Synthesis of N (IrValine)-L-phenylglycine rvlethl Ester Hydrochloride _ -- 148 -_ Following General Procedure A"' and using N (tert-butoxycarbonyl)-L-valine (Sigma) and L-phenylglycine methyl ester hydrochloride (Sachem), the Boc-protected dipepdde was prepared as a crude solid or foam. The resulting crude dipeptide was deprotected using General Procedure B"' to afford the title compound as a crude solid or foam.
Example C8 Synthesis of N [(S)-2-Aminocyclohexylacetyl)-I~phenylglycine Methl Ester Hydrochloride Following General Procedure A"' and using N (tent-butoxycarbonyI)-(S)-aminocyclohexylacetic acid (e.g., Boc-L-cyclohexylglycine) and L-phenylglycine methyl ester hydrochloride (Bachem), the Boc-protected dipeptide was prepared as a crude solid or foam. The resulting crude dipeptide was deprotected using General Procedure B"' to afford the title compound as a crude solid or foam.
The following Examples D1-D4 illustrate the synthesis of various intermediates useful as starting materials for this invention. Similar intermediates can be prepared using these procedures and commerically available or known starting materials.
Example D 1 Synthesis of 3,5-Difluorophenyl-a-fluoroacetic Acid Methyl 3,5-difluoromandelate was prepared following General Procedure G
below and using commmerically available 3,5-difluoromandelic acid. The resultant a-hydroxy methyl ester was fluorinated according to the general procedure described in W. J. Middleton, et al., Org. Synth. Col. Vol. VI, 835.
Specifically, a solution of diethylaminosulfur trifluoride (1.1 ec~ in CHZCl2 was cooled to 0°C and treated with methyl 3,5-difluoromandelate (1.0 ec~ as a solution in CHZC12. After 10 min. the cooling bath was removed and the reaction was stirred at ambient temperatc~re for 30 min. The reaction was monitored by tlc (Rf = 0.65, 1:1 ethyl acetate/hexanes). The mixture was then poured onto ice and the layers separated. The organic phase was washed with saturated aqueous NaHC03 and brine. The organic layer was dried over Na2S0,, filtered, and concentrated in vac;uo. The product was purified by LC2000 chromatograpy (180 mL/min) using 10% EtoAc/hexanes as the eluent.
The resulting methyl 3,5-difluorophenyl-c~-fluoroacetate was hydrolyzed by dissolving the ester in 70% aqueous dioxame and treating with lithium hydroxide (2.0 eq.). No starting material remained by tlc after 2 h. The dioxane was removed via rotary evaporation. The aqueous mixture was first washed with ethyl acetate and then acidified with 0.01 N HCI. The aqueous layer was extracted with ethyl acetate. The organic phase was washed with brine, dried over NazS04, filtered, and concentrated. 'the crude solid was recrystallized from ethyl acetate/hexanes affording 3,5-difluorophenyl-a-f(uoroacetic acid as a white solid having a melting point of 90-110°C.
CaHsFsOz (MW = 190.1); mass spectroscopy: 190.1.
Example D2 Synthesis of (S)-2-Hydroxy-2-methyl-1-phenylprop-1-ylamine (S)-2-Hydroxy-2-methyl-1-phenylprop-1-ylamine was prepared by adding 5.0 equivalents of methyl magnesium bromide to a solution of L-phenylglycine methyl ester hydrochloride in THF at 0 C. The reaction mixture was stirred for 1 hour and then quenched with sodium bicarbonate. After standard work-up conditions, the residue was purified by silica gel chromatography using 10 MeOH/CHCl3 as the eluent.
Example D3 Synthesis of Methyl (S)-2-Amino-2-(6-methoxy-2-naphthyl)acetate (S)-2-(tent-Butoxycarbonylamino)-2-(6-methoxy-2-naphthyl)acetic acid was prepared from 2-(6-methoxy-2-naphthyl)acetic acid according to the general method described by D.A. Evans, et al., J. Amer. Chem. Soc., (1990), 112, 4011-4030. Briefly, (S)-3-(6-methoxy-2-naphthylacetyl)-4-benzyl-2-ozazolidinone was converted to (S)-3-((S)-6-methoxy-2-naphthyl-a-azidoacetyl)-4-benzyl-2-ozazolidinone via standard enolate azidation procedures using potassium 1,1,1,3,3,3-hexamethyldisilazane and trimethylsilyl azide at -78°C.
Treatment of the azide derivative with 3 equivalents of lithium hydroxide in THF then provided (S)-2-azido-2-{6-methoxy-2-naphthyl)acetic acid. Reduction IO of this intermediate, as its sodium salt, in 1:1 1,4-dioxane/water (0.05 M) with 1 atm of hydrogen, 10% Pd/C at 25°C afforded (S)-2-azido-2-(6-methoxy-2-naphthyl)acetic acid, which was then converted, without isolation, to its N-Boc derivative on treatment with 1.4 equivalents of di-ten-butyl dicarbonate and 0.47 equivalents of sodium carbonate. The product was isolated by the acidification to pH 2 with 1 N NaHS04 and extraction with three portions of ethyl acetate. The product was recrystallized from ethyl acetate/hexanes to afford a white solid, m.p. - 176°C (shrink); 197-199°C (dec).
NMR data was as follows:
'HMR (DMSO-db): b = 12.78 (s, 1H), 7.84-7.77 (m, 3H), 7.62 (d, J=8 Hz, 1H), 7.49 (d, J=8 Hz, 1H), 7.31 (d, J=2 Hz, 1H), 7.17 (dd, J=9, 2 Hz, 1H), 5.22 (d, J=8 Hz, 1H), 3.87 (s, 3H), 1.39 (s, 9H).
(S)-2-(tent-Butoxycarbonylamino)-2-(6-methoxy-2-naphthyl)acetic acid was then converted into the methyl ester using General Procedure G below. The methyl ester was then dissolved in CHZCIz and this solution cooled to 0°C.
Trifluoroacetic acid (50 molar eq.) was added and the reaction was allowed to warm to room temperature and stirring was continued for 2 hrs. The reaction mixture was then concentrated and the residue extracted into CHZCIz and washed with sodium bicarbonate solution. The organic layer was dried over Na2S04, filtered and concentrated to yield methyl (S)-2-amino-2-(6-methoxy-2-naphthyl)acetate.

Example D4 Synthesis of Methyl 2-Amino-2-(thieno[2;,3-b]thiophen-2-yl)acetate To a 3.75 mole equivalents of sodium hydride (oil free) was added DMF
and the resulting mixture was cooled to 0°C. A solution of methyl thieno[2,3-b]thiophen-2-carboxylate (1 mole eq.) andl methyl methylsulfinyl methyl sulfide (I.1 mole eq.) in DMF was then added dropwise and the reaction mixture was stirred at 0°C for 30 min and then allowed to warm to room temperature and stirring was continued for 3 h. The reaction was then quenched with methanol and the product extracted into EtOAc. Tt~e organic extracts were washed with water followed by brine, and then dried o~~er Na2S04, filtered and concentrated to give a gummy brown oil. The residue was slurried in diethyl ether and the resulting solid collected. The solid was then dissolved in hot ethyl acetate and decolorizing carbon was added. The mixture was then filtered and solvent removed to give a solid, which was used without further purification.
Acetic anhydride (10 mole eq.) and acetic acid (1.8 mole eq.) were mixed together and heated to 70°C for 15 min. at~d then cooled to 65°C. The solid sulfone from above was added in portions .and the reaction was allowed to stir at 70°C for 30 min. and then cooled and c~~ncentrated. The resulting solid was taken up in ethyl acetate and washed with ~~odium bicarbonate solution, followed by 1 N NazS203 solution. The solution was then dried over MgS04, filtered and concentrated to give methyl 2-1';eto-2-(thieno[2,3-b]thiophen-2-yl)thioacetate as a solid, which was used without further purification.
To the 2-keto compound (0.0165 moles) (4.Og) was added 270 mL of methanol and 16.5 mL of 1 N NaOH. The reaction was allowed to stir for 6 h at room temperature and then methoxyamin~e (1.38 g, 0.0165 moles) was added and stirring was continued for 18 h. The rf:action mixture was then concentrated and the residue dissolved in ethyl acetate and washed with water.
The aqueous layer was then acidified with in HCI and the oily product was extracted into ethyl acetate and washed with brine. The organic layer was dried over MgS04, filtered and concentrated to give 4.0 g of 2-(hydroxyimino)-2-(thieno[2,3-b]thiophen-2-yl)acetic acid as a yellow solid.
The methyl ester was then prepared using General Procedure G below and the oxime was reduced to an amino group using General Procedure R below to afford methyl 2-amino-2-{thieno[2,3-b]thiophen-2-yl)acetate.
Example D5 Synthesis of N Methyl-N'-BOC-Leucinamide A solution of 0.9968 g (4 mmol) of N BOC-leucine (Bachem) and 1.2323 g (7.6 mmol) of CDI in 40 mL of THF was stirred for 1 hour, and then 0.5402 g (8 mmol) of methylamine hydrochloride (Aldrich) and 0.8092 g (8 mmol) of N
methylmorpholine were added. The mixture was stirred for 16 hours, evaporated at reduced pressure to dryness, and the residue was washed thproughly with water, 1N NaOH, water, followed by diethyl ether to yield 0.886 g (3.09 mmol, 70 % ) of the title compound.
Example D6 Synthesis of N-BOC-Norleucine amide To a stirred mixture of 3.47 g (15 mmol) of BOC-norleucine (Bachem), 3.44 g (22.5 mmol) of 1-hydroxybenzotriazole monohydrate and 50 mL of dichloromethane at 0°C was added 3.45 g (1.2 mmol) of EDC. The resulting mixture was stirred at 0°C for 1 hour and then ammonia gas was bubbled ___ through the mixture for 10 min. The cooling bath was allowed to warm to room temperature and the mixture stirred for 18 hours. The mixture was evaporated at reduced pressure to dryness, triturated with 20% Na2C03. The resulting solid was collected by filtration and washed with water to yield 2.69 g ( 11.7 mmol, 78 % ) of the title compound.

Example D7 Synthesis of N [N (3,5-Difluorophenyla<:etyl)-Iralaninyl]-Iralanine The title compound was prepared by dissolving 1.98 g (0.006 mots) of N
[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester (from Example 85 below) in 60 mL dioxane and IS mL of H20 and adding LiOH (0.25 g, 0.006 mol) that has been dissolved in 15 mL of H20. After stirring for 3 hours, the dioxane was removed under reduced pressure and the residue diluted with EtOAc, the layers were separated and the aqueous layer acidified to pH 2.
The aqueous layer was back extracted with EtOAc :(~ X 100 ml), and the combined organics were dried over NaZS(~4 and the solvent was removed under reduced pressure after filtration. The resiidue was recrystallized from EtOAc/isooctane giving I.7 g (90 %). C,4H,6FzN204 requires C, 53.50 H, 5.13 N, 8.91. Anal found C, 53.30 H, 5.26 rl, 8.98.
Example D8 Synthesiis of m-Nitrophenylacetyl-L-alanine 2,4,5-Trichlorophenyl Ester m-Nitrophenylacetyl-L-alanine (1 eq.) and 2,4,5-tricholophenol (1.3 eq.) were stirred in dicholomethane. A 1.0 M solution of 1,3-dicyclohexylcarbodiimide in dichloromethaune (1.2 eq.) was added and the mixture was stirred at ambient temperature; for 16 hours. The resulting mixture was filtered and the filtrate was concentrated under reduced pressure. The resulting oil was purified by silica gel chromatography using 1:2 ethyl acetate/hexanes as the eluant to provide thf: title compound as a pink solid.
For C"H,3C13N205: Calc. 47. 30 % C, 3 . 04 % H, 6.49 % N. Found 47.57 % C, 3 .18 % H, 6.47 % N.
Example D9 Synthesi!~ of D,Ira-Methylphenylgl~rcine Ethyl Ester The title was prepared using the procedures described in J.J. Fitt and H.
W. Gschwend, J. Org. Chem., 42, No. 15, 2639 (1977). More specifically, D,L-phenylglycine (Aldrich) was stirred in dimethylformamide dimethylacetal and the mixture was heated at reflux under an atmosphere of dry nitrogen for 4 hours. After cooling, the mixture was concentrated under reduced pressure to provide a yellow oily solid. The mixture was scurried in diethyl ether and filtered through Celite. The filtrate was concentrated to an orange oil which was purified by vacuum distillation to provide a yellow oil which solidified.
The yellow solid was stirred in dry THF at -20 C under dry nitrogen. Lithium bis(trimethylsilyl)amide (1.05 eq, 1.OM solution in THF) was added dropwise.
The resulting mixture was allowed to warm to -10 C and stirring was continued for 1 hour at that temperature. Methyl iodide (1.05 eq) was added and the mixture was allowed to warm ambient temperature with stirring. After 14 hours, the mixture was concentrated. The residue was partitioned between aqueous potassium carbonate and chloroform. The organic portion was dried (sodium sulfate) and concentrated under reduced pressure. The product was purified by silica gel chromatography to yield a yellow oil. The yellow oil was stirred in absolute ethanol. Dry zinc chloride (4 eq.) was added and the mixture was heated at reflux. After 14 hours, the mixture was concentrated under reduced pressure to provide a yellow oil. The oil was partitioned between aqueous potassium carbonate and chloroform. The organic portion was dried (sodium sulfate) and concentrated under reduced pressure. The title compound was purified by silica gel chromatography.
Example D 10 Synthesis of D,IrPhthalimidoalanine Ethyl Ester Hydrochloride N {Diphenylmethylene)glycine ethyl ester (1 eq.) (Aldrich) was stirred in dry THF at -78°C under an atmosphere of dry nitrogen. Lithium bis(trimethylsiyl)amide ( 1.02 eq, 1.0 M solution in THF) was added dropwise.
The resulting mixture was stirred 1 hour at -78°C. A THF solution of N-(bromomethyl)phthalimide (1.1 eq) {Aldrich) was added and the mixture was WO 98/22494 PCT/US97/20$04 allowed to warm to ambient temperature. and then stirring was continued for 1 hour. Hydrochloric acid (600mL, 2N) vvas added and the mixture wa,~.stirled for 20 minutes. The THF was removed on a rotoevaporator. The resulting aqueous mixture was washed with diethyl ether, and then concentrated (to 100 mL) to yield a thick slurry. A white solid was collected, washed with cold water and dried in a vacuum oven to yield the title compound which was used without further purification.
Example D I 1 Synthe;~is of N (3-Nitrophenylacetyl)-Lralanine The title compound was prepared by dissolving 9.27 g (0.0348 mols) of the N (3-nitrophenylacetyl)-L-alanine methyl Ester in 60 mL of dioxane and 15 mL
of Hz0 and adding LiOH (3.06 g, 0.0731 mol) that has been dissolved in 15 mL of HZO. After stirring for 4 hours, the dioxane was removed under reduced pressure and the residue diluted with EtOAc, the layers were separated and the aqueous layer acidified to pH 2. 'fhe aqueous layer was back extracted with EtOAc {4 X 100 ml), the combined organics were dried over Na2S04 and the solvent was removed under reduced pressure after filtration. The residue was recrystallized from EtOAc/isooctane giving 7.5 g (85 %). C"H,zNz05 requires C, 52.38 H, 4.80 N, 11.11. Anal found C, 52.54 H, 4.85 N, 11.08.
falzs = - 29.9 Q 589 nm.
Example :D 12 SynthesL~ of Methyl 2-Amino-2-(3-fluorophenyl)acetate Hydrochloride Potassium cyanide (6.3, 0.1 mol) and ammonium carbonate (15.7 g, 0.2 mol) were dissolved in 50 mL of water (in a well ventilated fume hood). 3-Fluorobenzaldehyde (S.0 g, 0.04mo1) was dissolved in 50 mL of EtOH and - added to the reaction. After stirring at reflex under nitrogen atmosphere for 17 hours, the reaction was cooled to 23°C, the pH adjusted to 2.0 by the addition of 5 N HCl and cooled to 5°C. The resulting hydantoin was collected, rinsed with cold water and vacuum dried giving 3.59 of an off white solid. The hydantoin was hydrolyzed at reflux using 1 N NaOH giving 2-amino-2-{3-fluorophenyl)acetic acid which was esterified via Procedure H in methanol to give the title compound.
Example D 13 Synthesis of N [N (S)-2-Aminobutanoyl]-Irphenylglycine tent-Butyl ester A mixture of N [N (benzyloxycarbonyl)-(S)-2-aminobutanoyl]-L-phenylglycine tent-butyl .ester {4.13 g) (prepared from N (benzyloxycarbonyl)-(S)-2-aminobutanoic acid (Novabiochem) and L-phenylglycine tent-butyl ester hydrochloride (Novabiochem) using General Procedure D) and 20% Pd(OH~/C
(0.360 g) in EtOH (200 mL) was shaken in a Parr Apparatus under a hydrogen atmosphere (40 psi) for 4 hours. The solids were removed by filtration through a plug of Celite, while rinsing with EtOH. The filtrate was concentrated to an off-white oil, which was used without further purification. 'H-NMR in CDC13 revealed that - 10% traps-esterification to the ethyl occurred during this reaction. The ethyl ester was removed by flash chromatography after subsequent reaction of this compound.
Example' D 14 Synthesis of N [N IrValinyl]-Irphenylgiycine lent-Butyl ester A mixture of N [N (benzyioxycarbonyl)-L-valinyl]-L-phenylglycine tert-butyl ester (4.63 g) (prepared from N (benzyloxycarbonyl)-L-valine (Aldrich) and L-phenylglycine ten-butyl ester hydrochloride (Novabiochem) using General Procedure D) and 20% Pd(OH)z/C (0.360 g) in EtOH (200 mL) was shaken in a Pan Apparatus under a hydrogen atmosphere (40 psi) for 4 hours.
The solids were removed by filtration through a plug of Celite, while rinsing with EtOH. The filtrate was concentrated to an off white solid, which was used without further purification. 'H-NMR in CDC13 revealed that -1 %
traps-esterification to the ethyl occurred during this reaction. The ethyl ester was removed by flash chromatography after subsequent reaction of this compound.
Example: D 15 Synthesis of (S)-Phenylglycino:l Methyl Ether (S)-(+)-2-phenylglycinol (I eq.) (Ald;rich) was stirred in dry THF under an atmosphere of dry nitrogen. Sodium hydride (1 eq.) was added and the resulting mixture was stirred for I hour at ambient temperature. A THF
solution of iodomethane (I eq.) was added and the mixture was stirred for I
hour. The mixture was concentrated to provide a residue which was taken up In water and extracted with chloroform. The organic extracts were concentrated under reduced pressure to yield the title compound as an oil which was purified by silica gel chromatography to yield a crude product which was used without further purification.
Example D 16 Synthesc~ of (S)-2-Hydroxy-2-methyl-1-;phenylprop-1-ylamine To a stirred, cooled (0°C) suspension of 5.6 g (27.8 mmol) of L-phenylglycine methyl ester hydrochloride (Aldrich) in 200 mL of dry THF was added methylmagnesium bromide (46.3 mL, 138.9 mmol, 3.0 M in diethyl ether). During the addition, the internal temperature increased to 24°C.
Stirring was continued for 1 hour, after which the reaction was carefully quenched by addition of saturated sodium bicarbonate solution. The reaction mixture was partitioned between ethyl acetate and aqueous sodium bicarbonate solution, back extracting the aqueous layer ~,vith 3 volumes of ethyl acetate.
The combined organics were dried over anhydrous sodium sulfate and concentrated under reduced pressure. The product was purified by flash ' chromatography on silica gel, eluting with 10% methanol in chloroform (neutralized with ammonium hydroxide) to afford 1.96 g to the title compound.

Example D I7 Synthesis of __,-5-Chloro-2-thiophenecarboxaldehyde A solution of 2-chlorothiophene (Aldrich; 1 molar eq.) in THF was cooled to -78 ° C and treated with n-butyllithium ( 1. 6M in hexanes; 1.1 molar eq. ) in a dropwise manner. The resultant yellow solution was stirred at -78°C for minutes. Dimethylformamide (1.1 molar eq.) was added dropwise and the reaction stirred and additional 30 minutes. The mixture was diluted with methylene chloride and washed with 10% acetic acid, 1 M potassium carbonate, and brine. The organic phase was dried over NaZS04, filtered, and concentrated. The residue was purified by HPLC eluting with 15 % ethyl acetate/hexanes to afford the title compound.
Example D 18 Synthesis of (S)-(-)-a-Methylbenzylisocyanide Prepared according to the general procedure of Wolber, E. K. A. ;
Ruchardt, C. Chem. Ber. 1991, 124, 1667. To a suspension of 1,1'-carbonyldiimidazole (1.6 molar eq.; Aldrich) in acetonitrile at 0°C was treated with methanesulfonic acid (3.2 molar eq.; Aldrich) in a dropwise fashion. A
very thick suspension results. S-(-)-a-Methylbenzyl formamide (1 molar eq.;
from Example D 19 below) was added as a solution in acetonitrile via cannulation. The mixture was stirred overnight at ambient temperature. The suspension was filtered, washing with acetonitrile. The filtrate was concentrated and purified via flash chromatography eluting with 30% ethyl acetate/hexanes. The oil was further purified via bulb-to-bulb distillation (80°C, 0.04 mm Hg) giving a pale yellow oil in 51 % yield. Calcd for C9H9N:
C, 82.41; H, 6.92; N, 10.68. Found: C, 82.56; H, 6.82; N, 10.71.
Example D 19 Synthesis of (S)-(-)-a-Methylbenzyl formamide (S)-(-)-a-Methylbenzylamine (1 mol~~r eq.) was treated with ethyl formate (80 molar eq.; Aldrich). A precipitate formed immediately. The suspension was heated to reflux (SS°C) for 3 hours. The precipitate went into solution upon heating. The solution was cooled to ambient temperature and concentrated via rotary evaporation. The resultant solid was used without purification.
Examples D20 Synthe~~is of 3-(Phenyl)benzaldehyde A solution of 3-bromobiphenyl (Aldrich; 1 molar eq.) in dry THF was cooled to -78°C and treated with ten-butyllithium (Aldrich; 1.7 M in hexanes, 2 molar eq.) in a dropwise manner. The :reaction was allowed to stir at -78°C
for 40 minutes. Dimethylformamide (Ald:rich; 2.5 molar eq.) was added and stirring continued an additional 20 minute:.. The mixture was partitioned in a separatory funnel between methylene chloride and water. The organic layer was dried over NaZS04, filtered, and concE:ntrated. The residue was purified via HPLC eluting with 5 % ethyl acetate/he~xanes. The desired aldehyde was obtained in 71 % yield.
Example D21 Synthesis of 4-(Cyclohexyl)be~nzaldehyde 18-Crown-6 (Aldrich; 4 molar eq.) and pyridinium chlorochromate (Aldrich; 4 molar eq.) were added together in chloroform and stirred for 20 minutes. 4-Cyclohexylbenzylalcohol (from Example D22 below; 1 molar eq.) was added and stirring continued for 3 hours. Ether was added and the mixture filtered through a plug of silica eluting with ether. The solvent was removed via rotary evaporation. The residue was di;~solved in ether and washed with water. The organic layer was dried over NazS04, filtered, and concentrated.

__ __ 16p __ Example D22 Synthesis of 4-(Cyclohexyl)benzyl Alcohol To a solution of 4-cyclohexylbenzoic acid (Aidrich; 1 molar eq.) in toluene was added diiso-butylaluminum hydride (Aldrich; 1 M in toluene; 4 molar eq.) over a 2 hour period. After addition was complete, the reaction was heated to 60°C for 1 hour. The reaction was cooled to 5°C and quenched with saturated aqueous ammonium chloride. The layers were separated and the aqueous layer extracted with ethyl acetate. The combined organics were filtered to remove salts and concentrated.
Example D23 Synthesis of 3,5-Difluorophenyl-a,a-difluoroacetic Acid A solution of ethyl 3,5-difluorophenyl-«,a-difluoroacetate (from Example D24 below; 1 molar eq. ) in 50 % aqueous ethanol was treated with lithium hydroxide (1.5 molar eq.). The solution was stirred for 3 hours at ambient temperature then concentrated via rotary evaporation. The residue was taken up in water; a small amount of 1 N NaOH was added to make basic. The aqueous mixture was extracted with ether. The aqueous layer was acidified to pH 3 with 1 N HCI. The acid was extracted thrice with methylene chloride.
The combined methylene chloride extracts were dried over Na2S0~, filtered, and concentrated.
Example D24 Synthesis of Ethyl 3,5-Difluorophenyl-a,a-difluoroacetate Ethyl 3,S-difluorophenyl-a-ketoacetate (Rieke Metals, Inc. #14014; 1 molar eq.) was treated with (diethylamino)sulfur trifluoride (DAST) (2.5 molar eq.).
The reaction was stirred at ambient for 72 hours then heated to 50°C for 6 hours. The mixture was poured over ice and extracted with methylene chloride. The organic layer was washed with saturated sodium bicarbonate, dried over NaZS04, filtered, and concentrated. The residue was purified via 13PLC eluting with 2 % ethyl acetate/hexanes.
Example D25 Synthesis of N [N (3,5-diftuorophenylacetyl)-lL-alaninyl]-D,I~.phenylglycine N [N (3,5-difluorophenyIacetyl)-L-alminyl]-L-phenylglycine methyl ester (from Example 111 below) was hydrolyze,i according to Procedure AF. The acid was recrystaIlized from isooctane/EtOAc providing a mixture of diastereomers at the phenylglycine center. Elemental analysis; C~9H,8FzN404 requires C, 60.63 H, 4.82 N, 7.44. Foun~~; C, 60.65 H, 5.02 N, 7.37. Mass spectroscopy (MH+ 377).
Example D26 Synthesis of 3-(4-Iodophenyl)propylamine N (3-bromopropyl)phthalimide (1 eq., .Aldrich) and 4-iodophenol (1 eq., Aldrich) and potassium carbonate (2 eq.) was stirred in acetonitrile. The mixture was heated at reflux. After 64. hour, the reaction mixture was concentrated to a thick mixture which was ;,lurried in water. A white solid was collected, washed with water and vacuum dried.
The white solid was stirred in ethanol. Anhydrous hydrazine (2 eq.} was added and mixture was heated at reflux for 18 hours. The reaction mixture was concentrated to yield a solid which was treated with 1N NaOH and extracted with CHCl3. The organic portion was dried, concentrated then diluted with ether: The mixture was treated with dry H(~l. The title compound was collected as a white solid and vacuum dried.
Example L~27 Synthesis of 2-Amino-1-phthalimidopenl:ane Hydrochloride WO 98122494 PCTIUS97l20804 2-Amino-1-pentanol was stirred in a mixture of chloroform and saturated aqueous sodium bicarbonate. Di-tert-butyl dicarbonate (1.05 eq.) was added in one portion and the mixture was stirred until starting material was consumed.
The organic portion was separated, dried (sodium sulfate) and concentrated.
The crude material was purified by silica gel chromatrography using 1:1 ethyl acetate/hexanes.
The product was dissolved in THF. Triethylamine (1.1 eq.) was added and the mixture was cooled in an ice bath. Methanesuifonyl chloride (1.1 eq.) was added dropwise and the mixture was stirred until starting material was consumed. The mixture was concentrated under reduced pressure then was partitioned between ethyl acetate and water. The organic portion was separated, dried (sodium sulfate) and concentrated to yield a white solid which was chromatographed on silica gel using 30% ethyl acetate in hexanes and finally crystallized from 1-chlorobutane/hexanes.
The crystalline product was stirred in dry DMF and potassium phtalimide (1.1 eq.) was added. The mixture was stirred for 18 hours then was concentrated under reduced pressure. The residue was partitioned between ethyl acetate and water. The organic portion was dried and concentrated to yield a white solid. The solid was taken up in chloroform and filtered through a plug of silica. Fluent containing product was concentrated to yield the crude product as a white solid.
The white solid was taken up in dry dioxane and resulting solution was saturated with gaseous HCI. After stirring for 30 minutes, the mixture was concentrated to yield a white solid which was triturated in ether. The title compound was collected, washed with ether and dried in a vacuum oven.
Example D28 Synthesis of D,L-3,5-Difluorophenylglycine WO 98122494 PCTlUS97/20804 KOH (11.76 grams), LiCI (2.95 grams), saturated aqueous ammonia (20 mL), and benzyltriethylammonium chloride (0.805 grams) were stirred and chilled in CH2Clz (17 mL). Gaseous ammonia was bubbled into this mixture with chilling (0°C) to saturation. To the ;resulting mixture was added 3,5-difluorobenzaldehyde (5.0 grams) (Lancaster) and chloroform (4.46 mL), dissolved in CHZC12 (17.5 mL) with concurrent saturation with ammonia gas.
The resulting mixture was stirred cold for 4 hours and at 22.5°C for 96 hours.
Water (60 mL) and CHZC12 (20 mL) were added; the layers separated, and the aqueous layer was extracted 3 times more with CHZC12. The aqueous layer was reduced in vacuo by 50 % . The pH was ad justed to 6.5 with cold conc. HCl whereupon white crystals of D,L-3,5 diflu~~rophenylglycine formed (3.4343 grams).
Example D29 Synthesis of - I,-3,5-Difluorophenylglycine Methyl Ester Tartate Salt 3.43 Grams of D,L-3,5 difluorophenyl,glycine (from Example D28 above) was slurried in 50 mL methanol and 2.5 m:L conc. HZS04. The reaction mixture was heated under gentle reflux for 18 hours. The mixture was chilled in and ice bath and the pH of the solution was adjusted to 7.0 with saturated aqueous ammonia. The volatile organic solvents were removed in vacuo and the aqueous portion was extracted three times with CHZCl2; the combined organic layers dried, filtered, and reduced i,n vacuo to provide 2.680 grams of crude ester. This ester, benzaldehyde (1.4085 grams), and (-) tartaric acid (1.9921 grams), were dissolved in 20.5 mL of hot ethanol and stirred slowly __ 25- for 72 hours as the title compound crystallized. The product was filtered and dried to provide 3.4805 grams of the (-) tar~:arate salt.
Example D30 Synthesis of N (3,5-Difluorophenylacetyl)-Ir3,5-difluorophenylglycine __ 1~ __ L-3,5-Difluorophenylglycine (0.4291 g) (prepared from L-3,5-difluorophenylglycine (-)-tartarate salt (from Example D29 above) by neutralization) and 3,5-difluoroacetic acid 0.367 gram were dissolved in THF.
EEDQ coupling using General Procedure AN afforded 0.7441 grams of the title compound as the methyl ester. The ester was dissolved in 1,4-dioxane (10 mL), chilled and LiOH.H20 (89.0 mg) in water (10 mL) was added slowly and the mixture was stirred for 2 hours at 22.5°C. EtOAc (30 mL) and 1N HCl were added and the aqueous layer extracted two times. The combined organic layers were dried (MgS04) and reduced in vacuo to provide the title compound (700.8 mg).
Each of the compounds set forth in the following examples was prepared by one of the following general procedures, unless otherwise indicated.
GENERAL PROCEDURE A
EDC Coupling~Procedure I
To a 1:I mixture of the corresponding carboxylic acid and amino ester/amide in CHZCIZ or DMF at 0°C was added 1.5 equivalents triethylamine, followed by 2.0 equivalents hydroxybenzotriazole monohydrate, then 1.25 equivalents of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC). The reaction mixture was stirred overnight at room temperature and then transferred to a separatory funnel. The mixture was washed with water, saturated aqueous NaHC03, 1 N aqueous hydrochloric acid, and saturated aqueous sodium chloride, and then dried over MgS04. The solution was stripped free of solvent on a rotary evaporator to yield the crude product.
GENERAL PROCEDURE B
EDC Coupline Procedure II
The carboxylic acid was dissolved in methylene chloride in a round-bottomed flask. The amino acid (1 eq.), N methylmorpholine (5 eq.) and hydroxybenzotriazole monohydrate (1.2 eq.) were added in sequence. A

cooling bath was applied to the round-botl:omed flask until the solution reached 0°. At that time, 1.2 eq. of 1-(3-dimethy:laminopropyl)-3-ethylcarbodiimide hydrochloride was added. The solution was then allowed to stir overnight and come to room temperature under N2 pressure. The reaction mixture was then S washed with saturated aqueous Na2C03, 0.1 M citric acid, and brine before drying with NazS04 and removing the solvents to yield the crude product. Pure products were typically obtained by flash chromatography in an appropriate solvent.
GENERAL PROCEDURE ~
EDC Coupling Procedure III
A round-bottomed flask was charged v~ith the appropriate carboxylic acid (1.0 eq), hydroxybenzotriazole hydrate (l.:l eq) and the appropriate amine (1.0 eq) in THF under a nitrogen atmosphere. An appropriate amount (1.1 eq. for the free amine and 2.2 eq. for amine hydrochloride salt) of a suitable base, 1S such as Hunig's base was added to the stiwed mixture, followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide lhydrochloride (EDC) (1.1 eq).
After stirring for about 4 h to 17 h at room temperature, the solvent was removed at reduced pressure and the residue taken up in EtOAc (or a similar solvent)/H20. The extracts were washed with saturated NaHC03, 1 N aqueous hydrochloric acid, brine and dried over Na2S04. In some cases, the isolated product required further purification using ~~tandard procedures, such as chromatography and/or recrystallisation.
GENERAL PROC.'EDURE D
EDC Coupling-Procedure IV
A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at 0°C was charged with THF, ;an amine or amine hydrochloride (1.0 eq.), carboxylic acid (l.l eq.), 1-hydro~xybenzotriazole hydrate (1.15-1.2 eq), N,N-diisopropylethylamine (2.3 eq.), followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (1.1S-1.2 eq.).

The cooling bath was removed and the mixture allowed to warm to room temperature with stirring for 10-20 hours. The mixture was diluted with EtOAc and washed with 0.5 N aqueous. HCl (2x), dilute aqueous NaHC03 (lx), brine (lx) and dried over either NazS04 or MgS04. The drying agent was removed by filtration and the filtrate concentrated in vacuo. The residue was either used without further purification or purified by standard procedures, such as flash chromatography on silica gel and/or recrystallization.
GENERAL PROCEDURE E
EDC Coupling Procedure V
A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at 0°C or room temperature was charged with THF, carboxylic acid (1.0 eq), an amine or amine hydrochloride (1.0-1.1 eq.), 1-hydroxybenzotriazole hydrate (1.1-1.2 eq.), N,N-diisopropylethylamine (2.2-2.9 eq.), followed by 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (l.l-1.2 eq.). The cooling bath was removed and the mixture allowed to warm to room temperature with stirring for 10-20 hours. The mixture was diluted with EtOAc and washed with 0.5 N aqueous HC1 (2x), dilute aqueous NaHC03 (lx), brine (lx) and dried over either Na2S04 or MgS04. The drying agent was removed by filtration and the filtrate concentrated in vacuo. The residue was either used without further purification or purified using standard procedures, such as flash chromatography on silica gel and/or recrystallization.
GENERAL PROCEDURE F
EDC Coupline Procedure VI
A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at 0°C was charged with THF, carboxylic acid (1.0 eq.), an amine or amine hydrochloride (1.1 eq.), N,N-diisopropylethylamine (2.2-2.3 eq.), followed by 1-{3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (1.1-1.2 eq.). The cooling bath was removed and the mixture allowed to warm to room temperature with stirring for 10-20 hours. The mixture was diluted with EtOAc and washed with 0.~! N aqueous HCl (2x), dilute aqueous NaHC03 (lx), brine (lx) and dried over either Na2S04 or MgSO,. T~~ drying agent was removed by filtration and the filtrate concentrated in vacuo. The residue was either used without further Fmrification or purified using standard procedures, such as flash chromatography on silica gel and/or recrystallization.
GENERAL PROCEDURE G
Methyl Ester Preparation To 1-methyl-3-nitro-1-nitrosoguanidine (1.2 eq.) in diethyl ether cooled to 0°C was added 40% KOH until bubbling ceased. This mixture was then decanted into a plastic tube containing KOH pellets as a drying agent. The solution was then added to the appropriate carboxylic acid and the mixture was stirred until the reaction was complete (as determined, for example, by tlc).
The reaction was then quenched with acetic acid and extracted into EtOAc.
Removal of the solvent afforded the desired methyl ester.
GENERAL PROCEDURE H
Carboxylic Acid Ester Preparation To the appropriate amino acid or carboxylic acid in the appropriate alcohol was bubbled anhydrous HCL gas until the solution was saturated. The reaction was stirred overnight at 25°C and the solvent was then removed under reduced pressure. The residue was then dissolved in EtOAc and this solution was washed with sodium bicarbonate solution. The organic layer were then dried over sodium sulfate, filtered and solvent removed to afford the desired ester.
GENERAL PROCEDURE I
- tert-Butyl Ester 1~?reparation I
To a solution of an N CBZ-protected ~~mino acid in CHZC12 was added 1.5 equivalents of N,N'-diisopropyl-O-t-butyli;sourea (prepared by standard literature methods such as those found in ,~,~ynthesis (1979), p. 561), and the reaction was heated to reflux for I7 h. An additional 1.5 equivalents of isourea were then added, and reflux was continued for another 7 h. The reaction was then cooled to room temperature and filtered through a bed of Celite 545, then stripped to dryness to leave a clear oil. The residue was dissolved in hexanes and filtered to remove solids, and the filtrate was washed with saturated aqueous NaHC03, water, saturated aqueous NaCI, and dried over MgS04. The solution was concentrated under reduced pressure to leave the product.
GENERAL PROCEDURE J
tent-Butyl Ester Preparation II
The reaction was conducted in a sealed tube using the appropriate carboxylic acid, a catalytic amount of HZS04 (0.03 eq.) and an excess of condensed iso-butylene in dioxane or CHZC12 at -20°C. The reaction times varied from about 48 hours to about 120 hours. When the reaction was complete, the solvent was removed under reduced pressure and the residue dissolved in diethyl ether. This solution was washed with sodium bicarbonate solution and the organic layer dried over sodium sulfate, filtered and solvent removed. The resulting product was purified using standard procedures, such as HPLC or titration using, for example, diethyl ether/hexanes.
GENERAL PROCEDURE K
Amide Preparation I
To a solution of 3 equivalents of the desired amine in 1,2-dichloroethane was added 5.2 equivalents triethylaluminum subsurface. After stirring for 30 minutes at room temperature, a solution of the desired ester dissolved in 1,2-dichloroethane was added. The reaction was refluxed until tlc showed complete conversion, typically 3h. The reaction was then cooled to 0°C and quenched with 10% aqueous hydrochloric acid (Note: the acid should be added slowly as some foaming occurs during its addition). The mixture was transferred to a separatory funnel and the layers were separated. The aqueous phase was washed with ethyl acetate, and the organic phases were washed with saturated aqueous NaCI, dried over MgS04, and concentrated under reduced pressure to leave the crude product.
Alternatively, if the product is acid soluble, after the reaction is quenched, the reaction volume was reduced to about one-third of its initial volume under reduced pressure. To the resulting solution was added 20 % aqueous potassium sodium tartrate (Rochelle's salt) and ethyl acetate. The pH of the solution was then adjusted to -13, and the aluminum salts dissolved in the aqueous solution.
The organic phase was separated, and the ;aqueous phase was extracted with ethyl acetate. The combined organic solution was washed with saturated aqueous NaCI, dried over MgS04, and concentrated under reduced pressure to leave the crude product.
GENERAL PROCEDURE L
Amide Preparation II
The carboxamide was prepared from its corresponding ester using the procedure described in Hogberg, T. , et. al. " J. Organic Chem. , 1987, 52, 2036.
GENERAL PROCEDURE M
Amide Preparation III
To the appropriate carboxylic acid (1.0~ eq.) in THF was added N
methylmorpholine (1.1 eq.) and the solution was cooled to -20°C to 0°C. iso-butyl chloroformate (1.1 to 2. l eq.) was xh~~n added and the reaction mixture was stirred at -20°C to 0°C for 30 min. A mixture of the appropriate amino acid, water and 1.5 eq. of potassium carbonate was then added, and the resulting mixture was allowed to warm to room temperature and stir for 2 hrs.
The reaction mixture was then poured into 'water and washed with EtOAc. The pH of the water layer was then adjusted to 2.0 with 5 N HCl and the water layer was extracted with EtOAc. The combined organic layers were dried over sodium sulfate, filtered and the solvent removed under reduced pressure. The resulting crude amide was used without further purification or purified using standard procedures such as chromatography or titration using, for example, diethyl ether/hexanes er EtOAc/hexanes.
GENERAL PROCEDURE N
Hydrolxsis of Carboxylic Acid Esters To the ester in a 1:1 mixture of CH30H/H20 was added 2-5-equivalents of KZCO3. The mixture was heated to 50°C for 0.5-1.5 h until tlc showed complete reaction. The reaction was cooled to room temperature and the methanol was removed on a rotary evaporator. The pH of the remaining aqueous solution was adjusted to about 2, and ethyl acetate was added to extract the product. The organic phase was then washed with saturated aqueous NaCI
and dried over MgS04. The solution was stripped free of solvent on a rotary evaporator to yield the product.
GENERAL PROCEDURE O
Removal of N Carbobenzyloxy (CBZI Protecting Groups The N CBZ-protected compound was dissolved in ethanol in a hydrogenation flask and a catalytic amount of 10 % Pd/C was added. The mixture was hydrogenated at 20 psi Hz on a Parr shaker for 30 min. The reaction was then filtered through a pad of Celite 545 and stripped free of solvent on a rotary evaporator to yield the product.
GENERAL PROCEDURE P
Removal of the N tert-Boc Protecting Group The N tent-Boc-amine was dissolved in a suitable dry solvent (such as 1,4-dioxane or ethyl acetate) and the solution was cooled in an ice bath. Gaseous HCl was introduced into the solution until the mixture was saturated with HCI.
The mixture was then stirred until the reaction was complete. The resulting mixture was concentrated under reduced pressure to yield the amine hydrochloride. The amine hydrochloride was used without purification or was triturated using, for example, diethyl ether and the resulting solid was collected by filtration.
GENERAL PRC)CEDURE Q
Halide ExchangeSFir~kelstein) Reaction The corresponding alkyl bromide or alkyl chloride was dissolved in 20 mL
of methyl ethyl ketone and 1 eq. of NaI was added. The reaction was heated to 60°C and stirred overnight. The cooled reaction mixture was extracted with dichloromethane (2 x 30 mL) and the combined extracts were roto-evaporated at reduced pressure to give the crude product. Pure products were typically obtained by flash chromatography in an appropriate solvent.
GENERAL PROCEDURE R
Oxime Reduction I
To the oxime ester in the alcohol corresponding to the ester was added formic acid (500 eq.) and water (500 eq.). The reaction mixture cooled to 5°C
and zinc dust (3.8 eq.) was added in portions over 20 min. The reaction was then allowed to warm to room temperature and stirring was continued for 3 hours. The reaction was then filtered over HYFLO and the solvent removed under reduced pressure. The residue was dissolved in EtOAc and this solution washed with saturated sodium bicarbonate ;solution. The organic layer was then dried over sodium sulfate, filtered and solvent removed to afford the product.
GENERAL PROCEDURE S
° Reduction of Esters to Alcohols To a 0°C solution of the starting ester in anhydrous THF was added 1.0 equivalents of LiBH4 in THF. The reaction was stirred at room temperature overnight and then quenched with water. The THF was removed on a rotary evaporator and ethyl acetate was added. The phases were separated and the organic phase was washed with saturated aqueous sodium chloride solution, dried over magnesium sulfate, and concentrated under reduced pressure to afford the alcohol product.
GENERAL PROCEDURE T
SDI Coupling Procedure A solution of the appropriate acid (3.3 mmol) and 1,1'-carbodiimidazole (CDI) in 20 mL THF was stirred for 2 h. The amino acid ester hydrochloride (3.6 mmol) was added, followed by 1.5 mL (10.8 mmol) of triethylamine. The reaction mixture was stirred overnight and then dissolved in 100 mL of diethyl ether, washed with 10% HCl three times, brine once, 20% potassium carbonate once and brine once. The solution was dried over magnesium sulfate, filtered, and evaporated at reduced pressure to yield the product.
GENERAL PROCEDURE U
EDC Coupling Procedure VII
A mixture of the appropriate carboxylic acid (1 eq.), 1-hydroxybenzotriazoie (1.6 eq.), the appropriate amine (1 eq.), N
methylmorpholine (3 eq.) and dichloromethane (or DMF for insoluble substrates), cooled in an ice-water bath, was stirred until a clear solution was obtained. EDC (1.3 eq.) was added to the reaction mixture and the cooling bath was allowed to warm to ambient temperature over 1-2 h. The reaction was then stirred overnight. The reaction mixture was then evaporated at reduced pressure to dryness under vacuum and 20% aqueous potassium carbonate was added to the residue. The mixture was shaken vigorously and allowed to stand for hours or overnight, if necessary, until the oily product to solidify. The solidified product was then filtered off, washed thoroughly with 20% potassium carbonate, water, ZO% HCI, and water to give the product. No racemization was observed using this procedure.
GENERAL PROCEDURE V
O-Acvlation of Alcohols To a solution of the alcohol (e.g., N [(S)-1-hydroxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide from Example 228 below) in pyridine was added 4 equivalents of acetic anhydride and the reaction was stirred at room temperature for 2.5 h. The reaction was quenched onto ice and then ethyl acetate was added and the phases were separated. The organic phase was washed with 10% HCI, water, saturated aqueous NaCI, and dried over MgS04.
The solution was stripped free of solvent on a rotary evaporator to yield the product.
GENERAL PROCEDURE W
O-Esterification c~f Alcohols To a suspension of 0.95 equivalents of NaH in THF was added an alcohol (e.g., N [(S)-1-hydroxyhex-2-yl]-N'-(3,5-diiluorophenylacetyl)-L-alaninamide from Example 228 below) dissolved in THF. This solution was cooled to 0°C, then 1.1 equivalents of an acyl chloride (e.g. trimethylacetyl chloride) was added. The reaction was stirred at room temperature overnight, then was quenched with water and ethyl acetate. ThE: organic phase was washed with water, saturated aqueous NaCI, and dried over MgS04. The solution was stripped free of solvent on a rotary evaporator to yield the crude product.
GENERAL PROCEDURE X
BOP Coupling Procedure A solution of the carboxylic acid (1.0 e:q.) and N-methyl morpholine (1.5 eq.) in dichloromethane was cooled to -20°C under nitrogen. BOP (1.05 eq.) was added in one portion and the reaction rnixture was maintained at -20°C for 15 minutes. The appropriate alcohol (1.2 eq.) was added and the reaction mixture was allowed to warm to room temperature and stirring was continued for 12 hours. The reaction mixture was thf;n poured into water and extracted . with ethyl acetate (3x) and the combined organic layers were washed with saturated aqueous citric acid (2x), saturated aqueous sodium bicarbonate (2x), brine (lx), and then rotoevaporated at reduced pressure to provide the crude product.
GENERAL PROCEDURE Y
BOC Removal Using TFA
The Boc-protected compound was added to a 1:1 mixture of dichloromethane and trifluoroacetic acid (TFA) and the reaction mixture was stirred until tlc indicated complete conversion, typically 2 hours. The solution was then stripped to dryness. The residue was suspended in dichloromethane and again stripped to dryness to remove excess TFA. The residue was placed under high vacuum for several hours to afford the desired TFA salt.
GENERAL PROCEDURE Z
Amide Preparation IV
The trichlorophenyl ester ( 1 eq. ) was stirred in DMF or THF and the oxime or amine (1.2 eq.) was added. The mixture was stirred at ambient temperature for 1-4 hours. In cases where the hydrochloride salt form of an amine was used, a suitable base such as diisopropylethylamine (1.2 eq.) was also added. The resulting mixture was concentrated under reduced pressure to yield an oil or residue which was used without further purification or was purified by standard procedures, such as silica gel chromatography and/or recrystallization.
GENERAL PROCEDURE AA
Sodium Borohydride Reduction The ketone was dissolved in MeOH and treated with 1.0 equivalent of sodium borohydride. The reaction was stirred until tlc showed the starting material was consumed, typically 1 hour. The reaction mixture was then evaporated at reduced pressure and chromatographed to afford the alcohol product.
T

__ 175 -_ GENERAL PROCEDURE AB
Preparation Amino Acid Derivatives Using ChiraI Amines (S)-(+)-a-Methylbenzyl amine was added dropwise to a solution of 4 (phenyl)benzaldehyde (1 molar eq.) in TH:F followed by the addition of 1.0 molar eqivalent of zinc chloride. The reaction mixture was allowed to stir at room temperature for 5 h. The cloudy mixture was then cooled to -30°C
and treated with tert-butylisocyanide (1.05 molar eq.). After 20 minutes, N (3,5-difluorophenylacetyl)-L-alanine was added and stirring was continued at -30°C
for 120 h. The reaction mixture was then poured into a seperatory funnel and diluted with CHZCIZ, washed with sodium bicarbonate. The organic layer was then washed with 0.5 N HCI, followed by brine. The organic layer was then dried over NaZS04, filtered and concentrated to give N tent-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninylJ-N'-(S)-a-methylbenzyl-2-amino-2-(4-phenylphenyl)acetamide, as a mixture of isomers. At this stage, the isomers were typically separated by HPLC chromatography using, for example, a gradient of 30 to 35 % EtOAc/hexanes. Tlhe a-methylbenzyl protecting group was then removed from the S,S isomer by added 10 molar equivalents of triethylsilane and 20 molar equivalents of rrifluoroacetic acid to the S,S
isomer.
The reaction was then heated to 37°C for 3 h and then poured into ethyl acetate and washed with sodium bicarbonate. The; organic layer was dried over NazS04, filtered and concentrated. The residue was purified by recrystallisation from ethyl acetate or ethyl acetate/hexanes. Various other aldehydes and carboxylic acids can be used in this procedure to provide for a variety of compounds useful in this invention.
___ 25 GENERAL PROCEDURE AC
Oxime Reduction II
To a solution of the oxime ester in the alcohol corresponding to the ester was added a catalytic amount of acetic acid and 0.1 mole equivalent of 10 %
Pd/C. The reaction vessel (Parr shaker) was charged with hydrogen to 40 PSI
and this mixture was shaken for 3 h. The reaction mixture was then filtered _- 176 -_ over HyFlo and concentrated. The residue was dissolved in ethyl acetate and washed with a saturated solution of sodium bicarbonate. The organic layer was then dried over Naz,S04, filtered and concentrated to give the desired amine.
GENERAL PROCEDURE AD
Mitsunobu Reaction To a solution of N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester in 20 mL of THF was added 1.3 equivalents each of triphenylphosphine and diethyl azodicarboxylate (DEAD), and 1.0 equivalents of an alcohol. The mixture was stirred a room temperature overnight and the solvent was then removed. The residue was purified by standard procedures, such as chromatography and/or recrystallization.
GENERAL PROCEDURE AE
O-Alkylation of ~rosine Derivatives To a solution of N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester in 20 mL of acetone was added 1.3 equivalents of an alkyl bromide and 3.0 equivalents of potassium carbonate as a fine powder and a catalytic amount of sodium iodide. The reaction mixture was stirred at room temperature overnight and then partitioned between DCM and water. The organic layer was dried over anhydrous sodium sulfate, stripped of solvents and purified using standard procedures, such as chromatography and/or recrystallization.
GENERAL PROCEDURE AF
Hvdrolvsis of Carboxylic Acid Esters A solution of the carboxylic acid ester (1.0 eq.) and lithium hydroxide (1.1 eq.) in 1:2 water/dioxane was stirred at 23°C for 1 hour. The reaction mixture was then acidified to pH 3 with 1 N HCl and extracted with ethyl acetate.
Concentration of the ethyl acetate extracts provided the product. In some cases, __ 177 -_ the product was further purified using standard procedures, such as chromatography and/or recrystailization.
GENERAL PROCEDURE AG
Methyl Ester Formation from Amino Acids - 5 The amino acid (amino acid or amino .acid hydrochloride) is suspended in methanol and chilled to 0°C. HCl gas is bubbled through this solution for 5 minutes. The reaction is allowed to warm to room temperature then stirred for 4 hours. The solvents are then removed to afford the desired amino acid methyl ester hydrochloride. This product is usually used without further purification.
GENERAL PROCEDURE AH
EEDQ Coupling Procedure A round bottom flask containing a magnetic stir bar under as atmosphere of nitrogen at room temperature was charged 'with THF, the carboxylic acid (1 eq.), the amine hydrochloride (1.1 eq.) and EEDQ (1.1 eq.) and the reaction mixture was allowed to stir for 15 minutes. 4-Methylmorpholine (1.1 eq.) was added to the reaction and stirnng was continued at room temperature for 15-20 hours. The reaction mixture was then concentrated in vacuo and the resulting residue was partitioned between ethyl aceta~.e and water. The organic phase was separated and washed with saturated act. NH4C1 (2x), saturated aq.
NaHC03 (2x), followed by brine (lx). Organic phase dried over Na2S04. The drying agent was removed by filtration and the filtrate concentrated in vacuo.
The residue was either used without further purification or purified using standard procedures, such as flash chromatography on silica gel and/or recrystallization.
GENERAL PROCEDURE AI
N tent-BOC Protection of Amino Acids __ 178 -_ A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at room temperature was charged with dioxane, water, 1.0 N aq.
sodium hydroxide, and the amino acid (1 eq). Stirring was initiated and the flask was cooled in an ice bath. Di-t-butyldicarbonate ( 1.1 eq) was added to the reaction mixture, followed by removal of the ice bath and slow warming to room temperature over 1 hour. The reaction was partially concentrated on the rotary evaporator followed by the addition of ethyl acetate. The flask was re-cooled in an ice bath and the mixture was acidified to a pH of 2-3 through the addition of potassium bisulfate. The reaction was transferred into a seperatory funnel and the organic layer was separated. The aqueous layer was extracted with ethyl acetate and the combined organic layers were dried over NaZS04.
The drying agent was removed by filtration and the filtrate concentrated in vacuo. The solid was used without further purification.

15- Removal of N CarbobenzYloxy~CBZ) Protecting Groins A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at room temperature was charged with methanol, tetrahydrofuran, 20% Pd(OH)2/C (1 mass eq.), and the CBZ-protected dipeptide. Stirring was initiated and the flask was purged (3x) with hydrogen. The reaction mixture was allowed to stir at room temperature overnight under an atmosphere of hydrogen. The reaction was filtered and the filtrate was concentrated in vacuo.
The resulting solid was used as is or purified via silica gel chromotography.
GENERAL PROCEDURE AK
Addition of N Carbobenzvtoxy fCBZ) Protecting Groups A round bottom flask containing a magnetic stir bar under an atmosphere of nitrogen at room temperature was charged with water, sodium carbonate (2.2 eq.), and amino acid (1.0 eq.). The slurry was stirred at room temperature for 1 hour. Benzylchloroformate was added to the reaction and stirring was continued overnight. The reaction mixture was extracted with CHZC12 (3x) and __ 179 -_ the combined organic extracts were acidified to a pH of 2-3. The resulting solid was isolated via vacuum filtration.
GENERAL PROCEDURE AL
Preparation of Amino Acid Deriv-atives Using Chiral Amines II
A solution of aryl aldehyde (1 molar ~eq.) in THF was treated with S-(-)-a-methylbenzylamine (1 molar eq.), followed by MgS04. The reaction mixture was stirred for 1 hour then treated with ten-butylisocyanide (1.5-2.0 molar eq.) and N (3,5-difluorophenylacetyl)-L-alaninE: (1.5-2.0 molar eq.). The reaction was allowed to stir for 60 hours. The reaction was diluted with methylene chloride and washed with 0.01 N HCl and saturated aqueous NaHC03. Each aqueous wash was back-extracted with methylene chloride. The combined organics were washed with brine, dried over NaZSO,, filtered and concentrated to give N ten-butyl-N'-[1V (3,5-difluorophc:nylacetyl)-L-alaninyl]-N'-R-a-methylbenzyl-2-amino-2-DL-(aryl)acetamide. At this stage, the isomers were separated if possible by HPLC chromatography using, for example, a gradient of 20 to 25 % ethyl acetate/hexanes. The a-methylbenzyl protecting group was then removed from the peptide by adding 10 molar equivalents of triethylsilane and 20 molar equivalents of trifluoroacetic, acid to the compound. The reaction was heated to 37°C for 3 hours and then poured into ethyl acetate and washed with sodium bicarbonate. The organic layer was drieri over Na2S04, filtered, and concentrated. The residue was purified by trituration with ether or ether/hexanes. Various other aldehydes, isocyanides, and carboxylic acid can be used in this procedure to provide for a variety of compounds useful in this invention.
GENERAL PROCEDURE AM
Preparation of Amino Acid Derivatives Using Chiral Amines III
A solution of an aromatic aldehyde (3 molar eq.) and S-(-)-a-methylbenzylamine (1 molar eq.) in methanol was treated with titanium(IV) isopropoxide (1.5 molar eq.). After stirring the mixture at ambient temperature __ 180 -_ for 6 hours, ten-butylisocyanide (1.1 molar eq.) was added followed by N (3,5-difluorophenylacetyl)-L-alanine (1.2 molar eq.) 40 minutes later. The reaction mixture was stirred for 72 hours. The methanol was removed via rotary evaporation. The residue was dissolved in methylene chloride and washed with 0.01 N HCI. The emulsion was filtered through celite washing with methylene chloride. The layers were separated; the organic phase was washed with saturated NaHC03 and brine. The organic layer was dried over Na2S0,, -- - filtered, and concentrated to give N ten butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-N'-R-a-methylbenzyl-2-amino-2-DL-(aryl)acetamide. At this stage the isomers were separated if possible by HPLC chromatography using, for example, a gradient of 20 to 25 % ethyl acetate/hexanes. The a-methylbenzyl protecting group was then removed from the peptide by adding 10 molar equivalents of triethylsilane and 20 molar equivalents of trifluoroacetic acid to the compound. The reaction was heated to 37°C for 3 hours and then poured into ethyl acetate and washed with sodium bicarbonate. The organic layer was dried over Na2S04, filtered, and concentrated. The residue was purified by trituration with ether or ether/hexanes. Various other aldehydes, isocyanides, and carboxylic acid can be used in this procedure to provide for a variety of compounds useful in this invention.
GENERAL PROCEDURE AN
EEDO Coupling Procedure II
To a 1:1 mixture of the corresponding carboxylic acid and amino esterlamide in THF at 0°C was added 1.1 equivalents of EEDQ. The reaction mixture was stirred for 18 hours at 22.5°C. The solvent was removed under reduced pressure or under a stream of nitrogen and the residue dissolved in EtOAc. The organic solution was washed 1 time with saturated NaHC03 solution, 1 time with N HCI, and dried over MgS04. The organic solution was reduced in vacuo to yield the product.

GENERAL PRO(~EDURE AO
Preparation of Prig Amides A sealable pressure tube containing a magnetic stir bar under an atmosphere of nitrogen at room temperature was charged with a methyl ester ( 1 eq.), sodium cyanide (0.1 eq.) and a 7M solution of ammonia in methanol.
The tube was sealed and heated to 45°C with stirring for 18 hours.
The reaction was allowed to cool to room temF~erature and the resulting precipitate was isolated by vacuum filtration. The so:fid was either washed with methanol or recrystallyzed from ethyl acetate/methaiiol.
Example 1 Synthesiis of Methyl N [N (3,5-Difluorophenylacetyl)-L~alaninyl]
(S)-2-aminohexanoate Following General Procedure A (without the 1N HCl wash) and using N
(3,S-difiuorophenylacetyl)-L-alanine (from Example B2) and norleucine methyl ester hydrochloride (Sigma), the title comFbund was prepared as a solid (mp =
142-143°C). The reaction was monitored by tlc (Rf = 0.71 in 10%
CH30H/CHzCIz, 0.22 in 50% EtOAc/hexanes) and the product was purified by silica plug chromatography using CHzCIz a.s the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 6.90 (d, J=7.6~~ Hz, 1H), 6.80 (m, 3H), 6.70 (m, 1H), 4.62 (quint, J=7.2 Hz, 1H), 4.48 (m, 1H), 3.72 (s, 3H), 3.51 (s, 2H), 1.78 (m, 1H), 1.60 (m, 1H), 1.36 (dye=T.02 Hz, 3H), 1.25 (m, 4H), 0.85 (m, 3H).
'3C-nmr (CDCl3): 8 = 173.23, 172.69, 169.97, 165.30, 165.12, 162.00, 139.01, 138.88, 138.76, 112.93, 112.83, :l 12.70, 112.60, 103.63, 103.30, 102.97, 52.94, 49.38, 43.28, 32.32, 27.95, 22.75, 19.23, 14.35.
C,gH24FZNz04 (MW = 370.40); mass spectroscopy (MH+) 371.

Example 2 Synthesis of __ -N [N (3,5-Difiuorophenylacetyl)-I~alaninyl]-L-histidineMethyl Ester Following General Procedure A and using N (3,5-difluorophenyiacetyl)-L-alanine (from Example B2) and L-histidine methyl ester dihydrochloride (Sigma), the title compound was prepared as a solid (mp = 195-197°C).
The reaction was monitored by tlc (Rf = 0.29 in 10%'o CH30H/CHZCl~.
NMR data was as follows:
'H-nmr (CD30D): b = 7.60 (s, 1H), 7.00-6.81 (m, 4H), 4.70 (t, 1H), 4.39 (q, 1H), 3.72 (s, 3H), 3.60 (s, 2H), 3.22-3.00 (m, 2H), 1.38 (d, 3H).
'3C-nmr (CD30D): 8 = 175.46, 172.56, 172.94, 166.64, 166.47, 163.38, 163.20, 141.73, 141.60, 141.47, 136.85, 113.92, 113.82, 113.70, 113.59, 103.89, 103.55, 103.21, 54.55, 53.31, 51.00, 43.21, 43.19, 30.36, 18.44.
C,8H2oFzN404 (MW = 394.38); mass spectroscopy (MH+) 395.
Example 3 Synthesis of N Benzyl-N'-[N (3,5-difluorophenylacetyl) L-alaninyl]-(S)-2-aminohexanamide Following General Procedure K and using methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate (from Example 1 above) and benzylamine (Aldrich), the title compound was prepared as a solid (mp =
> 200°C). The reaction was monitored by tlc (Rf = 0.29 in 5 CHjOH/CHZCl2) and the product was purified by preparative plate chromatography.
NMR data was as follows:
'H-nmr (CDCi3): b = 7.05 (m,SH), 6.65 (m, 3H), 4.10 (m, 4H), 3.35 (d, 2H), 1.35 (m, 9H), 0.65 (m, 3H).
'3C-nmr (CDC13): 8 = 175.48, 174.75, 173.16, 166.64, 166.46, 163.37, 141.55, 141.42, 140.38, 130.04, 129.95, 129.05, 128.95, 128.73, 113.94, 113.83, 113.71, 113.60, 103.90, 103.88, 103.56, 103.22, 55.43, 51.26, 44.53, 43.21, 33.38, 29.56, 23.91, 18.28, 14.7f~.
C24H29F2N3~3 (M~ = 445.51); mass spectroscopy (MH+) 446.
ExamF~le 4 Synthesis of N 2-(N,N Dimethylamino)ethyl-N'-[N (3,5-difluorophenylacetyl) L-alaninylJ-(S)-2-a~minohexanamide Following General Procedure K and using methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl)-(S)-2-arninohexanoate (from Example 1 above) and N,N dimethylethylenediamine (Aldrich), the title compound was prepared as a solid (mp = 182-187°C). The reaction was monitored by tlc (Rf = 0.51 in % CH30H/CHZCl2) and the product was purified by preparative plate chromatography using 15 % CH30H/CHZC'.12 as the eluent.
NMR data was as follows:
15 'H-nmr (CDCl3): 8 = 7.21 (d, 1H), Ei.80 (m, 5H), 4.64 (m, 1H), 4.48 (q, 1H), 3.57 (s, 2H), 3.30 (q, 2H), 2.41 (t, 2H), 2.22 (s, 6H), 1.70 (m, 2H), 1.32 (m, 7H), 0.87 (m, 3H).
'3C-nmr (CDCl3): 8 = 172.2, 172.0, 170.0, 165.4, 165.3, 163.9, 162.1, 162.0, 139.1, 138.8, 113.1, 112.8, 103.6., 103.3, 103.0, 58.1, 54.0, 49.7, 45.7, 43.3, 38.1, 33.2, 28.2, 23.0, 19.2, 14.4.
CZ,H32FZN403 (MW = 426.51); mass spectroscopy (MH+) 427.
Example 5 Synthesiis of N (2-Methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-Iralaninyl]-(S)-2-aminohexanamide Following General Procedure K and using methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-am:inohexanoate (from Example 1 above) and 2-methoxyethylamine (Aldrich), the title compound was prepared as a solid (mp = > 200°C). The reaction was monitored by tlc (Rf = 0.42 in 10%

_ -- 184 _-CH30H/CHzCl2) and the product was purified by flash chromatography using 12 % CH30H/CHZCIz as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.85 (bd, J=8.79 Hz, 0.5H), 7.64 (bd, J=7.81 Hz, 0.5H), 7.35 (m, 1H), 7.16 (bd, J=7.27 Hz, 0.5H), 7.06 (bs, 0.5H), 6.83 (m, 2H), 6.68 (m, 1H), 4.70 (m, 2H), 3.56 (d, J=9.89 Hz, 2H), 3.40 (m, 7H), 1.57 (m, lOH), 0.84 (m, 3H).
'3C-nmr (CDC13): b = 172.62, 172.58, 172.14, 172.04, 170.02, 169.91, 165.33, 165.15, 162.08, 112.99, 112.92, 112.82, 112.77, 112.66, 112.59, 103.54, 103.34, 103.31, 103.29, 71.46, 71.44, 59.27, 59.24, 53.76, 49.64, 49.43, 43.29, 39.79, 33.26, 33.22, 28.10, 28.03, 22.97, 22.91, 19.71, 19.61, 19.56, 19.51, 14.46, 14.43.
CZOFi29F,N3O4 (MW = 413.47); mass spectroscopy (MH+) 414.
Example 6 Synthesis of N 2-(N,N-Dimethylamino)ethyl-N'-(N (3,5-difluorophenylacetyl) Iralaninyl]-L-phenylalaninamide Following General Procedure K and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester (from Example 94 below) and N,N
dimethylethylenediamine (Aldrich), the title compound was prepared as a solid (mp = 174-182°C). The reaction was monitored by tlc (Rf = 0.31 in 10%
CH30H/CH,CIz) and the product was purified by preparative plate chromatography using 10% CH30H/CHZCIZ as the eluent.
NMR data was as follows:
'H-nmr (CD30D): 8 = 7.22 (m, 5h), 6.85 (m, 3H), 4.5 i (m, IH), 4.18 (m, 1H), 3.57 (m, 2H), 3.50-2.45 (m, 6H), 2.39 (s, 6H), 1.26 (d, 2.4H), 1.10 (d, 0.6H).
'3C-nmr (CD30D): 8 = 176.03, 175.50, 174.20, 173.99, 173.50, 173.22, 166.63, 166.46, 163.36, 163.19, 141.65, 141.52, 141.39, 139.38, 139.00, 130.90, 130.74, 130.05, 130.01, 128.37, 128.30, 114.03, 113.93, 113.80, 113.70, 103.96, 103.62, 103.57, 103.28, 59.18, 59.14, 56.78, 56.51, 51.93, 51.74, 45.53, 45.47, 43.21, 43.18, 42.92, 38.84, 38.65, 37.94, 37.85, 18.09, 17.73.
C24H~2N403 (M~ = 4.53); mass ;~peotroscopY (MH+) 461.
ExamplE; 7 s synthesis of N (4-PyridyI)methyl-N'-[N (3,5-difluorophenylacetyl) I~alaninyl]-Irp6enylalaninamide Following General Procedure K and u.;ing N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester (from Example 94 below) and 4-(aminomethyl)pyridine (Aldrich), the title compound was prepared as a solid (mp = > 200°C). The reaction was monitored by ilc (Rf = 0.46 in 10%
CH30H/CH~CIz) and the product was purified by recrystallization from ethyl acetate.
NMR data was as follows:
'H-nmr (CD30D): b = 8.37 (d, 2H), 1.25 (m, 5H), 7.11 (d, 2H), 6.85 (m, 3H), 4.56 (t, 1H), 4.29 (m, 3H), 3.64 (s, a!H), 3.08 (m, 2H), 1.30 (d, 3H).
'3C-nmr (CD30D): b = 175.46, 174.01, 173.26, 166.60, 166.43, 163.34, 163.16, 150.97, 150.44, 141.59, 141.45, 138.84, 130.95, 130.13, 128.44, 124.28, 113.98, 113.87, 113.75, 113.64, 103.91, 103.57, 103.23, 62.08, 57.01, 43.33, 43.12, 38.93, 21.41, 18.16, 15.02.
CZeHzeF2N403 (MW = 480.52); mass spectroscopy (MH+) 481.
Example 8 Synthesis. of N-(3-Pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl) ~alaninyl]-Irphen;ylalaninamide Following General Procedure K and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester (from Example 94 below) and 4-. (aminomethyl)pyridine (Aldrich), the title compound was prepared as a solid (mp = 199-210°C). The reaction was monitored by tlc (Rf = 0.46 in 10%

CH30H/CHZCI2, minor isomer Rf = 0.50) and the product was purified by preparative plate chromatography using 10 % CH30H/CHZC12 as the eluent.
NMR data was as follows:
'H-nmr (CD30D): 8 = 8.42 (m, 2H), 7.61 (m, 1H), 7.29 (m, 6H), 6.90 (m, 3H), 4.61 (m, 1H), 4.33 (m, 3H), 3.58 (s, 1.SH), 3.54 (s, 0.5H), 3.10 (m, 2H), 1.33 (d, 2.25H), 1.15 (d, 0.75H).
- '3C-nmr (CD30D): b = 176.00, 175.34, 174.03, 173.81, 173.23, 166.61, 166.44, 163.35, 163.17, 149.93, 149.20, 141.48, 139.20, 138.72, 138.10, 138.03, 136.88, 136.79, 130.89, 130.70, 130.06, 130.02, 128.40, 128.33, 125.71, 113.97, 113.87, 113.74, 113.64, 103.92, 103.58, 103.53, 103.23, 56.88, 56.66, 55.74, 53.21, 43.22, 43.15, 42.89, 42.06, 41.98, 39.04, 38.88, 38.77, 18.18, 17.79.
Cz6HzeFzN403 (MW = 480.52); mass spectroscopy (MH+) 481.
Example 9 Synthesis of N (4-Pyridyl)methyl-N'-[N (3,5-difluorophenylacetyl) I~alaninyl)-(S)-2-aminohexanamide Following General Procedure K and using methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl)-(S)-2-aminohexanoate (from Example 1 above) and 4-(aminomethyl)pyridine (Aldrich), the title compound was prepared as a solid (mp = 181-205°C). The reaction was monitored by tlc (Rf = 0.51 in 10% CH30H/CHZCIz) and the product was purified by preparative plate chromatography using 10% CH30H/CHZC12 as the eluent.
NMR data was as follows:
'H-nmr (CD30D): b = 8.48 (m, 0.8H), 8.42 (m, 1.2H), 7.37 (d, J=6.10, 0.8H), 7.28 (d, J=6.I l, 1.2H), 6.85 (m, 3H), 4.39 (m, 4H), 3.61 (s, 0.8H), 3.53 (d, J=2.99, 1.2H), 2.05-1.25 {m, 9H), 0.90 (m, 3H).
'3C-nmr (CD30D): 8 = 176.61, 175.71, 175.33, 175.29, 173.32, 173.24, 166.49, 166.32, 163.22, 163.05, 151.30, 151.24, 150.55, 150.41, 141.54, 141.41, 124.35, 124.20, 113.95, 113.85, 113.72, 113.62, 103.86, 103.57, __ 187 -_ 103.52, 103.18, SS.72, SS.64, 51.98, 43.38, 43.19, 42.82, 33.07, 32.57, 29.87, 29.67, 23.90, 23.82, 18.24, 17.86, 14.80.
C~HzaFzNa03 (MW = 446.50); mass spectroscopy (MH+) 447.
Examph~ 10 Synthesis of ten-butyl N [N (3,5-Diiluorophenylacetyl) L-alaninyl]-(S)-2-aminohexanoate Step A - t-Butyl Ester Formation To a solution of Z-norleucine-OH in (:HZCIz was added 1.S equivalents of N,N'-diisopropyl-O-t-butylisourea (prepared by the method of Synthesis (1979) p.561 for review) and the reaction was he<<ted to reflux for 17 hours. An additional 1.S equivalents of isourea was then added, and reflux was continued for another 7 hours. The reaction was then cooled to room temperature and filtered through a bed of Celite S4S, then :dripped to dryness to leave a clear 1S oil. The residue was dissolved in hexanes and filtered to remove solids, and the filtrate was washed with saturated aqueous NaHC03, water, saturated aqueous NaCI, and dried over MgS04. The solution was concentrated under reduced pressure to leave the product.
Step B - CBZ Removal The CBZ-protected amino ester was dissolved in ethanol in a hydrogenation flask and a catalytic amount of 10% Pd/C was added. The mixture was hydrogenated at 20 psi HZ on a Parr shaker for 30 min. The reaction was then filtered through a pad of Celite S4S and stripped free of solvent on a rotary __ evaporator to yield the product, norleucine tent-butyl ester hydrochloride.
2S Step C
Following General Procedure D and using N (3,S-difluorophenylacetyl)-L-alanine (from Example B2 above) and the norleucine tent-butyl ester hydrochloride, the title compound was prepared as a semi-solid. The reaction was monitored by tlc (Rf = 0.41 in 50% EtOAc/hexanes) and the product was __ 188 -_ purified by flash chromatography using 50% EtOAc/hexanes as the eluent, followed by preparative plate chromatography using 50 % EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.63 (d, J=7.7 Hz, 1H), 7.34 (d, J=7.7 Hz, 1H), 6.8 (m, 2H), 6.7 (m, 1H), 4.8 (m, 1H), 4.36 (q, J=5.6 Hz, 1H), 3.52 (s, 2H), 1.8-1.1 (m, 15H), 0.8 (m, 3H).
'3C-nmr (CDCl3): 8 = 173.0, 171.8, 170.2, 165.1, 165.0, 161.9, 161.7, 139.6, 139.4, 139.3, 112.8, 112.7, 112.6, 112.5, 103.2, 102.9, 102.6, 82.3, 53.6, 49.3, 43.0, 32.2, 28.4, 27.8, 22.7, 19.4, 14.7, 14.2.
CZ,H3oF2N2O4 (MW = 412.48); mass spectroscopy (MH+) 413.
Example 11 Synthesis of N [N (Pent-4-enoyl)-L-alaninyl]-L-phenylalanine Methyl Ester IS Following General Procedure A and using N (L-alaninyl)-L-phenylalanine methyl ester (prepared by coupling N BOC-L-alanine (Sigma) and L
phenylalanine methyl ester (Sigma) using General Procedure A, followed by removal of the BOC-group using General Procedure Y) and pent-4-enoic acid {Aldrich), the title compound was prepared as a solid (mp = 125.5-126.5°C).
The reaction was monitored by tlc (Rf = 0.32 in 50% EtOAc/hexanes; O.SI in 10% CH30H/CHZCIZ) and the product was purified by flash chromatography using 10 % CH30H/CHZCIZ as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.27 (bd, J=7.82 Hz, 1H), 7.25-7.05 (m, 5H), 6.72 (bd, J=7.57 Hz, 1H), 5.75 (m, 1H), 4.96 (m, 2H), 4.59 (quint, J=7.2 Hz, 1H), 3.65 (s, 3H), 3.05 (m, 4H), 2.40-2.18 (m, 4H), 1.28 (d, J=7.02 Hz, 3H) .
'3C-nmr (CDCl3): 8 = 173.06, 172.77, 172.36, 137.47, 136.53, 129.76, 129.07, 116.09, 54.10, 52.87, 49.06, 38.31, 25.93, 30.03, 19.17.
C,gH24N204 {MW = 332.40); mass spectroscopy (MNa+) 355Ø

WO 98/22494 PCTlUS97/20804 Example: I2 Synthesis of N [N (Dec-4-enoyl)-I~alaninylJ-L-phenylalanine Methyl Ester Following General Procedure A and using N (L-alaninyl)-L-phenylalanine methyl ester (prepared by coupling N BOC-L-alanine (Sigma) and L-phenylalanine methyl ester (Sigma) using General Procedure A, followed by removal of the BOC-group using General Procedure Y) and dec-4-enoic acid -- - (prepare from ethyl dec-4-enoate (ICM) using General Procedure N), the title compound was prepared as a solid (mp = 115.5-117.5°C). The reaction was monitored by tlc (Rf = 0.52 in 50% EtOAc/hexanes; 0.60 in 10%
CH30H/CH~CIz) and the product was purified by flash chromatography using 10% CH30H/CHzCl2 as the eluent.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.54 (bd, J=7.69 Hz, 1H), 7.22-7.04 (m, 5H), 6.91 (bd, J=7.69 Hz, 1H), 5.37 (m, 2H), 4.73 (q, J=6.9 Hz, 1H), 4.63 (quint, J=7.2 Hz, 1H), 3.61 (s, 3H), 3.02 (m, 2H), 2.40-2.10 (m, 4H), 1.89 (m, 2H), I.35-1.I3 (m, 9H), 0.82 (m, 3H).
'3C-nmr (CDCl3): b = 173.26, 173.05, 172.38, 136.65, 132.30, 129.74, 128.99, 128.68, 127.48, 54.19, 52.74, 48.!7, 38.28, 36.70, 33.04, 31.93, 29.68, 29.09, 23.06, 19.23, 14.61.
C23H~N204 (MW = 402.54); mass spectroscopy (MNa+) 425Ø
Example 13 Synthesis of N [N (3,5-Difluorophenylar.etyl)-L-alaninylJ-L-4-[3-(N,N dimethylamino)propoxyJ~phenylalanine Methyl Ester Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2) and L-4-[3-(N,rJ dimethylamino)propoxyJ-phenylalanine methyl ester (prepared from iV BOC-L-tyrosine methyl ester (Bachem) and 3-dimethylamino-1-propanol (Aldrich) using a Mitsunobu procedure essentially as described in Gener~~l Procedure AD, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid {mp = 153-155°C). The reaction was monitored by tlc (Rf = 0.36 in 10 % MeOH/DCM/ 1 % TEA) and the product was purified by acid/base washes.
NMR data was as follows:
'H-nmr (CDC13): -8 = 6.973-6.947 (d, 2H); 6.794-6.766 (d, 2H); 6.743-6.714 (d, 2H); 6.735-6.676 (t, 1H); 4.761-4.735 (q, 1H); 4.511-4.463 (q, 1H);
3.967-3.924 (t, 2H); 3.703 (s, 3H); 3.473 (s, 2H); 3.019-2.977 (t, 2H); 2.443-2.394 (t, 2H); 2.233 (s, 6H); 1.944-1.897 (t, 2H); 1.319-1.296 (d, 3H).
'3C-nmr (CDCl3): b = 172.292; 172.256; 169.808; 158.747; 130.731;
127.887; 115.149; 112.900; 112.672; 66.690; 56.945; 54.039; 52.971; 49.400;
46.105; 43.302; 37.421; 28.129; 19.029.
C26H33FZN3~5 (~'~' = 505); mass spectroscopy (MH+) 506.
Example 14 Synthesis of - N [N (3,5-Difiuorophenylacetyl)-L-alaninyl]-Ir4-[(tent-butyloxycarbonyl)methoxy]phenylalanine Methyl Ester Following General Procedure AE and using tent-butyl bromoacetate (Aldrich) and N [N (3,S-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester (from Example 15 below), the title compound was prepared as a solid (mp - 116-119°C). The reaction was monitored by tlc (Rf = O.S4 in SO%
EtOAc/hexanes) and the product was purified by silica gel column chromatography.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.648-7.615 (d, 1H); 7.513-7.407 (d, 1H); 6.943-6.914 (d, 2H); 6.756-6.669 (d+t, 4H); 6.621-6.562 (t, 1H); 4.662-4.590 (q+quintex, 2H); 4.382 (s, 2H); 3.571 (s, 3H); 3.406 (s, 2H); 3.006-2.648 (m, 2H); 1.417 (s, 9H); 1.243-1.221 (d, 3H).
'3C-nmr (CDC13): b = 173.14; 173.001; 172.294; 170.273; 168.614;
168.546; 165.107; 161.816; 157.428; 139.493; 130.749; 129.385; 115.077;
112.803; 103.250; 828.270; 66.039; 54.661; 52.730; 49.172; 42.832; 37.288;
28.509; 19.018.

CnH32FZN20., (MW = 534); mass spectroscopy (MH+) 535.
Example 15 Synthesis of N (N (3,5-Difluorophenylacetyl)-L-alaninyl]-L-tyrosine Methyl Fster Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-tyrosine methyl ester (Bachem), the title compound was prepared as a solid (rnp = 85-88°C). The reaction was monitored by tlc (Rf = 0.27 in 50 % EtO~~c/hexanes) and the product was purified by silica gel column chromatography.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.036 (b, 1H); 7.369-7.344 (d, 1H); 7.205-7.151 (d, 1H); 6.869-6.841 (d, 2H); 6.763-6.738 (d, 2H); 6.657-6.615 (m, 3H); 4.741-4.697 (q, 1H); 4.566-4.491 (q, 1H); 3.671 (s, 3H); 3.415 (s, 2H); 3.061-2.771 (dm, 2H); 1.271-1.250 (d, 3H).
'3C-nmr (CDCl3): b = 173.049; 172.1166; 172.444; 170.768; 165.211;
161.917; 156.098, 130.862; 127.542; 116.093, 112.990; 112.659; 103.236;
61.112; 54.306; 49.441; 42.947; 18.923.
CZ,HZZFZN205 (MW = 420); mass spextroscopy (MH+) 421.
Example 16 Synthesis of N (N (3,5-Diffuorophen;ylacetyl)-L-alaninyl]
Ir4-(carboxymethoxy)phenylalanine Methyl Ester Following General Procedure N and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[(tent-butyloxycarbonyl)mfahoxy]phenylalanine methyl ester (from Example 14 above), the title compound was prepared. The reaction was monitored by tlc (Rf = 0.49 in 10% MeC~H/DCM + 1 % AcOH) and the product was purified by silica gel column chromatography.
NMR data was as follows:

'H-nmr (CDC13): 8 = 7.817 (s, 1H); 7.648-7622 (d, 1H); 7.544-7.520 (d, 1H); 6.956-6.914 (d, 2H); 6.762-6.703 (d+d, 4H); 6.650-6.590 (t, 1H); 4.678-4.636 (q, 1H); 4.567-4.503 (quinex + s, 3H); 3.622 (s, 3H); 3.431 (s, 2H);
2.987-2.811 (m, 2H); 1.241-1.219 (d, 3H).
'3C-nmr (CDCl3): b = 173.618; 173.534; 172.215; 171.209; 171.108;
165.148; 164.973; 161.855; 161.683; 157.309; 139.052; 130.887; 129.376;
115.104; 112.895; 112.667; 103.083; 65.324; 54.155; 52.933; 50.538; 49.384;
- - 42.683; 37.168; 18.678.
Cz3H2aFzNzO, (MW = 478); mass spectroscopy (MH+) 479.
Example 17 Synthesis of N-[N (3,S-Difluorophenylacetyl)-Iralaninyl]-Ir4-(2-morpholinoethoxy)phenytalanine Methyl Ester Following General Procedure AD and using N [N (3,5-difluorophenylacetyl}-L-alaninyl]-L-tyrosine methyl ester (from Example 15 above) and 4-(2-hydroxyethyl)morpholine (Aidrich), the title compound was prepared as a solid (mp = 138-141 °C). The reaction was monitored by tlc (Rf = 0.56 in 10%MeOH/DCM + 1 %TEA) and the product was purified by silica gel column chromatography, followed by trituation using diethyl ether.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 6.974-6.945 (d, 2H); 6.795-6.726 (d+t, 2H}; 6.697-6.682 (t, 1H); 4.755-4.689 (q, 1H}; 4.535-4.468 (quintex, 1H); 4.050-4.012 (t, 2H); 3.723-3.606 (t+s, 7H); 3.463 (s, 2H); 3.039-2.892 (m, 2H); 2.779-2.741 (t, 2H); 2.562-2.531 (t, 4H); 1.297-1.274 (d, 3H).
'3C-nmr (CDC13): 8 = 1721.477; 172.428; 172.303; 169.925; 158.397;
130.778; 128.504; 115.179; 112.988; 112.769; 112.659; 67.457; 66.249;
58.187; 54.631; 54.119; 52.956; 49.358; 43.202; 37.496; 19.028.
Cz.,H33F2N3O6 (MW = 533); mass spectroscopy (MH+) 534.

Example 18 Synthesis of Methyl N [N (3,5-Dif7uorophenylacetyl)-L-alaninyl) (S)-2-amino-6-(N,N diimE~thylamino)hexanoate Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and NE,.Ne-dimethyl-L-lysine methyl ester hydrochloride (Bachem), the title compound was prepared as a solid (mp =
123-126°C). The reaction was monitored by tlc (Rf = 0.22 in 10%
MeOH/DCM + 1 % TEA) and the product was purified by silica gel column chromatography.
NMR data was as follows:
'H-nmr (CDC13): b = 7.019-6.993 (d, 1H); 6.828-6.801 (dd, 2H); 6.753-6.723 (m, 1H); 6.617-6.592 (d, 1H); 4.557-4.447 (q+q, 2H); 3.730 (s, 3H);
3.522 (s, 2H); 2.593-2.572 (m, 2H); 2.196 (s, 6H); 1.837-1.642 (m, 2H);
1.486-1.344 (m+d, 7H).
'3C-nmr (CDCl3): 8 = 173.070; 172.5~44, 169.809; 112.986; 112.655;
103.384: 59.393; 52.991; 49.368; 45.947; 43.427; 43.403; 43.375; 31.870;
27.376; 23.378; 19.155.
CZOHz9FzN3O4 (MW = 413); mass spectroscopy (MH+) 4I4.
Example: 19 Synthesiis of Methyl N-[N (3,5-Difluoroplhenylacetyl)-Iralaninyl) (S)-2-amino-3-(2-pyridyl) propionate Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2) and methyl (S)-2-amino-3-(2-pyridyl)propionate hydrochloride (Synthetech), the title compound was prepared as a solid (mp =
12I-124°C). The reaction was monitored by tlc (Rf = 0.39 in 10%MeOH/DCM) and the product was purified by silica gel column ' chromatography.
NMR data was as follows:

'H-nmr (CDCl3): 8 = 8.474-8.458 {d, 1H); 7.767-7.631 (m, 1H); 7.625-7.574 (t, 1H); 7.178-7.102 (t+d, 2H); 6.818-6.811 (d, 2H); 6.734-6.667 (t, 1H); 6.593-6.542 (m, 1H); 4.933-4.873 (m, 1H); 4.566-4.496 (m, 1H); 3.646 (s, 3H); 3.499 {s, 2H); 3.375-3.196 (m, 2H); 1.393-1.370 (d, 3H).
'3C-nmr (CDC13): 8 = 172.453; 172.020; 169.527; 157.454; 149.608;
137.449; 124.366; 124.328; 122.694; 113.032; 112.992; 112.661; 103.333;
53.032; 52.997; 52.349; 52.252; 49.427; 49.405; 43.464, 43.437, 38.486;
19.548; 19.232.
CZOH2,FzN3O4 (MW = 405); mass spectroscopy (MH+) 406.
Example 20 Synthesis of Methyl N [N (3,5-Difiuorophenylacetyl)-I~alaninylJ
(S)-2-amino-3-(3-pyridyl)propionate Following General Procedure A and using N (3,5-difluorophenylacetyl}-L-alanine (from Example B2) and methyl (S)-2-amino-3-(3-pyridyl)propionate hydrochloride (Synthetech), the title compound was prepared as a solid (mp =
101-103°C). The reaction was monitored by tlc (Rf = 0.48 in 10%
MeOH/DCM) and the product was purified by silica gel column chromatography.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 8.492-8.396 (m, 1H}; 8.359-8.322 (m, 1H); 7.505-7.452 (m, 1H); 7.248-7.170 (m, 1H); 6.976-6.908 (m, 1H); 6.855-6.668 (m, 3H); 6.352-6.288 (m, 1H); 4.866-4.798 (m, 1H); 4.784-4.429 (m, 1H); 3.750 (s, 3H); 3.513 (s, 2H); 3.220-2.964 (m, 2H); 1.310-1.287 (d, 3H).
'3C-nmr (CDCl3): 8 = 172.867; 171.831; 170.307; 161.942; 150.892;
150.753; 148.907; 148.750; 137.523; 137.388; 132.460; 124.106; 124.034;
112.981; 112.754; 103.228; 53.623; 53.461; 53.146; 49.368; 49.259; 43.137;
43.115; 43.086; 35.485; 18.664.
CZOH2,F2N3O4 (MW = 405); mass spectroscopy (MH+) 406.

Example 21 Synthesis of N [N (3,5-Difluorophen;ylacetyl)-L-alaninylj Irproline Methyl Fster Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-proline methyl ester hydrochloride (Sachem), the title compound was prepared as a viscous solid. The reaction was monitored by tlc (Rf = 0.57 in 10 % iMeOH/DCM) and the product was purified by acid/base washes.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.524-7.498 (d, 1H}; 6.813-6.793 (d, 2H); 6.681-6.613 (m, 1H); 4.788-4.717 (m, 1H); 4.4fs4-4.442 (m, 1H); 3.705-3.590 (m+s, 4H); 3.465 (s, 2H); 2.217-1.902 (nn, SH); 1.332-1.309 (d, 3H).
'3C-nmr (CDC13): b = 172.753; 172.152; 169.843; 165.185; 161.894;
112.953; 112.850; 112.727; 112.624; 103.331, 102.996, 102.662; 59.352;
52.735; 47.495; 47.267; 43.069; 29.472; :?5.403; 18.243.
C17H20F2N2~4 ~' = 354); mass spet~troscopy (MH+) 355.
Example. 22 Synthesis of Methyl 1-[N-(3,5-Difluorophenylacetyl)-I~alaninyl]piperidine-2-carboxylate Following General Procedure B and u~;ing N (phenylacetyl)-L-alanine (from Example B1 above) and methyl pipecolinab~ hydrochloride {Aldrich), the title compound was prepared as an oil. The reaction was monitored by tlc (Rf =
0.30 in 50% EtOAc/hexanes) and the product was purified by silica gel chromatography.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.2 (m, SH), 6.~~5 (dd, J=7.2, 15.2, 7.2 Hz, 1H), 5.21 (dd, J=5.0, 11.0, 5.0 Hz, 1H), 4.89 (q, J=7.1, 7.1 Hz, 1H), 3.7 (m, 1H), 3.59 (s, 3H), 3.47 (s, 2H), 3.1 (m, 1:H), 2. i6 (d, J=11.5 Hz, 1H), 1.4 (m, 4H), 1.22 (dd, J=1.3, 4.4, 1.2 Hz, 3):1).

WO 98/22494 PCT/I1S97l20804 '3C-nmr (CDCl3): b = 172.6, 171.8, 170.7, 135.5, 129.8, 129.3, 127.6, 52.9, 52.8, 46.0, 43.9, 27.1, 26.8, 25.6, 21.4, 19.9, 18.5. --C,BH~,N204 (MW = 332); mass spectroscopy (MH+) 333.
Example 23 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl) I~alaninyl]-(S)-2-amino-3-(4-pyridyl) propionate Step A - Preparation of 3-(3-pyridyl)alanine methyl ester dihydrochloride Sodium metal (1.40 g, 61 mmol) was dissolved in EtOH (100mL) and diethyl acetamidomalonate (6.62 g, 30.5 mmol) and 3-picoiylchloride hydrochloride (S.OOg, 30.5 mmol) were added. The mixture was heated to reflux for 6 hours, and then cooled and filtered to remove NaCI (washed with EtOH). The solvent was removed in vacuo and the mixture was taken up into saturated aqueous NaHC03 (100 mL) and extracted with EtOAc (3 x 100 m L).
The solvent was removed and the residue purified by silica gel flash chromatography {95:5 CHZCIz/MeOH) to give diethyl 2-(3-pyridylmethyl)-2-acetamidomalonate (2.84 g, 30%).
Diethyl 2-(3-pyridylmethyl)-2-acetamidomalonate was dissolved in 6N HCl (30 mL) and heated to reflux for 19 hours whereupon it was cooled to room T

WO 98122494 PCT/US97l20804 temperature and the HCl solution was removed by evaporation in vacuo. The intermediate amino acid dihydrochloride salt was taken up into MeOH (30 mL) saturated with HCl gas and stirred for 3.:5 hours. The MeOH/HCI was removed by evaporation in vacuo to give 3-(3-pyridyl)alanine methyl ester dihydrochloride (2.235 g, 100%).
Step B - Preparation of Methyl N [N (3~,5-Difluorophenylacetyl)-L-alaninyl)-(S)-2-amino-3-(4-pyridyl)prnpionate Following General Procedure A and using N (3,S-difluorophenyIacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-amino-3-(4-pyridyl)propionate hydrochloride (prepared by the method set forth above using 4-picolylchloride hydrochloride), the title compound was prepared as a solid.
The reaction was monitored by tlc {Rf = 0.49 in 10% MeOH/DCM) and the product was purified by silica gel column chromatography.
NMR data was as follows:
1S 'H-nmr (CDCl3): b = 8.423-8.335 (d~d, 2H); 7.832-7.754 (q, IH); 7.342-7.246 (dd, 1H); 7.032-6.972 (dd, 2H); 6.'764-6.667 (t, 2H); 6.659-6.599 (m, 1H); 4.837-4.768 (m, 1H); 4.590-4.S1S (m, 1H); 3.675 (s, 3H); 3.426 (s, 2H);
3.112-2.804 (m, 2H); 1.256-1.106 (dd, 31~).
'3C-nmr (CDCl3): 8 = 173.037; 171.',39; 170.258; 170.225; 165.201;
16S.OI2; 161.904; 161.721; 150.183; 150.063; 146.115; 146.012; 139.100;
125.180; 125.122; 112.951; 112.915; 112.846; 103.492; 103.153; 53.088, 49.318; 42.977, 37.593; 37.547; 19.297; 18.882.
CZOH,,FzN304 (MW = 405); mass spectroscopy (MH+) 406.
. . Example; 24 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-Iralaninyl)-2-amino-3-methoxypropionate Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-3-methoxypropionate hydrochloride (Bachem), the title compound was prepared as a solid (mp =

165-168°C). The reaction was monitored by tlc (Rf = 0.48 in IO~Yo MeOH/DCM) and the product was purified by acid/base washes.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 6.971-6.944 (d, 1H); 6.813-6.801 (m, 2H); 6.741-6.678 (m, IH); 6.585-6.526 (m, 1H); 4.692-4.561 (quintex + q, 2H); 3.836-3.802 (m, 1H); 3.738 (s, 3H); 3.592-3.516 (m+ds, 3H); 3.312 (s, 3H); 1.408-1.355 (dd, 3H).
'3C-nmr (CDCl3): b = 172.705; 172.680; 170.908; 113.019; 112.978;
112.687; 112.646; 103.347; 72.434; 72.405; 59.885; 59.837; 53.263; 53.240;
49.413; 49.329; 19.389; 18.9196.
C,6HZOFzN,05 (MW = 358); mass spectroscopy (MH+) 359.
Example 25 Synthesis of Methyl N-[N (3,5-Difluorophenylacetyl)-Iralaninyl)-2-amino-3-morpholinopropionate Step A methyl l2-N-CBZ-amino)-3-morpholino-propionate To a solution of N-CBZ-dehydro-alanine methyl ester (Sigma) in acetonitrile was added 2.0 equivalent of morpholine and 0.25 equivalents of anhydrous ferric chloride. The mixture was stirred for 16 hours and monitored by TLC. The solvent was stripped off and the residue extracted with ethyl acetate and washed with 1N HC1. The aqueous layer was basified with 1N
potassium carbonate to pH = 9 and extracted with ethyl acetate again, dried over sodium sulfate and rotovapped to dryness to give methyl (2-N-CBZ-amino)-3-morpholino-propionate as a clear tan oil. See Perez et aL, Tetrahedron 51(3) 8355-62 (1995) Step B Methyl N (N (3,5-Difluorophen ly acet r5._.l -L-alaninyl~-2-amino-3-morpholinopropionate Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-3-morpholinopropionate hydrochloride (prep~~red by General Procedure O above from methyl (2-N-CBZ-amino)-3-morpholino-propionate), the title compound was prepared as a viscous solid. The reaction was monitored by tlc (Rf = 0.44 in 10% MeOH/DCM) and the product wa:~ purified by acid/base washes.
NMR data was as follows:
'H-nmr (CDC13): b = 7.408-7.384 (d, 1H); 7.247-7.173 (m, 1H); 6.774-6.614 (m+t, 3H); 4.605-4.468 (m, 1H); 3.667 (s, 3H); 3.642 (s, 2H); 3.576-3.561 (t, 4H); 3.479-3.461 (s+s, 2H); 2.639-2.618 (d, 2H); 2.395-2.366 (m, 4H); 1.344-1.307 (t, 3H).
'3C-nmr (CDCl3): b = 173.120; 172.245; 172.192; 170.275; 170.159;
165.189; 165.020; 161.897; 161.727; 139.167; 112.937; 112.863; 112.759;
112.610; 112.533; 103.103; 102.774; 67.379; 67.301; 59.346; 59.110; 54.030;
52.936; 51.116; 49.283; 43.053; 18.980; 118.921.
IS C19H26F2N3~5 (Mw = 413); mass specaroscopy (MH+) 414.
Example 26 Synthesis of N-(2-Methoxyethyl)-N'-[N-(3,,5-difluorophenylacetyl) I~alaninyl]-~4-(2-morpholino~ethoxy)phenylalaninamide Following General Procedure K and using 2-methoxyethylamine (Aldrich) and N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)-phenylalanine methyl ester (from Example 17 above), the title compound was prepared as a solid (mp = 165-168°C). The reaction was monitored by tlc (Rf = 0.67 in IO% MeOH/DCM+1% TEA) and the product was purified by acidlbase washes.
NMR data was as follows:
'H-nmr (CDC13): b = 8.258-8.232 (d, IH); 8.014-7.989 (d, 1H); 7.532-7.370 (t, 1H); 7.035-7.008 (d, 2H); 6.842-6.630 (m, 5H); 4.980-4.905 (m, 1H); 4.794-4.772 (m, 1H); 4.026-3.992 (t, 2H); 3.713-3.642 (t, 4H); 3.594-3.453 (dd, 2H); 3.404-3.267 (t, 2H); 3.179 (s, 3H); 2.930-2.914 (t, 2H);
2.763-2.731 (t, 2H); 2.538-2.502 (m, 4H); 1.335-1.314 (d, 3H).

__ 200 __ '3C-nmr (CDCl3): b = 172.956; 172.918; 171.756; 170.142; 161.677;
158.131; 130.973; 129.270; 114.968; 114.875; 112.908; 112.696; 112.571;
71.423; 71.367; 67.440; 66.164; 59.072; 58.232; 58.188; 54.636; 42.827;
42.800; 39.757; 39.642; 20.449; 20.135.
CZ9H38FzN4O6 (MW = 576); mass spectroscopy (MH+) 577.
Example 27 Synthesis of N (2-Methoxyethyl)-N'-[N (3,5-difluorophenylacetyl) Iralaninyl]-2-amino-3-methoxypropionamide Following General Procedure K and using 2-methoxyethylamine (Aldrich) and methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionate (from Example 24 above), the title compound was prepared as a solid (mp = 181-184°C). The reaction was monitored by tic (Rf =
0.43 in 10% MeOH/DCM) and the product was purified by acid/base washes.
NMR data was as follows:
1H-nmr (CDC13): 8 = 6.728-6.706 (d, 2H); 6.648-6.586 (t, 1H); 4.244-4213 (m, 1H); 4.092-4.068 (m, 1H); 3.553-3.503 (m, 2H); 3.393-3.347 (m, 2H); 3.210-3.073 (m+s, 7H); 3.053 (s, 3H); 1.183-1.138 (d, 3H).
'3C-nmr (CDCl3): 8 = 176.31; 173.28; 172.59; 141.65; 114.02; 113.79;
113.69; 109.467; 103.528; 80.369; 73.210; 72.265; 72.011; 59.839; 59.801;
59.374; 55.584; 51.773; 51.731; 51.445; 42.915; 40.846; 17.751.
C,eH25F,N3O5 (MW = 401); mass spectroscopy (MH+) 402.
Example 28 Synthesis of N [N (3,5-Difluorophenylacetyl)-Lralaninyl]glycine Methyl Ester Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and glycine methyl ester hydrochloride (Bachem), the title compound was prepared as a solid (mp = 158-160°C).
The reaction was monitored by tlc (Rf = 0.61 in 10%MeOH/DCM) and the product was purified by silica gel chromatography.
NMR data was as follows:
'H-nmr (CDC13): 8 = 6.882-6.866 (m, 1H); 6.827-6.794 (m, 2H); 6.748-6.689 (t, 1H); 6.520-6.494 (d, 1H); 4.611-4.563 (quintex, IH); 4.00-3.99 (d, - 2H}; 3.746 (s, 3H); 3.528 (s, 2H); 1.389-:1.366 (d, 3H).
'3C-nmr (CDCl3): b = 172.926; 172.524; 170.524; 113.056; 112.951;
- _ / 12.723; 103.769; 103.437; 103.214; 103.105; 85.309; 53.009; 49.333;
43.292; 41.692; 18.810.
C,4H,6FZN,0, (MW = 314); mass specaroscopy (MH+) 315.
Example 29 Synthesis of N (2-Methoxyethyl)-N'-[N (3"S-dif7uorophenylacetyl) L-alaninyl]-2-amino-3-(4-pyridyl)propionamide Following General Procedure K and using 2-methoxyethylamine and methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-pyridyl)propionate (from Example 23 above), the title compound was prepared as a solid (mp =
202-206 ° C) . The reaction was monitored by tlc (Rf = 0.72 in 10 % MeOH/DCM) and the product was pmi Pied by acid/base washes.
NMR data was as follows:
'H-nmr (CDC13): 8 = 8.214-8.198 (d, 2H); 7.117-7.100 (d, 2H); 6.707-6.687 (m, 2H); 6.638-6.576 (t, 1H}; 4.498-4.448 (m, 1H); 3.985-3.939 (q, 1H); 3.386 (s, 2H); 3.190-3.084 (m, 4H); 3.060 (s, 3H); 2.918-2.629 {m, 2H);
1.077-0.905 (d, 3H).
'3C-nmr (CDC13): 8 = 175.831; 173.2:?9; 150.440; 150.249; 126.887;
113.995; 113.662; 103.662; 103.529; 72Ø31; 59.370; 55.201; 51.674; 42.949;
40.889; 38.350; 17.933.
C22HzeFzN404 (~ = 448); mass spectroscopy {MH+) 449.

Example 30 Synthesis of N (2-Methoxyethyl)-N'-[N (3,5-ditluorophenylacetyl) Iralaninyl]-2-amino-3-(2-pyridyl) propionamide Following General Procedure K and using 2-methoxyethylamine and methyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-pyridyl)propionate (from Example 19 above), the title compound was prepared as a solid (mp =
183-187 ° C) . The reaction was monitored by tlc (Rf = 0. 39 in 10 MeOH/DCM) and the product was purified by recrystallization from MeOH/DCM.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.457-8.442 (d, IH); 8.029-8.005 (d, 1H); 7.642-7.585 (t, 1H); 7.395-7.379 (m, 1H); 7.267-7.141 (d+t, 2H); 6.828-6.802 (m, 2H); 6.754-6.679 {t, 1H); 6.604-6.581 (m, 1H); 4.871-4.809 (q, 1H); 4.532-4.485 (quintex, 1H); 3.537 (s, 2H); 3.342-3.118 (m, 6H); 3.248 (s, 3H);
1.394-1.371 (d, 3H).
'3C-nmr (CDCl3): b = 172.360; 171.140; 158.43; 149.113; 137.59;
124.98; 122.54; 113.02; 112.69; 103.40; 71.376; 59.203; 53.143; 49.984;
43.355; 43.328; 39.685; 39.626; 19.295.
2O CZZH2eFzNaOa (MW = 448); mass spectroscopy (MH+) 449.
Example 31 Synthesis of Methyl N-[N-(3,5-Difiuorophenylacetyl) Iralaninyl]-(S)-2-amino-3-(thiazol-4-yl) propionate Following General Procedure A and using N (3,5-difluorophenylacetyl)---, L-alanine (from Example B2 above) and methyl {S)-2-amino-3-(thiazol-4-yl)propionate hydrochloride (General Procedure H with methanol and HCl on methyl (S)-2-amino-3-(thiazol-4-yl)propyl acid (Synthetech)), the title compound was prepared as a solid (mp = 136-139°C). The reaction was monitored by tlc (Rf = 0.4 in 10 % MeOH/DCM) and the product was purified by recrystallization from DCM.

NMR data was as follows:
1H-nmr (CDCl3): b = 8.737-8.731 (d., 1H); 7.410-7.385 {d, 1H); 7.065-7.059 (d, 1H); 6.828-6.802 (m, 2H); 6.74.7-6.687 (m, 1H); 6.542-6.518 (d, 1H); 4.904-4.844 (q, 1H); 4.553-4.505 (quintex, 1H); 3.678 (s, 3H); 3.515 (s, 2H); 3.402-3.232 (dq, 2H); 1.384-1.361 (d, 3H).
'3C-nmr (CDC13): b = 172.497; 171.726; 169.619; 153.831; 152.613;
116.431; 113.019; 112.688; 112.014; 103.396; 53.113; 52.625; 49.476;
43.460; 43.435; 32.850; 19.422.
C,gH,9FZN3O4S (MW = 411); mass sF~ectroscopy (MH+) 412.
ExamplE: 32 Synthesiis of Methyl 2-[N (3,5-Difluorophenylacetyl)-Iralaninyl]
1,2,3,4-tetrahydroisoquinoline-3-carboxylate Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 1,2,3,4-tetrahydroisoquinoline-3-carboxylate {Aldrich), the title compound was prepared as a solid (mp = 37-40°C). The reaction was monitored by tlr. (Rf = 0.64 in 10% MeOH/DCM).
NMR data was as follows:
'H-nmr (CDCl3): b = 7.500-7.475 (d, 1H); 7.161-7.057 (m, 4H); 6.815-6.795 (dm, 2H); 6.656-6.596 (t, 1H); 5.3~s6-5.088 (m, 2H); 4.924-4.841 (m, 1H); 4.718-4.453 (m, 1H); 3.530 (s, 3H); 3.500 (s, 2H); 3.329-3.058 (m, 2H);
1.423-1.400, 1.327-1.304 (d, 3H).
'3C-nmr (CDCl3): 8 = 173.428; 173.329; 171.690; 171.559; 169.558;
165.020; 161.899; 161.728; 139.368; 132, 549; 128.912; 127.723; 126.648;
112.929; 103.360; 60.915; 53.318; 53.001; 46.377; 43.121; 31.027; 21.537;
19.545; 18.771; 14.716.
Cz2HzzFzNzOd (M~' = 416); mass spe~~troscopy (MH+) 417.

__ 2p4 __ Example 33 Synthesis of N (3-Methoxybenzyl)-N'-[N (3,5-diftuorophenylacetyl) I~alaninyl]-L-phenylalaninamide Following General Procedure B and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine (prepared by coupling N {3,5-difluorophenyiacetyl)-L-alanine (from Example B2 above) with L-phenylalanine methyl ester ___ _ hydrochloride (Sigma) using General Procedure E, followed by hydrolysis using General Procedure C) and 3-methoxybenzylamine ('TCI), the title compound was prepared as a solid (mp = 117-130°C). The reaction was monitored by tlc (Rf = 0.8 in 3 % MeOH/methylene chloride) and the product was purified by recrystallization from MeOH.
NMR data was as follows:
IH-nmr (DMSO-db): 8 = 8.4 (t, 1H), 8.32 (d, 1H), 8.1 (d, 1H), 6.95-7.2 (m, 9H), 6.7 (m, 3H), 4.5 (m, 1H), 4.2 (m, 3H), 3.7 (s, 3H), 3.5 (s, 2H), 3.3 (d, 2H), 3.0 (m, 2H), 2.5 (s, 3H), 1.2 {m, 4H).
'3C-nmr (DMSO-db): 8 = 172.40, 171.08, 169.28, 159.62, 141.09, 138.06, 129.62, 129.51, 128.41, 126.63, 119.56, 112.97, 112.79, 112.59, 112.46, 55.31, 48.77, 40.69, 40.42, 40.28, 40.14, 40.03, 39.86, 39.70, 39.58, 39.46, 39.44, 39.31, 39.20, 39.03, 18.45.
CZ8H29N3O4F2 (MW = 509); mass spectroscopy (MH+) 509.
Example 34 Synthesis of Methyl N (N (3,5-Difluorophenylacetyl)-Iralaninyl]-(S)-2-amino-3-(1-naphthyl)propionate Following General Procedure B and using N {3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-amino-3-(1-naphthyl)propionate hydrochloride (Bachem), the title compound was prepared as a solid (mp = 103-130°C). The reaction was monitored by tlc (Rf =
0.8 in 5 % MeOH/methylene chloride) and the product was purified by flash column chromatography using 6% MeOH/methylene chloride as the eluent.

NMR data was as follows:
'H-nmr (CDC13): b = 8.10 (d, 1H), 7.85 (d, 1H), 7.71 (d, 1H), 7.50 (m, 3H), 7.35 (t, 1H), 7.20 (d, 1H), 6.70 (m, 4H), 6.30 (d, 1H), 4.90 (m, 1H), 4.45 (m, 1H), 3.3-3.7 (m, 8H), 1.7 (bs, 1H), 1.3 (d 3H).
'3C-nmr (CDC13): b = 172.43, 172.:!9, 169.77, 134.41, 132.61, 132.58, - 129.51, 128.63, 128.33, 128.28, 128.06" 126.97, 126.80, 126.42, 126.29, 125.94, 125.86, 124.06, 123.90, 112.96, 112.63, 103.44, 78.03, 77.61, 77.19, 61.01, 54.02, 53.83, 52.99, 51.40, 49.3:3, 43.29, 35.64, 18.82, 14.77.
CzaH2aNz04Fz (MW = 442); mass spectroscopy (MH+) 442.
Example 35 Synthesis of ' Methyl N [N (3,5-Difluorophenylacetyl)-I~alaninyl]-(S)-2-amino-3-(2-naphthyl) propionate Following General Procedure B and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-amino-3-(2-naphthyl)propionate hydrochloride (Bachem), the title compound was prepared as a solid (mp = 166°C). The reaction vvas monitored by tlc (Rf = 0.55 in 5 % MeOH/methylene chloride) and the product was purified by preparative tlc using 5 % MeOH/methylene chloride as tree eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 1.3 (d, 3H), 3.2 (m, 2H), 3.3 (s, 2H), 3.7 (s, 3H), 4.55 (m, 1H), 4.9 (quart, 1H), 6.7 (m, 413), 7.05 (d, 1H), 7.20 (d, 1H), 7.45 (m, 2H), 7.55 (s, 1H), 7.80 (m, 3H}.
'3C-nmr (CDCIj): 8 = 172.43, 172.26, 169.86, 133.93, 133.76, 133.02, 128.86, 128.64, 128.23, 128.20, 127.69, 126.85, 126.45, 112.95, 112.62, 103.37, 78.05, 77.62, 77.20, 53.93, 53.0:5, 49.37, 43.12, 38.46, 18.81.
C2aH2aN20aF2 (MW = 442); mass spectroscopy (MH+) 442.

Example 36 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl) I~alaninyl]-(S)-2-amino-3-(2-thienyl) propionate Following General Procedure B and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above} and methyl (S)-2-amino-3-(2-tluenyl)-propionate (Bachem), the title compound was prepared as a solid (mp = 145-147°C). The reaction was monitored by tlc (Rf = 0.9 in 100% EtOAc) and the product was purified by preparative tlc using EtOAc as the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 7.15 (d, 1H), 6.9 (t, 1H), ~.7-6.8 {m, 5H); 6.3 (d, 1H), 4.8 (m, 1H), 4.5 (m, 1H), 3.8 (s, 3H), 3.5 (s, 2H), 3.35 (d, 2H), 1.35 (d, 3H).
'3C-nmr (CDC13): 8 = 172.22, 171.56, 169.79, 137.47, 127.71, 125.55, 113.04, 112.71, 103.48, 78.03, 77.60, 77.18, 53.78, 53.25, 49.51, 43.41, 32.37, 18.97.
Cl9HZOIV2O4FzS (MW = 410); mass spectroscopy (MH+) 410.
Example 37 Synthesis of N [N (3,5-Difluorophenylacetyl)-Iralaninyl]-L-phenylalanine Benzyl Fster Following General Procedure B and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-phenylalanine benzyl ester hydrochloride (Bachem), the title compound was prepared as a solid (mp =
i70-171°C). The reaction was monitored by tlc (Rf = 0.7 in 5%
MeOH/methylene chloride) and the product was purified by recrystallization from MeOH.
NMR data was as follows:
'H-nmr (MeOH): 8 = 7.3 (m, lOH), 6.9 (m, 3H), 5.2 (s, 2H), 4.75 (t, J=7 Hz, 1H), 4.4 (quart, J=6 Hz, 1H), 3.6 {s, 2H), 3.1 (m, J= 6 Hz, 2H), 1.35 (d, J =7 Hz, 3H).

_ __ 207 __ 13C-nmr (MeOH): b = 175.29, 173.0!x, 172.78, 141.54, 138.35, 137.53, 130.88, 130.08, 130.05, 129.92, 128.42, 113.93, 113.83, 113.60, 103.90, 103.55, 103.21, 68.59, 55.87.
Cz7HzbN20aFz (MW = 480); mass spe~troscopY (MH'') 480.
Example 38 Syntheses of N [N (3,5-Difluorophen~ylacetyl)-L-alaninyl]
L-phenylalanine 3-Bromopropyl Ester Following General Procedure B and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine (prepared by coupling N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-phenylalanine (Aldrich) using General Procedure B) and 3-bromo-1-propanol (Aldrich), the title compound was prepared as a solid (mp = 138-142°C'). The reaction was monitored by tlc (Rf = 0.75 in 60% EtOAclhexanes) and the product was purified by flash column chromatography using 60 % EtOAc:/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.3-6.6 (m, lOH), 4.8 (m, 1H), 4.55 (m, 1H), 4.2 (t, J=6 Hz, 2H), 3.51 (s, 2H), 3.3 (m, 211), 3.05 (m, J=6 and 8 Hz, 2H), 2.1 (m, 2H), 1.3-1.2 (m, J=7 Hz, 3H).
'3C-nmr (CDCl3): b = 172.49, 171.78, I7I.71, 170.01, 169.96, 165.31, 162.02, 161.84, 138.91, 138.78, 138.66, 136.26, 136.19, 129.76, 129.72, 129.22, 129.18, 127.80, 113.04, 113.02, 112.93, 112.91, 112.82, 112.79, 112.71, 112.69, 103.72, 103.69, 103.36, :103.05, 103.03, 63.75, 63.70, 54.11, 53.91, 49.38, 49.32, 43.26, 38.56, 38.51, 31.92, 29.76, 29.71, 19.14, 19.06.
Cz3HzsNzO4F2Br (MW = 511. I); mass spectroscopy (MH+) 512.
Example: 39 Synthesis of N [N (3,5-Difluorophenylacetyl)-I~alaninyl]
I,-phenylalanine 3-Iodopropyl Ester Following General Procedure B and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine (prepared by coupling N (3,5-difluorophenyiacetyl)-L-alanine (from Example 82 above) and L-phenylalanine (Aidrich) using General Procedure B) and 3-iodo-l-propanol (Aldrich) , the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.45 in 5 %
MeOH/methylene chloride) and the product was purified by preparative tlc using 5 % MeOH/methylene chloride.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.4-7.0 (m, 5H), 6.9-6.6 (m, 4H), 6.3 (m, 1H), 4.8 (m, 1H), 4.5 (m, 1H), 4.2 (t, 2H), 3.5 (s, 2H), 3.1 (m, 4H), 2.1 (m, 2H), 1.7 (s, 1H), 1.35-1.25 (m, 3H).
'3C-nmr (CDC13): b = 172.24, 171.72, 169.95, 136.12, 136.09, 129.77, 129.75, 129.28, 129.24, 127.87, 113.06, 113.02, 112.73, 112.70, 103.80, 103.49, 103.47, 65.73, 65.70, 54.00, 53.84, 49.42, 49.33, 43.38, 38.54, 38.50, 32.57, 18.97, 18.91.
Example 40 Synthesis of N [N-(3,5-Difluorophenylacetyl)-Iralaninyl]
I~leucine ten-Butvl Ester Following General Procedure B and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-leucine tent-butyl ester hydrochloride (Bachem), the title compound was prepared as a solid (mp = 128°C). The reaction was monitored by tlc (Rf = 0. 85 in 5 % MeOH/methylene chloride) and the product was purified by flash column chromatography using 5 %
MeOH/methylene chloride as the eluent.
NMR data was as follows:
'H-nmr (CDCl3}: 8 = 6.9-6.5 (m, 5H), 4.6 (m, 1H), 4.4 (m, IH), 3.5 (s, 2H), 1.7-1.4 (m, 15H), 0.9 (t, 6H).
'3C-nmr (CDCl3): b = 172.41, 172.20, 169.87, 165.30, 162.00, 161.83, 139.01, 138.89, 112.92, 112.82, 112.69, 112.59, 103.62, 103.29, 102.95, 82.50, 78.03, 77.61, 77.18, 52.12, 49.3>, 43.34, 41.86, 28.52, 25.42, 23.26, 22.46, 19.18.
C~H3o1Vz04F2 (MW = 412.48); masse spectroscopy (M:~+) 413.
Example 41 Synth~~is of N'-[N (3,5-Difluorophenylacetyl)-L-alaninyl]
2-amino-2-(2-pyridyl)acetamide Following General Procedure L and using ethyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetate (from Example 65 below), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.1 in 9:1 CHCI3IMeOH) and the product was purified by recrystaIlizaion from EtOH.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.54 (m, lei), 8.43 (d, 1H), 7.77 (m, 1H), 7.59 (bs, 1H), 7.46 (m, 1H), 7.33 (m, 1H), 7.'22 (m, 1H), 7.09 (m, 1H), 6.98 (m, 2H), 5.41 (m, 1H), 4.46 (m, 1H), 4.46 (rn, 1H), 3.52 (s, 2H), 1.26 (m, 3H).
C,eH,.,N303FZ (MW = 376.3); mass spectroscopy (MH+) 377.
Example 42 Synthesis of N'-[N (3,5-Difluorophenylacetyl)-I~alaninyl)-2-amino-2-(3-pyridyl)acetamide Following General Procedure L and using ethyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetate (from Example 53 below), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.1 in 9:1 CHCI3/MeOH) and the product was purified by recrystallization from EtOH.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.64 (m, 1H), 8.55 (d, 1H), 8.52 (d, 1H), 8.41 (d, 1H), 7.79 (m, 1H), 7.37 (m, 1H), 7.3 2 (m, 1H), 7.09 (m, 1H), 6.98 (m, 2H), 5.42 (m, 1H), 4.42 (m, 1H), 3.53 (s" 2H), 1.26 (m, 3H).

C,aH,~N,03F2 (MW = 376.3); mass spectroscopy (MH+) 377.
Example 43 Synthesis of N [N (3,5-Difluorophenylacetyl)-I~alaninyl]-NE-(tent-butoxycarbonyl)-D-lysine Methyl Fster Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and NE-(tent-butoxycarbonyl)-L-lysine methyl ester (Bachem), the title compound was prepared as an oil. The reaction was monitored by tlc (Rf = 0.40 in 50 % EtOAc/hexanes) and the product was purified by flash chromotography using 50 % EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 6.80 (d, 2H), 6.66 (t, 1H), 4.82 (bs, 1H), 3.73 (s, 3H), 3.52 (s, 2H), 3.04 (bs, 2H), 1.60-I.IS (m, 2H), 1.38 (s, 9H), 1.32 (d, 2H), 1.20-1.30 (m, 2H).
'3C-nmr (CDC13): b = 173.00, 172.80, 165.28, 165.11, 161.98, 161.78, 156.79, 138.95, 129.06, 128.72, 103.59, 103.26, 102.92, 79.81, 52.99, 52.76, 49.44, 43.25, 31.92, 29.98, 28.99, 22.95, 18.94.
C23H33F2N3O6 (MW = 485.53); mass spectroscopy (MH+) N/A.
Example 44 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-4-phenylbutanoate Following General Procedure A and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-amino-4-phenylbutanoate (prepared from (+)-«-amino-4-phenylbutyric acid (Bachem) using General Procedure AG), the title compound was prepared as a solid (mp = 147-149.5°C). The reaction was monitored by tlc (Rf = 0.32 in 50%
EtOAc/hexanes) and the product was purified by flash chromotography using EtOAc/hexanes as the eluent.
NMR data was as follows:

WO 98/22494 PCT/(JS97/20804 'H-nmr (CDC13): 8 = 7.63 (bd, 2H), 7.04 (m, SH), 6.56-6.82 (m, 3H), 4.80 (p, 1H), 4.48 (q, 1H), 3.65 (s, 3H), 3.49 (s, 2H), 2.50-2.65 (m, 2H), 1.80-2.16 (m, 2H), 1.29 (d, 3H).
'3C_nmr (CDC13): b = 173.48, 172.81, 170.43, 165.17, 161.71, 140.91, 139.34, 129.07, 129.01, 128. 89, 126.81, 126.76, 112.90, 112.67, 103.37, 103.03, 102.69, 52.86, 52.71, 49.36, 42.!9, 33.79, 32.21, 19.34.
C22H24F2N204 (MW = 418.44); mass spectroscopy (MH*) 419.
Example 45 Synthesis of N [N (3,5-Difluorophenyiacetyl)-Iralaninyl]glycine 2-:Phenylethyl Ester Following General Procedure X and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]glycine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]glycine benzyl ester (from Example 73 below) using General Procedure O) and 2-phenylethanol (Aldrich), the title compound was prepared as a solid (mp = 154.0-155.2°C). The reaction was monitored by tlc (Rf = 0.15 in 15%
EtOAc/hexanes) and the product was purifued by flash chromotography using 15 % EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.35-7.20 (m, _'iH), 6.76 (bs, 1H), 6.72-6.67 (m, 3H), 6.54 (bd, 1H), 4.58 (p, 1H), 4.34 (t., 2H), 3.96 (d, 2H), 3.52 (s, 2H), 2.93 (t, 2H), 1.26 (d, 3H).
'3C-nmr (CDC13): 8 = 172.9, 170.1, 169.9, 137.8, 129.4, 129.1, 127.3, 112.94, 103.4, 103.0, 65.5, 49.3, 43.2, 4I.8, 35.4, 18.8.
C2'H22NzOoFz (MW = 404.42); mass spectroscopy (MH+) 405.
Example 46 Synthesis of N-[N (3,5-Difluorophenylacetyl) I~alaninyl]glycine 3-P'henylpropyl Ester Following General Procedure X and using N [N (3,5-difluorophenyiacetyl)-L-alaninyl]glycine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]glycine benzyl ester (from Example 73 below) using General Procedure O) and and 3-phenyl-1-propanol (Aldrich), the title compound was prepared as a solid (mp = 137°C). The reaction was monitored by tlc (Rf = 0.15 in 50%
EtOAc/hexanes) and the product was purified by flash chromotography using 50 ~ EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.55-7.32 (m, 5H), 6.73 (d, 2H), 6.65 (m, 1H), 4.74 (p, 1H), 4.14 (t, 2H), 3.93 (m, 2H), 3.49 (s, 2H), 2.66 (t, 2H), 1.94 (p, 2H), 1.41 (d, 3H).
13C-nmr (CDCl3): 8 = 173.8, 170.5, 170.1, 165.2, 165.0, 161.9, 161.7, 141.5, 139.2, 129.1, 128.9, 126.7, 112.9, 112.8, 103.4, 103.1, 102.8, 65.4, 49.3, 42.9, 41.8, 32.6, 30.6, 19.3.
I5 Cz2Hz4NzOaF2 (MW = 418.44); mass spectroscopy {MH+) 419.
Example 47 Synthesis of N'-[N (3,5-Difluorophenylacetyl)-L-alaninyl]
2-amino-2-(4-pyridyl)acetamide Following General Procedure L and using ethyl N [N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-pyridyl)acetate (from Example 66), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.1 in CHCI3/MeOH 9:1) and the product was purified by silica gel chromatography using 9:1 CHCl3/MeOH as the eluent.
NMR data was as follows:
'H-nmr {DMSO-db): b = 8.53 (m, 2H), 8.88 (bs, 1H), 7.41 (m, 2H), 7.12 (m, 1H), 7.02 (m, 2H), 5.46 (m, 1H), 4.46 (m, 1H), 3.55 and 3.52 (s, 2H), 1.21 (m, 3H).
C,BH,gN403Fz (MW = 376.3); mass spectroscopy (MH+) 377.

Example; 48 Synthesis of N [N (Phenylacetyl)-L-alaninyf~-L-threonine Met6y1 Ester Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B1 above) and L-threonine methyl ester hydrochloride (Bachem), the title compound was prepared as a solid.
NMR data was as follows:
- - 'H-nmr (CDCl3): 8 = 7.45 (d, J=8.9 EIz, 1H), 7.11-7.27 (m, 6H}, 4.55 (quintet, J=7.2 Hz, 1H), 4.43 (dd, J=2.6,8.8 Hz, 1H}, 4.20 (m, 1H), 3.62 (s, 3H), 3.46 (s, 2H), 1.29 (d, J=7.0 Hz, 3H;1, 1.04 (d, J=6.4 Hz, 3H).
'3C-nmr (CDCl3): b = 172.8, 171.1, 170.9, 134.5, 128.9, 128.4, 126.8, 67.5, 57.7, 52.1, 48.7, 42.8, 19.6, 18.3.
C,6HZ,N205 (MW = 322.36); mass spectroscopy (MH+) 323.
Example 49 Synthesi~~ of N'-[N (Phenylacetyl)-I~alaninyl]-L-leucinamide Following General Procedure T and using N (phenylacetyl)-L-alanine (from Example B 1 above) and L-leucinamide hydrochloride (Aldrich), the title compound was prepared as a solid (mp = 207-209°C). The product was purified by extraction with EtOAc and washing with aqueous potassium carbonate and aqueous hydrochloric acid.
NMR data was as follows:
'H-nmr (CD30D): 8 = 7.00-7.12 (m, 5H), 4.10-4.20 (m, 2H), 3.34 (s, 2H), 1.30-1.50 (m, 2H), 1.12-1.23 (m, 4H), 0.65-0.76 (m, 6H).
'3C-nmr (CD30D): b = 177.5, 174.9, 1.74.1, 136.8, 130.1, 129.6, 127.9, 52.8, 50.7, 43.4, 41.9, 25.8, 23.5, 21.8, 1'7.7.
Example :50 Synthesis of N'-[N (Phenylacetyl)-Iralaninyl]-L-alaninamide WO 98/Z2494 PCT/US9?/20804 Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B 1 above) and L-alaninamide hydrochloride (Bachem), the title compound was prepared as a solid (mp = > 260°C). The product was purified by washing with aqueous sodium hydroxide and aqueous hydrochloric acid.
NMR data was as follows:
'H-nmr (DMSO-d6): 8 = 8.27 (d, J=7.1 Hz, 1H), 7.88 (d, J=7.6 Hz, 1H), 7.26 (m, 6H), 6.99 (s,-1H); 4.25 (quintet, J=7.1 Hz, 1H), 4.16 (quintet, J=7.1 Hz, 1H), 3.46 (s, 2H), 1.19 (t, 7=6.3 Hz, 6H).
'3C-nmr (DMSO-d6): b = 174.1, 171.8, :170.0, 136.3, 129.0, 128.1, 126.3, 48.3, 47.9, 42.0, 18.3, 18.1.
Example 51 Synthesis of N'-[N (Phenylacetyl)-I~alaninylJ-I~phenyiaianinamide Following General Procedure T and using N. (phenylacetyl)-L-alanine (from - Example B1 above) and L-phenylalaninamide (Bachem), the title compound was prepared as a solid (mp = 224-225°C).
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.24 (d, J=7.2 Hz, 1H), 7.89 (d, J=8.2 Hz, IH), 7.36 (s, IH), 7.13-7.34 (m, lOH), 7.11 (s, 1H), 4.40 (m, 1H), 4.21 (quintet, J=7.1 Hz, 1H), 3.44 (d, 2H), 3.01 (dd, 3=4.9, 13.7 Hz, 1H), 2.82 (dd, J=9.0, 13.7 Hz, 1H), 1.13 (d, J=6.9 Hz, 3H).
'3C-nmr (DMSO-db): 8 = 172.7, 172.0, 170.0, 137.8, 136.3, 129.2, 129.0, 128.2, 128.0, 126.3, 126.2, 53.6, 48.5, 41.9, 37.3, 18Ø
_._ - Example 52 Synthesis of N'-[N (Phenylacetyl)-L-aianinyi)-Irvaiinamide Following General Procedure T and using N (phenylacetyl)-L-alanine (from , Example B 1 above) and L-valinamide hydrochloride (Bachem), the title compound was prepared as a solid (mp = > 261 °C).

NMR data was as follows:
' 'H-nmr (DMSO-d~: b = 8.31 (d, J=7.5 Hz, 1H), 7.62 (d, J=9.0 Hz, 1H), 7.38 (s, 1H), 7.15-7.30 (m, 5H), 7.05 (s, 1H), 4.34 (quintet, J=7.2 Hz, ' 1H), 4.08 (dd, J=6.4, 15.3 Hz, 1H), 3.45 (s, 2H), 1.91 (m, 1H), 1.19 (d, J=7.0 Hz, 3H), 0.79 (d, J=6.7 Hz, 3H), 0.76 (d, J=6.8 Hz, 3H).
'3C-nmr (DMSO-d~): b = 172.8, 172.1, 170.0, 136.3, 129.0, 128.2, 126.3, 57.2, 48.2, 42.0, 30.5, 19.2, 17.9, 17.8.
Example 53 Synthesis of Ethyl N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(3-pyridyl)acetate (prepared as described in P. Kolar et al., J. Heterocyclic Chem., 28, 1715 (1991) and references cited therein), the title compound was prepared as a solid (mp = 146-157°C). The reaction was monitored by tlc (Rf = 0.1 in CHC13/MeOH 98:2) and the product was purified by silica gel chromatography using 959:5 CHCI3/MeOH as the eluent, followed by recrystallization from chlorobutane.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.60 (m, 1H), 8.56 and 8.52 (m, 1H), 7.91 (m, 1H), 7.63 (m, 1H), 7.22 (m, 1H), 6.90 (m, 1H), b.74 (m, 2H), 5.55 (m, 1H), 4.69 (m, 1H), 4.17 (m, 2H), 3.50 and 3.41 (s, 2H), 1.33 and 1.29 (d, 3H), 1.21 (m, 3H), 1.18 (m, 3H).
C2oHZ,N3O4F2 (MW = 405.4); mass spectroscopy (MH+) 405.
' Example 54 Synthesis of N Methyl-N'-[N (phenylacetyl)-L-alaninyl]-Irleucina~mide Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B1 above) and N methyl-L-leucinamide (prepared from N methyl-N'--_ 216 --BOC-L-leucinamide (from Example D5 above) using General Procedure Y), the title compound was prepared as a solid (mp = 233-235°C). The product was ' purified by recrystallization from MeC?H.
NMR data was as follows:
'H-nmr (CDC13ICD30D): b = 7.25-7.40 {m, SH), 4.36 (quartet, J=7.2 Hz, 1H), 4.27 (dd, J=5.1, 14.6 Hz, 1H), 3.56 (s, 2H), 2.72 (s, 3H), 1.40-1.61 (m, 2H), 1.32 (d, J=7.1 Hz, 3H), 0.89 (d, J=6.2 Hz, 3H), 0.86 (d, J=6.2 Hz, 3H).
Example 55 Synthesis of N,N Dimethyl-N'-[N (phenylacetyl) L-aianinyl]-L~-phenylalaninamide Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B1 above) and N,N dimethyl-L-phenylalaninamide {prepared by coupling N BOC-L-phenylalanine (Bachem) with dimethylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp =
152-155 °C). The product was purified by extraction with EtOAc, washing with aqueous sodium carbonate and aqueous hydrochloric acid, and trituration with Et20.
NMR data was as follows:
'H-nmr (CDC13): b = 7.49 (d, J=8.2 Hz, 1H), 7.20-7.26 (m, 8H), 7.14 (m, 2H), 6.45 (d, J=7.5 Hz, 1H), 5.08 {quartet, J=8.0 Hz, 1H), 4.60 (quintet, J=7.3 Hz, 1H), 3.56 (s, 2H), 2.95 (m, 2H), 2.86 (s, 3H), 2.61 (s, 3H), I.26 (d, J=6.9 Hz, 3H).
'3C-nmr (CDCl3): d = 171.6, 170.8, 170.4, 136.0, 134.7, 129.3, 129.2, 128.9, 128.8, 128.3, 127.1, 50.2, 48.7, 43.4, 39.5, 36.8, 35.6, 18.8.

Example 56 Synthesis of __ -N,N Dimethyl-N'-[N (phenylacetyl)-Iralaninyl]-L.~leucinamide Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example Bl above) and N,N dimethyi-L-leucinamide (prepared by coupling N
BOC-L-leucine (Bachem) with dimethylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 130-132°C).
The product was purified by extraction b:y EtOAc, washing with aqueous sodium carbonate and aqueous hydrochloric acid, and trituration with Et~O.
NMR data was as follows:
'H-nmr (CDCI3): 8 = 7.23-7.36 (m, SH), 7.04 (d, J=8.7 Hz, 1H), 6.30 (d, J=7.6 Hz, 1H), 4.92 (m, 1H), 4.56 (quintet, J=7.2 Hz, 1H), 3.56 (s, 2H), 3.07 (s, 3H), 2.94 (s, 3H), I.33-1.64 (m, 3H), 1.27 (d, J=6.9 Hz, 3H), 0.94 (d, J=6.4 Hz, 3H), 0.88 (d, J=6.5 Hz, 3H).
'3C-nmr (CDCI3): b = 172.0, 171.7, 170.4, 134.6, 129.2, 128.8, 127.2, 48.7, 47.3, 43.5, 42.1, 36.9, 35.8, 24.6, 23.3, 21.8, 18.6.
Example 57 Synthesis of N,N Dimethyl-N'-jN (phenylacetyl)-I~alaninyl]-Irvalinamide Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B1 above) and N,N dimethyl-L=valinamide (prepared by coupling N
BOC-L-valine (Bachem) with dimethylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 147-149°C).
The product was purified by extraction b;~ EtOAc, washing with aqueous sodium carbonate and aqueous hydrochloric acid, and trituration with Et~O.
NMR data was as follows:
'H-nmr (CDCI3): b = 7.24-7.38 (m, SH), 6.64 (d, IH), 6.05 (d, IH), 4.74 (dd, J=5.9, 8.9 Hz, 1H), 4.50 (quintet, :f=7.1 Hz, 1H), 3.59 (s, 2H), 3.08 (s, 3H), 2.96 (s, 3H), 1.97 (m, 1H), 1.28 (d, J=7.0 Hz, 3H), 0.91 (d, J=6.8 Hz, 3H), 0.84 (d, 1=6.8 Hz, 3H).
'3C-nmr (CDC13): 8 = 172.3, 171.4, 170.4, 134.6, 129.0, 128.5, 126.8, 53.5, 48.5, 43.2, 37.3, 35.6, 31.2, 19.2, 18.6, 17.5.
C,gH~N303 (MW = 333.43); mass spectroscopy (MH+) 334.
Example 58 Synthesis of N Methyl-N'-[N (phenylacetyl)-L-alaninyl]-Irphenylalaninamide Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B 1 above) and N methyl-L-phenylalaninamide (prepared by coupling N BOC-L-phenylalanine (Bachem) with methylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid. The product was purified by washing with aqueous sodium carbonate and aqueous hydrochloric acid.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 8.23 (d, J=7.0 Hz, IH), 7.95 (d, J=8.2 Hz, 1H), 7.79 (d, J=4.4 Hz, 1H), 7.10-7.32 (m, IOH), 4.37 (quintet, J=5.4 Hz, 1H), 4.19 (quintet, J=7.1 Hz, 1H), 3.44 (s, 2H), 2.9b (dd, J=5.5, 13.7 Hz, IH), 2.78 (dd, J=9.2, 13.7 Hz, 1H), 2.52 (d, J=4.4 Hz, 3H), 1.11 (d, J=7.0 Hz, 3H).
'3C-nmr (DMSO-d6): b = 172.0, 171.0, 170.1, 137.8, 136.3, 129.11, 129.07, 128.2, 128.1, 126.31, 126.26, 53.9, 48.5, 41.9, 37.5, 25.5, 18Ø
Example 59 Synthesis of N-Methyl-N'-[N (phenylacetyl)-I~-alaninyl]-Irvalinamide Following General Procedure U and using N (phenylacetyl)-L-alanine (from Example B 1 above) and N methyl-L-valinamide (prepared by coupling N BOC-L-valine (Bachem) with methylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the FLOC-group using General Procedure Y}, the title compound was prepared as a solid. The product was purified by washing with aqueous sodium carbonate and aqueous hydrochloric acid.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.30 (d, J=T.6 Hz, 1H), 7.88 (d, J=4.7 Hz, - 1H), 7.69 (d, J=9.1 Hz, 1H), 7.17-7.32 (m, 5H), 4.34 (quintet, J=7.2 Hz, 1H), 4.04 (dd, J=7.0, 8.9 Hz, 1H), 3.45 ta, 2H), 2.56 (d, J=4.6 Hz, 3H), 1.87 (m, 1H), 1.18 (d, J=7.0 Hz, 3H), 0.'76 (d, J=6.6 Hz, 3H), 0.75 (d, J=6.7 Hz, 3H).
'3C-nmr (DMSO-db): b = 172.0, 171.1',, 170.0, 136.3, 129.0, 128.1, 126.3, 57.6, 48.2, 42.0, 30.6, 25.4, 19.2, 18.1, 17.9.
Example 60 Synthesc~ of N Methyl-N'-[N (3,5-difiuorophenylacetyl)-Lralaninyl]-(S)-2-am inohexanamide Following General Procedure U and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N methyl-L-norleucinamide (prepared by coupling N BOC-L-norleucine (Bachem) with methylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid. The product was purified by washing with aqueous sodium carbonate and aqueous hydrochloric acid.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.37 (d, 7.1, 1H), 7.88 (d, 8.1, IH), 7.78 (d, 4.4, 1H), 7.08 (t, 9.5, 1H), 6.98 (d, 6.90, 2H), 4.27 (quintet, 7.0, 1H), 4.13 (quartet, 5.5, 1H), 3.51 (s, 2H), 2.54 (d, 4..4, 3H), 1.58 (m, IH), 1.46 (m, 1H), 1.19 (m, 7H), 0.81 (t, 6.5, 3H).
'3C-nmr (DMSO-d6): b = 172.0, 171.9, 169.0, 162.2(dd, J=I3.6, 244.0 Hz), 140.7, 112.2(dd, J=8.3, 17.0 Hz), 101.9(t, J=25.5 Hz), 52.4, 48.4, 41.3, 31.8, 27.4, 25.5, 21.8, 17.9, 13.8.
C,aHZSN303F2 (MW = 369.42); mass spectroscopy (MH+) 384.

Example 61 Synthesis of N,N Dimethyl-N'-[N (3,5-difluorophenylacetyl) Iralaninyl]-(S)-2-aminohexanamide Following General Procedure U and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N,N dimethyl-L-norleucinamide (prepared by coupling N BOC-L-norleucine (Sachem) with dimethylamine hydrochloride (Aldrich) using General Procedure B, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 138-140°C). The product was purified by extraction with EtOAc and washing with aqueous sodium carbonate and aqueous hydrochloric acid.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.11 (d, 8.1, 1H), 6.81 (m, 2H), 6.71 (m, 1H), 6.60 (d, 7.6, 1H), 4.89 (q, J=5.0, 1H), 4.57 (quint, J=7.1, 1H), 3.53 (s, 2H), 3.08 (s, 3H), 2.97 (s, 3H), 1.70 (m, 1H), 1.55 (m, 1H), 1.20-1.38 (m, 7H), 0.85 (t, 6.9, 3H).
'3C-nmr (CDCl3): b = 171.6, 171.5, 168.9, 163.0 (dd, J=12.9, 247.3 Hz), 138.4, 112.2 (dd, J=7.8, 17.0 Hz), 102.7 (t, J=25.0 Hz), 49.1, 48.9, 42.9, 37:1, 35. 8, 32.6, 27.1, 22.4, 19.1, 13. 8.
2O C,gH2-,N3O3F2 (MW = 383.44); mass spectroscopy (MH+) 384.
Example 62 Synthesis of N'-[N (3,5-Difluorophenylacetyl)-I,-alaninyl]-(S)-2-aminohexanamide Following General Procedure U and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-norleucinamide (prepared from N
BOC-L-norleucinamide (from Example D6 above) using General Procedure Y), the title compound was prepared as a solid (mp = >215°C). The product was purified by precipitation from water.
NMR data was as follows:

'H-nmr (DMSO-db): b = 8.37 (d, 7.~1, 1H), 7.83 (d, 8.0, IH), 7.29 (s, 1H), 6.95-7.14 (m, 4H), 4.29 (quintet, J-=7.2, 1H), 4.14 (quartet, J=5.0, 1H), 3.52 (s, 2H), 1.61 (m, 1H), 1.46 (m, 1H;1, I.21 (m, 7H), 0.82 (m, 3H).
'3C-nmr (DMSO-db): b = 173.6, 171.9, 168.9, 162.0 (dd), 140.7, 112.2 (dd, J=7.5, 16.6 Hz), 101.9 (t), 52.2, 48.3, 41.3, 31.8, 27.4, 21.8, 18.0, 13.8.
C"Hz3N303F2 (MW = 355.39); mass spectroscopy (MH+) 356.
Example 63 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-Ir.alaninyl]-2-amino-2-(3-~methoxyphenyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(3-methoxyphenyl)acetate hydrochloride (prepared by the Bucherer Modification of the Strecker procedure as described in J. I'. Greenstein et al., "The Chemistry of Amino Acids", Vol. 1, p. 698, Wiley, IVew York (1961)), the title compound was prepared as a solid (mp = 163-170°C). The reaction was monitored by tlc (Rf = 0.45 in 9:1 CHCl3/MeOH) and the product was purified by silica gel chromatography using 97:3 CHCl3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.27 (m, 1H) , i'.18 and 7.06 (m, 1H), 6.87-6.67 (m, 6H), 6.25 (m, 1H), 5.46 (m, IH), 4.58 (m, 1H), 3.82 (s, 3H), 3.71 and 3.69 (s, 3H), 3.53 and 3.48 (s, 3H), 1.39 and 1.30 (d, 3H).
CZ,HZZNZOSFZ (MW = 420.42); mass spectroscopy (MH+) 421.
Example 64 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl) I~-alaninyl]-2-amino-2-(4-methoxyphenyl)acetate _ -- 222 --Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(4-methoxyphenyl)acetate hydrochloride {prepared by the Bucherer Modification of the Strecker procedure as described in J. P. Greenstein et al., "The Chemistry of Amino Acids", Vol. 1, p. 698, Wiley, New York {1961)), the title compound was prepared as a solid (mp = 170-174°C). The reaction was monitored by tlc (Rf = 0.1 in 98:2 CHCI3/MeOH) and the product was purified by silica gel chromatography using 98:2 CHCI3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.26 (m, 2H), 7.01-6.68 (m, 5H), 6.14 (m, IH), 5.41 (m, IH), 4.56 (m, 1H), 3.80 (s, 3H), 3.74 and 3.71 (s, 3H), 3.54 and 3.47 (s, 3H), 1.39 and 1.29 (d, 3H).
C21HZZNZOSFz (MW = 420.42); mass spectroscopy (MH+) 421.
Example 65 Synthesis of Ethyl N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(2-pyridyl)acetate hydrochloride (prepared as described in P. Kolar et al., J. Heterocyclic Chem., 28, 1715 (1991) and references cited therein), the title compound was prepared as a solid (mp = I23-125°C). The reaction was monitored by tlc (Rf =
0.1 in 98:2 CHC13/MeOH) and the product was purified by silica gel chromatography using 95:5 CHCl3/MeOH as the eluent, followed by recrystallization from chlorobutane.
NMR data was as follows:
1H-nmr (CDCl3): 8 = 8.53 (m, 1H), 7.70 (m, 2H), 7.48 (m, 1H), 7.27 (m, 1H), 6.86 (m, 2H), 6.74 (m, 1H), 6.52 (m, 1H), 5.58 (m, IH), 4.67 (m, 1H), 4.18 (m, 2H), 3.54 and 3.50 (s, 2H), 1.48 and 1.39 (d, 3H), 1.21 (m, 3H).
C2oHz,N3O4F2 (MW = 405.4); mass spectroscopy (MH+) 405.

ExamplE: 66 Synthesiis of Ethyl N [N (3,5-Diflu orophenylacetyl)-Lralaninyt]-2-amino-2-(4-pyridyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(4-pyridyl)acetate hydrochloride (prepared as described in P. Kolar et al., J. Heterocyclic Chem., 28, 1715 (1991) and references cited therein), the title compound was prepared as a solid (mp = 175-181 °C). The reaction was monitored by tlc (Rf =
0.1 in 98:2 CHC13/MeOH) and the product was Fmrified by silica gel chromatography using 95:5 CHCI3/MeOH as the eluent, followed by recrystallization from chlorobutane.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.59 (m, 2H), 7.39 (m, 1H), 7.26 (m, 2H), 6.80 (m, 3H), 6.21 (m, 1H), 5.51 (m, 1H), 4.6.2 (m, 1H), 4.21 (m, 2H), 3.57 and 3.51 (s, 2H), 1.38 (m, 3H), 1.23 (m, 3H)..
CzoHz,N3O4F2 (MW = 405.4); mass spectroscopy (MH+) 405.
Example; 67 Synthesis of N [N (Cyclohexylaceayl)-Iralaninyl]-Lrphenylalanine :Ylethyl Ester Following General Procedure U and using cyclohexylacetic acid (Aldrich) and N (L-alaninyl)-L-phenylalanine methyl ester (prepared by coupling N BOC-L-alanine (Bachem) with L-phenylalanine methyl ester hydrochloride (Bachem) using General Procedure U, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 156-158°C). The reaction was monitored by tl.c (Rf = 0.25 in 1:1 EtOAc/hexanes).
NMR data was as follows:
'H-nmr (CDCl3): 8 = 0.95 (m, 2H), 1..10-1.38 (m, 3H), 1.33 (d, J=7.0 Hz, 3H), 1.60-1.86 (m, 6H), 2.02 (d, J=7.S Hz, 2H), 3.10 (m, 2H), 3.71 (s, 3H), 4.49 (m, 1H), 4.81 (m, IH), 6.10 (d, J=7.3 Hz, 1H), 6.65 (d, J=7.7 Hz, 1H), 7.11 (m, 2H), 7.26 (m, 3H).
'3C-nmr (CDC13): 8 = 18.4, 26.0, 26.1, 33.0, 33.1, 35.3, 37.8, 44.5, 48.5, 52.4, 53.3, 127.1, 128.6, 129.2, 135.6, 171.6, 172.0, 172.2.
C21H3~2~4 ~ = 374.48); mass spectroscopy (MH+) 375.
Example 68 Synthesis of N [N (Cyclopentylacetyl)-Iralaninyl]
I~phenylalanine Methyl Ester Following General Procedure U and using cyclopentylacetic acid (Aldrich) and N (L-alaninyl)-L-phenylalanine methyl ester (prepared by coupling N BOC-L-alanine (Bachem) with L-phenylalanine methyl ester hydrochloride (Bachem) using General Procedure U, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 137-139°C). The reaction was monitored by tlc (Rf = 0.23 in 1:I
EtOAc/hexanes).
NMR data was as follows:
'H-nmr (CDCl3): b = 1.13 (m, 2H), 1.33 (d, J=7.0 Hz, 3H), 1.58 (m, 4H), 1.80 (m, 2H), 2.17 (m, 3H), 3.10 (m, 2H), 3.71 (s, 3H), 4.50 (m, 1H), 4.83 (m, 1H), 6.12 (d, J=7.4 Hz, 1H), 6.69 (d, J=7.7 Hz, 1H), 7.2 (m, 2H), 7.25 (m, 3H).
13C-nmr (CDCl3): 8 = 18.3, 24.9, 32.4, 32.5, 37.0, 37.7, 42.7, 48.4, 52.3, 53.3, 127.1, 128.5, 129.2, 135.7, 171.6, 172.0, 172.6.
CZOH2gN2O4 (MW = 360.46); mass spectroscopy (MH+) 361.
Example 69 Synthesis of N [N (Cyclohex-1-enylacetyl)-Iralaninyl]
L-phenylalanine Methyl Fster Following General Procedure U and using cyclohex-1-enylacetic acid (Alfa) and N {L-alaninyl)-L-phenylalanine methyl ester (prepared by coupling N BOC-L-alanine (Bachem) with L-phenylalanine methyl ester hydrochloride (Bachem) using General Procedure U, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 139-142°C). The reaction was monitored by d.c (Rf = 0.27 in 1:1 EtOAc/hexanes).
NMR data was as follows:
'H-nmr (CDCl3): b = 1.31 (d, J=7.0 Hz, 3H), 1.58 (m, 4H), 1.89 (m, 2H), 2.C14 (br s, 2H), 2.83 (s, 2H), 3.Ci0-3.20 (m, 2H), 3.71 (s, 3H), 4.47 (m, 1H), 4.81 (m, 1H), 5.60 (s, 1H), 6.26 (d, J=7.3 Hz, 1H), 6.67 (d, J=7.7 Hz, 1H), 7.11 (m, 2H), 7.26 (m, 3H).
'3C-nmr (CDCl3): b = 18.1, 21.9, 22.7, 25.3, 28.3, 37.7, 46.0, 48.4, 52.3, 53.3, 127.1, 127.2, 128.5, 129.1, 132.2, 135.7, 171.0, 171.6, 171.8.
CZ,Hz8N204 (MW = 372.47); mass sp~:ctroscopy (MH+) 373.
Example: 70 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl) I~alaninyl]-1-aminocyclop~ropane-1-carboxylate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 1-aminocyclopropane-1-carboxylate hydrochloride (Sigma), the titlf: compound was prepared as a solid.
The reaction was monitored by tlc (Rf = CL3 in 95:5 CHCl3/MeOH) and the product was purified by silica gel chromatography using 97:3 CHC13/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 6.96 (bs, 1H), Ei.82 (m, 2H), 6.69 (m, 1H), 6.48 (d, 1H), 4.50 (m, 1H), 3.67 (s, 3H), 3.54 (s, 2H), 1.58 (m, 2H), 1.40 (d, 2H), 1.12 (m, 2H).
Optical Rotation: [a]23 = -18° (c 1, M:eOH).

Example 71 Synthesis of N 2-(N,N Dimethylamino)ethyl-N methyl-N'-[N (3,5-difluorophenylacetyl)-I~alaninyl]-Iralaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and N,N,N'-trimethylethylene-diamine (Aldrich), the title compound was prepared as a solid.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.37 (m, 2H), 8.19 (d, 1H), 8.08 (d, 2H), 7.10 (m, 1H), 6.99 (m, 2H), 4.67 (m, 1H), 4.30 (m, 1H), 3.52 (s, 2H), 3.01 and 2.86 (s, 3H), 2.47 (t, 1H}, 2.31 (t, 1H), 2.15 (s, 6H), I.19 (m, 6H).
Optical Rotation: [«]23 = -85° (c 1, MeOH).
C,9HZ8N4O3Fz (MW = 398.45); mass spectroscopy (MH+) 398.
Example 72 Synthesis of N [N (Cyclopropylacetyl)-L-alaninyl]
L-phenylalanine Methyl Ester Following General Procedure U and using cyclopropylacetic acid (Lancaster) and N (L-alaninyl}-L-phenylalanine methyl ester (prepared by coupling N BOC-L-alanine (Bachem) with L-phenylalanine methyl ester hydrochloride (Bachem) using General Procedure U, followed by removal of the BOC-group using General Procedure Y), the title compound was prepared as a solid (mp = 128-131 °C). The reaction was monitored by tlc (Rf =
0.14 in 1:1 EtOAclhexanes).
NMR data was as follows:
1H-nmr (CDC13): b = 0.17 (m, 2H), 0.59 (m, 2H), 0.92 (m, 1H), 1.35 (d, J=7.0 Hz, 3H), 2.11 (m, 2H), 3.05 (dd, J=6.7, 13.9 Hz, 1H), 3.16 (dd, J=5.5, 13.9 Hz, 1H), 3.73 (s, 3H), 4.52 (m, 1H), 4.82 (m, 1H), 6.47 (d, 3=7.1 Hz, 1H), 6.70 (d, J=7.5 Hz, 1H), 7.12 (m, 2H), 7.28 (m, 3H).
'3C-nmr (CDC13): 8 = 4.6, 6.9, 18.2, 37.7, 41.2, 48.4, 52.4, 53.2, 127.1, 128.5, 129.2, 135.7, 171.7, 171.9, 172.3.

C,aHz4Nz04 (MW = 332.40); mass spectroscopy (MH+) 333.
Example 73 Synthe:~is of N [N (3,5-Difluor~ophenylacetyl)-L-alaninyl]glycine Benzyl Ester Following General Procedure A and ,using N (3,5-difluorophenylacetyl)-L--._ _ alanine (from Example B2 above) and glycine benzyl ester (prepared from N
BOC-glycine (Bachem) and benzyl alcohol (Aldrich) using General Procedure X, followed by removal of the BOC-groyp using General Procedure Y), the title compound was prepared as a solid (mp = 167.5°C). The reaction was monitored by tlc (Rf = 0.35 in 2 % MeOH/CHzCIz) and the product was purified by flash chromotography using 2 ~lo MeOH/CH2C12 as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.12 (m, 5H), 6.71 (m, 3H), 6.60 (m, 2H), 4.95 (s, 2H), 4.18 (q, 1H), 3.76 (dd, 2H), 3.35 (s, 2H), 1.13 (d, 3H).
'3C-nmr (CDCl3): 8 = 176.0, 172.9, 171.5, 166.46, 163.30, 141.54, 137.70, 130.11, 129.88, 113.98, 113.87, 113.75, 113.64, 103.89, 103.55, 103.21, 68.44, 50.93, 43.25, 42.61, 18.6:5.
CZOHzoNzO4F2 (MW = 390.39); mass spectroscopy (MH+) 391.
Example 74 Synthesis of N-[N (Isovaleryl)-I~.phenylglycinyl]-Iralanine Ethyl Ester Following General Procedure C and using N (isovaleryl)-L-phenylglycine (prepared from isovaleric acid (Aldrich) aad L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure C, followed by hydrolysis using General Procedure AF) and L-alanine ethyl ester hydrochloride (Sigma), the title compound was prepared as a solid (mp = 198-201 °C). The reaction was monitored by tlc (Rf = 0.3 in 1:1 EtOAc/hexanes) and the product was purified by silica gel chromatography using 5 % MeOH/CHC13 as the eluent, followed by rerystallization from EtOAc.

NMR data was as follows:
'H-nmr (DMSO-d~(1:5 mixture of diastereomers): b = 1.25 and 1.30 (two d, 3H), 5.57 (d, 1H), 5.60 (d, 1H).
C,$HZ6NZO4 (MW = 334.42); mass spectroscopy (MH+) 335.
Example 75 Synthesis of N [N (3-Nitrophenylacetyl)-Iralaninyl]
I,-phenylalanine Methyl Ester Following General Procedure Z and using N (3-nitrophenylacetyl)-L-alanine i0 2,4,5-trichlorophenyl ester (from Example D8 above) and L-phenylalanine methyl ester hydrochloride (Sigma), the title compound was prepared as a solid (mp = 154-158°C). The reaction was monitored by tlc (Rf = 0.3 in 1:1 EtOAc/hexanes) and the product was purified by silica gel chromatography using 50-100% EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (DMSO-d6)(1:3 mixture of diastereomers): b = 1.00 and 1.18 (two d, 3H), 2.96 (m, 2H).
CZ,Hz3N3O6 (MW = 413.43); mass spectroscopy (MH+) 413.
Example 76 Synthesis of N-[N-(3-Nitrophenylacetyl)-If-alaninylJ-Iralanine Ethyl Ester Following General Procedure Z and using N (3-nitrophenylacetyl)-L-alanine 2,4,5-trichlorophenyl ester (from Example D8 above) and L-alanine ethyl ester hydrochloride (Sigma), the title compound was prepared as a solid (mp = 193-195°C). The reaction was monitored by tlc (Rf = 0.4 in EtOAc) and the product was purified by silica gel chromatography using EtOAc as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.20 (m, 9H), 3.65 (s, 2H); 4.05 (m, 2H).
Optical Rotation: [a]zo = -27.3 ° Q 589nm, (c = 1.02, DMSO).

C~6HZ~N3O6 (MW = 351.36); mass spectroscopy (MH+) 352.
Example 77 Synthesis of N [N (3-Nitrophenylacetyl)-L-alaninyl]glycine Ethyl Ester Following General Procedure C andl using N (3-nitrophenylacetyl)-L-alanine (prepared from 3-nitrophenylacetic acid (Aldrich) and L-alanine ethyl ester hydrochloride (Sigma) using General Pr~xedure C, followed by hydrolysis using General Procedure AF) and glycine ethyl ester hydrochloride (Sigma), the title compound was prepared as a solid (mp = 164-165°C). The product was purified by silica gel chromatography using EtOAc as the eluent, followed by recrystallization from EtOAc.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.20 (m, fiH), 4.08 (q, 2H); 4.32 (m, 1H).
Optical Rotation: [a]2o = -25° (g~ Sf39 nm, (c = 1.00, DMSO).
C,sH,9N306 (MW = 337.33); mass spectroscopy (MH+) 338.
Example 78 Synthmis of N Hydroxy-N'-[N (3.-nitrophenylacetyl) Iralaninyl]-D,L-threoninamide Following General Procedure Z and using N (3-nitrophenylacetyl)-L-alanine 2,4,5-trichlorophenyl ester (from Example D8 above) and D,L-threonine hydroxamate (Sigma), the title compound was prepared as a solid (mp = 180-183°C). The reaction was monitored by tlc (Rf = 0.25 in 15% MeOH/CHC13) and the product was purified by silica gel chromatography using 15 MeOH/CHCl3 as the eluent, followed by recrystallization from EtOAc.
NMR data was as follows:
'H-nmr (DMSO-db)(1:1 mixture of diastereomers): 8 = 1.22 (m, 3H); 0.98 (m, 3H).
GsHzoNaO~ (MW = 368.35); mass spectroscopy (MH+) 368.

Example 79 Synthesis of N [N (lsovaleryl)-L-p6enylglycinyl]-lralanine iso-butyl Fster Following General Procedure C and using N (isovaleryl)-L-phenylglycine (prepared from isovaleric acid (Aldrich) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure C, followed by hydrolysis using General Procedure AF) and L-alanine iso-butyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and 2-methyl-1-propanol (Aldrich) using General Procedure C (with catalystic DMAP), followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 181-186°C). The reaction was monitored by tlc (Rf = 0.4 in 1:1 EtOAc/hexanes) and the product was purified by silica gel chromatography using 1:1 EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.31 (d, 3H); 5.59 (d, 1H).
Optical Rotation: (a]2o = + 19.0° ~a 589 nm, (c = 1.03, DMSO}.
C2oH29NZO4 (MW = 362.47); mass spectroscopy (MH+) 363.
Example 80 Synthesis of Methyl N-[N (3-nitrophenylacetyl)-Iralaninyl]-2-amino-3-(3-hydroxyphenyl)propionate Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (prepared from 3-nitrophenylacetic acid (Aldrich) and L-alanine ethyl ester hydrochloride (Sigma) using General Procedure C, followed by hydrolysis using General Procedure AF) and methyl 2-amino-3-(3-hydroxyphenyl)propionate (prepared from 2-amino-3-(3-hydroxyphenyl)propionate (Biosynth AG, Switzerland) and methanol using General Procedure H), the title compound was prepared as a solid (mp = 155-159°C). The reaction was monitored by tlc (Rf = 0.4 in EtOAc) and the product was purified by silica gel chromatography using EzJAc as the eluent.
NMR data was as follows:

'H-nmr (DMSO-db)(1:1 mixture of diastereomers): 8 = I.02 and 1.20 (two d, 3H); 3.62 (2 s, 3H).
CzIH~NZO.~ (MW = 429.43); mass spectroscopy (MH+) 429.
Example 81 Synthesis of N [N (3-Nitrophenylacetyl)-Iralaninyl]-Irtyrosine Ethyl Ester Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (prepared from 3-nitrophenylacetic acid (~'~Idrich) and L-alanine ethyl ester hydrochloride (Sigma) using General Procedure C, followed by hydrolysis using General Procedure AF) and L-tyrosine ethyl ester (Sigma), the title compound was prepared as a solid (mp = 117-119°C:). The reaction was monitored by tlc (Rf = 0.5 in EtOAc) and the product was purified by silica gel chromatography using EtOAc as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.07 (t, 3H); 1.20 (d, 3H); 9.23 (s, 1H).
Optical Rotation: [a]2o = -13.1 ° Q 5139 nm, (c = 1.08, DMSO).
CzZH25N30~ (MW = 443.46); mass sF~ectroscopy (MH+) 443/444.
Example 82 Synthesis of N-[N-(Isovaleryl)-Irisoleucinyll]-L-alanine iso-butyl Fster Following General Procedure C and using N (isovaleryl)-L-isoleucine (prepared from isovaleric acid (Aldri~h) a~~d L-isoleucine methyl ester hydrochloride (Aldrich) using General Procedure C, followed by hydrolysis using General Procedure AF) and L-alanir~e iso-butyl ester hydrochloride - 25 (prepared from N BOC-L-alanine (Sigma) and 2-methyl-1-propanol (Aldrich) using General Procedure C (with catalystic: DMAP), followed by removal of the BOC-group using General Procedure P), t;he title compound was prepared as a solid (mp = 142-146°C). The reaction w,as monitored by tlc (Rf = 0.4 in 1:1 EtOAc/hexanes) and the product was purified by silica gel chromatography using 1:1 EtOAc/hexanes as the eluent. -NMR data was as follows:
'H-nmr (DMSO-d6)(1:4 mixture of diastereomers): 8 = 1.26 (d, 3H), 7.70, 7.80 (doublets, IH); 8.30, 8.40 (doublets, 1H).
C,aH~,N204 (MW = 342.48); mass spectroscopy (MH+) 343.
Example 83 Step A --Synthesis of N [N [N-(ten-Butoxycarbonyl)-Irvalinyl]-D,Ir phenylglycinyl]-Iralanine iso-butyl Ester Following General Procedure A and using N [N BOC-L-valinyl]-D,L-phenylglycine (prepared by coupling N-BOC-L-valine (Bachem) and L-phenylglycine methyl ester hydrochloride (Sigma) using General Procedure C, followed by hydrolysis of the methyl ester using General Procedure AF) and L-alanine iso-butyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and 2-methyl-1-propanol (Aldrich) using General Procedure C (with catalytic DMAP), followed by removal of the BOC-group using General Procedure P), the title compound was prepared. The reaction was monitored by tlc (Rf = 0.3 in 5 % MeOHlCH2C12) and the product was purified by silica gel chromatography using 5 % MeOH/CHZC12 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db)(1:1 mixture of diastereomers): b = 1.25 (d, 3H); 5.58 (d, 1H).
CZSHs9N30e (MW = 477.61); mass spectroscopy (MH+) 478.
Step B --Synthesis of N [N (IrValinyl)-Irphenylglycinyl]-Iralanine iso-butyl Ester Hydrochloride Following General Procedure P and using the product from Example 83 -Step A above, the title compound was prepared as a solid (mp = 225-232°C).
The product was purified by trituration in Et20.
NMR data was as follows:

'H-nmr (DMSO-d6)(1:2 mixture of diastereomers): b = 1.26, 1.32 (doublets, 3H); 5.60, 5.65 (doulets, 1H).
CZOH32N3O,Cl (MW = 413.94); mass spectroscopy (MH+) 378 (free base).
Step C -Synthesis of N [N [N (Isova~leryl)-If-valinyl]-I~-p6enylglycinyl]-D-alanine iso-butyl Ester Following General Procedure C and using isovaleric acid (Aldrich) and the product from Example 83 - Step B above, the rifle compound was prepared as a solid (mp = 217-221 °C). The reaction w;as monitored by tlc (Rf = 0.25 in 5 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 5 % MeOH/CHCl3) as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db)(1:3 mixture of dia.stereomers): b = 5.52, 5.58 (doublets, 1H).
CZSH39N3O5 (MW = 461.60); mass spectroscopy (MH+) 462.
Example; 84 Synthesiis of N-[N (Isovaleryl)-L-phenylalaninyl]-I~alanine iso-butyl Fster Following General Procedure C and using isovaleric acid (Aldrich) and N
(L-phenylalaninyl)-L-aianine iso-butyl ester hydrochloride (prepared from N
BOC-L-phenylalanine (Sigma) and L-alanine iso-butyl ester hydrochloride (prepared as described in Example 83A above) using General Procedure C, followed by removal of the BOC-group usiing General Procedure P), the title compound was prepared as a solid (mp = 135-138°C). The reaction was monitored by tlc (Rf = 0.3 in 3 % MeOH/CHCI3) and the product was purified by silica gel chromatography using 3 % Me;OH/CHCI3 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 0.75 (d, 3H), 0.84 (d, 3H); 0.90 (d, 6H); 1.33 (d, 3H) .
Optical Rotation: [a]2o = +4.71 ° ~ ~~89 nm, (c = 1.02, DMSO).

C2,H3zN2O4 (MW = 376.50); mass spectroscopy (MH+) 376.
Example 85 Synthesis of N [N (3,5-Difluorophenyiacetyl)-I~alaninyl)-If-alanine Ethyl Ester Following General Procedure C and using 3,5-difluorophenylacetic acid (Oalcwood) and L-alanine ethyl ester hydrochloride (Sigma), the title compound was prepared as a solid (mp = 197-199°C). The reaction was monitored by tlc (Rf = 0.6 in EtOAc) and the product was purified from bi-products by silica gel chromatography using EtOAc as the eluent, followed by recrystallization from EtOAc.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.22 (m, 9H); 3.52 {s, 2H).
Optical Rotation: [a]ZO = -76.1 ° Q 589 nm, (c = 1.01, DMSO).
C16H21~2~4F2 (~ = 342.34); mass spectroscopy (MH+) 343.
Example 86 Synthesis of Ethyl 1-[N-(3-Nitrophenylacetyl) Iralaninyl)indoline-(S)-2-carboxylate Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (prepared from 3-nitrophenylacetic acid (Aldrich) and L-alanine ethyl ester hydrochloride (Sigma) using General Procedure C, followed by hydrolysis using General Procedure AF) and ethyl (S)--indoline-2-carboxylate (prepared from (S)-indoline-2-carboxylic acid (Aldrich) and ethanol using General Procedure H), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.4 in 2:1 EtOAc/hexanes) and the product was purified by silica gel chromatography using 2:1 EtOAc/hexanes as the eluent.
NMR data was as follows:
1H-nmr (DMSO-db)(1:2 mixture of diastereomers): b = 1.05, 1.17 (triplets, 3H); 1.29, 1.39 (doublets, 3H).
3O Cz2Hz3N306 (MW = 425.44); mass spectroscopy (MH+) 425.

-- z3s --Example 87 Synthesis of N'-[N (3,5-Difiuorophenylacetyll)-i,ralaninyl]-Iralaniaamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-alaninamide hydrochloride (Sigma), the title compound was prepared as a salif~ (mp = 285-288°C). The reaction was monitored by tlc (Rf = 0.35 in 10% l~ieOH/CHC13) and the product was purified by silica gel chromatography usin;; 10% MeOH/CHCl3 as the eluent, followed by recrystallization from EtOH.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.21 (m, 6H); 7.95 (d, 1H); 8.37 (d, 1H).
Optical Rotation: [a]zo = -26.84° Q 589 nm, (c = 1.01, DMSO).
C,4H"N303Fz (MW = 313.31); mass spectroscopy (MH+) 314.
Example. 88 Synthesis of N Methoxy-N methyl-iV'-[N (isovaleryl) Irphenylglycinyl]-l~alaninamide Following General Procedure C and a<.~ing N [N (isovaleryl)-L-phenylglycinylJ-L-alanine (prepared from r~ [N (isovaleryl)-L-phenylglycinylJ-L-alanine ethyl ester (from Example 74 above) using General Procedure AF) and N,O-dimethylhydroxylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.6 in EtOAc) and the product was purified by silica gel chromatography using EtOAc as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db)(1:1 mixture of diastereomers): b = 3.67, 3.73 (singlets, 3H), 5.62 (m, 1H).
C,BHZ,N304 (MW = 349.43); mass spectroscopy (MH+) 350.

Example 89 Synthesis of N iso-butyl-N'-(N (3,5-difluoropbenylacetyl) L-alaninyl]-~alaninamide Following General Procedure C and using N'-(N (3,S-difluorophenylacetyl)-L-alaninyl]-L-alanine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester (from Example 85 above) using General Procedure AF) and iso-butylamine (Aldrich), the title compound was prepared as a solid (mp = 258-260°C). The reaction was monitored by tlc (Rf =
0.4 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography using 10% MeOH/CHCl3 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): b = 0.80 (d, 6H); 1.20 (m, 6H).
Optical Rotation: [a]Zo = -30.4° Q 589 nm, (c = 1.01, DMSO).
C,BHZSN303F2 (MW = 369.41); mass spectroscopy (MH+) 369.
Example 90 Synthesis of N,N Di-n-propyl-N'-[N-(3,5-difluorophenylacetyl) Iralaninyl]-L-alaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl)-L-alanine (prepared from N (N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester (from Example 85 above) and di-n-propylamine (Aldrich), the title compound was prepared as a solid (mp = 137-146°C).
The reaction was monitored by tlc (Rf = 0.5 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using 5 % MeOH/CHCl3 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-d6)(1:2 mixture of diastereomers): b = 3.50 (s, ZH), 4.30 (m, 1H), 4.63 (m, 1H).
3O CZOHZ9N3O3F2 (MW = 397.46); mass spectroscopy (MH+) 397.

ExamFde 91 Synthesis of N'-[N (3,5-Difluorophenylace~tyl)-Iralaninyl]-Lrvaliaamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-valinamide hydrochloride (Sigma), the title compound was prepared as a solid. The reaction was monitored by ttc (Rf = 0.3 in IO% MeOH/CHCl3) and the product was purified by silica gel chromatography using 10% MeOH/CHC13 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db)(1:4 mixture of di.astereomers): b = 1.22 (m, 3H); 1.97 (m, IH).
C,6Hz,N303F2 (MW = 341.36) mass spectroscopy (MH+) 342.
Examp',le 92 Synthe~~is of 15- N (4-Nitrophenyl)-N'-[N (3,5-difluorophenylacetyl)-I~.alaninyl]-Ir;alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyI)-L-alanine (from Example B2 above) and N (4-nitrophenyl)-L-alaninamide hydrochloride (Fluka), the title compound was prepared as a solid (mp = 242-244°C). The reaction was monitored by ~.lc (Rf = 0.4 in 10%
MeOH/CHCl3) and the product was purified by silica gel chromatography using 10%
MeOH/CHCIj as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.24 (d, 3H); 1.33 (d, 3H).
___ 25 Optical Rotation: [a]ZO = -5.18° Q 5.39 nm, (c = 1.00, DMSO).
CZQHZpIV~O5F2 (MW = 434.40); mass spectroscopy (MH+) 434.
Example: 93 Synthesis of N'-[N [N (Isovaleryl)-Lrphenylglycinyl]-L-alaninyl]-l~phenylalaninamide Following General Procedure C and using N (isovaleryl)-L-phenylglycine (prepared from isovaleric acid (Aldrich) and L-phenyiglycine methyl ester hydrochloride (Aldrich) using General Procedure C, followed by hydrolysis using General Procedure AF) and N'-(L-alaninyl)-L-phenylalaninamide hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylalaninamide (Sigma) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 272-276°C). The reaction was monitored by tlc (Rf = 0.25 in % MeOH/CHC13) and the product was purified by silica gel chromatography 10 using 10% MeOH/CHCl3 as the eluent.
NMR data was as follows:
'H-nmr {DMSO-d6){1:1 mixture of diastereomers): 8 = 1.07, 1.17 (doublets, 3H); 5.40, 5.52 (doublets, 1H}.
CzsHs2Na0a (MW = 452.55); mass spectroscopy (MH+) 453.
Example 94 Synthesis of N [N (3,5-Difluorophenylacetyl)-I~-alaninyl]
L-phenylalanine Methyl Ester Following General Procedure C and using 3,5-difluorophenylacetic acid (Oakwood) and N (L-alaninyl)-L-phenylalanine methyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylalanine methyl ester hydrochloride (Sigma) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 173-175°C). The reaction was monitored by tlc (Rf = 0.6 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography usin-g 4% MeOH/CHCl3 as the eluent, followed by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.17 (d, 3H); 3.48 (s, 2H).
Optical Rotation: [«]ZO = -32.47° ~ 589 nm, (c = 1.OI, MeOH).
CZ,HzZN204F2 {MW = 404.41 ); mass spectroscopy (MH+) 404.

Example 95 Synthesis of N'-[N (3,5-Difluorophenylacetyl)-L-alaninyl]-Irphenylalaninamide Following General Procedure C and using 3,5-difluorophenylacetic acid (Oalcwood) and N'-(L-alaninyl)-L-phenylalaninamide hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phe;nylalaninamide (Sigma) using General Procedure C, followed by removal of the BOC-group using General Procedure - - P), the title compound was prepared as a solid (mp = 252-253°C).
The reaction was monitored by tlc (Rf = 0.5 in 15 % MeOH/CHC13) and the product was purified by silica gel chromal:ography using 15 % MeOH/CHCl3 as the eluent, followed by recrystallization from EtOH.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.15 (d, 3H); 3.51 (s, 2H).
Optical Rotation: [«]ZO = -24.4° Q 589 nm, (c = 1.01, DMSO).
CzoHz,IV3O3F2 (MW = 389.41); mass spectroscopy (MH+) 389.
Example 96 Synthesis of N iso-butyl-N'-[N-(isovaleryl)-Iri~henylglycinyl]-L-alaninamide Following General Procedure C and using N [N (isovaleryl)-L-phenylglycinyl]-L-alanine (prepared from N [N (isovaleryl)-L-phenylglycinyl]-L-alanine ethyl ester (from Example 74 above) using General Procedure AF) and iso-butylamine (Aldrich), the title compound was prepared as a solid (mp =
227-232°C). The reaction was monitored by tlc (Rf = 0.3 in 5%
MeOH/CHC13) and the product was purified by silica gel chromatography using 5 %a MeOH/CHC13 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6)(1:4 mixture of di~~stereomers): 8 = 1.58 (m, 1H); 1.95 (m, 1H); 5.55 (d, 1H).
CZOH3,N3O3 (MW = 361.48); mass spectroscopy (MH+) 361.

Example 97 Synthesis of N (2-Methoxyethyl)-N'-[N (3,5-difluorophenylacetyn Iralaninyl]-Irphenylalaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester (from Example 94) using General Procedure AF) and 2-methoxyethylamine (Aldrich), the title compound was prepared as a solid (mp = 206-208°C). The reaction was monitored by tlc (Rf = 0.3 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using 10%a MeOH/CHCl3 as the eluent, followed by recrystallization from I-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.14 (d, 3H); 4.22 (m, IH); 4.45 (m, 1H).
Optical Rotation: [a]Za = -25° Q 589 nm, (c = 1.00, DMSO).
CZ3HZ.,N304Fz (MW = 447.49); mass spectroscopy (MH+) 447.
Example 98 Synthesis of N (4-Nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-I~alaninyl]-I~-alaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester (from Example 85 above) using General Procedure AF) and 4-nitrobenzylamine (Aldrich), the title compound was prepared as a solid (mp = 257-259°C). The reaction was monitored by tlc (Rf --- = 0.4 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using 10 % MeOH/CHCl3 as the eluent, followed by recrystallization from EtOH/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 3.53 (s, 2H); 4.39 (d, 2H).
Optical Rotation: [a]zo = -29.3° ~a 589 nm, (c = 1.00, DMSO).

CZ,HZZN405F2 (MW = 448.43); mass spectroscopy (MH+) 448.
Examplie 99 Synthe:;is of N (4-Nitrophenyl)-N'-[N (N (isovaleryl)-L-phenylglycinyl]-L-ala vinyl]-L-alaninamide Following General Procedure C and using N [N (isovaleryl)-L-phenylglycinyl]-L-alanine (prepared from N [N (isovaleryl)-L-phenylglycinyl]-L-alanine ethyl ester (from Example 74 above) using General Procedure AF) and N (4-nitrophenyl)-L-alaninamide hydrochloride (Fluka), the title compound was prepared as a solid (mp = 255-257°1~). The reaction was monitored by tlc (Rf = 0.5 in 10% MeOH/CHC13) and the: product was purified by silica gel chromatography using 10 % MeOH/CHCI; as the eluent, followed by recrystallization from 1-chIorobutane/acet~nitrile.
NMR data was as follows:
'H-nmr (DMSO-db)(1:2 mixture of diastereomers): b = 5.45, 5.55 (doublets, 1H); 10.20, 10.54 (singlets, IfI).
CZSH3~N4O6 (MW = 497.56); mass spectroscopy (MH+) 497.
Exampin 100 Synthe;~is of N (4-Nitrophenyl)-N'-[N (3,5-difluorophenylacetyl)-Lralaninyl]-Lrphe~nylalaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N i;4-nitrophenyl)-L-phenylalaninamide hydrochloride (Lancaster), the title compound was prepared as a solid (mp =
253-254°C). The reaction was monitored by tlc (Rf = 0.5 in 10%
MeOH/CHC13) and the product was purified by silica gel chromatography using 8% MeOH/CHCl3 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.17 (d, 3H); 10.52 (s, 1H).
Optical Rotation: [a]ZO = +40.6° Q 589 nm, (c = 1.00, DMSO).

C2~24N4~SF2 (MW = 510.50); mass spectroscopy (MH+) 510.
Example 101 Synthesis of N Benzyl-N methyl-N'-[N (3,5-difluorophenylacetyl)-Iralaninyl]-L-alaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester (from Example 85 above) using General Procedure AF) and N benzyl-N methylamine (Aldrich), the title compound was prepared as a solid (mp = 167-169°C). The reaction was monitored by tlc (Rf = 0.4 in 5 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 5 % MeOH/CHCI3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6)(1:3 mixture of diastereomers): b = 3.52 (singlets, 2H);
2.95 (s, 2H).
Optical Rotation: [«]ZO = -55.8° Q 589 nm, (c = 1.01, DMSO).
C22HzsN303FZ (MW = 417.45); mass spectroscopy (MH+) 417.
Example 102 Synthesis of N (3,5-Difluorobenzyl)-N'-[N (3,5-difluorophenylacetyl) I~alaninyl]-L-alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (3,5-difluorobenzyl)-L-alaninamide hydrochloride (prepared from N BOC-L-alanine (Sigma) and 3,5-difluorobenzylamine (Lancaster) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 267-269°C). The reaction was monitored by tlc (Rf = 0.25 in 10 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 10 % MeOH/CHC1.3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 1.21 (d, 3~~, 1.24 (d, 3H).
Optical Rotation: [«]ZO = +26.9° Cg? 589 nm, (c = 1.01, DMSO).
C21H21N3~3F4 (MW = 439.41); mas;c spectroscopy (MH+) 439.
Example 103 Synthesis of N-(3-Nitrobenzyl)-N'-[N (3.,5-difluorophenylacetyl) L-alaninyl]-I~alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (3-nitrobenzyl)-L-alaninamide hydrochloride (prepared from N BOC-L-~~lanine (Sigma) and 3-nitrobenzylamine hydrochloride (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 245-247°C). The reaction was monitored by tlc (Rf = 0.4 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using 10% MeOH/CHC13 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.21 (d, 3~i); 1.25 (d, 3H).
Optical Rotation: [a]Zo = -32.8° Q _'i89 nm, (c = 1.00, DMSO).
Cz,H2zN405F2 (MW = 448.43); mas:~ spectroscopy (MH+) 449.
Example 104 Synthesis of N-Benzyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N benzyl-L-alaninamide hydrochloride (prepared from N BOC-L-alanine (Sigma',) and benzylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 260-262°C).
The reaction was monitored by tlc (Rf = 0.3 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography using 10% MeOH/CHC13 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.20 (d, 3H); 1.24 (d, 3H).
Optical Rotation: [a]ZO = -29.3° Q 589 nm, (c = 1.03, DMSO).
CZ,H~N303F2 (MW = 403.43); mass spectroscopy (MH+) 403.
Example 105 Synthesis of N (4-Nitrobenzyl)-N'-[N (3,5-difluorophenylacetyl) Lralaninyl]-I~phenylalaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester (from Example 94) using General Procedure AF). and 4-nitrobenzylamine hydrochloride (Aldrich), the title compound was prepared as a solid (mp = 248-250°C). The reaction was monitored by tlc (Rf = 0.4 in 12 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 12 % MeOH/CHCl3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.15 (d, 3H); 7.35 (d, 2H); 8.12 (d, 2H).
Optical Rotation: [a]Zo = -27.6° Q 589 nm (c = 1.01, DMSO).
CZ~HZ6N405F2 (MW = 524.52); mass spectroscopy (MH+) 524.
Example 106 Synthesis of N-[N-(3,5-Diffuorophenylacetyl)-L-alaninyl]
L-tryptophan Methyl Ester Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-~tryptophan methyl ester hydrochloride (Sigma), the title compound was prepare~~ as a solid (mp = 191-193°C).
The reaction was monitored by tlc (Rf = 0.4 in 10 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 5 % MeOH/CHCl3 as the eluent, followed by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.20 (d, 3H); 3.55 (s, 3H}.
Optical Rotation: [a]ZO = -8.82° Q :i89 nm (c = 1.02, DMSO).
C~H~N304F2 (MW = 443.45); mass spectroscopy (MH+) 443.
Example 107 Synthesis of N (4-Methoxybenzyl)-N'-[N ~(3,5-difluorophenylacetyl}
L-alaninyl]-I,r~alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (4-methoxybenzyl)-L-alaninamide hydrochloride (prepared from N BOC-L-~~lanine (Sigma) and 4-methoxybenzylamine hydrochloride (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp == 234-236°C). The reaction was monitored by tlc (Rf = 0.3 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography using IO% MeOH/CHC13 as the eluent, followed by recrystallization from EtOH/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.20 (d, 6Ff); 3.51 (s, 2H); 3.72 (s, 3H).
Optical Rotation: [a]2o = +27.9° Q 589 nm ( c = 1.00, DMSO).
C2zHzsN30aF2 (MW = 433.46); mass spectroscopy (MH+) 433.
Example 108 Synthe:~is of N-[N-(Phenylacetyl)-L-phenylglycinyl]-Iralanine Ethyl Ester Following General Procedure C and using phenylacetic acid (Aldrich) and N (L-phenylglycinyl)-L-alanine ethyl ester hydrochloride (prepared from N
BOC-L-phenylglycine (Advanced Chemtech) and L-alanine ethyl ester hydrochloride (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 208-210°C). The reaction was monitored by tlc (Rf = 0.4 in MeOH/CHC13} and the product was purified by silica gel chromatography using 5 % MeOH/CHCl3 as the eluent, followed by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 3.55 (s, 2H); 5.55 (d, 1H).
Optical Rotation: [a]ZO = +44.8° Q 589 nm (c = 1.02, DMSO).
CZ,H24NzO4 (MW = 368.43); mass spectroscopy (MH+) 369.
Example 109 Synthesis of N [N (N-(3,5-Difluorophenylacetyl)-L-alaninyl)-I~phenylalaninyl]-L-phenylglycine Methyl Ester Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine (prepared from N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-phenyIalanine methyl ester (from Example 94) using General Procedure AF) and L-phenylglycine methyl ester hydrochloride (Aldrich), the title compound was prepared as a solid (mp = 203-207°C). The reaction was monitored by tlc (Rf = 0.3 in 10 °'o MeOH/CHC13) and the product was purified by silica gel chromatography using 10% MeOH/CHCl3 as the eluent, followed by trituration using 1-chlorobutane.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.13 (d, 3H); 3.62 (s, 3H).
Optical Rotation: [a]ZO = +42.1 ° Q 589 nm (c = 1.03, DMSO).
CZ9Hz9N3O5F2 (MW = 537.56); mass spectroscopy (MH+) 537.

Example 110 Synth~as of N [N (Cyclohexylacety:l)-Irphenylglyciayl]
I~alanine Ethyl Ester Following General Procedure C and using cyclohexylacedc acid (Aldrich) and N (L-phenylglycinyl}-L-alanine ethyl aster hydrochloride (prepared from N
BOC-L-phenylglycine (Advanced Chemtec;h) and L-alanine ethyl ester hydrochloride (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 196-198°C). The reaction was monitored by tlc {Rf = 0.3 in 5%
MeOH/CHCl3) and the product was purified by silica gel chromatography using 5 % MeOH/CHCl3 as the eluent, followed by trituradon using 1-chlorobutane.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 2.08 (d, 2H;); 5.56 (d, 1H).
Optical Rotation: [a]ZO = +26.3° Q 589 nm (c = 1.01, DMSO).
CZ,H3oNzO4 (MW = 374.48); mass spectroscopy (MH+) 375.
Example 111 Synthesiis of N [N (3,5-Difluorophen~~lacetyl)-L-alaninyl]-L-phenylglycine Methyl Ester Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-pihenylglycine methyl ester hydrochloride (Aldrich), the title compound was prepared as a solid (mp =
198-200°C). The reaction was monitored by tlc (Rf = 0.4 in 4%
MeOH/CHCl3) and the product was purified by silica gel chromatography using 4% Me.OH/CHC13 as the eluent, followed '~by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6): 8 = 1.26 (d, 3H); 3.64 (s, 3H).
Optical Rotation: (DMSO) [a]ZO = +69.9° Q 589 nm (c = 1.01, DMSO).

CZOH2oNz04F2 (MW = 390.39); mass spectroscopy (MH*) 391.
Example 112 Synthesis of N [N [N (3,5-Difluorophenylacetyl)-~alaninyl]-Iralaninyl]-L-phenylglycine Methyl Ester Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (L-alaninyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 243-245°C). The reaction was monitored by tlc (Rf = 0.5 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using 10 % MeOH/CHCl3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.19 (d, 3H); 1.24 (d, 3H).
Optical Rotation: [a]ZO = +38.2° ~ 589 nm (c = 1.02, DMSO).
C23HZSNs05Fz (MW = 461.46); mass spectroscopy (MH+) 461.
Example 113 Synthesis of N (2-Phenylethyl)-N'-[N (3,5-difluorophenylacetyl) I,-alaninyl]-Iralaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (2-phenylethyl)-L-alaninamide hydrochloride (prepared from N BOC-L-alanine (Sigma) and phenethylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp =
241-243°C). The reaction was monitored by tlc (Rf = 0.3 in 8%
MeOH/CHCl3) and the product was puri .feed by silica gel chromatography using 8% MeOH/CHC13 as the eluent, followed by recrystallization from acetonitrile.

NMR data was as follows:
'H-nmr (DMSO-d~: 8 = 1.14 (d, 3H); 1.21 (d, 3H).
Optical Rotation: [a]ZO = -33.7° rg? 589 nm (c = 1.00, DMSO).
CnHuN303F2 (MW = 417.45); mass spectroscopy (MH+) 417.
Example; 114 Synthesis of N'-[N (3,5-Difluorophenylacetyl) .f~alaninyl]-I~tryptophanamide Following General Procedure C and using 3,5-difluorophenylacetic acid (Oalcwood) and N'-(L-alaninyl)-L-tryptophanamide hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-tryptophanamide hydrochloride (Sigma) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 199-202°C). The reaction was monitored by tlc (Rf = 0.3 in 15% MeOH/CHCl3) and the product was purified by silica gel chromatography using 15 %
MeOH/CHCl3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.I7 (d, 3H); 4.26 (m, 1H); 4.44 (m, 1H).
Optical Rotation: [a]zo = -31.0° ~ 589 nm (c = 1.05, DMSO).
C22HZZN403Fz (MW = 428.44); mass spectroscopy (MH+) 428.
Example 115 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-Iralaninyl]
(S)-2-amino-3-cyclohexylpropionate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-amino-3-cyclohexylpropionate (Novabiochem), the title compound was prepared as a solid (mp = 116-119°C). The reaction was monitored by tlc (Rf = 0.4 in 4%
MeOH/CHCl3) and the product was purified by silica gel chromatography using 4% MeOH/CHCIj as the eluent, followed by recrystallization from 1-chlorobutane/hexanes.

NMR data was as follows:
'H-nmr (DMSO-d6): b = 1.22 (d, 3H); 3.62 (s, 3H).
Optical Rotation: [a]ZO = -21.2° (~ 589 nm (c = 1.01, DMSO).
CZ,H~,NZO,FZ (MW = 410.46); mass spectroscopy (MH+) 411.
Example 116 Synthesis of N (2-Methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-I~-alaninyl]-(S)-2-amino-3-(4-nitrophenyl)propionamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (2-methoxyethyl)-(S)-2-amino-3-(4-nitrophenyl)propionamide hydrochloride (prepared from N BOC-L-4-nitrophenyialanine (Advanced Chemtech) and 2-methoxyethylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 263-265°C). The reaction was monitored by tlc (Rf = 0.5 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using 10%
MeOH/CHCl3 as the eluent, followed by recrystallization from EtOH/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.15 (d, 3H); 4.23 (m, 1H); 4.54 (m, 1H).
Optical Rotation: [a]ZO = -19.9° Q 589 nm (c = 1.00, DMSO).
CzsHz6N40eF2 {MW = 492.48); mass spectroscopy (MH+) 493.
Example 117 Synthesis of . .- N-[N-(3-Nitrophenylacetyl)-Iralaninyl]-Irserine Ethyl Ester Following General Procedure C and using 1V {3-nitrophenylacetyl)-L-alanine (prepared from 3-nitrophenylacetic acid (Aldrich) and L-alanine ethyl ester hydrochloride (Sigma) using General Procedure C, followed by hydrolysis using General Procedure AF) and L-serine ethyl ester hydrochloride (Sigma), the title compound was prepared as a solid (mp = 179-181 °C). The reaction was WO 98/22494 PCTlUS97/20804 monitored by tlc (Rf = 0.2 in 5 % MeOH/CHCI3) and the product was purified by silica gel chromatography using 5% MeOH/CHC13 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = I.20 (m, 6~1); 4.30 (m, IH); 4.41 (m, 1H); 5.04 (t, 1H).
Optical Rotation: [a)ZO = -19.7° (~ 589 nm (c = 1.01, DMSO).
C~6HZ,N3O, (MW = 367.36); mass syectroscopy (MH+) 368.
Example: 118 Synthesis of N [(R)-a-Methylbenzyl)-N'-[N-(3,~-difluorophenylacetyl)-I~alaninyl)-L-a~laninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (:R)-a-methylbenzyl-L-a~laninamide hydrochloride (prepared from N BOC-L-alanine (Sigma) and (R)-a-methylbenzylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 240-242°C). The reaction was monitored by tlc (Rf =
0.4 in 10% MeOH/CHC13} and the product was purified by silica gel chromatography using 9 % MeOH/CHCI~ as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.19 (t, 6H); 1.31 (d, 3H).
Optical Rotation: [a]ZO = +I.0° Q Sfi9 nm (c = 1.00, DMSO).
Ca2H2sN303F2 (MW = 417.45); mass spectroscopy (MH+) 417.
Example 119 Synthesis of N [(S)-a-Methylbenzyl)-N'-[N (3,5-difluorophenylacetyl) L-alaninyl)-I,-ataninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (S)-a-methylbenzyl-L-alaninarnide hydrochloride (prepared from N BOC-L-alanine (Sigma) and (R)-a-methylbenzylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 293-295°C). The reaction was monitored by tlc {Rf =
0.4 in 10 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 10 % MeOH/CHC13 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.20 (m, 6H); 1.30 (d, 3H).
Optical Rotation: [a]ZO = -65.9° Qa 589 nm (c = 1.05, DMSO).
CZ~H25N303F2 (MW = 417.45); mass spectroscopy (MH+) 4i7.
Example 120 Synthesis of N (4-F'luorobenzyl)-N'-[N (3,5-difluorophenylacetyl)-Iralaninyl]-L-alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (4-fluorobenzyl)-L-alaninamide - hydrochloride (prepared from N BOC-L-alanine (Sigma) and 4-fluorobenzylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 257-259°C). The reaction was monitored by tlc (Rf =
0.4 in i0% MeOH/CHC13) and the product was purified by silica gel chromatography using 9 % MeOH/CHCl3 as the eluent, followed by trituration using 1-chlorobutane.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.20 (m, 6H); 3.52 (s, 2H).
Optical Rotation: [a]ZO = -28.7° Q 589 nm (c = 1.00, DMSO).
CZ,HZZN3O3F3 (MW = 421.42); mass spectroscopy (MH+) 421.

Example 121 Synth~~is of N (4-Pyridylmethyl)-N'-[N (3,5-difluorophenylacetyl) Iralaninyl]-I~alaninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (4-pyridylmethyl)-L-alaninamide dihydrochloride (prepared from N BOC-L-alanine (Sigma) and 4-(aminomethyl)pyridine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 244-247°C). 'lfie reaction was monitored by tlc {Rf = 0.3 in 10% MeOH/CHCl3) and the product was purified by silica gel chromatography using IO% MeOH/CHCI:; as the eluent, followed by re;crystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.21 (d, 3H); 1.26 (d, 3H).
Optical Rotation: [a]ZO = -30.3° Qa 5'89 nm (c = 1.00, DMSO).
C2oH22N4O3F2 (MW = 404.42); mass spectroscopy (MH+) 405.
Example. 122 Synthesis of N (4-Trifluoromethylbenzyl)-N'-~[N (3,5-difluorophenylacetyl)-Iralaninyl]-Ira~laninamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N {~4-trifluoromethylbenzyl)-L-alaninamide hydrochloride (prepare:d from N BOC-L-alanine (Sigma) and 4-(trifluoromethyl)benzylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 244-247°C). The reaction was monitored by tlc (Rf = 0.4 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography using 8 % MeOH/CHC13 as the eluent, followed by triturated using 1-chlorobutane.
NMR data was as follows:

'H-nmr {DMSO-db): b = 3.52 (s, 2H); 4.35 (d, 2H).
Optical Rotation: [a]ZO = -27.4 ° Q 589 nm (c = 1.05, DMSO).
C22H22N3~3F5 ~ = 471.43); mass spectroscopy (MH+) 471.
Example 123 Synthesis of Ethyl N [N (3,5-Difluorophenylacetyl) Iralaninyl]-2-amino-2-phenylpropionate Following General Procedure C and using 3,5-difluorophenylacetic acid (Oakwood) and ethyl N {L-alaninyl}-2-amino-2-phenylpropionate hydrochloride (prepared from N BOC-L-alanine (Sigma) and D,L-a-methylphenylglycine ethyl ester (from Example D9 above) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 128-130°C). The reaction was monitored by tlc (Rf = 0.2 in 3 % MeOH/CHCl3) and the product was purified by silica gel chromatography using 3 % MeOH/CHC13 as the eluent.
NMR data was as follows:
'H-nmr {DMSO-db)(1:1 mixture of diastereomers): b = 1.72, 1.77 (singlets, 3H); 3.52 (s, 2H).
C2zH2aN20aF2 (MW = 418.44); mass spectroscopy (MH+) 418.
Example 124 Synthesis of N [N (3,5-Difluorophenylacetyl)-Iralaninyl]
L-phenylalanine tent-Butyl Ester Following General Procedure C and using 3,5-difluorophenylacetic acid (Oakwood) and N (L-alaninyl)-L-phenylalanine tert-butyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylalanine tert-butyl ester hydrochloride (Advanced Chemtech) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a gel. The reaction was monitored by tlc (Rf = 0.5 in 4 MeOH/CHC13) and the product was purified by silica gel chromatography using 4 % MeOH/CHC13 as the eluent. _ NMR data was as follows:
'H-nmr (DMSO-d~: b = 1.19 (d, 3H~); 1.30 (s, 9H).
C24H28N2~4F2 (MW = 446.50); mass spectroscopy (MH+) 446.
Example 125 Synthe<~is of Methyl N-[N-(3,5-difluorophenylacetyl)-Iralaninyl]-2-amino-2;-methylpropionate Following General Procedure C and using N (3,5-difluorophenylacetyl}-L-alanine (from Example B2 above) and methyl 2-aminoisobutyrate (prepared from 2-aminoisobutyric acid (Aldrich) using General Procedure H), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf =
0.25 in CHC13/MeOH 95:5}.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.32 (m, 3~f), 7.13 (m, 1H}, 7.00 (m, 2H), 4.31 (m, 1H); 3.53 (m, SH), 7.08 (m, 1H), 1.36 (s, 3H), 1.34 (s, 3H), 1.19 (d, 3H).
Optical Rotation: (a]23 = -25° (c 1, MeOH).
C,6HZOIV2O4Fz (MW = 342.34); mass spectroscopy (MH+) 343.
Example 126 Synthesis of Ethyl N [N (3,5-difluorophenylacetyl)-I~-alaninyl]
2-amino-2-cyclohexylacetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-cyclohexylacetate hydrochloride (prepared from cyclohexylgl.ycine (Advanced Chemtech) using General Procedure H), the title compound was prepared as a solid (mp = 146-150°C). The reaction was monitored by tl~c (Rf = 0.3 in 3 % MeOH/CHC13) and the product was purified by silica gel chromatography using 3 MeOH/CHC13 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-d6)(1:1 mixture of diastereomers): b = 1.60 (m, 6H); 3.50 (s, 2H).
CZ,HZaN204F2 (MW = 410.46); mass spectroscopy (MH+) 410.
Example 127 Synthesis of N (2-Methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-I~alaninyl)-Irphenylglycinamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (2-methoxyethyl)-L-phenylglycinamide hydrochloride (prepared from N BOC-L-phenylglycine (Advanced Chemtech) and 2-methoxyethylamine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 252-254°C). The reaction was monitored by tlc (Rf = 0.3 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography using 10 % MeOH/CHCl3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr {DMSO-db): b = 1.22 (d, 3H); 5.43 (d, 1H).
Optical Rotation: [a]zo = +6.17° Q 589 nm (c = 1.04, DMSO).
CZZHzsNs04F2 (MW = 433.46); mass spectroscopy (MH+) 434.
Example 128 Synthesis of N [N-(Isovaleryl)-2-amino-2-cyclohexylacetyl]
L-alanine Ethyl Ester Following General Procedure C and using N (isovaleryl)-2-amino-2-cyclohexylacetic acid (prepared from isovaleric acid (Aldrich) and D,L-a-_-- 257 --cyclohexylglycine ethyl ester hydrochloride (prepared from cyclohexylglycine (Advanced Chemtech) and ethanol using General Procedure H) using General Procedure C, followed by removal of the BOC-group using General Procedure P) and L-alanine ethyl ester hydrochloridc: (Sigma), the title compound was prepared as a solid (mp = 220-224°C). 'The reaction was monitored by tlc (Rf = 0.2 in 5 % MeOH/CHC13) and the product was purified by silica gel chromatography using 5 % MeOH/CHCl3 as the eluent, followed by recrystallization from 1-chlorobutane/acet~onitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 0.85 (d, 6H:); 4.04 (m, 2H).
C,aH32Nz04 (MW = 340.46); mass spectroscopy (MH+) 341.
Example 129 Synthe<~is of N 2-(N,N Dimethylamino)ethyl-N'-[N (3,S-difluorophenyiacetyl)-L-alaninyl]-L-phenylglycinamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N ~!-(N,N dimethylamino)ethyl-L-phenylglycinamide dihydrochloride (prepared from N BOC-L-phenylglycine (Advanced Chemtech) and N,N dimethyle~hylenediamine (Aldrich) using General Procedure C, followed by remov~~l of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 234-236°C).
The reaction was monitored by tlc (Rf = 0.3 in 15 % MeOH/CHC13) and the product was purified by silica gel chroma~:ography using 10% MeOH/CHCl3, followed by slurrying in acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 1.22 (d, 3H); 5.41 (d, 1H).
Optical Rotation: [a]ZO = +5.7° Q 589 nm (c = 1.01, DMSO).
C23HZ8N4O3F2 (MW = 446.50); mass spectroscopy (MH+) 446.

WO 98!22494 PCT/US97/20804 __ 258 -_ Example 130 Synthesis of _ -N (2-Pyridylmethyl)-N'-[N (3,5-difluorophenylacetyl)-i~-alaninylJ-L-phenylglycinamide Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and N (2-pyridy!methyl)-L-phenylglycinamide dihydrochloride (prepared from N BOC-L-phenylglycine (Advanced Chemtech) and 2-(aminomethyl)pyridine (Aldrich) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 272-275°C). The reaction was monitored by tlc (Rf = 0.4 in 10 % MeOH/CHCl3) and the product was purified by silica gel chromatography using IO% MeOH/CHCl3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 1.24 (d, 3H); 5.50 (d, 1H).
Optical Rotation: [a]ZO = +12.4° Qa 589 nm (c = 1.02, DMSO).
C2sHzaNaOsFz (MW = 466.49); mass spectroscopy (MH+) 467.
Example 131 Synthesis of N [N-(3-Pyridylacetyl)-Iralaninyl]-Irphenylalanine Methyl Ester Following General Procedure C and using 3-pyridylacetic acid hydrochloride (Aldrich) and N (L-alaninyl)-L-phenylalanine methyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylalanine methyl ester hydrochloride (Sigma) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 150-152°C). The reaction was monitored by tlc (Rf = 0.3 in 10 % MeOH/CHCI3) and the product was purified by silica gel chromatography using 10 % MeOH/CHCl3 as the eluent, followed by recrystallization from acetonitrile.
NMR data was as follows:

'H-nmr (DMSO-db): 8 = 1.16 (d, 3Hf); 347 (s, 2H).
Optical Rotation: [a]~ _ -19.0° Q 589 nm (c = 1.03, DMSO).
C2QH~N3O4 (MW = 369.42); mass spectroscopy (MH+) 369.
Example 132 Synth~~is of N [N (2-Pyridylacetyl)-I,-alaninylj~-I~phenylalanine Methyl Fster Following General Procedure C and using 2-pyridylacetic acid hydrochloride (Aldrich) and N (L-alaninyl)-L-phenylalanine methyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylalanine methyl ester hydrochloride (Sigma) using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 137-139°C). ';Che reaction was monitored by tlc (Rf = 0.4 in 8 % MeOH/CHCI3) and the product was purified by silica gel chromatography using 8 % MeOH/CHCI3 ;~s the eluent, followed by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.17 (d, 3H); 3.65 (s, 2H).
Optical Rotation: [a]zo = -17.48° Q >89 nm (c = 1.09, DMSO).
CzoH23N3O4 (MW = 369.42); mass spectroscopy (MH+) 369.
Example 133 Synthesis of N [N-(4-Pyridylacetyl)-Iralaninyl]-L-phenylalanine Methyl Fster Following General Procedure C and using 4-pyridylacetic acid hydrochloride (Aldrich) and N (L-alaninyl;i-L-phenylalanine methyl ester hydrochloride (prepared from N BOC-L-alanine (Sigma) and L-phenylalanine methyl ester hydrochloride (Sigma) using General Procedure C, followed by removal of the BOC-group using General :Procedure P), the title compound was prepared as a solid (mp = 152-154°C). The reaction was monitored by tlc (Rf = 0.4 in 10% MeOH/CHC13) and the product was purified by silica gel chromatography using 10% MeOHICHC13 as the eluent, followed by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6): 8 = 1.17 (d, 3H); 3.47 (s, 2H).
Optical Rotation: [a]ZO = -17° (g? 589 nm (c = 1.00, DMSO).
CZOH~N3O, (MW = 369.42); mass spectroscopy (MH+) 369.
Example 134 Synthesis of Ethyl N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-fluorophenyl}acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(4-fluorophenyi)acetate hydrochloride (prepared from 4-fluorophenylglycine (Fluka) and ethanol using General Procedure H), the title compound was prepared as a solid (mp = 169-183°C). The reaction was monitored by tic (Rf = 0.3 in 4% MeOH/CHCl3) and the product was purified by silica gel chromatography using 4 %
MeOH/CHC13 as the eluent, followed by recrystallization from 1-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-d6)(1:1 mixture of diastereomers): 8 = 3.49, 3.53 (singlets, ZH); 5.40 (m, 1H).
Cz,Hz,Nz04F3 (MW = 422.4); mass spectroscopy (MH+) 422.
Example 135 Synthesis of Ethyl N [N (3,~-Difluorophenylacetyl)-Iralaninyl]-2-amino-2-(2-fluorophenyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(2-fluorophenyl)acetate hydrochloride (prepared from 2-fluorophenylglycine (Fluka) and ethanol using General Procedure H), the title compound was prepared as a solid (mp = 153-170°C). The reaction was monitored by tlc (Rf = 0.3 in 5 % MeOH/CHC13) and the product was purified by silica gel chromatography using 5 %
MeOH/CHC13 as the eluent, followed by recrystallization from I-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db)(1:1 mixture of di~~stereomers): b = 3.50, 3.54 (ringlets, 2H), 5.66 (m, 1H).
CZ,HZINz04F3 (MW = 422.40); mass spectroscopy (MH+) 422.
Example 136 IO Synthes:is of N-(N (3,5-Difluorophenylac;etyl)-Irphenylglycinyl) Iralanine Etlhyl Ester Following General Procedure C and using 3,5-difluorophenylacetic acid (Oakwood) and N (L-phenylglycinyl)-L-al~u~ine ethyl ester hydrochloride (prepared from N BOC-L-phenylglycine (~~dvanced Chemtech) and L-alanine ethyl ester hydrochloride (Aldrich) using Cieneral Procedure C, followed by removal of the BOC-group using General :Procedure P), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.3 in 3 MeOH/CHCl3) and the product was purififxi by silica gel chromatography using 3 % MeOH/CHC13 as the eluent, followed by recrystallization from I-chlorobutane/acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 3.50 (s, 2H), 5.53 (d, 1H).
CZ,HZ,N204F2 (MW = 404.42); mass spectroscopy (MH+) 405.
Example 137 Synthesis of Ethyl N (N (3,5-Difluorophenylacetyl)-. Iralaninyl)-2-amino-3-phthalimidopropionate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-3-phthalimidopropionate hydrochloride (from Example D 10 above), the title compound was prepared as a solid (mp = 197-201 °C). The reaction was monitored by tlc (Rf = 0.5 in % MeOH/CHC13) and the product was purified by silica gel chromatography using 5 o MeOH/CHC13 as the eluent.
5 NMR data was as follows:
'H-nmr (DMSO-d6)(1:1 mixture of diastereomers): b = 7.88 (m, 4H), 8.29 (t, 1H), 8.48, 8.55 (doublets, 1H).
Cz4Hz3Ns06F2 (MW = 487.46); mass spectroscopy (MH+) 487.
Example 138 10 Synthesis of N [N (3,5-Difluorophenylacetyl)-Iralaninyl]
Irphenylglycine Neopentyl Ester Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-phenylglycine neopentyl ester hydrochloride (prepared from N BOC-L-phenylglycine (Advanced Chemtech) and 2,2-dimethyl-1-propanol (Aldrich) using General Procedure C (with catalytic DMAP), followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 133-136°C).
The reaction was monitored by tlc (Rf = 0.7 in 10 % MeOH/CHC13) and the product was purified by silica gel chromatography using 4 % MeOH/CHC13 as the eluent, followed by recrystallization from 1-chlorobutane/hexanes.
NMR data was as follows:
'H-nmr (DMSO-d6): 8 = 3.50 (s, 2H), 5.42 (d, 1H).
Optical Rotation: [a]ZO = +45.9° ~a 589 nm (c = 1.02, DMSO).
Cz,,H28N204F2 (MW = 446.50); mass spectroscopy (MH+) 446.
Example 139 Synthesis of N tent-Butyl-N'-[N (3,5-difluorophenylacetyl) Iralaninyl]-I~phenylglycinamide Following General Procedure AB and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above), S-(+)-a-methylbenzylamine (Aldrich), benzaldehyde (Aldrich) and ten-butylisocyanide (Aldrich), the title compound was prepared as a solid (mp = 233-235°C'.). The reaction was monitored by tlc (Rf = 0.4 in 10 % MeOH/CHC13) and the product was purified by silica gel chromatography using 8 % MeOH/CHC13 ~~s the eluent, followed by recrystallization from 1-chlorobutane/aceto~nitrile.
- - NMR data was as follows:
'H-nmr (DMSO-d6)(1:1 mixture of dia.stereomers): 8 = 3.52 (s, 2H), 5.40 -(m, 1H).
CZ;HZ~N3O3F2 (MW = 431.49); mass spectroscopy (MH+) 432.
Example 140 Synthesis of N [N (3,5-Difiuoropheny!acetyl)-L-alaninyl]-Irphenylglycine test-Butyl Fster Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-phenylglycine tent-butyl ester hydrochloride (Advanced Chemtech), the title compound was prepared as a solid (mp = 145-147°C). The reaction w<~s monitored by tlc (Rf = 0.5 in 5%
MeOH/CHCl3) and the product was purified by silica gel chromatography using 2.5 % MeOH/CHC13 as the eluent, followed by recrystallization from 1-chlorobutane/hexanes.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 1.26 (d, 3H); 5.20 (d, 1H).
Optical Rotation: [a]ZO = +14.8° Q ~~89 nm (c =1.01, MeOH).
C23H26N2~4F2 (MW = 432.47); mass ;spectroscopy (MH+) 433.
Example 141 Synthesis of N'-[N (3,5-Difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide __ 2~ __ Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-phenylglycinamide hydrochloride (prepared from N BOC-L-phenylglycine (Advanced Chemtech) and ammonia using General Procedure C, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 288-290°C). The reaction was monitored by tlc (Rf = 0.4 in 15% MeOH/CHC13) and the product was purified by silica gel chromatography using 15 ~
MeOH/CHCI3 as the eluent, followed by recrystallization from EtOH.
NMR data was as follows:
'H-nmr (DMSO-db): b = 1.22 (d, 3H), 5.36 (d, 1H).
Optical Rotation: [a]ZO = +27.5° Q 589 nm (c = 1.03, DMSO).
C,9H,9N3O3F2 (MW = 375.38); mass spectroscopy (MH+) 376.
Example 142 Synthesis of 4-[N [N (3-Nitrophenylacetyl)-L-alaninyl]-IrvalinylJmorpholine Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D11 above) and 4-(L-valinyl)morpholine (prepared from N
BOC-L-valine (Aldrich) and morpholine (Aldrich) using General Procedure M, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf =
0.5 in 9:1 CHCl3/MeOH) and the product was purified by silica gel chromatography using 98:2 CHCI3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 8.12 (d, 2H), 8.08 (dd, 1H), 7.59 (d, 1H, J=7 Hz), 7.42 (t, 1H), 7.32 (d, J=8 Hz, 1H), 7.03(d, J=8 Hz, 1H), 4.78 (m, 1H), 4.68 (m, 1H), 3.61 (m, lOH), 1.90 (m, 1H), 1.96 (d, 3H), 1.31 (d, 3H), 0.88 (d, 3H), 0.80 (d, 3H).
Optical Rotation: [aJz3 = -5 ° (c 5, MeOH).

Example 143 Synthesis of N [N (3-Nitrophenylacetyl)-I~nlaninyl]-L-valine Ethyl Ester Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D 11 above) and L-valine ethyl ester hydrochloride (Aldrich), the title compound was prepared as a soliid. The reaction was monitored by tlc (Rf = 0.2 in 97:3 CHCI3/MeOH) and thaw product was purified by silica gel chromatography using 97:3 CHC13/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.13 (m, 2H), 7.62 (d, J~7 Hz, 1H), 7.47 (t, 1H), 6.52 (m, 2H), 4.57 (m, 1H), 4.46 (m, 113), 4.19 (m, 2H), 3.65 (s, 2H), 2.13 (m, 1H), 1.38 (d, 3H), 1.22 {t, 3H), 0.8:? (d, 3H).
Optical Rotation: [a]23 = -24.3° Q _'i89 nm (c 1, DMSO).
C,BHZSN306 (MW = 379.42); mass spectroscopy (MH+) 380.
Example 144 Synthesis of N [N-{3-Nitrophenylacetyl)-I~alayzinyl]-L-threonine Methyl Ester Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D11 above) and L-threoni,ne methyl ester hydrochloride (Aldrich), the title compound was preparf:d as a solid. The reaction was monitored by tlc (Rf = 0.1 in 95:5 CHCl3/MeOH) and the product was purified by silica gel chromatography using 95:5 I~HC13/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 8.08 (d, IH), '7.96 (d, 1H), 7.59 (d, 1H), 7.45 (d, 1H), 7.34 (t, 1H), 7.20 (d, 1H), 4.43 {m, 1H), 4.39 (dd, 1H), 4.13 (m, 1H), 3.59 (s, 3H), 3.51 (s, 2H), I.20 (d, 3H), 1.03 (d, 3H).
Optical Rotation: [a]23 = -20.8° (c 5, MeOH).
C,6HZON20, (MW = 367.3); mass spectroscopy (MH+) 368.

Example 145 Synthesis of 4-[N [N (3-Nitropbenylacetyl)-I~alaninyl]-(S)-2-amino-3-tent-butoxybutyrylJmorpholine Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D 11 above) and 4-[(S)-2-amino-3-ten-butoxybutyrylJ-morpholine (prepared from N BOC-D-tent-butyl-L-threonine (Sigma) and morpholine (Aldrich) using General Procedure M, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.1 in 95:5 CHCl3/MeOH) and the product was purified by silica gel chromatography using 96:4 CHCl3/MeOH
as the eluent.
NMR data was as follows:
'H-nmr (CDC13): 8 = 8.12 (m, 2H), 7.66 (d, 1H), 7.47 (t, 1H), 6.88 (d, 1H), 6.32 (d, 1H), 4.78 (m, 1H), 4.50 (m, 1H), 3.90-3.40 (m, 11H), 1.40 (d, 3H), 1.18 (s, 9H), 1.0 (d, 3H).
C23H33N3O~ (MW = 478.5); mass spectroscopy (MH+) 479.
Example 146 Synthesis of 4-(N [N-(3-Nitrophenylacetyl)-IralaninylJ-IrisoleucinylJmorpholine Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D 11 above) and 4-(L-isoleucinyl)morpholine (prepared from N
BOC-L-isoleucine (Aldrich) and morpholine (Aldrich) using General Procedure M, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 156-160°C). The reaction was monitored by tlc (Rf = 0.45 in 9:1 CHCl3/MeOH) and the product was purified by silica gel chromatography using 98:2 CHCl3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.16 (d, 1H), 8.09 (d, 1H), 7.63 (d, 1H), 7.45 (t, 1H}, 7.30 (d, 1H), 6.89 (d, 1H), 4.78 (m, 1H), 4.62 (m, 1H), 3.6 (m, lOH), 1.65 (m, 1H), 1.4 (m, 1H), 1.29 (d, 3H), 1.03 (d, 3H), 0.90-0.76 (m, 6H).

Optical Rotation: [a]23 = -55° (~ 589 nm (c 1, MeOH).
Example: 147 Synthesis of N [N (3-Nitrophenylacetyl)-L-alaninyl]-L-isoleucine Methyl Fster Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D11 above) and L-isoleucine methyl ester hydrochloride (Aldrich), the title compound was prepare'3 as a solid. The reaction was monitored by tlc (Rf = 0.15 in 97:3 CHC'l3/MeOH) and the product was purified by silica gel chromatography using 97:3 CHCI3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 8.12 (m, 2H), '7.66 (d, 1H), 7.49 (t, 1H), 6.50 (m, 2H), 4.52 (m, 2H), 3.72 (s, 3H), 3.61 (s, 2H), 1.87 (m, 1H), 1.32 (m, 4H), 1.07 (m, 1H), 0.81(d, 6H).
Optical Rotation: [a]23 = -7.3 ° (c 5, :MeOH).
C,gHz5Nz06 (MW = 379); mass spectroscopy (MH+) 379.
Example 148 Synthesis of N [N (3-Nitrophenylacetyl)-~If-alaninyl]-L-isoleucine Following General Procedure AF and using N [N (3-nitrophenylacetyl)-L
alaninyl]-L-isoleucine methyl ester (from Example 147 above), the title compound was prepared as a solid.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.41 (d, 1H;1, 8.15 (s, 1H), 8.07 (d, 1H), 7.91 (d, 1H), 7.68 (d, 1H), 7.53 (t, 1H), 4.36 (m, 1H), 4.12 (m, 1H), 3.62 (s, 2H), 1.71 (m, 1H), 1.31 (m, 1H), 1.18 (d, 3H), 1.07 (m, 1H), 0.79 (m, 6H).
Optical Rotation: [a]23 = -42° (c 5, ll~IeOH).
C,~H23N206 (MW = 365.3); mass spectroscopy (MH+) 366.

Example 149 Synthesis of N [N [N (3-Nitrophenylacetyl)-L.alaninyl]-I~threoninyl]
Irvaline Ethyl Ester Following General Procedure C and using N [N (3-nitrophenylacetyl)-L-alaninyl]-L-threonine (prepared from N [N (3-nitropheny!acetyl)-L-alaninyl]-L-threonine methyl ester (from Example 144 above) using General Procedure AF) and L-valine ethyl ester hydrochloride (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.1 in 96:4 CHCI3/MeOH) and the product was purified by silica gel chromatography using 96:4 CHCl3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 8.12 (m, 1H), 7.60 (d, 1H), 7.48 (t, 1H), 7.05 (d, 1H), 6.98 (d, 1H), 6.48 (d, 1H), 4.60 (m, 1H), 4.47 (m, 3H); 4.22 (m, 2H) 3.65 (s, 2H), 2.19 (m, 1H), 1.38 (d, 3H), 1.28 (t, 3H), 1.09 (d, 3H), 0.87 (m, 6H) .
Optical Rotation: [a)23 = -85° (c 5, MeOH).
Example 150 Synthesis of Methyl N [N (3-nitrophenylacetyl)-Iralaninyl]-(S)-2-aminopentanoate Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D 11 above) and methyl (S)-2-aminopentanoate hydrochloride (prepared from (S)-2-aminopentanoic acid (Novabiochem) using General Procedure H), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.4 in 9:1 CHCl3/MeOH).
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.39 (m, 1H), 8.28 (m, 1H), 8.19 (m, 1H), 8.11 (m, 1H), 7.73 (d, 1H), 7.61 (d, 1H), 4.36 (m, 1H), 4.22 (m, 1H), 3.64 (m, 5H), 1.62 (m, 2H), 1.26 (m, 2H), 1.22 (d, 3H), 0.86 (m, 3H).
Optical Rotation: [«]z3 = -29° (c 1, MeOH).

WO 98!22494 PCT/LTS97/20804 C"H~N306 (MW = 365); mass spectroscopy (MH+) 366.
Example: 151 Synthesis of N [N (3-Nitropheny!acetyl)-L-alaninyl]-L-leucine Methyl Ester Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D 11 above) and L-leucine methyl ester hydrochloride (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.75 in 9:1 CHCl3/MeOH) and the product was purified by silica gel chromatography using 97:3 CHCl3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.12 (m, 2H), 13.04 (m, 1H), 7.58 (m, 1H), 7.48-7.30 (m, 2H), 7.11 (d, 1H), 4.63 (m, 1H), 4.48 (m, 1H), 3.68 (s, 2H), 3.64 (s, 3H), 1.63 (m, 1H), 1.31 (m, 2H), 0.8.'i (d, 3H), 0.82 (m, 3H).
Optical Rotation: [a]~ _ -32° (c 1, MeOH).
IS C,gH25N3O6 (MW = 379); mass spectroscopy (MH+) 380.
Example 152 Synthesiis of N [N-(3,5-Difluorophen~rlacetyl)-L-alaninyl]
I~leucine Metthyl Ester Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-le;ucine methyl ester hydrochloride (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.5 in 9:1 CHC13/:MeOH).
NMR data was as follows:
'H-nmr (CDC13): b = 6.78 (m, 2H), fi.69 (m, 1H), 4.52 (m, 2H), 3.73 (m, 1H), 3.52 (d, 2H), 1.63 (m, 2H), 1.315 (m, 3H), 0.88 (m, 3H).
Optical Rotation: [a]23 = -34° (c l, hieOH).
C~aH24NzOaFz (Mw = 370); mass spectroscopy (MH+) 370.

__ 270 -_ Example I53 Synthesis of _.-.
N 2-Methoxyethyl-N'-[N (3,5-difluorophenylacetyl)-Iralaninyl]-I~alaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl}-L-alaninyl]-L-alanine (from Example D7 above) and 2-methoxyethylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.35 in 9:1 CHCl3/MeOH}.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 8.32 (m, 1H), 7.98 (d, 1H), 7.82 (m, 1H), 7.07 (m, 1H), 6.97 (m, 2H), 4.25 (m, 2H), 3.52 (s, 2H), 3.32 (m, 3H), 3.20 (m, 4H), 1.19 (m, 6H).
Optical Rotation: [a]23 = -50° (c 1, MeOH).
C,-,HZ3N304F2 (MW = 37I}; mass spectroscopy (MH+) 372.
Example 154 Synthesis of N 2-(N,N Dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl) Iralaninyl]-Iralaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and N,N dimethyl-ethylenediamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.05 in 9:1 CHCl3/MeOH).
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.38 (m, 1H), 8.02 (m, 1H), 7.66 (m, 1H), 7.09 (m, 1H), 6.97 (m, 2H), 4.22 (m, 2H), 3.53 (s, 2H), 3.08 (m, 2H), 2.22 (m, 2H), 2.11 (m, 6H), 1.21 (d, 6H).
Optical Rotation: [a]23 = -55° (c 1, MeOH).
C,8HZ6N~03F2 {MW = 384); mass spectroscopy (MH+) 384.

Example 155 Synthe<as of N Cyclohexyl-N'-[N (3,S~~difluorophenylacetyn L-alaninyl)-L-alaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and cyclohexylamine (Aldrich), the title compound was prepared as a solid (mp = 239-244°C). The reaction was monitored by tlc (Rf = 0.25 in 9:1 C;HC13/MeOH).
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.39 (m, 1F1}, 7.94 (m, 1H), 7.56 (m, 1H), 7.08 (m, 1H), 6.97 (m, 2H), 4.20 (m, 2H), 3.:32 (s, 2H), 3.27 (m, 1H), 1.64 (m, 4H), 1.54 (m, 2H), 1.20 (m, lOH).
Optical Rotation: [a]23 = -58° (c l, DdeOH).
CZOHz,N303Fz (MW = 395); mass spectroscopy (MH+) 395.
Example 156 Synthesis of N Neopentyl-N'-[N (3,5-difluorophenylacetyl) L-alaninyl]-Ira~laninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and neopentylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.25 in 9:1 CHCI3lMeOH).
NMR data was as follows:
'H-nmr (DMSO-db): ~S = 8.37 (d, 1H}, 8.01 (m, 1H), 7.67 (m, 1H), 7.11 (m, 1H), 6.98 (m, 2H), 4.28 (m, 2H), 3.51 (s, 2H), 2.88 (m, 2H), 1.23 (d, 3H), 0.80 (m, 9H).
Optical Rotation: [a]23 = -54° (c 1, hZeOH).
C~9HZ~N303Fz (MW = 383); mass spectroscopy (MH+) 383.

Example 157 Synthesis of N Tetrahydrofurfuryl-N'-[N (3,5-difluorophenylacetyi) Iralaninyi]-Iralaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and tetrahydrofurfurylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.20 in 9:1 CHCl3/MeOH).
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.36 (d, 1H), 8.01 (m, 1H), 7.81 (m, 1H), 7.11 (m, 1H), 6.99 (m, 2H), 4.25 (m, 2H), 3.77 (m, 2H), 3.58 (m, 1H), 3.51 (s, 2H), 3.21 (m, 1H), 1.78 (m, 4H), 1.46 (m, 1H), 1.19 (m, 6H).
Optical Rotation: [a]23 = -70° (c 1, MeOH).
C~gHZ5N3O4F2 (MW = 397); mass spectroscopy (MHO) 398.
Example 158 Synthesis of N 2-Pyridylmethyl-N'-[N (3,5-difluorophenylacetyl) I~-alaninyi]-I,-alaninamide Following General Procedure C and using N (N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and 2-(aminomethyi)pyridine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = O.I in 9:1 CHC13/MeOH).
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.49 (m, 1H), 8.41 {m, 2H), 8.14 (d, 1H), 7.74 (m, 1H), 7.28 (m, 2H), 7.09 (m, 1H), 6.98 (m, 2H), 4.33 (m, 4H), 3.52 (s, 2H), 1.24 (m, 6H).
Optical Rotation: [a]z3 = -68° (c 5, MeOH).
CzoHZZN~03F2 (MW = 404); mass spectroscopy (MH'') 405.
, Example 159 Synthesis of 3-[N [N (3,5-Difluorophenylacetyl)-L-alaninyl]
Iralaninyl]thiazolidine Following General Procedure C and u;~ing N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and thiazolidine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.25 in 9:1 CHCl3/MeOH).
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.34 (m, 2H), 8.22 (m, 1H), 7.09 (m, 1H), 6.98 (m, 2H), 4.68-4.23 (m, 4H), 3.81-3.6 (m, 2H), 3.52 (s, 2H), 3.01 (m, 2H), 1.19 (m, 6H).
Optical Rotation: [a]23 = -67° (c 1, MeOH).
C,.,Hz,N303Fz (MW = 385); mass specaroscopy (MH+) 385.
Example 160 Synthesi:~ of Methyl N [N (3,5-difluorophenylacetyl) L-alaninyl]-(S)-2-arninobutanoate Following General Procedure C and using N (3,5-difluorophenylacetyl}-L-alanine (from Example B2 above) and methyl (S)-2-aminobutanoate hydrochloride (prepared from (S)-(+)-2-aminobutyric acid (Aldrich) using General Procedure H), the title compound was prepared as a solid (mp = 103-106°C).
NMR data was as follows:
'H-nmr (CDC13): 8 = 6.83 (m, 2H), 6.72 (m, 1H), 6.49 (d, 1H), 4.55 (m, 1H), 4.48 (m, 1H), 3.72 (s, 3H), 3.49 (s, :ZH), 1.85 (m, 1H), 1.69 (m, 1H), 1.39 (d, 3H), 0.86 (t, 3H).
Optical Rotation: [a]23 = -70° (c 1, MeOH).
C,6HZON204F2 (MW = 342.35); mass spectroscopy (MH+) 342.

Example 161 Synthesis of Methyl N [N (3,5-difluorophenylacetyl) Iralaninyl]-(S)-2-aminopentanoate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-aminopentanoate hydrochloride (prepared from (S)-2-aminopentanoic acid (Novabiochem) using General Procedure H), the title compound was prepared as a solid (mp = 154-155 °C).
NMR data was as follows:
'H-nmr (CDCl3): b = 6.80 (m, 2H), 6.69 (m, 1H), 6.45 (d, 1H), 6.28 (d, 1H), 4.52 (m, 2H), 3.7I (s, 3H), 3.51 (s, 2H), 1.77 (m, 1H), 1.58 (m, 1H), 1.35 (d, 3H), 1.27 (m, 2H), 0.87 (t, 3H).
Optical Rotation: [«]23 = -69° (c 1, MeOH).
Example 162 Synthesis of Methyl N [N (3-nitrophenylacetyl)-L-alaninyl]
(S)-2-aminobutanoate Following General Procedure C and using N (3-nitrophenylacetyl)-L-alanine (from Example D 11 above) and methyl (S)-2-aminobutanoate hydrochloride (prepared from (S)-(+)-2-aminobutyric acid (Aldrich) using General Procedure H), the title compound was prepared as a solid (mp = 154-157°C).
NMR data was as follows:
'H-nmr (CDCl3): 8 = 8.13 (m, 1H), 8.04 (m, 1H), 7.57 (m, 1H), 7.3$
(m, 1H), 4.72 (m, 1H), 4.39 (m, 1H), 3.69 (s, 3H), 3.41 (s, 2H), 1.73 (m, 1H), 1.61 (m, 1H), 1.34 (d, 3H), 0.79 (t, 3H).
Optical Rotation: [a]z3 = -75° (c 1, MeOH).
Example 163 Synthesis of N (R)-sec-Butyl-N'-[N (3,5-difluorophenyiacetyl)-I~-alaninyl]-L-alaninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and (R)-(-)-sec-butylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf = 0.15 in 95:5 CHC:13/MeOH) and the product was purified by silica gel chromatography using 95:5 CHCl3 MeOH as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.39 (m, 1~I), 7.95 (m, 1H), 7.49 (m, II~), 7.09 (m, 1H), 7.01 (m, 2H), 4.20 {m, 4H), 3.61 (m, 1H), 3.52 (s, 2H), 1.34 (m, 2H), 1.21 (m, 6H), 0.97 (d, 3H), 0.79 (m, 3H).
Optical Rotation: [a]z3 = -SO° (c 1, rrIeOH).
C,aHz5N303F2 (MW = 369.41); mass spectroscopy (MH+) 370.
Example: i 64 Synthesis of 1-[N [N-(3,5-Difluorophenylacetyl)-I~-alaninyl]-L-alaninyl]p;yrrolidine Following General Procedure C and wising N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and pyrrolidine (Aldrich), the title compound was prepared as a solid. 'l~ he reaction was monitored by tlc (Rf = 0.15 in 95:5 CHCI3/MeOH) and the product was purified by silica geI
chromatography using CHCl3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 8.31 (m, 1Ff), 8.08 (m, 1H), 7.09 (m, 1H), 6.99 (m, 2H), 4.48 (m, 1H), 4.29 (m, 1H), 3._'>1 (s, 2H), 3.44-3.22 (m, 4H), 1.80 (m, 4H), 1.27 (m, 6H).
C,aH23N303F2 (MW = 367.40); mass spectroscopy (MH+) 367.
Example. 165 Synthesis of N (S)-sec-Butyl-N'-(N (3,5-difluorophenylacetyl) Ifalaninyl]-Ira~laninamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine (from Example D7 above) and (S)-(+)-sec-butylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc {Rf = 0.25 in 9:1 CHC13/MeOH) and the product was purified by silica gel chromatography using CHCI3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.38 (m, iH), 7.92 (m, IH), 7.30 (m, 1H), 7.18 (m, 1H), 6.99 (m, 2H), 4.20 (m, 4H), 3.62 (m, 1H), 3.52 (s, 2H), 1.34 (m, 2H), 1.20 (m, 6H), 1.01 (m, 3H), 0.81 (t, 3H).
Optical Rotation: [a]z3 = -52° {c 1, MeOH).
C,9HZSN3O3F2 (MW = 369.41); mass spectroscopy (MH+) 370.
Example 166 Synthesis of N [N (3,5-Difluorophenylacetyl)-Iralaninyl]-Irvaline Methyl Ester Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-valine methyl ester hydrochloride (Aldrich), the title compound was prepared as a solid.
NMR data was as follows:
'H-nmr (CDC13): 8 = 6.81 (m, 2H), 6.73 (m, 1H), 6.48 (d, 1H), 6.22 (d, 1H), 4.48 (m, 2H), 3.70 (s, 3H), 3.51 (s, 2H), 2.16 (m, 1H), 1.37 (m, 1H), 0.87 (t, 3H).
Optical Rotation: [a]z3 = -65 ° (c 1, MeOH).
C~.,HZZNz04Fz (MW = 356.37); mass spectroscopy (MH+) 360.
- - Example 167 Synthesis of N 2-Fluoroethyl-N'-[N (3,5-difluorophenylacetyl) Iralaninyl]-L-alaninamide Following General Procedure C and using N (N (3,5-difluorophenylacetyl)-L-alaninylj-L-alanine (from Example D7 above) and 2-fluoroethylamine __ 277 -_ hydrochloride (Aldrich), the title compound was prepared as a solid (mp =
230-235 °C).
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.38 (d, 1H)., 8.04 (m, 2H), 7.07 (m, 1H), 6.99 (m, 2H), 4.39 (m, 2H), 4.24 (m, 1H), 3.5:3 (s, 2H), 3.35 (m, 2H), 1.20 (m, - 6H).
Optical Rotation: [a]~ _ -33 ° (c 1, MeOH).
C,bH2o1V3O3F, (MW = 359.37); mass spectroscopy (MH+) 359.
Example 168 Synthesis of N [(S)-6-Methyl-3-o~;ohept-2-yl]-N' (3,5-difluorophenylacetyl)-I~alaninamide Following General Procedure M and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and (S)-Ei-methyl-3-oxohept-2-ylamine hydrochloride (prepared by treating N BOC'-L-alanine N methoxy-N methyl amide (Weinreb et al., Tetrahedron Lett., 22, 3815 (1981)) with isopropyl magnesium bromide (Aldrich), followed by removal of the BOC group using General Procedure P), the title compound was prepared as a solid. The product was purified by silica gel chromatography using CHCI3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDCI3): 8 = 6.84 (m, 2H), 6.69 (m, 1H), 6.31 (m, 1H), 4.50 (m, 2H), 3.51 (s, 2H), 2.48 (m, 2H), 1.47 (m, 2H), 1.32 (m, 7H), 0.90 (d, 6H) .
Optical Rotation: [a]23 = -42 ° {c 1, MeOH).
C,9H26NZO3F2 (MW = 368); mass spectroscopy (MH+) 368.
Example 169 SynthesL~ of N 4-Nitrobenzyl-N'-[N (3,5-~difluorophenylacetyl) I~alaninyl]-(S)-2-am~inobutyramide __ 278 --Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S}-2-aminobutyric acid (prepared from methyl N [N (3,5-difluorophenylacetyl)-L-alaninylJ-{S)-2-anlinobutanoate (from Example 160 above) using General Procedure AF) and 4-nitrobenzylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf =
0.3 in 95:5 CHCI3/MeOH) and the product was purified by silica gel chromatography using 97:3 CHCI~/MeOH as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.57 (t, 1H), 8.40 (d, 1H), 8.21 (d, 2H), 8.02 (d, 1H), 7.50 (d, 2H), 7.08 (m, 1H), 6.98 (m, 2H), 4.42 (d, 2H), 4.37 (m, 1H), 4.17 (m, 1H), 3.53 {s, 2H), 1.64 (m, 2H), 1.21 (m, 3H), 0.83 (t, 3H}.
Optical Rotation: [a]23 = -42° (c l, MeOH).
C2zH2aNaOsFz (MW = 462.45); mass spectroscopy (MH+) 462.
Example 170 Synthesis of N 4-Nitrobenzyl-N'-[N (3,5-difluorophenylacetyl) L-alaninyl]-(S)-2-aminopentanamide Following General Procedure C and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoic acid (prepared from methyl N [N (3,5-difluorophenylacetyl)-L-alaninylJ-(S)-2-aminopentanoate (from Example 161 above) using General Procedure AF) and 4-nitrobenzylamine (Aldrich), the title compound was prepared as a solid. The reaction was monitored by tlc (Rf =
0.3 in 95:5 CHC13/MeOH) and the product was purified by recrystallization from acetonitrile.
NMR data was as follows:
'H-nmr (DMSO-db): & = 8.57 (m, 1H), 8.41 (d, 1H), 8.22 (d, 2H), 8.06 (d, 1H), 7.51 (d, 2H), 7.12 (m, 1H), 7.00 (m, 2H}, 4.43 (d, 2H), 4.30 (m, 2H), 3.56 (s, 2H), 1.65 (m, 2H), i.29 (m, 5H), 0.91 (t, 3H).
Optical Rotation: [aJ23 = +97° (c 1, MeOH).
C23H26N4~SF2 (M~ = 476.4); mass spectroscopy (MH+) 476.

Example a 71 Synthesis of _ -Methyl N [N (3,5-Difluoroph~enylacetyi)-L-alaninyl]-2-amino-2-(3-ffuorolphenyl)acetate Following General Procedure C and usiing N (3,5-difluorophenylacetyl)-L-- alanine (from Example B2 above) and methyl 2-amino-2-(3-fluorophenyl)acetate hydrochloride (from Example D 12 above), vthe title compound was- prepared as a solid. The reaction was monitored by tlc (Rf = 0.2 in 95:5 CHCI3/MeOH) and the product was purified by silica gel clhromatography using 95:5 CHCI3/MeOH as the eluent.
NMR data was as follows:
'H-nmr (CDC13): b = 7.36 (m, 1H), 7.18 (m, 1H), 7.13 (m, 1H), 7.06 (m, 1H), 6.87 (m, 2H), 6.74 (m, 1H), 6.OS~ (m, 1H), 5.49 (d, 1H), 4.59 (m, 1H), 3.74 (s, 3H), 3.57 (s, 2H), 1.35 (d, 3H), 0.97 (d, 3H).
IS CZpH~gNZO4Fg (MW = 408.38); mass spectroscopy (MH+) 408.
Example 172 Synthesis of N'-[N (3,5-Difluorophenylacetyl)-I~.alaninyl]
(S)-2-amino-2-(2-thienyl)acetamide Following General Procedure L and usiing methyl N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate (from Example 178 below), the title compound w;~s prepared as a solid (mp =
decomposition at 190°C). The product wa~~ purified by preparative LC

chromatography using 8:2 EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDC13/DMSO-db): b = 8.9-6.14 (Ar + NH's 10 H), 5.43-5.39 (m, 1H), 4.16-4.10 (m, J=7 Hz, 1H), 3.19 (s, 2H), 1.15 (d, J=7.05 Hz, 3H).
C,~H,~FZN303S (MW = 381.4); mass spectroscopy (MH+) 381.
- Example 173 SynthesLC of Methyl N [N-(3,5-Difluorophenylacetyl) I~alaninyl]-2-amino-2-(5-chlorolbenzothiophen-2-yl)acetate __ 280 __ Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(5-chlorobenzothiophen-2-yl)acetate (prepared from 5-chlorobenzothiophene-2-acetic acid [CAS No. 23799-65-7) using General Procedure G, followed by amination using a procedure essentially the same as that described in Example D4 above), the title compound was prepared as a solid (mp = 189-190°C).
The product was purified by titration using Et20/hexanes.
NMR data was as follows:
'H-nmr (CDC13): b = 7.7-7.63 (m, 2H), 7.33-7.17 (m, 2H), 6.89-6.63 (m, 3H), 6.16-6.03 (m, 1H), 5.85 (dd, 1H), 4.7-4.53 (m;-1H), 3.83 (s, 1.5H), 3.8 (s, 1.5H), 3.59 (s, 1H), 3.5 (s, 1H), 1.4 (dt, 3H).
CzzH19C1F,N204S (MW = 481); mass spectroscopy (MH*) 480.
Example 174 Synthesis of Ethyl N [N (3,5-Difluorophenylacetyl)-Iralaninyl)-2-amino-2-(benzothiophen-2-yl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(benzothiophen-2-yl)acetate [CAS No. 98800-64-7], the title compound was prepared as a solid (mp = 189-190°C). The product was purified by preparative LC 2000 chromatography using 2:8 EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): 8 = 7.8-7.75 (m, 2H), 7.34-7.27 (m, 2H), 7.25-7.09 (m, 3H), 6.81-6.76 (m, 1H), 6.76-6.63 (m, 1H), 6.23 (dd, J=7 Hz, 1H), 5.84(d, J=7.07 Hz, 1H), 4.61-4.59 (m, 1H), 4.33-4.2 (m, 2H), 3.54 (s, 1H), 3.50 (s, 1H), 1.70 (d, J=11.9 Hz, 1.5H), 1.38 (d, 1=11.9 Hz, 1.5 H), 1.36-1.23 (dt, 3H).
Cz3HzzNz04SFz (MW = 460.49); mass spectroscopy (MH+) 460.

-- 28I -_ Example 175 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl) Iralaninyl]-2-amino-2-(benzothiophen-3-yl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(benzothiophen-3-yl)acetate (prepared from 2-amino-2-(benzothiophen-3-yl)acetic acid (CAS
95834-94-9] using General Procedure H), the title compound was prepared as a solid (mp = 185-186°C).
NMR data was as follows:
'H-nmr (CDC13): b = 7.86 (m, 2H), 7.4-7.3 (m, 3H), 7.4-7.2 (m, 2H), 6.9-6.6 (m, 3H), 6.3-6.13 (m, 1H), 5.95-5.85 (m, 1H), 4.55-4.5 (m, 1H), 3.75 (s, 1.SH), 3.65 (s, 1.5H), 3.55 (s, 1H), 3.35 (s, 1H), 1.4 (d, 1.SH), 1.3 (d, 1.5H).
CzzH2o1'I20aF2S (M~ = 446); mass sp~wctroscopy (MH+) 446.
Example 176 Synthesis of Methyl N-[N (3,5-Difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-thienyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(2-thienyl)acetate (prepared from L-a-2-thienylglycine (Sigma) using General Procedure G), the title compound was prepared as a solid (mp = 161-162°C). The product was purified by preparative LC 2000 chromatol;raphy using 1:4 EtOAc/hexanes.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.3-6.65 (Ar, 7H), 6.25 (bt, 1H), 5.8 (dd, 1H), 4.68-4.5 (m, 1H), 3.85 (s, 1H), 3.75 (s, 1:H), 3.52 (s, 1H), 3.5 (s, 1H), 1.35 (overlaying d, 3H).
C,aH,aN204FZS (MW = 396); mass sp~yctroscopy (MH+) 396.1.

Example 177 Synthesis of _ -Ethyl N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-5-yl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and ethyl 2-amino-2-(benzothiophen-5-yl)acetate {prepared as described in S. Kukolja et al., J. Med. G'hem., 1985, 28, 1896-1903), the title compound was prepared as a solid (mp = 126.5-127.5°C). The product was purified by preparative LC 2000 chromatography using 1:1 hexanes/EtOAc as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 8.1 (s, 1H), 8.05 (s, 1H), 7.6-7.5 (m, 2H), 7.4-7.25 (m, 3H), 7.15 (bd, J =12 Hz, 5H), 7.05 (bd, J =12 Hz, 5H), 6. 89-6.675 (m, 2H), 6.225 (bd, J=12 Hz, 5H), 6.075 (bd, J =12 Hz, 5H), 4.55 (q, J=7.5 Hz, 1H), 4.2 (dq, 2H), 3.575 (s, 1H), 3.242 (s, 1H), 1.4 (d, J=7.05 Hz, 1.5H), 1.15 (d, J=7.05 Hz, 1.5H).
C~H22Nz04F2S (MW = 460); mass spectroscopy (MH+) 460.1.
Example 178 Synthesis of Methyl N-[N (3,5-Difluorophenylacetyl)-L-alaninyi]-(S)-2-amino-2-(2-thienyl)acetate Following General Procedure G and using N [N (3,5-difluorophenylacetyl}-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetic acid (from Example 180 below), the title compound was prepared as a solid (mp = 180-181 °C). The product was purified by preparative LC 2000 chromatography using 6:4 EtOAc/hexanes as the eluent.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.3-6.6 (Ar + NH, 7H), 6.37 (bd, J=7 Hz, 1H), 5.77 (d, J=7 Hz, 1H), 4.6-4.56 (m, J=7 Hz, 1H), 3.7 (s, 3H), 3.4 (s, 2H), 1.38 (d, J=7 Hz, 3H).
CIBH,gNz04SFz (MW = 396); mass spectroscopy (MH+) 396.1.
r Example; 179 Synthesis of tent-Butyl N [N (3,5-Dufluorophenylacetyl)-Iralaninyl]-(S)-2-aminc~2-(2-thienyl)acetate Following General Procedure J and using N [N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetic acid (from Example 180 below), the title compound was prepared as a solid (m~p = 117-118°C). The product was purified by tituraration using ether/hexane~s.
NMR data was as follows:
'H-nmr (CDCl3): b = 7.24 (d, J=6.5 Hz, 1H), 7.05-6.63 (m, 6H), 6.19 (bd, J=7.2 Hz, 1H), 5.66 (d, J=7.5 Hz, 1H), 4.6-4.5 (m, 1H), 3.5 (s, 2H), 1.44 (s, 9H), 1.38 (d, J=7.1 Hz, 3H).
CZ,H~N204SFz (MW = 438.5); mass spectroscopy (MH+) 438.
Example 180 Synthesiis of N [N (3,5-Difluorophen~rlacetyl)-L-alaninyl]
(S)-2-amino-2-(2-thienyl)acetic Acid Following General Procedure M and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and L-a-2-thienylglycine (Sigma), the title compound was prepared as a solid. The product was purified by tituration using EtOAc/hexanes.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.73 (d, J='1 Hz, 1H), 8.38 (d, J=7 Hz, 1H), 7.56-7.4 (m, 1H), 7.2-6.9 (m, 4H), 5.54 (d, J=8 Hz, 1H), 4.5-4.3 (m, 1H), 3.33 (s, 2H), 1.23 (d, J=7 Hz, 3H).
C,-,H,bNz04SF2 (MW = 382); mass spectroscopy (MH+) 382.
Example 181 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-I,-alaninyl]-2-amino-2-(1H tetra~zol-5-yl)acetate WO 98!22494 PCT/US97/20804 Following General Procedure C and using N (3,5-difiuorophenylacetyl)-L-aianine (from Example B2 above) and methyl 2-amino-2-(1H tetrazol-5-yl)acetate (prepared from ethyl 1H-tetrazole-5-acetate [CAS 173367-99-2] using procedures essentially the same as those described in S. Kukolja, J. Med.
Chem. , 1985, 28, 1886-1896), the title compound was prepared as a solid. The reaction was product was purified by tituration using EtOAc/hexanes.
NMR data was as follows:
'H-nmr (DMSO-db): b = 9.13 (d, J=7.6 Hz, IH), 8.39 (t, J=7 Hz, 1H), 7.1-6.95 (m, 3H), 5.9 (dd, 1H), 4.4-4.3 (m, 1H), 4.14 (q, J=7 Hz, 2H), 3.5 (s, 3H), 1.27-1.11 (m, 6H).
C~6H,8N604F2 (MW = 396.3); mass spectroscopy (MH+) 396.3.
Example 182 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(6-methoxy-2-naphthyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (S)-2-amino-2-(6-methoxy-2-naphthyl)acetate (from Example D3 above), the title compound was prepared as a solid (mp = 177-178°C). The product was purified by tituration using hexanes/EtOAc.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 8.84 (d, J=9 Hz, IH), 8.4 (d, J=9 Hz, 1H), 7.90-7.76 (m, 2H), 7.247-6.90 (m, 5~; 5.5 (J=7 Hz, 1H), 4.243 (d, J=3.5 Hz, 1H), 3.86 (s, 3H), 3.6 (s, 3H), 3.29 (s, 2H), 1.26 (d, J=7.5 Hz, 3H).
C2sH2aNzOsF2 (MW = 470.48); mass spectroscopy (MH+) 470.
Example 183 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-I~alaninyl]
2-amino-2-(3-trifluoromethylphenyl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(3-trifluoromethylphenyl)acetate (prepared from 2-(hydroxyimino)-2-(3-trifluoromethylphenyl)acetic acid [CAS 17!811-81-5J using General Procedures G and R above), the title compound was prepared as a solid (mp = I33-134°C). The product was purified by titmation from EtOAc/hexanes.
NMR data was as follows:
'H-nmr (CDCI3): b = 7.57-7.37 (m, 4H), 6.8-6.6 (m, 3H), 6.05 (BA, 1H), 5.5 (A, J=7.5Hz, 1H), 3.7 (s, 1.5H), 3.6'75 (s, 1.5H), 3.5 (s, 1H), 3.45 (s, 1H), 1.33 (d, J=7.5 Hz, 1.5H), 1.275 (d, J=7.5 Hz, 1.5H).
CZ,HI9NzO4F5 (MW = 458.39); mass spectroscopy (MH+) 459.
Example 184 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-L~alaninyl)-2-amino-2-(4,5,6,7-tetrahydrobenzothiophen-2-yl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(4,5,6,7-tetrahydrobenzothiophen-2-yl)acetate (prepared from N Boc-2-amino-2-{4,5,6,7-tetrahydrobenzothiophen-2-yl)acetic acid [C'AS 95361-97-O] using General Procedures G above and the Boc removal procedure described in Example D3 above), the title compound was prepared as a solid. The product was purified by tituration using Et20/hexanes.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.05 (d, J=5 Hz:, 1H), 7.02 (d, J=5 Hz, 1H), 6.82-6.66 (m, 3H), b.31 (bd, J=8 Hz, 1H), 5.66 (dd, J=7.2 Hz, 1H), 4.63-4.55 (m; 1H); 3.76 (s, 1.5H), 3.75 (s, 1.5H), 3,52 (s, 1H), 3.50 (s, 1H), 2.67-2.65 (m, 2H), 2.54-2.52 (m, 2H), 1.77-1.7 (m, 4H), 1.36 (dd, J=7 Hz, 3H).
CZZHZQN204F2S (MW = 450); mass spectroscopy (MH+) 450.

Example 185 Synthesis of Methyl N (N (3,5-Dif7uorophenylacetyI)-lialaninyl]
2-amino-2-(thieno[2,3-b]thiophen-2-yl)acetate Following General Procedure C and using lV (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(thieno[2,3-b]thiophen-2-yl)acetate (from Example D4 above), the title compound was prepared as a solid. The product was purified by titruadon from Et~O/hexanes.
NMR data was as follows:
'H-nmr (CDC13): b = 7.35 (d, J=7.5 Hz, 1H), 7.2-7.0 (m, 3H), 6.9-6.69 (m, 3H), 6.13-6.0 (m, 1H), 5.8 (dd, 1H), 4.63-4.5 (m, 1H), 3.8 (s, 3H), 3.58 (s, 1H), 3.469 (1H), 1.4 (dd, 3H).
CzaH18IV2O4F2S2 (MW = 452); mass spectroscopy (MH+) 452.
Example 186 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl) Iralaninyl]-2-amino-2-(2-methylthiazol-4-yl)acetate Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl 2-amino-2-(2-methylthiazol-4-yl)acetate (prepared from N Boc-2-amino-2-(2-methylthiazol-4-yl)acetic acid [CAS 105381-90-6] using General Procedure H above), the title compound was prepared as a solid. The product was purified by tituration using EtzO/hexanes.
NMR data was as follows:
'H-nmr (CDC13): 8 = 7.2-6.66 (pr + NH, SH), 5.69-5.6 (m, 1H), 4.8-4.69 (m, 1H), 3.76 (s, 3H), 3.56 (s, 1H), 3.5 (s, 1H), 2.69 (s, 3H), 1.4 (d, J=14 Hz, 1.SH), 1.35 (s, J=14 Hz, 1.SH).
C18H,9Nj04F2S {MW = 411); mass spectroscopy (MH+) 411.
Example 187 Synthesis of Methyl (3S,4S)-N [N (3,5-Difluorophenylacetyl)-L-alaninyl]-4-amino-3-hydroxy-5-phenylpentanoate __ 287 --Following General Procedure C and using N (3,5-difluorophenylacetyl)-L-alanine (from Example B2 above) and methyl (3S,4S)-4-amino-3-hydmxy-5-phenylpentanoate (Novabiochem), the title compound was prepared as a solid.
The reaction was monitored by tlc (Rf = 0.2 in 95:5 CHCl3/MeOH) and the product was purified by flash column chromatography using 95:5 CHCI3/MeOH
as the eluent.
NMR data was as follows:
'H-nmr (CDC13): 8 = 8.29 (d, 1H), 7.65 (d, 1H), 7.40-7.20 (m, SH), 7.10 (m, 1H), 6.99 (m,2H), 5.27 (d, 1H), 4.47 (bs, 2H), 4.09 (m, 2H), 3.57 and 3.51 (m, 3H), 2.72 (m, 2H), 2.31 (m, 2H), 1.19 {m, 2H).
Optical Rotation: [a]z3 = -66° (c 1, I~feOH).
Cz3Hz6NzOsF2 (MW = 448); mass spe~~troscopy (MH+) 449.
Example 188 Synthesis of Methyl N [N (3,5-Difluorophenylacetyl)-Iralaninyl]-(S)-2-aminohe:r-4-enoate Step A - Synthesis of (S)-3-(Hex-4-enoyl)-4-(phenyhnethyl)-2-oxazolidinone To a mechanically stirred solution of S~.50 g (83.2 mmol, 1.10 equiv.) of 4-hexenoic acid (commericially available from Lancaster, Catalog #252-427-6) and 13.9 mL (10.1 g, 99.7 mmol, 1.33 eqiaiv.) of triethylamine in 150 mL of dry THF, cooled to -78°C under dry Nz, was added 10.71 mL (10.49 g, 87.0 mmol, 1.15 equiv.) of pivaloyl chloride (Aldrich). The mixture was warmed to 0°C for 60 min, and then recooled to -78°C. A solution of 13.4 g (75.6 mmol, 251.00 equiv) of (S)-(-)-(phenylmethyl)-2-ox~~zolidone (Aldrich) and 22 mg of triphenylmethane (indicator) in 150 mL of dry THF, stirred at -30°C to -45°C
under N2, was treated dropwise with n-but~yllithium ( -- 2.5 M in hexanes) (Aldrich) until an orange color persisted (--30 mL required). The resulting solution was cooled to -78°C and then add~rd, via rapid cannulation, to the above stirred mixture containing the mixed anhydride. The residual lithiated oxazolidone was rinsed in with two 10-mL portions of dry THF and the __ 288 --resulting mixture was stirred at -78°C for 1.5 h, and then at 0°C for 1 h. The mixture was partitioned between CHZC12 and pH 7 phosphate buffer. The CHzCIz phase was washed with saturated aqueous NaHC4j followed by half saturated aqueous NaCl, dried (MgS04), and evaporated in vacuo. The residual cream-colored solid (22.4 g) was chromatographed (Waters Prep 2000, 5.0 cm x 25 cm 10 ~c Kromasil KR60-lOSIL-5025 column) in two batches eluting with 85:15 hexanes/EtOAc. The chromatographed product was recrystallized from hexane to yield 14.34 g (first crop, 69 % ) of the title compound as fine white needles. 'H NMR (300 MHz, CDCI3) b 7.37-7.20 (m, 5H, -C6H5), 5.60-5.43(m, 2H, CH=CHCH3), 4.71-4.63(m, 1H, NCH(Ph) CHzO), 4.23-4.14(m, 2H, NCH(Ph)CHzO), 3.295(dd, J= I3.3, 3.3 Hz, 1H, CHHC6H5), 3.11-2.90 (m, 2H, CHzC=O), 2.758 (dd, J=13.3, 9.6 Hz, 1H, CHHC6H5), 2.42-2.34 (m, 2H, CH=CHCHZ), 1.67-1.65 {m, 2H, CH=CHCH ).
Step B -- Synthesis of (4S)-3-[(S)-2-Azidohex-4-enoyl]-4-(phenylmethyl)-2-oxazolidinone A solution of 5.47g (20.0 mmol, 1.00 equiv) of the product from Step A
above in 60 mL of dry THF, stirred at -78°C under dry Nz, was added via rapid cannulation to a stirred, cooled (-78°C) solution of 43.6 mL
(22.0 mmol, 1.10 equiv) of potassium hexamethyldisilazide (0.505 M in toluene) (Aldrich) and 60 mL of dry THF. The residual imide solution was rinsed in with two 5-mL portions of dry THF. The resulting solution was stirred at -78°C for min. To the above solution of the K-enolate, stirred at -78°C under dry N2, was added a cooled (-78°C) solution of 7.43 g (24.0 mmol, I.2 equiv) of trisyl azide (prepared as described in R. E. Harmon et al. , J. Org. Chem. , 1973, 38, 11-16) in 60 mL of dry THF via rapid cannulation. (Note the reaction e~rothermed to -68°C during the addition). After 1-2 min, 4.24 mL
(4.45g, 74.1 mmol, 3.7 equiv) of glacial acetic acid was added in one portion. The resulting mixture was stirred at -78°C for 15 min, and was then allowed to warm to 25°C on stirnng overnight. The mixture was partitioned between CH2Clz and pH 7 phosphate buffer. The aqueous phase was extracted with CHZC12 (3X) and the organic extracts were combined, washed with dilute aqueous NaHC03, dried (MgS04), and evaporated in vacuo. The residual oil (9.55 g) was chromatographed (Waters Prep 2000, S.Ocm x 25 cm 10 ~c Kromasil KR60-10SIL-5025 column) eluting with a 3 L linear gradient from 30:70 to 80:20 CHZC12/hexanes. After rechromatographing the mixed fractions (2X), a total of 5.27 g (84% yield) of the title compound (faster eluting, major diastereomer) was isolated as a colorless, viscous oil. 1H NMR (300 MHz;
CDC13) b 7.38-7.20 (m, SH, -C6H5), 5.73-_'i.62 (m, 1H, CH=CHCH3), 5.52-5.41 (m, 1H, CH=CHCH3), S.OlI (dd, J==8.3, 5.5 Hz, IH, CH(N3) C=0), 4.71-4.63 (m, 1H, NCH(Ph)CH20), 4.236 (d, J=5.1 Hz, 2H, NCH(Ph)CH20), 3.338 (dd, J= 13.4, 3.3 Hz, 1H, CHHC61~~5), 2.827 (dd, J= 13.4, 9.5 Hz, 1H, CHHC6H5), 2.64-2.46 (m, 2H, CHZCH=CHCH3), 1.694 (dd, J=6.4, 1.1 Hz, 3H, CH=CHCH ).
Step C -- Synthesis of (S)-2-Azidohex-4-enoic Acid A solution of 5.00 g (15.91 mmol) of ~:he product from Step B above in 240 mL of THF and 80 mL of deionized water, stirred at 0°C under N2, was treated with 762 mg (31.8 mmol, 2.00 equiv) of LiOH (anhydrous powder).
After stirring at 0°C for 30 min, 100 mL a~f 0.5 N aqueous NaHC03 was added and the THF was removed by rotary evaporation in vacuo. The residue was diluted to 400-500 mL with HZO and extracaed with 5 portions of CHZCI2. The aqueous phase was acidified to pH 1-2 by the cautious addition of 5 N HCI, and then was extracted with 4 portions of FaOAc. The EtOAc extracts were combined, dried (Na2S04), and evaporated in vacuo to yield 2.45 g (99%) of the title compound as a light amber oil. 'H NMR (300 MHz, CDC13) b 11.38 (br s, 1H, COZH), 5.73-5.62 (m, 1H, CH3(~H=CH), 5.48-5.38 (m, 1H,CH=CHCHZ), 3.928 (dd, J= 7.8, 5.4 Hz, IH, CH(N3)COZH), 2.66 2.47(m, 2H, CH=CHCHZ), 1.703 (dd, J=X6.4, 1.1 Hz, 3H, CH3.
Step D -- Methyl N [N tent-Butox;ycarbonyl-Iralaninyl]-(S)-2-aminohex-4-enoate A solution of 504.7 mg (3.25 mmol) o:F the product from Step C above in diethyl ether, cooled to 0°C, was treated dropwise with ethereal diazomethane (prepared as described in L. F. Fieser et al., "Reagents for Organic Synthesis", Vol. 1, p. 191, Wiley & Sons (1967)) until a yellow color persisted. 1fie excess diazomethane was removed by entraining with NZ, and the ether was evaporated under a stream of N2. The residual oil was dissolved in 10 mL of anhydrous methanol. The solution was cooled to 0°C under dry NZ and 1.24 g (6.54 mmol, 2.0 equiv) of anhydrous SnCl2 was added. The mixture was stirred at <_25°C for 4 h, and the solvent was evaporated in vacuo to afford a solid tin-amine complex.
A solution of 1.23 g (6.50 mmol, 2.00 equiv.) of N Boc-L-alanine (Sigma) and 0.715 mL (0.658 g, 6.50 mmol, 2.0 equiv.) of 4-methylmorpholine (redistilled, 99.5 % ) (Aldrich) in 15 mL of anhydrous THF, cooled to -15 to -20°C under dry NZ, was treated dropwise with 0.861 mL (0.907 g, 6.50 mmol, 2.00 equiv.) of iso-butyl chloroformate (Aldrich). After stirring at -15 to -20°C for 20 min, the resulting mixture containing the mixed anhydride was added via cannulation to the solid tin-amine complex (vide supra). The residual mixed anhydride was rinsed in with 7 mL of THF and 1.1 g (13.1 mmol, 4.0 equiv.) of NaHC03 powder and 5 mL of Hz0 was added. The mixture was stirred at 0°C for 5 h. An additional 1.1 g (13.1 mmol, 4.0 equiv.) of NaHC03 powder and 5 mL of H20 was added and the mixture was stirred at 20°C for 1.5 h. The mixture was filtered to remove the gelatinous precipitate, and the filter cake was washed with several portions of EtOAc. The filtrate was washed with saturated aqueous NaHC03 (the aqueous phase was back-extracted with 3 portion of EtOAc), followed by pH 4-5 phosphate buffer (the aqueous phase was back-extracted with 3 portions of EtOAc). The organic - _ 25 phase was dried (Na2S04) and evaporated in vacuo. The residual straw colored oil (1.21 g) was chromatographed (Waters Prep 2000, 5.0 cm x 25 cm 10 ~
Kromasil KR60-IOSIL-5025 column) eluting with a 3-L linear gradient from 80:20 to 40:60 hexane/EtOAc to yield 0.9088 g (89 % ) of the title compound as a white solid. 'Tlc Rf 0.25 [silica, hexane/EtOAc 6:4)]; 'H NMR (300 MHz, CDCl3) b 6.61 (d, J= 7.6 Hz, 1H, NH), 5.60-5.48(m, 1H, CH=CHCH3), WO 98/22494 PCT/US9'7/20804 5.33-5.23 (m, 1H, CH=CHCH3), 5.08 (d, J=7.3 Hz, 1H, NH), 4.591 (dt, Jd = 7.8 Hz, J, = 5.7 Hz, 1H, HNC~- (CH2CH=CHCH3)), 4.19 (br m, 1H, HNCH(CH3), 3.74(s, 3H, OCH3), 2.56-2.39 (sym m, 2H, CH CH=CHCH3), 1,658 (dd, J= 6.4, 1.2 Hz, 3H, CHzCH=CHCH ), 1.454 (s, 9H, OC(CH3)3o 1.358 (d, J=7.1 Hz, 3H, HNCH(CH3)).
Step E - Synthesis of Methyt N ~:N (3,5-Difluorophenylacetyl)-I
alaninyl]-(S)-2-aminohex-4-enoate A solution of 0.811 g (2.58 mmol) of the product from Step D above in 5 mL of CHZC12 was cooled to 0°C under dry N, and S~.mL of trifluoroacetic acid was introduced by syringe at <_4°C. The solution was stirred at 0°C for 40 min. Toluene (15 mL) was added and the mixture was evaporated in vacuo on the rotary evaporator. The addition of toluene and solvent evaporation was repeated. The residue was dissolved in 20 mL of CHZCIz and the solution was cooled to 0°C under dry N2. To this was added 1.35 mL (1.00 g, 7.74 mmol, 3.0 equiv) of ethyldiisopropylamine (Aldrich), followed by the dropwise addition at <_ 6°C of 0.728 mL (0.938 g, ~~.16 mmol, 2.0 equiv) of 3,5-difluorophenylacetyl chloride (prepared from 3,5-difluorophenylacetic acid (Aldrich) using General Procedure H'). The resulting solution was stirred at 0°C for 2 h. Excess saturated aqueous NaHC03 was added and the two phase mixture was stirred in an ice bath for 30 min. The mixture was diluted with CHZC12 and washed successively with aqueous NaHC03/Na2C03 (pH IO), 1 N
aqueous NaHS04, and saturated aqueous Na.CI. The CHzCl2 solution was dried (NazS04) and evaporated in vacuo to afford 1.17 g of a yellow solid. This was recrystallized from EtOAc to yield 602 mg (63 % ) of the title compound as a fluffy white solid. This material was found by 300 mHz 'H NMR analysis to consist of a 92:8 mixture of E and Z isomers, respectively.
NMR data was as follows:
'H-nmr (300 MHz, CDC13): b = 6.85-fi.69 (m, 3H), 6.335 (br d, J=7.8 Hz, IH), 6.289 (br d, J=7.0 Hz, 1H), 5.5E~-5.47 (m, 1H), 5.28-5.18 (m, 1H), 4.58-4.45 (m, 2H) 3.745 (s, 3H), 3.528 (s, 2H), 2.457 (apparent t, J=6.4 Hz, 2H), 1.650 (dd, J=6.5, l.3Hz, 3H), 1.58 (dm, J=6.5 Hz, 0.08H), 1.375 (d, J=7.0 Hz, 3H).
IR (CHC13) 3421, 1742, 1667, 1626, 1597, 1503, and 1120 cm-' Anal. Calcd for C,eHnF2N20,: C, 58.69; H, 6.02; N, 7.60. Found: C, 58.83, H, 5.89; N, 7.67.
C18H22F2N2~5 (~ = 368); mass spectroscopy (MH+) 368.
--- Example 189 Synthesis of N [N (Cyclopropylacetyl)-Iralaninyl]-IO I~phenylglycine tent-Butyl Fster Following General Procedure U and using cyclopropylacetic acid (Lancaster) and N (L-alaninyl)-L-phenylglycine ten-butyl ester (General Procedure U of Z-alanine (Bachem) to phenylglycine-t-butyl (Novabio) and then General Procedure O), the title compound was prepared as a solid (mp =
105-107°C). The reaction was monitored by tlc (Rf = 0.33 in 1:1 EtOAc/hexane, 0.13 in 5 % MeOH/DCM).
NMR data was as follows:
'H-nmr (CDCl3): b = 0.15 (m, 2H), 0.56 (m, 2H), 0.91 (m, 1H), 1.38 (m, 12H), 2.09 (d, J = 7.1 Hz, 2H), 4.62 (m, 1H), 5.39 (d, J = 7.2 Hz, 1H), 6.52 (d, J = 7.2 Hz, 1H), 7.31 (m, 6H).
'3C-nmr (CDCl3): 8 = 4.53, 4.55, 6.9, 18.4, 27.8, 4I.2, 48.4, 57.1, 82.6, 127.0, 128.2, 128.7, 136.8, 169.4, 171.4, 172.3.
CZOHz8N2O4 (MW = 360.46); mass spectroscopy (MH+) 361.
Example 190 Synthesis of N ten-Butyl-N'-[N (3,5-Difluorophenylacetyl)-I~alaninyl]
(S)-2-amino-2-(4-phenylphenyl)acetamide Following General Procedure AB and using 3,5-difluorophenylacetyl)-L
alanine (from Example B2 above) and 4-biphenylcarboxaldehyde (Aldrich) , the fi title compound was prepared as a solid (mp = 266-267°C). The product was purified by recrystallizadon from EtOAc and/or EtOAc/hexanes.
NMR data was as follows:
1H-nmr (DMSO-db): b = 8.42 (d, 1~1, J=7 Hz) , 8.31 (d, 1H, J=7 Hz), 7.91 (s, 1H), 7.6-7.56 (m, 4H) , 7.42-7.:59 (m, SH), 7.2-7.69 (m, 3H), 5.42 - (d, 1H, 1=8 Hz), 4.42 (pentet, 1H, J=8 Hz), 3.5 (s, 1H) , 1.2 (doublet on top of a singlet, 12H).
CzgH3~N3O3F2 (MW = 508); mass sp~rctroscopy (MH+) 508.4.
Example 191 Synthesis of N [N (3,5-Difluorophenylacetyl)-(S)-2-aminobutanoyl]
L-phenylglycine t~ert-Butyl Ester Following General Procedure D and using 3,5-difluorophenylacetic acid (Aldrich) and N [(S)-2-aminobutanoyl]-L-phenylglycine ten-butyl ester (from Example D 13 above), the title compound 'was prepared as a solid (mp = 138.7-140.0°C). The reaction was monitored by tlc (Rf = 0.24 in 2/1 hexanes:EtOAc) and the product was purified by flash chromromatography and HPLC.
NMR data was as follows:
'H-nmr (DMSO-db, 250 MHz): 8 = 8.66 (d, J=6:75 Hz, 1H), 8.30 (d, J=8.26 Hz, 1H), 7.37 (bs, SH), 7.11-6.9Ei (m, 3H), 5.23 (d, J=7.00 Hz, 1H), 4.36 (td, J=7.88, 5.50 Hz, 1H), 3.53 (AE'~q, JAH= 14.05 Hz, nvAA=7.75 Hz, 2H), 1.85-1.48 (m, 2H), 1.34 (s, 9H~; 0:88 (t, J=7.38 Hz, 3H).
Optical Rotation: [a]ZO = 21.8° (c 1.0, MeOH).
CzaHzaNzOaF2 (MW = 446.50); mass spectroscopy (MH+, minus COZ-tBu) 345.2.
Example 192 Synthes~; of N [N (3,5-Difluorophen~rlacetyl)-L-valinyl]-L-phenylglycine test-Butyl Fster Following General Procedure D and using 3,5-difluorophenylacetic acid (Aldrich) and N (L-valinyl)-L-phenylglycine ten-butyl ester (from Example D14 above), the title compound was prepared as a solid (mp = 170.5-171.8°C).
The reaction was monitored by tlc (Rf = 0.39 in 2:1 hexanes/EtOAc) and the product was purified by flash chromromatography and HPLC.
NMR data was as follows:
'H-nmr {DMSO-db, 250 MHz): 8 = 8.71 (d, J=6.75 Hz, 1H), 8.22 (d, J=9.26 Hz, 1H), 7.37 (bs, 5H), 7.11-6.96 (m, 3H), 5.23 (d, J=6.50 Hz, 1H), 4.36 (dd, J=8.88, 6.38 Hz, 1H), 3.55 (ABq, JAB= 13.88 Hz, nv"B= 21.56 Hz, 2H), 2.10-1.95 (m, 1H), 1.34 (s, 9H), 0.88 (d, J=6.75 Hz, 3H), 0.86 (d, J=6.50 Hz, 3H).
Optical Rotation: [a]zo = 20.8° (c 1.0, MeOH).
Cz5H3oN204F2 (MW = 460.53); mass spectroscopy (MH+, minus COZ-tBu) 359.2.
Example 193 Synthesis of N [N-(3,5-Difluorophenylacetyl)-I~methioninylJ
Irphenylglycine Methyl Ester Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (L-methioninyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-L-methionine (Sigma) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure E, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 189.3°C). The reaction was monitored by tlc (Rf = 0.53 in 5:95 MeOH/CHZC12) and the product was purified by recrystallization from ethyl acetate/hexanes.
NMR data was as follows:
'H-nmr (DMSO-db): b = 8.85 (d, J=6.7 Hz, 1H), 8.41 (d, J=8.1 Hz, 1H), 7.38 (m, 5H), 7.09 (m, 1H), 6.98 (m, 2H), 5.38 (d, J=6.6 Hz, 1H), 4.47 (m, J=8.2 Hz, 1H), 3.62 (s, 3H), 3.51 (d, 2H), 2.46 (t, 2H), 2.04 (s, 3H), 1.89 (m, 2H).

'3C-nmr (DMSO-db): 8 = 172.036, :171.729, 169.883, 164.658, 164.479, 161.406, 161.227, 141.689, 141.557, 141.427, 136.524, 129.512, 129.213, 128.717, 126.274, 113.187, 113.085, 112.961, 112.862, 103.023, 102.684, 102.340, 93.065, 57.205, 53.063, 42.23:1, 33.075, 30.221, 15.465.
CzzHz4NzOaFxS (MW = 450.51); mass spectroscopy (MH+) 450.
Example 194 Synthesis of N [N (3,5-Difluorophe:nylacetyl)-I,-valinyl]
L-phenylglycine Methyl Ester Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (L-valinyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-L-valine (Sigma) .and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure E, followed by removal of the BOC-group using General Procedure P), I:he title compound was prepared as a solid (mp = 226.5°C). The reaction was monitored by tlc (Rf = 0.49 in 5:95 MeOH/CHzCIz) and the product was purified by flash chromotography using MeOH/CH2Clx as the eluent.
NMR data was as follows:
'H-nmr (DMSO-db): 8 = 8.84 (d, J=6.2 Hz, 1H), 8.23 (d, J=8.8 Hz, IH), 7.38 (m, 5H), 7.07 (m, 1H), 6.98 (nn, 2H), 5.37 (d, J=6.5 Hz, 1H), 4.34 (m, J=8.9 Hz, 1H), 3.55 (m, 5H), 2.01 (m, 1H), 0.87 (m, 6H).
'3C-nmr (DMSO-db): 8 = 171.988, 1 '1.690, 169.861, 164.633, 164.456, 161.382, 161.204, 141.987, 141.859, 141.727, 136.553, 129.470, 129.192, 128.791, 113.128, 113.026, 112.902, 112.803, 102.961, 102.619, 102.281, 57.914, 57.262, 52.935, 42.274, 31.728, 19.845, 18.815.
CzzHz4NzOaFz (MW = 418.44); mass spectroscopy (MH+) 418.1.
Example 195 Synthesis of N [N (3,5-Difluorophenylac~etyl)-2-aminobutanoyl]-Irphenylglycine rviethyl Ester Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (2-aminobutanoyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-L-aminobutyric acid (Sigma) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure E, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 215.3°C). The reaction was monitored by tlc (Rf =
0.46 in 5:95 MeOH/CH2C12) and the product was purified by recrystallization from ethyl acetate/hexanes.
NMR data was as follows:
'H-nrnr (DMSO-db): 8 = 8.83 (d, J=6.8 Hz, 1H), 8.32 (d, J=8.1 Hz, 1H), 7.38 (m, 5H), 7.08 (m, IH), 6.98 (m, 2H), 5.38 (d, J=6.8 Hz, 1H), 4.35 (m, J=7.9 Hz, 1H), 3.61 (s, 3H), 3.52 (d, 2H), 1.64 (m, 2H), 0.88 (t, 3H).
'3C-nmr (DMSO-db): b = 171.684, 170.934, 168.984, 164.193, 163.980, 160.295, 160.083, 141.059, 140.902, 140.743, 135.857, 128.689, 128.372, 127.892, 112.387, 112.257, 112.131, 111.999, 102.254, 101.845, 101.438, 56.351, 53.441, 52.212, 41.436, 25.675, 10.067.
CZ,HZ,N204F2 (MW = 404.42); mass spectroscopy (MH+) 405.1.
Example 196 Synthesis of N [N (3,5-Difluorophenylacetyl)-L.leucinyl]-I~phenylglycine Methyl Ester Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (L-leucinyl)-L-phenyl$lycine methyl ester hydrochloride (prepared from N BOC-L-leucine (Aldrich) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure E, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 178.4°C). The reaction was monitored by tlc (Rf = 0.51 in 5:95 MeOH/CHzCIz) and the product was purified by flash chromotograph using MeOH/CH,C12 as the eluent.
NMR data was as follows:

'H-nmr (DMSO-db): b = 8.85 (d, J=6.8 Hz, 1H), 8.33 (d, J=8.3 Hz, IH), 7.37 (m, 5H), 7.08 (m, 1H), 6.95 (rn, 2H), 5.37 (d, J=6.8 Hz, 1H), 4.46 (m, J=8.3 Hz, 1H), 3.60 (s, 3H), 3.49 (dl, 2H), 1.55 (m, 3H), 0.89 (d, 3H), 0.82 (d, 3H).
'3C-nmr (DMSO-db): b = 172.225, 1 x'0.899, 168.888, 164.197, 163.984, 160.298, 160.086, 141.029, 140.887, 140.723, 135.875, 128.657, 128.348, 127.944, 112.340, 112.207, 112.084, 111.,951, 102.251, 101.842, 101.435, 56.343, 52.214, 50.697, 41.510, 40.982, 24.449, 23.056, 21.575.
C23H26N2~4F2 ~ = 432.47); mass spectroscopy (MH+) 432.1.
Example 197 Synthesis of N [N (3,5-Difluorophenylacetyl)-L-phenylalaninylJ
L-phenylglycine r~tethyl Ester Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (L-phenylalaninyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-L-phenylalanine (A:ldrich) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure E, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 188.3°C). The reaction vvas monitored by tlc (Rf =
0.59 in 5:95 MeOH/CHzCIz) and the product was purified by flash chromotography using MeOH/CHzCl2 as the eluent.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 8.99 (d, J=6.9 Hz, 1H), 8.44 (d, J=8.6 Hz, 1H), 7.4 (m, 5H), 7.21 (m, 5H), 7.03 (m, lH), 6.77 (m, 2H), 5.42 (d, J=6.9 Hz, 1H), 4.70 (m, J=8.5 Hz, 1H), 3.63 (s, 3H), 3.40 (m, 2H), 3.08 (m, 1H), 2.76 (m, 1H).
'3C-nmr (DMSO-db): 8 = 171.428, 170.896, 168.853, 164.127, 163.915, 160.222, 160.010, 140.756, 140.601, 140.438, 137.662, 135.918, 130.638, 129.247, 128.737, 128.415, 127.908, 126.281, 112.147, 112.025; 111.892, 102.189, 101.782, 101.373, 56.411, 53.461, 52.306, 41.513, 37.796.
C26H2GN2~4F2 (MW = 466.49); mass spectroscopy (MH+) 466.

__ 298 --Example 198 Synthesis of N [N (3,5-Difluorophenylacetyl)glycinyl]
L-phenylglycine Methyl Fster Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (glycinyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-glycine (Aldrich) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure E, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 142.3°C). The reaction was monitored by tlc (Rf = 0.33 in 5:95 MeOH/CHZCl2) and the product was purified by recrystallization from diethyl ether/hexanes.
NMR data was as follows:
'H-nmr (DMSO-d6): b = 8.82 (d, J=7.2 Hz, 1H), 8.39 (t, 1H), 7.37 (m, 5H), 7.05 (m, 3H), 5.44 (d, 7.1 Hz, 1H), 3.83 (d, 2H), 3.62 (s, 3H), 3.53 (s, 2H).
'3C-nmr (DMSO-db): b = 170.956, 169.427, 168.788, 164.226, 164.013, 160.329, 160.115, 140.817, 140.663, 140.499, 136.222, 128.728, 128.338, 127.687, 112.494, 112.360, 112.238, 112.104, 102.310, 101.900, 101.492, 56.200, 52.321, 41.731, 41.464.
C,9H,gN204F2 (MW = 376.36); mass spectroscopy (MH+) 376Ø
Example 199 Synthesis of N [N (3,5-Difluorophenylacetyl)-I~-phenylglycinyl]-I~phenylglycine Methyl Ester Following General Procedure E and using 3,5-difluorophenylacetic acid (Aldrich) and N (L-phenylglycinyl)-L-phenylglycine methyl ester hydrochloride (prepared from N BOC-L-phenylglycine (Novabiochem) and L-phenylglycine methyl ester hydrochloride (Aldrich) using General Procedure AH, followed by removal of the BOC-group using General Procedure P), the title compound was prepared as a solid (mp = 222.8°C). The reaction was monitored by tlc (Rf =

0.61 in 5:95 MeOH/CHZCIz) and the product was purified by recrystallization from ethyl acetate.
NMR data was as follows:
'H-nmr (DMSO-db): b = 9.22 (d, J=6.8 Hz, IH), 8.85 (d, J=8.2 Hz, 1H), 7.37 (m, lOH), 7.08 (m, 1H), 6.97 (d, 2H), 5.69 (d, J=8.2 Hz, 1H), 5.43 (d, J=6.8 Hz, 1H), 3.61 (d, 2H), 3.55 (s, 3H).
'3C-nmr (DMSO-db): 8 = 170.606, 169.727, 168.777, 164.194, 163.982, 160.296, 160.082, 140.920, 140.757, 140.603, 138.391, 135.900, 128.732, 128.425, 128.233, 127.871, 127.556, 127.222, 112.467, 112.340, 112.209, 112.082, 102.292, 101.884, 101.475, 56.431, 55.621, 52.203, 41.205.
CZSH2~N204F2 (MW = 452.46); mass spectroscopy (MH+) 452.2.
Example. 200 Synthesis of N-[N (Phenylacetyl)-~alaninyl]-I~alanine Methyl Ester Following General Procedure A and using N (phenylacetyl)-L-alanine (from Example Bl above) and L-alanine methyl ester hydrochloride (Aldrich), the title compound was prepared as a solid (mp = 140.5-142°C). The reaction was monitored by tlc (Rf = 0.17 in 50% EtOAc/hexanes).
NMR data was as follows:
'H-nmr (CDCl3): 8 = 1.3-1.4 (m, 6Hj, 3.55 (s, 2H), 3.75 (s, 3H), 4.4-4.6 (m, 2H), 6.1-6.3 (brd, 1H), 6.6-6.7 (brd, 1H), 7.2-7.4 (m, 5H).
'3C-nmr (CDCl3): 8 = 18.4, 19.0, 44.1, 48.6, 49.3, 53.0, 127.9, 129.5, 129.8, 135.1, 171.5, 172.4, 173.6.
CISH2~2~4 (~ = 292.34); mass spectroscopy (MH+) 293.
- 25 Example 201 Synthesis of N (N (Phenylacetyl)-L-alaninyl]-L-leucine Methyl Ester Following General Procedure A and using N (phenylacetyl)-L-alanine (from Example B 1 above) and L-leucine methyl eater hydrochloride (Aldrich), the title -_ 300 __ compound was prepared as a solid (mp = 102.5-105°C). The reaction was monitored by tic (Rf = 0.25 in 50% EtOAc/hexanes).
NMR data was as follows:
'H-nmr (CDC13): b = 0.8-0.95 (m, 6H), 1.3 (d, J=7 Hz, 3H), 1.4-1.6 (m, 3H), 3.58 (s, 2H), 3.75 (s, 3H), 4.4-4.6 (m, 2H), 6.2 (brd, 1H), 6.7 (brd, 1H), 7.2-7.4 (m, 5H).
'3C-nmr (CDC13): 8 = 18.7, 22.3, 23.4, 25.3, 41.5, 44.1, 49.2, 51.4, 52.8, 127.9, 129.5, 129.8, 135.0, 171.5, 172.6, 173.7.
C,aHz6N20a (~' = 334.42); mass spectroscopy (MH+) 335.
Example 202 Synthesis of N-[N-(Phenylacetyl)-I,-alaninyl)-Irisoleucine Methyl Ester Following General Procedure A and using N (phenylacetyl)-L-alanine (from Example B1 above) and L-isoleucine methyl ester hydrochloride (Sigma), the title compound was prepared. The reaction was monitored by tlc (Rf = 0.24 in 50% EtOAc/hexanes).
NMR data was as follows:
'H-nmr (CDCl3): b = 0.8-0.95 (m, 6H), 1.0-1.2 (m, 1H), 1.2-1.4 (m including 1.3 (d, J=7 Hz, 4H)), 1.8-1.9 (m, 1H), 3.58 (s, 2H), 3.75 (s, 3H), 4.4-4.6 (m, 2H), 6.2 (brd, 1H), 6.7 (brd, 1H), 7.2-7.4 (m, 5H).
'3C-nmr (CDCl3): 8 = 12.1, 16.0, 18.5, 25.6, 38.1, 44.1, 49.3, 52.7, 57.2, 127.9, 129.6, 129.8, 135.0, 171.5, 172.5, 172.6.
C,8Hz6N204 (MW = 334.42); mass spectroscopy (MH+) 335.
Example 203 ~ Synthesis of N-[N (Phenylacetyl)-I~-alaninyl]-Irproline Methyl Ester Following General Procedure A and using N (phenylacetyl)-L-alanine (from Example B 1 above) and L-proline methyl ester hydrochloride (Bachem), the DEMANDES OU BREVETS VOLUMINEUX
LA PRESENTE PARTIE DE CETTE DEIVIANDE OU CE BREVET
COMPREND PLUS D'UN TOME.
CECI EST lE TOME ~ Df:
NOTE: Pour tes tomes additionels, veuillez contacter to Bureau canadien des brevets JUMBO APPLlCATIONSIP,ATENTS

THAN ONE VOLUME
THIS 1S VOLUME ~ OF 2 NOTE: For additional volumes-please cantact'the Canadian Patent Ofifice

Claims (89)

WHAT IS CLAIMED IS:

1. A method for inhibiting, .beta.-amyloid peptide release and/or its synthesis in a cell which method comprises administering to such a cell an amount of a compound or a mixture of compounds effective in inhibiting the cellular release and/or synthesis of .beta.-amyloid peptide wherein said compounds are represented by formula I:
wherein R1 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkenyl, substituted alkynyl, aryl, heteroaryl and heterocyclic;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclic;
each R3 is independently selected from the group consisting of hydrogen and methyl and R3 together with R4 can be fused to form a cyclic structure of from 3 to 8 atoms which is optionally fused with an aryl or heteroaryl group;
each R4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, substituted alkyl, substituted alkenyl and substituted alkynyl;
each R5 is selected from hydrogen and methyl or together with R4 forms a cycloalkyl group of from 3 to 6 carbon atoms;
X is selected from the group consisting of -C(O)Y and -C(S)Y where Y
is selected from the group consisting of (a) alkyl or cycloalkyl, (b) substituted alkyl with the proviso that the substitution on said substituted alkyl do not include .alpha.-haloalkyl, .alpha.-diazoalkyl, .alpha.-OC(O)alkyl, or .alpha.-OC(O)aryl groups, (c) alkoxy or thioalkoxy, (d) substituted alkoxy or substituted thioalkoxy, (e) hydroxy, (f) aryl, (g) heteroaryl, (h) heterocyclic, (i) -NR'R" where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, where one of R' or R" is hydroxy or alkoxy, and where R' and R" are joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl, alkoxy or carboxylalkyl groups, (j) -NHSO2-R8 where R8 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic, (k) -NR9NR10R10 where R9 is hydrogen or alkyl, and each R10 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and (l) -ONR9C(O)O]2R10 where z is zero or one, R9 and R10 are as defined above;
X can also be -CR6R6Y' where each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, alkoxy, substituted alkoxy, thioalkoxy, substituted thioalkoxy, -OC(O)R7, -SSR7, -SSC(O)R7 where R7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic, X' is hydrogen, hydroxy, or fluoro;
X" is hydrogen, hydroxy or fluoro, or X' and X" together form an oxo group, Z is selected from the group consisting of a bond covalently linking R1 to -CX'X"-, oxygen and sulfur;
n is an integer equal to 1 or 2; and pharmaceutically acceptable salts thereof with the provisos that:
A. when R1 is phenyl or 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -GH(OH)CH3, R5 is hydrogen, X1 and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH;
B. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3 derived from D-threonine, R5 is hydrogen, X1 and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH or -C(O)OCH3;
C. when R1 is phenyl, R2 is methyl, R4 is benzyl, R5 is hydrogen, X is methoxycarbonyl, X' and X" are hydrogen, Z is a bond, and n is 1, then R3 is not methyl;
D. when R1 is iso-propyl, R2 is -CH2C(O)NH2, R3 is hydrogen, R4 is iso-butyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
E. when R1 is phenyl, R2 is methyl, R5 is hydrogen, X is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R3, the nitrogen atom attached to R3, and R4 do not form 1, 2, 3, 4-tetrahydroiso-quinolin-2-yl or pyrrolidin-2-yl;
F. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not 4-amino-n-butyl;
G. when R1 is 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH2 or -CH2OH;
H. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -CH2OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not benzyl or ethyl;

I. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is methyl, R4 is methyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~;
J. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~ or -CH2OH;
K. when R1 is N (2-pyrrolidinonyl), R2 is methyl, R3 is hydrogen, R4 is benzyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
L. when R1 is 3,5-difluorophenyl, R2 is methyl derived from D-alanine, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH-benzyl;
M. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CH2OH;
N. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is 4-phenylphenyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHC(CH3)3; and O. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHCH(CH3)~.

2. A method for preventing the onset of AD in a patient at risk for developing AD which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically inert carrier and an effective amount of a compound or a mixture of compounds of formula I:
wherein R1 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkenyl, substituted alkynyl, aryl, heteroaryl and heterocyclic;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclic;
each R3 is independently selected from the group consisting of hydrogen and methyl and R3 together with R4 can be fused to form a cyclic structure of from 3 to 8 atoms which is optionally fused with an aryl or heteroaryl group;
each R4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, substituted alkyl, substituted alkenyl and substituted alkynyl;
each R5 is selected from hydrogen and methyl or together with R4 forms a cycloalkyl group of from 3 to 6 carbon atoms;
X is selected from the group consisting of -C(O)Y and -C(S)Y where Y
is selected from the group consisting of (a) alkyl or cycloalkyl, (b) substituted alkyl with the proviso that the substitution on said substituted alkyl do not include .alpha.-haloalkyl, .alpha.-diazoalkyl, .alpha.-OC(O)alkyl, or a-OC(O)aryl groups, (c) alkoxy or thioalkoxy, (d) substituted alkaxy or substituted thioalkoxy, (e) hydroxy, (f) aryl, (g) heteroaryl, (h) heterocyclic, (i) -NR'R" where R' and R" are independently selected from hydrogen, alkyl, alkenyl, atkynyl, substituted alkyl, substituted alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, where one of R' or R" is hydroxy or alkoxy, and where R' and R" are joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl, alkoxy or carboxylalkyl groups, (j) -NHSO2-R8 where R8 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic, (k) -NR9NR10R10 where R9 is hydrogen or alkyl, and each R10 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and (1) -ONR9[C(O)O]2R10 where z is zero or one, R9 and R10 are as defined above;
X can also be -CR6R6Y' where each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, alkoxy, substituted alkoxy, thioalkoxy, substituted thioalkoxy, -OC(O)R7, -SSR7, -SSC(O)R7 where R7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic, X' is hydrogen, hydroxy, or fluoro;
X" is hydrogen, hydroxy or fluoro, or X' and X" together form an oxo group, Z is selected from the group consisting of a bond covalently linking R1 to -CX'X"-, oxygen and sulfur;
n is an integer equal to 1 or 2; and pharmaceutically acceptable salts thereof with the provisos that:
A. when R1 is phenyl or 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH;
B. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3 derived from D-threonine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH or -C(O)OCH3;

C. when R1 is phenyl, R2 is methyl, R4 is benzyl, R5 is hydrogen, X is methoxycarbonyl, X' and X" are hydrogen, Z is a bond, and n is 1, then R3 is not methyl;
D. when R1 is iso-propyl, R2 is -CH2C(O)NH2, R3 is hydrogen, R4 is iso-butyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
E. when R1 is phenyl, R2 is methyl, R5 is hydrogen, X is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R3, the nitrogen atom attached to R3, and R4 do not form 1,2,3,4-tetrahydroiso-quinolin-2-yl or pyrrolidin-2-yl;
F. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not 4-amino-n-butyl;
G. when R1 is 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH2 or -CH2OH;
H. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -CH2OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not benzyl or ethyl;
I. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is methyl, R4 is methyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~;
J. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~ or -CH2OH;
K. when R1 is N-(2-pyrrolidinonyl), R2 is methyl, R3 is hydrogen, R4 is benzyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
L. when R1 is 3,5-difluorophenyl, R2 is methyl derived from D-alanine, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH-benzyl;

M. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CH2OH;
N. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is 4-phenylphenyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is l, then X is not -C(O)NHC(CH3)3; and O. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHCH(CH3).PHI..

3. A method for treating a patient with AD in order to inhibit further deterioration in the condition of that patient which method comprises administering to said patient a pharmaceutical composition comprising a pharmaceutically inert carrier and an effective amount of a compound or a mixture of compounds of formula I:
wherein R1 is selected from the group consisting of alkyl, alkenyl, alkynyl, cyclaalkyl, cycloalkenyl, substituted alkyl, substituted alkenyl, substituted alkynyl, aryl, heteroaryl and heterocyclic;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclic;
each R3 is independently selected from the group consisting of hydrogen and methyl and R3 together with R4 can be fused to form a cyclic structure of from 3 to 8 atoms which is optionally fused with an aryl or heteroaryl group;

each R4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, substituted alkyl, substituted alkenyl and substituted alkynyl;
each R5 is selected from hydrogen and methyl or together with R4 forms a cycloalkyl group of from 3 to 6 carbon atoms;
X is selected from the group consisting of -C(O)Y and -C(S)Y where Y
is selected from the group consisting of (a) alkyl or cycloalkyl, (b) substituted alkyl with the proviso that the substitution on said substituted alkyl do not include a-haloalky, .alpha.-diazoalkyl, .alpha.-OC(O)alkyl, or .alpha.-OC(O)aryl groups, (c) alkoxy or thioalkoxy, (d) substituted alkoxy or substituted thioalkoxy, (e) hydroxy, (f) aryl, (g) heteroaryl, (h) heterocyclic, (i) -NR'R" where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, where one of R1 or R" is hydroxy or alkoxy, and where R' and R" are joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl, alkoxy or carboxylalkyl groups, (j) -NHSO2-R8 where R8 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic, (k) -NR9NR10R10 where R9 is hydrol;en or alkyl, and each R10 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and (I) -ONR9[C(O)O]2R10 where z is zero or one, R9 and R10 are as defined above;

X can also be -CR6R6Y' where each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, alkoxy, substituted alkoxy, thioalkoxy, substituted thioalkoxy, -OC(O)R7, -SSR7, -SSC(O)R7 where R7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic, X' is hydrogen, hydroxy, or fluoro;
X" is hydrogen, hydroxy or fluoro, or X' and X" together form an oxo group, Z is selected from the group consisting of a bond covalently linking R1 to -CX'X"-, oxygen and sulfur;
n is an integer equal to 1 or 2; and pharmaceutically acceptable salts thereof with the provisos that:
A. when R1 is phenyl or 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH;
B. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3 derived from D-threonine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH or -C(O)OCH3;
C. when R1 is phenyl, R2 is methyl, R4 is benzyl, R5 is hydrogen, X is methoxycarbonyl, X' and X" are hydrogen, Z is a bond, and n is 1, then R3 is not methyl;
D. when R1 is iso-propyl, R2 is -CH2C(O)NH2, R3 is hydrogen, R4 is iso-butyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
E. when R1 is phenyl, R2 is methyl, R5 is hydrogen, X is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R3, the nitrogen atom attached to R3, and R4 do not form 1,2,3,4-tetrahydroiso-quinolin-2-yl or pyrrolidin-2-yl;

F. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not 4-amino-n-butyl;
G. when R1 is 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH2 or -CH2OH;
H. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -CH2OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not benzyl or ethyl;
I. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is methyl, R4 is methyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~;
J. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~ or -CH2OH;
K. when R1 is N (2-pyrrolidinonyl), R2 is methyl, R3 is hydrogen, R4 is benzyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
L. when R1 is 3,5-difluorophenyl, R2 is methyl derived from D-alanine, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH-benzyl;
M. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CH2OH;
N. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is 4-phenylphenyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHC(CH3)3; and O. when R1 is 3,5-difluorophenyl,R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHCH(CH3)~.

4. The method according to Claim 1, 2 or 3 wherein R1 is an unsubstituted aryl group and Z is a bond covalently linking R1 to -CX'X"-.

5. The method according to Claim 4 wherein the unsubstituted R1 aryl group is selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl.

6. The method according to Claim 1, 2 or 3 wherein R1 is a substituted aryl group and Z is a bond covalently linking R1 to -CX'X"-.

7. The method according to Claim 6 wherein said substituted aryl group is a mono-substituted, di-substituted or tri-substituted phenyl group.

8. The method according to Claim 7 wherein the substituted phenyl groups are selected from the group consisting of 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-nitrophenyl, 4-methylphenyl, 3-methoxy-phenyl, 3-nitrophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-bromophenyl, 3-thiomethoxyphenyl, 3-methylphenyl, 3-trifluoromethylphenyl, 2-hydroxy-phenyl, 2-methylphenyl, 2-fluorophenyl, 2-chlorophenyl, 3,4-difluorophenyl, 2,3,4,5,6-pentafluorophenyl, 3,4-dibromophenyl, 3,4-dichlorophenyl, 3,4-methylene-dioxyphenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 2,4-dichlorophenyl, and 2,5-difluorophenyl.

9. The method according to Claim l, 2 or 3 wherein R1 is an alkaryl group and Z is a bond covalently linking R1 to -CX'X"-.

10. The method according to Claim 9 wherein the R1 alkaryl group is selected from the group consisting of benzyl, 2-phenylethyl, and 3-phenyl-n-propyl.

11. The method according to Claim 1, 2 or 3 wherein R1 is selected from the group consisting of alkyl, alkenyl, cycloalkyl and cycloalkenyl groups and Z is a bond covalently linking R1 to -CX'X"-.

12. The method according to Claim 11 wherein R1 is alkyl.

13. The method according to Claim 11 wherein R1 is cycloalkyl.

14. The method according to Claim 11 wherein R1 is alkenyl.

15. The method according to Clairn 11 wherein R1 is cycloalkenyl.

16. The method according to Clairn 11 wherein the R1 alkyl, cycloalkyl, alkenyl and cycloalkenyl groups are selected from the group consisting of iso-propyl, n-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, -CH2CH=CH2, -CH2CH=CH(CH2)4CH3, nyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclohex-1-enyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclohexyl, -CH2-cyclopentyl, -CH2CH2-cyclopropyl, -CH2CH2-cyclobutyl, -CH2CH2-cyclohexyl, -CH2CH2-cyclopentyl, aminomethyl, and N-tert-butoxycarbonylaminomethyl.

17. The method according to Claim 1, 2 or 3 wherein R1 is selected from the group consisting of heteroaryl and substituted heteroaryl groups and Z
is a bond covalently linking R1 to -CX'X"-.

18. The method according to Claim 17 wherein the R1 heteroaryl and substituted heteroaryl groups are selected from the group consisting of pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, fluoropyridyls (including 5-fluoropyrid-3-yl), chloropyridyls (including 5-chloropyrid-3-yl), thien-2-yl, thien-3-yl, benzothiazol-4-yl, 2-phenylbenzoxazol-5-yl, furan-2-yl, benzofuran-2-yl, thionaphthen-2-yl, 2-chlorothiophen-5-yl, 3-methylisoxazol-5-yl, 2-(thiophenyl)thiophen-5-yl, 6-methoxythionaphthen-2-yl, 3-phenyl-1,2,4-thiooxadiazol-5-yl and 2-phenyloxazol-4-yl.

19. The method according to Claim 1, 2 or 3 wherein R2 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic.

20. The method according to Claim 9 wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, phenyl, 4-fluorophenyl, 3,5-difluoro-phenyl, 4-methoxyphenyl, benzyl, cyclopropyl, cyclohexyl, cyclopentyl, cycloheptyl, thien-2-yl, thien-3-yl, -CH2CH2SCH3, -CH2OCH2~, -CH(CH3)OCH2~, -CH(OH)CH3 and -CH2OH.

21. The method according to Claim 1, 2 or 3 wherein X' and X" are hydrogen and Z is a bond covalently linking R1 to -CX'X"-

22. The method according to Claim 2 i wherein R3 is selected from the group consisting of hydrogen, methyl or together with R4 and the nitrogen to which R3 is attached forms pyrrolidin-2-yl, 2,3-dihydroindol-2-yl, piperidin-2-yl, 4-hydroxy-pyrrolidin-2-yl and 1,2,3,4-tetrahydroisoquinolin-3-yl.

23. The method according to Claim l, 2 or 3 wherein R4 substituents are selected from the group consisting of hydrogen, methyl, ethyl, iso-propyl, n-propyl, n-butyl, sec-butyl, iso-butyl, cyclopentyl, cyclohexyl, allyl, iso-but-2-enyl, 3-methylpentyl, -CH2-cyclopropyl, -CH2-cyclohexyl, -CH2-indol-3-yl, phenyl, p-(phenyl)phenyl, m-(phenyl)phenyl o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, p-bromophenyl, m-methoxyphenyl, p-methoxyphenyl, phenethyl, benzyl, m-hydroxybenzyl, p-hydroxybenzyl, p-nitrobenzyl, m-trifluoromethylphenyl, p-(CH3)2NCH2CH2CH2O-benzyl, p-(CH3)3COC(O)CH2O-benzyl, p-phenylphenyl, 3,5-difluorophenyl, p-(HOOCCH2O)-benzyl, 2-aminopyrid-6-yl , 4-(N-morpholino-CH2CH2O)-benzyl, -CH2CH2C(O)NH2, -CH2-imidazol-4-yl, -CH2-(3-tetrahydrofuranyl), -CH2-thien-2-yl, -CH2-thiazol-4-yl, -CH2(1-methyl)cyclopropyl, -CH2-thien-3-yl, thien-3-yl, thien-2-yl, -CH2-C(O)O-t-butyl, -CH2-C(CH3)3, -CH2CH(CH2CH3)2, 2-methylcyclopentyl, -cyclohex-2-enyl, -CH[CH(CH3)2]COOCH3, -(CH2)2SCH3, -CH2CH2N(CH3)2, -CH2C(CH3)=CH2, -CH2CH=CHCH3 (cis and trans), -CH2OH, -CH(OH)CH3, -CH(O-t-butyl)CH3, -CH2OCH3, -(CH2)4NH-Boc, -(CH2)4NH2, -(CH2)4N(CH3)2, -CH2-pyridyl, pyridyl, -CH2-naphthyl, -CH2-(N-morpholino), p-(N-morpholino-CH2CH2O)-benzyl, benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, 5-chlorobenzo[b]thiophen-2-yl, 4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, tetrazol-5-yl, 5-chlorobenzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, 6-methoxynaphth-2-yl, -CH2-N-phthalimidyl, 2-methylthiazol-4-yl, and thieno[2,3-b]thiophen-2-yl, 5-bromothien-2-yl, 4-bromothien-2-yl, 5-chlorothien-2-yl, 3-phenoxyphenyl, 2-phenoxyphenyl, 4-ethylphenyl, 2-benzylphenyl, (4-ethylphenyl)phenyl, 4-tert-butylphenyl, 4-n-butylphenyl, o-(4-chlorophenoxy)phenyl, furan-2-yl, and 4-phenylacetyienylphenyl.

24. The method according to Claim 1, 2 or 3 wherein Z is a covalent bond linking R1 to -CX'X"- and R4 and R5 are fused to form a cycloalkyl group selected from the group consisting of cyclopropyl and cyclobutyl.

25. The method according to Claims 1, 2 or 3 wherein Z is a covalent bond linking R1 to -CX'X"-, X is -C(O)Y and Y is selected from the group consisting of hydroxy, alkoxy or substituted alkoxy.

26. The method according to Claim 25 wherein Y is alkoxy or substituted alkoxy selected from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, neo-gentoxy, benzyloxy, 2-phenylethoxy, 3-phenyl-n-propoxy, 3-iodo-n-propoxy, 4-bromo-n-butoxy, -ONHC(O)OC(CH3)3, -ONHC(CH3)3 and hydroxy.

27. The method according to Claims 1, 2 or 3 wherein Z is a covalent bond linking R1 to -CX'X"-, X is -C(O)Y and Y is -NR'R".

28. The method according to Claim 27 wherein Y is selected from the group consisting of amino (-NH2), -NH(iso-butyl), -NH(sec-butyl), N-methylamino, N,N-dimethyiamino, N-benzylamino, N-morpholino, azetidino, N-thiomorpholino, N-piperidinyl, N-hexamethyleneimino, N-heptamethylene-imino, N-pyrrolidinyl, -NH-methallyl, -NHCH2-(furan-2-yl), -NHCH2-cyclopropyl, -NH(tert-butyl), -NH(p-methylphenyl), -NHOCH3, -NHCH2(p-fluorophenyl), -NHCH2CH2OCH3, -NH-cyclopentyl, -NH-cyclohexyl, -NHCH2CH2N(CH3)2, -NHCH2C(CH3)3, -NHCH2-(pyrid-2-yl), -NHCH2-(pyrid-3-yl), -NHCH2-(pyrid-4-yl), N-thiazolindinyl, -N(CH2CH2CH3)2, -N[CH2CH(CH3)2]2, -NHOH, -NH(p-NO2-~), -NHCH2(p-NO2-~), -NHCH2(m-NO2-~), -N(CH3)OCH3, -N(CH3)CH2-~, -NHCH2-(3,5-di-fluorophenyl), -NHCH2CH2F, -NHCH2(p-CH3O-~), -NHCH2(m-CH3O-~), -NHCH2(p-CF3-~), -N(CH3)CH2CH2OCH3, -NHCH,CH2~, -NHCH(CH3)~, -NHCH2 (p-F-~), -N(CH3)CH2CH2N(CH3)2, -NHCH2-(tetrahydrofuran-2-yl), -NHCH2(p-trifluoromethylphenyl), -NHCH2C(CH3)=CH2, -NH-[(p-benzyl)pyrid-4-yl], -NH-[(2,6-dimethyl)pyrid-4-yl], -NH-(2-methylcyclohexyl), -NH-(4-methylcyclohexyl), -NH-[N-ethoxycarbonyl)-piperidin-4-yl, -NHOC(CH3)3, -NHCH2CH2CH2CH2-~, -C(O)NH(CH2)3O-(p-CH3)~, -C(O)NH(CH2)6NH2, -NH-(tetrahydrofuran-2-yl), -N(CH3)~, -NH(CH2)4NHC(O)-(2-hydroxy-4-azido)-phenyl and -NH(CH2)6 (biotinamidyl).

29. The method according to Claims 1, 2 or 3 wherein X is -C(O)Y
and Y is selected from the group consisting of -CH2CH2CH2CH(CH3)2, -CH2OH, -CH(OH)CH2CH3CH(CH3)2, -CH(OH)~, -CH(OH)CH2C(O)OCH3, -C(OH)(CH3)2, -CH2OCH3, -CH2OC(O)OCH3, and -CH2OC(O)C(CH3)3, methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, sec-butyl, tert-butyl, -CH2CH2CH(CH3)2, -CH2-pyridy-2-yl, -CH2-pyridy-3-yl, -CH2-pyridy-4-yl, -CH2-fur-2-yl, benzyl, cyclopentyl, phenyl, and -NH-SO2-CH3.

30. The method according to Claims 1, 2 or 3 wherein Z is a covalent bond linking R1 to -CX'X"-.

31. The method according to Claims l, 2 or 3 wherein the compound of formula I is selected from the group consisting of:
N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate methyl ester N-[N-(3,5-difluorophenykacetyl)-L-alaninyl]-L-histidine methyl ester N-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-(2-methoxyethyk)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-2-(N,N dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(3-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-pyridyl) methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate tert-butyl ester N-[N-(pent-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(dec-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[3-(N,N-dimethylamino)propoxy]phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[(tert-butyloxycarbonyl)methoxy]phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester N-(N (3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(carboxymethoxy)phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl}-L-alaninyl]-(S)-2-amino-6-(N,N-dimethylamino)hexanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(3-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-proline methyl ester 1-[N-(3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-morpholinopropionate methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalaninamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionamide N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(4-pyridyl)propionamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(2-pyridyl)propionamide --397--_ N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl)propionate methyl ester 2-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylate methyl ester N-(3-methoxybenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(1-naphthyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-naphthyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-thienyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine benzyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-bromo-propyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-iodopropyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-N-(tert-butoxycarbonyl)-L-lysine methyl ester methyl N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-4-phenylbutanoate N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine 2-phenylethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine 3-phenylpropyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-pyridyl)acetamide N-[N-(phenylacetyl)-L-alaninyl]-L-threonine methyl ester N'-[N-(phenylacetyl)-L-alaninyl]-L-leucinamide N'-[N-(phenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N'-[N-(phenylacetyl)-L-alaninyl)-L-valinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetate ethyl ester N-methyl-N'-[N (phenylacetyl)-L-alaninyl]-L-leucinamide N,N-dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N,N-dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-leucinamide N,N-dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-valinamide N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-valinamide N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N,N-dimethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-methoxyphenyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-methoxyphenyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-pyridyl)acetate ethyl ester N-[N-(cyclohexylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(cyclopentylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(cyclohex-1-enylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-1-aminocyclopropane-1-carboxylate methyl ester N-2-(N,N-dimethylamino)ethyl-N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine benzyl ester N-(N-(isovaleryl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-alanine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]glycine ethyl ester N-hydroxy-N'-[N-(3-nitrophenylacetyl)-L-alaninyl]-D,L-threoninamide N-(N-(isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-2-amino-3-(3-hydroxyphenyl)propionate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-tyrosine ethyl ester N-[N-(isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N-[N-[N-(isovaleryl)-L-valinyl]-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(isovaleryl)-L-phenylalaninyl]-L-alanine iso-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester 1-[N-(3-nitrophenylacetyl)-L-alaninyl]-indoline-(S)-2-carboxylate ethyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-methoxy-N-methyl-N'-[N (isovaleryl)-L-phenylglycinyl]-L-alaninamide N-iso-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N,N di-n-propyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-valinamide N-(4-nitrophenyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-[N (isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-iso-butyl-N'-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-nitrophenyl)-N'-(N-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-alaninamide N-(4-nitrophenyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-benzyl-N methyl-N'-[N-(3,5-difluorophenylacetyi)-L-alaninyl]-L-alaninamide N-(3,5-difluorobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(3-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-aianinyl]-L-alaninamide N-(4-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophan methyl ester N-(4-methoxybenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(phenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninyl]-L-phenylglycine methyl ester N-(N-(cyclohexylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine methyl ester N-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]-L-phenylglycine methyl ester N-(2-phenylethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-cyclohexylpropionate methyl ester N-(2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl}-L-alaninyl]-(S)-2-amino-3-(4-nitrophenyl)propionamide N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-serine ethyl ester N-[(R)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl}-L-alaninyl]-L-alaninamide N-[(S)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-fluorobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-pyridylmethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-trifluoromethylbenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-phenylpropionate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine tent-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-methylpropionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-cyclohexylacetate ethyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(isovaleryl)-2-amino-2-cyclohexylacetyl]-L-alanine ethyl ester N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-(2-pyridylmethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(2-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(4-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-fluorophenyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-fluorophenyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-phthalimidopropionate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine neopentyl ester N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valinyl]morpholine N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-threonine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-amino-3-tert-butoxybutyryl]morpholine 4-(N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucinyl]morpholine N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine N-(N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-threoninyl]-L-valine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-leucine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine methyl ester N-2-methoxyethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-neopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-2-pyridylmethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide 3-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]thiazolidine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-(R)-sec-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide 1-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]pyrrolidine N-(S)-sec-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-valine methyl ester N-2-fluoroethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[(S)-6-methyl-3-oxohept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-4-nitrobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutyramide N-4-nitrobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-fluorophenyl)acetate methyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(5-chlorobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-2-yl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-3-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-thienyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-5-yl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate ten-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alninyl]-(S)-2-amino-2-(2-thienyl)acetic acid N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(1H-tetrazol-5-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-(S)-2-amino-2-(6-methoxy-2-naphthyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-trifluoromethylphenyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4,5,6,7-tetrahydrobenzothiophen-2-yl)acetale methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(thieno[2,3-b]thiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-methylthiazoli-4-yl)acetate methyl ester (3S,4S)-N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-4-amino-3-hydroxy-5-phenylpentanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohex-4-enoate methyl ester N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-tert-butyl-N'-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(4-phenylphenyl)acetamide N-[N-(3,5-difluorophenylacetyl)-(S)-2-aminobutanoyl]-L-phenylglycine tert-Butyl Ester N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-leucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylalaninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-alanine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-leucine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-proline methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-N~-(tert-butoxycarbonyl)-L-lysine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-glycine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-valine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-[N-(phenylacetyl)-L-alaninyl)-(S)-2-aminopentanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valine N-[N-(phenylacetyI)-L-alaninyl]-L-N-methylalanine methyl ester N-[N-(isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N-Cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-hydroxyproline ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-lysine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-glutamide 1-[N-(3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N-[(S)-3-hydroxy-6-methylhept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenyl-.alpha.-fluoroacetyl)-L-alaniny]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-2-(S)-aminocyclohexylacetyl]-L-phenylglycine methyl ester N-[(1R,2S)-1-hydroxy-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(1R,2S)-1-hydroxy-1,2-diphenylfeth-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(1S,2R)-1-hydroxy-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-2-methoxyethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N-[(S)-.alpha.-hydroxy-.alpha.-phenyl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-1,2-diphenylethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-hydroxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-hydroxy-.alpha.'-(4-hydroxyphenyl)-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-2-pyridylmethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[.alpha.-hydroxy-.alpha.'-pyrid-2-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-hydroxy-.alpha.'-pyrid-4-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-hydroxy-4-methylpent-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-methoxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-hydroxy-3-methyl-but-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(6-aminopyrid-2-yl)acetate methyl ester N-[1-hydroxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-methoxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-methoxy-2-phenyl-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-acetoxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-(tert-butylcarbonyloxy)-hex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[2-hydroxy-1-(thien-2-yl)ethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-2-methyl-1-phenylprop-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-(thien-2-yl)glycinyl)-L-phenylalanine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(cyclopropaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(cyclopentaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(3,5-difluorophenylacetyl)-D,L-phenylglycinyl]-D,L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-D, L-valinyl]-D,L-phenylglycinamide N-[N-(2-thienylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(n-caprotyl)-L-alaninyl]-L-phe;nylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-norleucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-norvalinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-tert-leucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-isoleucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-cyclohexylalaninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(cyclopropyl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-3-yl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-2-yl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-D-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(4-methoxyphenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(cyclopropylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(cyclopentylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(tert-butylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(5-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(5-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(4-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-3-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(5-chlorothien-2-yl)glycinamide N-Cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-4-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenoxy)phenylglycinamide N-(S)-(-)-.alpha.-methylbenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-tert-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(ethyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(benzyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-bromophenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(cyclohexyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(4-ethylphenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(tert-butyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninylJ-D,L-3-(4-chlorophenoxy)phenylglycinamide N-cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(phenyl)phenylglycinamide N-[N-(3,5-difluorophenyl-.alpha.-hydroxyacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-tert-butyl-N'-[N-(3,5-difluorophenyl-.alpha.,.alpha.-difluoroacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine tert-butyl ester N-[(S)-1-oxo-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(pyrid-3-yl)glycine tert-butyl ester [N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl] morpholine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(2-methoxy)phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N-tert-butoxycarbonyl(hydroxyl amine) ester N-neopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-tetrahydrofurfuryl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methoxy-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide [N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]azetidine N-iso-butyl-N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-cyclopropanemethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methoxy-N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2-methylprop-2-enyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(pyrid-3-yl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(pyrid-4-yl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-furfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-cyclopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-1-benzylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N,N-dimethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2,2,6,6-tetramethylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2-methylcyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-4-methylcyclohexyl-N'-[N-(3,5-dlifluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-1-ethoxycarbonylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-D,L-phenylglycinamide N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butoxy-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N-tert-butyl(hydroxylamine) ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N-(1-ethoxyethen-1-yl)-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N-[N-(phenylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-4-(phenyl)butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-3-(4-iodophenoxy)propyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-6-(amino)hexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide Hydrochloride N-1-(phthalimido)pent-2-yl-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-(3,5-difluorophenyl)glycinyl]-L-(3,5-difluorophenyl)glycine methyl ester N-[N-3,5-difluorophenylacetyl)-L-alaninyl]-L-norleucine N-[N-(cyclopentaneacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine iso-propyl ester N-(isopropyl) N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(cyclopentylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-phenylglycine iso-butyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-D-phenylglycine methyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-(3-.alpha.-phenyl)proline methyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-azetidine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(5-chlorobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl)propionate tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-[N-(3,4-dichlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-bromophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-fluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(4-fluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-methylphenylacetyl)-L-alaninyl]-D-phenyiglycinamide N-[N-(4-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-trifluoromethylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-methoxyphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(2-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(1-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(2-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(phenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-{2-furanyl)acetamide N'-[N-(3,5-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N-(3,4-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanin-N-methylsulfonamide N"-methyl-N"-phenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-methyl-N"-phenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycinamide N"-methyl-N"-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-4-fluorobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N (3,S-difluorophenylacetyl)-L-alaninyl]-L-(4-fluoro)phenylglycine neopentyl ester N-[N-(2,3,4,5,6-pentafluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl)glycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl)glycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-(O-benzyl)serinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(O-benzyl)threoninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-threoninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-serinyl]-L-phenylglycine methyl ester N"-4-methylphenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N"-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenyl-glycinamide N'-[N-(3,5-difluorophenylacetyl)-L-methionyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycinamide N-[(R)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[1-phenyl-2-oxo-3-methylbutan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-pentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-(1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[1-phenyl-2-oxo-butan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[1-phenyl-2-oxo-4-methylpentan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-.alpha.-hydroxyphenylalanine methyl ester N"-[4-((2-hydroxy-4-azido)-phenyl)-NHC(O)-)butyl]N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-((S)-1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-phenylphenylglycine tert-butyl ester [N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(2,3-benzo[b]proline) methyl ester N"-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-n-butylphenylglycinamide N"-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(phenylacetenyl)phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N-[1,3-diphenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-2-cyclopentylethan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide;

N-[1-phenyl-2-oxo-hexan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-3-methylpentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N"-n-hexyl-6-biotinamidyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N'-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-methionine N'-[N-(2-tert-BOC-amino)propionyl)-L-alaninyl]-L-phenylglycine methyl ester N"-tert-butyl N'-[N-(3,5-difluorophenylacetyl)=L-alaninyl]-L-2-fluorophenyiglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-2-phenylglycine methyl ester N-[(S)-1-phenyl-2-oxo-3-phenylpropan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl]-D,L-2-phenylglycine N'-[N-(3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl]-D,L-2-phenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine N'-[N-(3,5-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine tert-butyl ester N-[2-hydroxy-1-(S)phenyleth-1-yl]-N'-[(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alaninamide N-[2-hydroxyeth-1-yl]-N'-[(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenyl-2-oxo-acetyl)-L-alaninyl]-L-2-phenylglycine tert-butyl ester [N-(2,5-dichlorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3,5-difluorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3,4-dichlorothiophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3-aminoproprionyl)-L-alaninyl]-L-phenylglycine tent-butyl ester; and [N-(3-tert-butoxycarbonylamino)propionyl)-L-alaninyl]-L-phenylglycine tert-butyl ester.

32. A pharmaceutical compositions comprising a pharmaceutically inert carrier and pharmaceutically effective amount of a compound of formula I:
wherein R1 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkenyl, substituted alkynyl, aryl, heteroaryl and heterocyclic;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclic;
each R3 is independently selected from the group consisting of hydrogen and methyl and R3 together with R4 can be fused to form a cyclic structure of from 3 to 8 atoms which is optionally fused with an aryl or heteroaryl group;
each R4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, substituted alkyl, substituted alkenyl and substituted alkynyl;
each R5 is selected from hydrogen amd methyl or together with R4 forms a cycloalkyl group of from 3 to 6 carbon atoms;
X is selected from the group consisting of -C(O)Y and -C(S)Y where Y
is selected from the group consisting of (a) alkyl or cycloalkyl, (b) substituted alkyl with the proviso that the substitution on said substituted alkyl do not include .alpha.-haloalkyl, .alpha.-diazoalkyl, .alpha.-OC(O)alkyl, or .alpha.-OC(O)aryl groups, (c) alkoxy or thioalkoxy, (d) substituted alkoxy or substituted thioalkoxy, (e) hydroxy, (f) aryl, (g) heteroaryl, (h) heterocyclic, (i) -NR'R" where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, where one of R' or R" is hydroxy or alkoxy, and where R' and R" are joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl, alkoxy or carboxylalkyl groups, (j) -NHSO2-R8 where R8 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic, (k) -NR9NR10R10 where R9 is hydrogen or alkyl, and each R10 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and (l) -ONR9[C(O)O]zR10 where z is zero or one, R9 and R10 are as defined above;
X can also be -CR6R6Y' where each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, alkoxy, substituted alkoxy, thioalkoxy, substituted thioalkoxy, -OC(O)R7, -SSR7, -SSC(O)R7 where R7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic, X' is hydrogen, hydroxy, or fluoro;

X" is hydrogen, hydroxy or fluoro, or X' and X" together form an oxo group, Z is selected from the group consisting of a bond covalently linking R1 to -CX'X"-, oxygen and sulfur;
n is an integer equal to 1 or 2; and pharmaceutically acceptable salts thereof with the provisos that:
A. when R1 is phenyl or 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH;
B. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3 derived from D-threonine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH or -C(O)OCH3;
C. when R1 is phenyl, R2 is methyl, R4 is benzyl, R5 is hydrogen, X is methoxycarbonyl, X' and X" are hydrogen, Z is a bond, and n is 1, then R3 is not methyl;
D. when R1 is iso-propyl, R2 is -CH2C(O)NH2, R3 is hydrogen, R4 is iso-butyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
E. when R1 is phenyl, R2 is methyl, R5 is hydrogen, X is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R3, the nitrogen atom attached to R3, and R4 do not form 1,2,3,4-tetrahydroiso-quinolin-2-yl or pyrrolidin-2-yl;
F. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not 4-amino-n-butyl;
G. when R1 is 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH2 or -CH2OH;

H. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -CH2OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not benzyl or ethyl;
I. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is methyl, R4 is methyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH.PHI.;
J. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH.PHI. or -CH2OH;
K. when R1 is N-(2-pyrrolidinonyl), R2 is methyl, R3 is hydrogen, R4 is benzyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
L. when R1 is 3,5-difluorophenyl, R2 is methyl derived from D-alanine, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH-benzyl;
M. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CH2OH;
N. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is 4-phenylphenyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHC(CH3)3; and O. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHCH(CH3).PHI..

33. The pharmaceutical composition according to Claim 32 wherein R1 is an unsubstituted aryl group and Z is a bond covalently linking R1 to -CX'X"-.

34. The pharmaceutical composition according to Claim 33 wherein the unsubstituted R1 aryl group is selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl.

35. The pharmaceutical composition according to Claim 32 wherein R1 is a substituted aryl group and Z is a bond covalently linking R1 to -CX'X"-.

36. The pharmaceutical composition according to Claim 35 wherein said substituted aryl group is a mono-substituted, di-substituted or tri-substituted phenyl group.

37. The pharmaceutical composition according to Claim 36 wherein the substituted phenyl groups are selected from the group consisting of 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-nitrophenyl, 4-methylphenyl, 3-methoxy-phenyl, 3-nitrophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-bromophenyl, 3-thiomethoxyphenyl, 3-methylphenyl, 3-trifluoromethylphenyl, 2-hydroxy-phenyl, 2-methylphenyl, 2-fluorophenyl, 2-chlorophenyl, 3,4-difluorophenyl, 2,3,4,5,6-pentafluorophenyl, 3,4-dibromophenyl, 3,4-dichlorophenyl, 3,4-methylene-dioxyphenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 2,4-dichlorophenyl, and 2,5-difluorophenyl.

38. The pharmaceutical composition according to Claim 32 wherein R1 is an alkaryl group and Z is a bond covalently linking R1 to -CX'X"-.

39. The pharmaceutical composition according to Claim 38 wherein the R' alkaryl group is selected from the group consisting of benzyl, 2-phenylethyl, and 3-phenyl-n-propyl.

40. The pharmaceutical composition according to Claim 32 wherein R1 is selected from the group consisting of alkyl, alkenyl, cycloalkyl and cycloalkenyl groups and Z is a bond covalently linking R1 to -CX'X"-.

41. The pharmaceutical composition according to Claim 40 wherein R1 is alkyl.

42. The pharmaceutical composition according to Claim 40 wherein R1 is cycloalkyl.

43. The pharmaceutical composition according to Claim 40 wherein R1 is alkenyl.

44. The pharmaceutical composition according to Claim 40 wherein R1 is cycloalkenyl.

45. The pharmaceutical composition according to Claim 40 wherein the R1 alkyl, cycloalkyl, alkenyl and cycloalkenyl groups are selected from the group consisting of iso-propyl, n-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, -CH2CH=CH2, -CH2CH=CH(CH2)4CH3, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclohex-1-enyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclohexyl, -CH2-cyclopentyl, -CH2CH2-cyclopropyl, -CH2CH2-cyclobutyl, -CH2CH2-cyclohexyl, -CH2CH2-cyclopentyl, aminomethyl, and N-tert-butoxycarbonylaminomethyl.

46. The pharmaceutical composition according to Claim 32 wherein R1 is selected from the group consisting of heteroaryl and substituted heteroaryl groups and Z is a bond covalently linking R1 to -CX'X"-.

47. The pharmaceutical composition according to Claim 46 wherein the R1 heteroaryl and substituted heteroaryl groups are selected from the group consisting of pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, fluoropyridyls (including 5-fluoropyrid-3-yl), chloropyridyls (including 5-chloropyrid-3-yl), thien-2-yl, thien-3-yl, benzothiazol-4-yl, 2-phenylbenzoxazol-5-yl, furan-2-yl, benzofuran-2-yl, thionaphthen-2-yl, 2-chlorothiophen-5-yl, 3-methylisoxazol-5-yl, 2-(thiophenyl)thiophen-5-yl, 6-methoxythionaphthen-2-yl, 3-phenyl-1,2,4-thiooxadiazol-5-yl and 2-phenyloxazol-4-yl.

48. The pharmaceutical composition according to Claim 32 wherein R2 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic.

49. The pharmaceutical composition according to Claim 48 wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, phenyl, 4-fluorophenyl, 3,5-difluoro-phenyl, 4-methoxyphenyl, benzyl, cyclopropyl, cyclohexyl, cyclopentyl, cycloheptyl, thien-2-yl, thien-3-yl, -CH2CH2SCH3, -CH2OCH2.PHI., -CH(CH3)OCH2.PHI., -CH(OH)CH3 and -CH2OH.

50. The pharmaceutical composition according to Claim 32 wherein X' and X" are hydrogen and Z is a bond covalently linking R1 to -CX'X"-.

51. The pharmaceutical composition according to Claim 50 wherein R3 is selected from the group consisting of hydrogen, methyl or together with R4 and the nitrogen to which R3 is attached forms pyrrolidin-2-yl, 2,3-dihydroindol-2-yl, piperidin-2-yl, 4-hydroxy-pyrrolidin-2-yl and 1,2,3,4-tetrahydroisoquinolin-3-yl.

52. The pharmaceutical composition according to Claim 32 wherein R4 substituents are selected from the group consisting of hydrogen, methyl, ethyl, iso-propyl, n-propyl, n-butyl, sec-butyl, iso-butyl, cyclopentyl, cyclohexyl, allyl, iso-but-2-enyl, 3-methylpentyl, -CH2-cyclopropyl, -CH2-cyclohexyl, -CH2-indol-3-yl, phenyl, p-(phenyl)phenyl, m-(phenyl)phenyl, o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, p-bromophenyl, m-methoxyphenyl, p-methoxyphenyl, phenethyl, benzyl, m-hydroxybenzyl, p-hydroxybenzyl, p-nitrobenzyl, m-trifluoromethylphenyl, p-(CH3)2NCH2CH2CH2O-benzyl, p-(CH3)3COC(O)CH2O-benzyl, p-phenylphenyl, 3,5-difluorophenyl, p-(HOOCCH2O)-benzyl, 2-aminopyrid-6-yl, 4-(N-morpholino-CH2CH2O)-benzyl, -CH2CH2C(O)NH2, -CHZ-imidazol-4-yl, -CH2-(3-tetrahydrofuranyl), -CH2-thien-2-yl, -CH2-thiazol-4-yl, -CH2(1-methyl)cyclopropyl, -CH2-thien-3-yl, thien-3-yl, thien-2-yl, -CH2-C(O)O-t-butyl, -CH2-C(CH3)3, -CH2CH(CH2CH3)2, 2-methylcyclopentyl, -cyclohex-2-enyl, -CH[CH(CH3)2]COOCH3, -(CH2)2SCH3, -CH2CH2N(CH3)2, -CH2C(CH3)=CH2, -CH2CH=CHCH3 (cis and trans), -CH2OH, -CH(OH)CH3, -CH(O-t-butyl)CH3, -CH2OCH3, -(CH2)4NH-Boc, -(CH2)4NH2, -(CH2)4N(CH3)2, -CH2-pyridyl, pyridyl, -CH2-naphthyl, -CH2-(N-morpholino), p-(N-morpholino-CH2CH2O)-benzyl, benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, 5-chlorobenzo[b]thiophen-2-yl, 4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, tetrazol-5-yl, 5-chlorobenzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, 6-methoxynaphth-2-yl, -CH2-N-phthalimidyl, 2-methylthiazol-4-yl, and thieno[2,3-b]thiophen-2-yl, 5-bromothien-2-yl, 4-bromothien-2-yl, 5-chlorothien-2-yl, 3-phenoxyphenyl, 2-phenoxyphenyl, 4-ethylphenyl, 2-benzylphenyl, (4-ethylphenyl)phenyl, 4-tert-butylphenyl, 4-n-butylphenyl, o-(4-chlorophenoxy)phenyl, furan-2-yl, and 4-phenylacetylenylphenyl.

53. The pharmaceutical composition according to Claim 32 wherein Z
is a covalent bond linking R1 to -CX'X"- and R4 and R5 are fused to form a cycloalkyl group selected from the group consisting of cyclopropyl and cyclobutyl.

54. The pharmaceutical composition according to Claim 32 wherein Z
is a covalent bond linking R1 to -CX'X"-, X is -C(O)Y and Y is selected from the group consisting of hydroxy, alkoxy or substituted alkoxy.

55. The pharmaceutical composition according to Claim 54 wherein Y
is alkoxy or substituted alkoxy selected from the gmup consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, neo-pentoxy, benzyloxy, 2-phenylethoxy, 3-phenyl-n-propoxy, 3-iodo-n-propoxy, 4-bromo-n-butoxy, -ONHC(O)OC(CH3)3, -ONHC(CH3)3 and hydroxy.

56. The pharmaceutical composition according to Claim 32 wherein Z
is a covalent bond linking R1 to -CX'X"-, X is -C(O)Y and Y is

57. The pharmaceutical composition according to Claim 56 wherein Y
is selected from the group consisting of amino (-NH2), -NH(iso-butyl), -NH(sec-butyl), N-methylamino, N,N-dimethylamino, N-benzylamino, N-morpholino, azetidino, N-thiomorpholino, N-piperidinyl, N-hexamethyleneimino, N-heptamethylene-imino, N-pyrrolidinyl, -NH-methallyl, -NHCH2-(furan-2-yl), -NHCH2-cyclopropyl, -NH(tert-butyl), -NH(p-methylphenyl), -NHOCH3, -NHCH2(p-fluorophenyl), -NHCH2CH2OCH3, -NH-cyclopentyl, -NH-cyclohexyl, -NHCH2CH2N(CH3)2, -NHCH2C(CH3)3, -NHCH2-(pyrid-2-yl), -NHCH2-(pyrid-3-yl), -NHCH2-(pyrid-4-yl), N-thiazolindinyl, -N(CH2CH2CH3)2, -N[CH2CH(CH3)2]2, -NHOH, -NH(p-NO2-~), -NHCH2(p-NO2-~), -NHCH2(m-NO2-~), -N(CH3)OCH3, -N(CH3)CH2-~, -NHCH2-(3,5-di-fluorophenyl), -NHCH2CH2F, -NHCH2(p-CH3O-~), -NHCH2(m-CH3O-~), -NHCH2(p-CF3-~), -N(CH3)CH2CH2OCH3, -NHCH2CH2~, -NHCH(CH3)~, -NHCH2-(p-F-~), -N(CH3)CH2CH2N(CH3)2, -NHCH2-(tetrahydrofuran-2-yl), -NHCH2(p-trifluoromethylphenyl), -NHCH2C(CH3)=CH2, -NH-[(p-benzyl)pyrid-4-yl], -NH-[(2,6-dimethyl)pyrid-4-yl], -NH-(2-methylcyclohexyl), -NH-(4-methylcyclohexyl), -NH-[N-ethoxycarbonyl]-piperidin-4-yl, -NHOC(CH3)3, -NHCH2CH2CH2CH2-~, -C(O)NH(CH2)3O-(p-CH3)~, -C(O)NH(CH2)6NH2, -NH-(tetrahydrofuran-2-yl), -N(CH3)~, -NH(CH2)4NHC(O)-(2-hydroxy-4-azido)-phenyl and -NH(CH2)6-(biotinamidyl).

58. The pharmaceutical composition according to Claim 32 wherein X
is -C(O)Y and Y is selected from the group consisting of -CH2CH2CH2CH(CH3)2, -CH2OH, -CH(OH)CH2CH2CH(CH3)2, -CH(OH)~, -CH(OH)CH2C(O)OCH3, -C(OH)(CH3)2, -CH2OCH3, -CH2OC(O)OCH3, and -CH2OC(O)C(CH3)3, methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, sec-butyl, tert-butyl, -CH2CH2CH(CH3)2, -CH2-pyridy-2-yl, -CH2-pyridy-3-yl, -CH2-pyridy-4-yl, -CH2-fur-2-yl, benzyl, cyclopentyl, phenyl, and -NH-SO2-CH3.

59. The pharmaceutical composition according to Claim 32 wherein Z
is a covalent bond linking R1 to -CX'X"-.

60. The pharmaceutical composition according to Claim 32 wherein the compound of formula I is selected from the group consisting of:
N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-histidine methyl ester N-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(3-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate tert-butyl ester N-[N-(pent-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(dec-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[3-(N,N-dimethylamino)propoxy]phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[(tert-butyloxycarbonyl)methoxy]phenylahmine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(carboxymethoxy)phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-(S)-2-amino-6-(N,N-dimethylamino)hexanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(3-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-proline methyl ester 1-[N-(3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-morpholinopropionate methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalaninamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(4-pyridyl)propionamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(2-pyridyl)propionamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl)propionate methyl ester 2-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylate methyl ester N-(3-methoxybenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(1-naphthyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-naphthyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-thienyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine benzyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-bromo-propyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-iodopropyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-N~-(tert-butoxycarbonyl)-L-lysine methyl ester methyl N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-4-phenylbutanoate N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine 2-phenylethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine 3-phenylpropyl ester N'-[N (3,5-difluorophenylacetyl)-L-aaninyl]-2-amino-2-(4-pyridyl)acetamide N-[N-(phenylacetyl)-L-alaninyl]-L-threonine methyl ester N'-[N (phenylacetyl)-L-alaninyl]-L-leucinamide N'-[N-(phenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N'-[N-(phenylacetyl)-L-alaninyl)-L-valinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetate ethyl ester N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-leucinamide N,N-dimethyl-N'-[N-(phenylacetyl}-L-alaninyl]-L-phenylalaninamide N,N-dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-leucinamide N,N-dimethyl-N'-(N-(phenylacetyl)-L-alaninyl]-L-valinamide N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-valinamide N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaininyl]-(S)-2-aminohexanamide N,N-dimethyl-N'-[N-(3,5-difluorophnnylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-methoxyphenyl)acetate methyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-methoxyphenyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-pyridyl)acetate ethyl ester N-[N-(cyclohexylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(cyclopentylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(cyclohex-1-enylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-1-aminocyclopropane-1-carboxylate methyl ester N-2-(N,N-dimethylamino)ethyl-N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine benzyl ester N-(N-(isovaleryl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-alanine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]glycine ethyl ester N-hydroxy-N'-(N-(3-nitrophenylacetyl)-L-alaninyl]-D,L-threoninamide N-[N-(isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-2-amino-3-(3-hydroxyphenyl)propionate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-tyrosine ethyl ester N-[N-(isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N-[N-[N-(isovaleryl)-L-valinyl]-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(isovaleryl)-L-phenylalaninyl]-L-alanine iso-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester 1-[N-(3-nitrophenylacetyl)-L-alaninyl]-indoline-(S)-2-carboxylate ethyl.
ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl)-L-alaninamide N-methoxy-N-methyl-N'-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninamide N-iso-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N,N-di-n-propyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-valinamide N-(4-nitrophenyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-L-alaninamide N'-[N-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluarophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-iso-butyl-N'-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-nitrophenyl)-N'-[N-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-alaninamide N-(4-nitrophenyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-L-phenylaianinamide N-benzyl-N methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(3,5-difluorobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(3-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophan methyl ester N-(4-methoxybenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(phenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninyl]-L-phenylglycine methyl ester N-[N-(cyclohexylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine methyl ester N-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]-L-phenylglycine methyl ester N-(2-phenylethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-cyclohexylpropionate methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-nitrophenyl)propionamide N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-serine ethyl ester N-[(R)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[(S)-.alpha.-methylbenzyl]-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-fluorobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-pyridylmethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-trifluoromethylbenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-phenylpropionate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine tent-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-methylpropionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-a.laninyl]-2-amino-2-cyclohexylacetate ethyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(isovaleryl)-2-amino-2-cyclohexylacetyl]-L-alanine ethyl ester N-2-(N,N dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-(2-pyridylmethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-L-phenylglycinamide N-[N-(3-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(2-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(4-pyridylacetyl)-L-alaninyl)-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-fluorophenyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-fluorophenyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-phthalimidopropionate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine neopentyl ester N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valinyl]morpholine N-(N-(3-nitrophenylacetyl)-L-alaninyl]-L-valine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-threonine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-amino-3-tert-butoxybutyryl]morpholine 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucinyl]morpholine N-(N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine N-[N-[N-(3-nitrophenylacetyl)-L-aIaninyl]-L-threoninyl]-L-valine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-leucine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-aianinyl]-L-leucine methyl ester N-2-methoxyethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-neopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-2-pyridylmethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide 3-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]thiazolidine N[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-(R)-sec-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide 1-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]pyrrolidine N-(S)-sec-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-valine methyl ester N-2-fluoroethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[(S)-6-methyl-3-oxohept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-4-nitrobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyi]-(S)-2-aminobutyramide N-4-nitrobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-fluorophenyl)acetate methyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(5-chlorobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-2-yl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-3-yl)acetate methyl ester N-[N-(3,5-difluorophenyiacetyl)-L-alaninyl]-2-amino-2-(2-thienyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-5-yl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate tent-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetic acid N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(1H-tetrazol-5-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(6-methoxy-2-naphthyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-trifluoromethylphenyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4,5,6,7-tetrahydrobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(thieno[2,3-b]thiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-methylthiazol-4-yl)acetate methyl ester (3S,4S)-N-[N-(3,5-difluorophenylacntyl)-L-alaninyl]-4-amino-3-hydroxy-5-phenylpentanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohex-4-enoate methyl ester N-[N-(cyclopropylacetyl)-L-alaninyly-L-phenylglycine tert-butyl ester N-tert-butyl-N'-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(4-phenylphenyl)acetamide N-[N-(3,5-difluorophenylacetyl)-(S)-2-aminohutanoyl]-L-phenylglycine tert-Butyl Ester N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-ptienylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-leucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylalaninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-alanine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-lencine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-proline methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(phenylacetyl)-L-aianinyl]-N~-(tert-butoxycarbonyl)-L-lysine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-glycine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-valine methyl ester N-(N-(phenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-[N-(phenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valine N-[N-(phenylacetyl)-L-alaninyl]-L-N methylalanine methyl ester N-(N-(isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N-Cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-hydroxyproline ethyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-lysine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-glutamide 1-[N-(3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N-[(S)-3-hydroxy-6-methylhept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluoraphenyl-a-fluoroacetyl)-L-alaniny]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-2-(S)-aminocyclohexylacetyl]-L-phenylglycine methyl ester N-[(1R,2S)-1-hydroxy-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(1R,2S)-1-hydroxy-1,2-diphenyleth-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(1S,2R)-1-hydroxy-1-phenylproh-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-2-methoxyethyl-N'-[N (3,5-diflucrrophenylacetyl)-L-alaninyl]-glycinamide N-[(S)-.alpha.-hydroxy-.alpha.-phenyl-iso-prohyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-1,2-diphenylethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-hydroxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-hydroxy-.alpha.'-(4-hydroxyphenyl)-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-2-pyridylmethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[.alpha.-hydroxy-.alpha.'-pyrid-2-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-hydroxy-.alpha.'-pyrid-4-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-hydroxy-4-methylpent-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-methoxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-hydroxy-3-methyl-but-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(6-aminopyrid-2-yl)acetate methyl ester N-[1-hydroxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-methoxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-methoxy-2-phenyl-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-acetoxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-(tert-butylcarbonyloxy)-hex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[2-hydroxy-1-(thien-2-yl)ethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-2-methyl-1-phenylprop-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-(thien-2-yl)glycinyl]-L-phenylalanine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(cyclopropaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(cyclopentaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(3,5-difluorophenylacetyl)-D,L-phenylglycinyl]-D,L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-D,L-valinyl]-D,L-phenylglycinamide N-[N-(2-thienylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(n-caprotyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-norleucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-norvalinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-tert-leucinyl)-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-isoleucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-cyclohexylalaninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(cyclopropyl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-3-yl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-2-yl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-D-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(4-methoxyphenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(cyclopropylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(cyclopentylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(tert-butylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-(5-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(5-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(4-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-3-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(5-chlorathien-2-yl) glycinamide N-Cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-4-(phenyl)phenyiglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenoxy)phenylglycinamide N-(S)-(-)-.alpha.-methylbenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(ethyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(benzyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-bromophenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(cyclohexyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(4-ethylphenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(tert-butyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-3-(4-chlorophenoxy)phenylglycinamide N-cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(phenyl)phenylglycinamide N-[N-(3,5-difluorophenyl-.alpha.-hydroxyacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-tert-butyl-N'-[N-(3,5-difluorophenyl-.alpha.,.alpha.-difluoroacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine tert-butyl ester N-[(S)-1-oxo-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(pyrid-3-yl)glycine tert-butyl ester [N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]morpholine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(2-methoxy)phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N-tert-butoxycarbonyl(hydroxyl amine) ester N-neopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methoxy-N'-[N-(3,5-difluorophen;ylacetyl)-L-alaninyl]-D,L-phenylglycinamide [N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]azetidine N-iso-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-cyclopropanemethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methoxy-N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2-methylprop-2-enyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(pyrid-3-yl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(pyrid-4-yl)methyl-N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-furfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-cyclopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-1-benzylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N,N-dimethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2,2,6,6-tetramethylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2-methylcyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-4-methylcyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-1-ethoxycarbonylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butoxy-N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N-tert-butyl(hydroxylamine) ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N-(1-ethoxyethen-1-yl)-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N-[N-(phenylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-4-(phenyl)butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-3-(4-iodophenoxy)propyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-6-(amino)hexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide Hydrochloride N-1-(phthalimido)pent-2-yl-N'-(3,5-difluorophenylacetyl)-L-alaminamide N-[N-(3,5-difluorophenylacetyl)-L-(3,5-difluorophenyl)glycinyl]-L-(3,5-difluorophenyl)glycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-norleucine N-[N-(cyclopentaneacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine isopropyl ester N-(isopropyl) N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(cyclopentylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-phenylglycine iso-butyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-D-phenylglycine methyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-(3-.alpha.-phenyl)proline methyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-azetidine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(5-chlorobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl) propionate tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide tert-butyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-(N-(3,4-dichlorophenylacetyl)-L-alaninyl)-D-phenylglycinamide N-[N-(3-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-bromophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-fluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(4-fluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(4-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-trifluoromethylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-methoxyphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(2-chlorophenylacetyl)-L-alaninyl)-D-phenylglycinamide N-[N-(1-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(2-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N-(N-(phenylacetyl)-L-alaninyl]-D-phenylglycinamide N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine N-(N-(3,5-difluorophenylacetyl)-L-alaninyl)-D-phenylglycinamide N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-furanyl)acetamide N'-[N-(3,5-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N-(3,4-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanin-N-methylsulfonamide N"-methyl-N"-phenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-methyl-N"-phenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycinamide N"-methyl-N"-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-4-fluorobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-L-(4-fluoro)phenylglycine neopentyl ester N-[N-(2,3,4,5,6-pentafluorophenylacetyl)-L-alaninyl)-L-(pyrid-3-yl) glycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl)glycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-(O-benzyl)serinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(O-benzyl)threoninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-threoninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-serinyl]-L-phenylglycine methyl ester N"-4-methylphenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N"-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenyl-glycinamide N'-[N-(3,5-difluorophenylacetyl)-L-methionyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycinamide N-[(R)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[1-phenyl-2-oxo-3-methylbutan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-pentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[1-phenyl-2-oxo-butan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[1-phenyl-2-oxo-4-methylpentan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-.alpha.-hydroxyphenylalanine methyl ester N"-[4-((2-hydroxy-4-azido)-phenyl)-NHC(O)-)butyl] N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[(S)-1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine tent-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-phenylphenylglycine tert-butyl ester [N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(2,3-benzo[b]proline) methyl ester N"-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-n-butylphenylglycinamide N"-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(phenylacetenyl)phenylglycinamide N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N-[1,3-diphenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-2-cyclopentylethan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide;
N-[1-phenyl-2-oxo-hexan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-3-methylpentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N"-n-hexyl-6-biotinamidyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N'-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-methionine N'-[N-(2-tert-BOC-amino)propionyl)-L-alaninyl]-L-phenylglycine methyl ester N"-tert-butyl N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-fluorophenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-2-phenylglycine methyl ester N-[(S)-1-phenyl-2-oxo-3-phenylpropan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide:
N'-[N-(3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl]-D,L-2-phenylglycine N'-[N-(3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl]-D,L-2-phenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine N'-[N-(3,5-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine tert-butyl ester N-[2-hydroxy-1-(S)phenyleth-1-yl)-N'-[(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alaninamide N-[2-hydroxyeth-1-yl]-N'-[(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenyl-2-oxo-acetyl)-L-alaninyl]-L-2-phenylglycine tert-butyl ester [N-(2,5-dichlorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3,5-difluorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3,4-dichlorothiophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3-aminoproprionyl)-L-alaninyl]-L-phenylglycine tert-butyl ester; and [N-(3-tert-butoxycarbonylamino)propionyl)-L-alaninyl]-L-phenylglycine tert-butyl ester.

61. A compound of formula I:
wherein R1 is selected from the group consisting of alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substituted alkenyl, substituted alkynyl, aryl, heteroaryl and heterocyclic;
R2 is selected from the group consisting of hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, aryl, heteroaryl and heterocyclic;

each R3 is independently selected from the group consisting of hydrogen and methyl and R3 together with R4 can be fused to form a cyclic structure of from 3 to 8 atoms which is optionally fused with an aryl or heteroaryl group;
each R4 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, aryl, cycloalkyl, cycloalkenyl, heteroaryl, heterocyclic, substituted alkyl, substituted alkenyl and substituted alkynyl;
each R5 is selected from hydrogen and methyl or together with R4 forms a cycloalkyl group of from 3 to 6 carbon atoms;
X is selected from the group consisting of -C(O)Y and -C(S)Y where Y
is selected from the group consisting of (a) alkyl or cycloalkyl, (b) substituted alkyl with the proviso that the substitution on said substituted alkyl do not include .alpha.-haloalkyl, .alpha.-diazoalkyl, .alpha.-OC(O)alkyl, or .alpha.-OC(O)aryl groups, (c) alkoxy or thioalkoxy, (d) substituted alkoxy or substituted thioalkoxy, (e) hydroxy, (f) aryl, (g) heteroaryl, (h) heterocyclic, (i) -NR'R" where R' and R" are independently selected from hydrogen, alkyl, alkenyl, alkynyl, substituted alkyl, substituted alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, where one of R' or R" is hydroxy or alkoxy, and where R' and R" are joined to form a cyclic group having from 2 to 8 carbon atoms optionally containing 1 to 2 additional heteroatoms selected from oxygen, sulfur and nitrogen and optionally substituted with one or more alkyl, alkoxy or carboxylalkyl groups, (j) -NHSO2-R8 where R8 is selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl and heterocyclic, (k) -NR9NR10R10 where R9 is hydrogen or alkyl, and each R10 is independently selected from hydrogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, aryl, heteroaryl, heterocyclic, and (1) -ONR9[C(O)O]zR10 where z is zero or one, R9 and R10 are as defined above;
X can also be -CR6R6Y' where each R6 is independently selected from the group consisting of hydrogen, alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic and Y' is selected from the group consisting of hydroxyl, amino, thiol, alkoxy, substituted alkoxy, thioalkoxy, substituted thioalkoxy, -OC(O)R7, -SSR7, -SSC(O)R7 where R7 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic, X' is hydrogen, hydroxy, or fluoro;
X" is hydrogen, hydroxy or fluoro, or X' and X" together form an oxo group, Z is selected from the group consisting of a bond covalently linking R1 to -CX'X"-, oxygen and sulfur;
n is an integer equal to 1 or 2; and pharmaceutically acceptable salts thereof with the provisos that:
A. when R1 is phenyl or 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH;
B. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3 derived from D-threonine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OH or -C(O)OCH3;
C. when R1 is phenyl, R2 is methyl, R4 is benzyl, R5 is hydrogen, X is methoxycarbonyl, X' and X" are hydrogen, Z is a bond, and n is 1, then R3 is not methyl;

D. when R1 is iso-propyl, R1 is -CH2C(O)NH2, R3 is hydrogen, R4 is iso-butyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
E. when R1 is phenyl, R2 is methyl, R5 is hydrogen, X is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R3, the nitrogen atom attached to R3, and R4 do not form 1,2,3,4-tetrahydroiso-quinolin-2-yl or pyrrolidin-2-yl;
F. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -C(O)OCH3, X' and X" are hydrogen, Z is a bond, and n is 1, then R4 is not 4-amino-n-butyl;
G. when R1 is 3-nitrophenyl, R2 is methyl, R3 is hydrogen, R4 is -CH(OH)CH3, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH2 or -CH2OH;
H. when R1 is phenyl, R2 is methyl, R3 is hydrogen, R5 is hydrogen, X
is -CH2OCH3, X' and X" are hydrogen, Z, is a bond, and n is 1, then R4 is not benzyl or ethyl;
I. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is methyl, R4 is methyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~;
J. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CHOH~ or -CH2OH;
K. when R1 is N (2-pyrrolidinonyl), R2 is methyl, R3 is hydrogen, R4 is benzyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)OCH3;
L, when R1 is 3,5-difluorophenyl, R2 is methyl derived from D-alanine, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NH-benzyl;
M. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is hydrogen, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -CH2OH;

N. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is 4-phenylphenyl, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHC(CH3)3; and O. when R1 is 3,5-difluorophenyl, R2 is methyl, R3 is hydrogen, R4 is phenyl derived from D-phenylglycine, R5 is hydrogen, X' and X" are hydrogen, Z is a bond, and n is 1, then X is not -C(O)NHCH(CH3)~.

62. The compound according to Claim 61 wherein R1 is an unsubstituted aryl group and Z is a bond covalently linking R1 to -CX'X"-.

63. The compound according to Claim 62 wherein the unsuhstituted R1 aryl group is selected from the group consisting of phenyl, 1-naphthyl and 2-naphthyl.

64. The compound according to Claim 61 wherein R1 is a substituted aryl group and Z is a bond covalently linking R1 to -CX'X"-.

65. The compound according to Claim 64 wherein said substituted aryl group is a mono-substituted, di-substituted or tri-substituted phenyl group.

66. The compound according to Claim 65 wherein the substituted phenyl groups are selected from the group consisting of 4-fluorophenyl, 4-chlorophenyl, 4-bromophenyl, 4-nitrophenyl, 4-methylphenyl, 3-methoxy-phenyl, 3-nitrophenyl, 3-fluorophenyl, 3-chlorophenyl, 3-bromophenyl, 3-thiomethoxyphenyl, 3-methylphenyl, 3-trifluoromethylphenyl, 2-hydroxy-phenyl, 2-methylphenyl, 2-fluorophenyl, 2-chlorophenyl, 3,4-difluorophenyl, 2,3,4,5,6-pentafluorophenyl, 3,4-dibromophenyl, 3,4-dichlorophenyl, 3,4-methylene-dioxyphenyl, 3,5-difluorophenyl, 3,5-dichlorophenyl, 2,4-dichlorophenyl, and 2,5-difluorophenyl.

67. The compound according to Claim 61 wherein R1 is an alkaryl group and Z is a bond covalently linking R1 to -CX'X"-.

68. The compound according to Claim 67 wherein the R1 alkaryl group is selected from the group consisting of benzyl, 2-phenylethyl, and 3-phenyl-n-propyl.

69. The compound according to Claim 61 wherein R1 is selected from the group consisting of alkyl, alkenyl, cycloalkyl and cycloalkenyl groups and Z
is a bond covalently linking R1 to -CX'X"-.

70. The compound according to Claim 69 wherein R1 is alkyl.

71. The compound according to Claim 69 wherein R1 is cycloalkyl.

72. The compound according to Claim 69 wherein R1 is alkenyl.

73. The compound according to Claim 69 wherein R1 is cycloalkenyl.

74. The compound according to Claim 69 wherein the R1 alkyl, cycloalkyl, alkenyl and cycloalkenyl groups are selected from the group consisting of iso-propyl, n-propyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, -CH2CH = CH2, -CH2CH = CH(CH2)4CH3, cyclopropyl, cyclobutyl, cyclohexyl, cyclopentyl, cyclohex-1-enyl, -CH2-cyclopropyl, -CH2-cyclobutyl, -CH2-cyclohexyl, -CH2-cyclopentyl, -CH2CH2-cyclopropyl, -CH2CH2-cyclobutyl, -CH2CH2-cyclohexyl, -CH2CH2-cyclopentyl, aminomethyl, and N-tert-butoxycarbonylaminomethyl.

75. The compound according to Claim 61 wherein R1 is selected from the group consisting of heteroaryl and substituted heteroaryl groups and Z is a bond covalently linking R1 to -CX'X"-.

76. The compound according to Claim 75 wherein the R1 heteroaryl and substituted heteroaryl groups are selected from the group consisting of pyrid-2-yl, pyrid-3-yl, pyrid-4-yl, fluoropyridyls (including 5-fluoropyrid-3-yl) chloropyridyls (including 5-chloropyrid-3-yl), thien-2-yl, thien-3-yl, benzothiazol-4-yl, 2-phenylbenzoxazol-5-yl, furan-2-yl, benzofuran-2-yl, thionaphthen-2-yl, 2-chlorothiophen-5-yl, 3-methylisoxazol-5-yl, 2-(thiophenyl)thiophen-5-yl, 6-methoxythionaphthen-2-yl, 3-phenyl-1,2,4-thiooxadiazol-5-yl and 2-phenyloxazol-4-yl.

77. The compound according to Claim 61 wherein R2 is selected from the group consisting of alkyl, substituted alkyl, cycloalkyl, aryl, heteroaryl and heterocyclic.

78. The compound according to Claim 77 wherein R2 is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, phenyl, 4-fluorophenyl, 3,5-difluoro-phenyl, 4-methoxyphenyl, benzyl, cyclopropyl, cyclohexyl, cyclopentyl, cycloheptyl, thien-2-yl, thien-3-yl, -CH2CH2SCH3, -CH2OCH2C.PHI., -CH(CH3)OCH2.PHI., -CH(OH)CH3 and -CH2OH.

79. The compound according to Claim 61 wherein X' and X" are hydrogen and Z is a bond covalently linking R1 to -CX'X"-.

80. The compound according to Claim 79 wherein R3 is selected from the group consisting of hydrogen, methyl or together with R4 and the nitrogen to which R3 is attached forms pyrrolidin-2-yl, 2, 3-dihydroindol-2-yl, piperidin-2-yl, 4-hydroxy-pyrrolidin-2-yl and 1,2,3,4-tetrahydroisoquinolin-3-yl.

81. The compound according to Claim 61 wherein R4 substituents are selected from the group consisting of hydrogen, methyl, ethyl, iso-propyl, n-propyl, n-butyl, sec-butyl, iso-butyl, cyclopentyl, cyclohexyl, allyl, iso-but-2-enyl, 3-methylpentyl, -CH2-cyclopropyl, -CH2-cyclohexyl, -CH2-indol-3-yl, phenyl, p-(phenyl)phenyl, m-(phenyl)phenyl, o-fluorophenyl, m-fluorophenyl, p-fluorophenyl, p-bromophenyl, m-methoxyphenyl, p-methoxyphenyl, phenethyl, benzyl) m-hydroxybenzyl, p-hydroxybenzyl, p-nitrobenzyl, m-trifluoromethylphenyl, p-(CH3)2NCH2CH2CH2O-benzyl, p-(CH3)3COC(O)CH2O-benzyl) p-phenylphenyl, 3,5-difluorophenyl, p-(HOOCCH2O)-benzyl, 2-aminopyrid-6-yl, 4-(N-morpholino-CH2CH2O)-benzyl, -CH2CH2C(O)NH2, -CH2-imidazol-4-yl, -CH2-(3-tetrahydrofuranyl), -CH2-thien-2-yl, -CH2-thiazol-4-yl, -CH2(1-methyl)cyclopropyl, -CH2-thien-3-yl, thien-3-yl, thien-2-yl, -CH2-C(O)O-t-butyl, -CH2-C(CH3)3, -CH2CH(CH2CH3)2, 2-methylcyclopentyl, -cyclohex-2-enyl, -CH[CH(CH3)2]COOCH3, -(CH2)2SCH3, -CH2CH2N(CH3)2, -CH2C(CH3)=CH2, -CH2CH=CHCH3 (cis and trans), -CH2OH, -CH(OH)CH3, -CH(O-t-butyl)CH3, -CH2OCH3, -(CH2)4NH-Boc, -(CH2)4NH2, -(CH2)4N(CH3)2, -CH2-pyridyl, pyridyl, -CH2-naphthyl, -CH2-(N-morpholino), p-(N-morpholino-CH2CH2O)-benzyl, benzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, 5-chlorobenzo[b]thiophen-2-yl, 4,5,6,7-tetrahydrobenzo[b]thiophen-2-yl, benzo[b]thiophen-3-yl, tetrazol-5-yl, 5-chlorobenzo[b]thiophen-3-yl, benzo[b]thiophen-5-yl, 6-methoxynaphth-2-yl, -CH2-N-phthalimidyl, 2-methylthiazol-4-yl, and thieno[2,3-b]thiophen-2-yl, 5-bromothien-2-yl, 4-bromothien-2-yl, 5-chlorothien-2-yl, 3-phenoxyphenyl, 2-phenoxyphenyl, 4-ethylphenyl, 2-benzylphenyl, (4-ethylphenyl)phenyl, 4-tert-butylphenyl, 4-n-butylphenyl, o-(4-chlorophenoxy)phenyl, furan-2-yl, and 4-phenylacetylenylphenyl.

82. The compound according to Claim 61 wherein Z is a covalent bond linking R1 to -CX'X"- and R4 and R5 are fused to form a cycloalkyl group selected from the group consisting of cyclopropyl and cyclobutyl.

83. The compound according to Claim 61 wherein Z is a covalent bond linking R1 to -CX'X"-, X is -C(O)Y and Y is selected from the group consisting of hydroxy, alkoxy or substituted alkoxy.

84. The compound according to Claim 83 wherein Y is alkoxy or substituted alkoxy selected from the group consisting of methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, iso-butoxy, tert-butoxy, neo-pentoxy, benzyloxy, 2-phenylethoxy, 3-phenyl-n-propoxy, 3-iodo-n-propoxy, 4-bromo-n-butoxy, -ONHC(O)OC(CH3)3, -ONHC(CH3)3 and hydroxy.

85. The compound according to Claim 61 wherein Z is a covalent bond linking R1 to -CX'X"-, X is -C(O)Y and Y is -NR'R".

86. The compound according to Claim 85 wherein Y is selected from the group consisting of amino (-NH2), -NH(iso-butyl), -NH(sec-butyl), N-methylamino, N,N-dimethylamino, N-benzylamino, N-morpholino, azetidino, N-thiomorpholino, N-piperidinyl, N-hexamethyleneimino, N-heptamethylene-imino, N-pyrrolidinyl, -NH-methallyl, -NHCH2-(furan-2-yl), -NHCH2-cyclopropyl, -NH(tert-butyl), -NH(p-methylphenyl), -NHOCH3, -NHCH2(p-fluorophenyl), -NHCH2CH2OCH3, -NH-cyclopentyl, -NH-cyclohexyl, -NHCH,CH2N(CH3)2, -NHCH2C(CH3)3, -NHCH2-(pyrid-2-yl), -NHCH2-(pyrid-3-yl), -NHCH2-(pyrid-4-yl), N-thiazolindinyl, -N(CH2CH2CH3)2, -N[CH2CH(CH3)2]2, -NHOH, -NH(p-NO2-~), -NHCH2(p-NO2-~), -NHCH2(m-NO2-~), -N(CH3)OCH3, -N(CH3)CH2-~, -NHCH2-(3,5-di-fluorophenyl), -NHCH2CH2F, -NHCH2(p-CH3O-~), -NHCH2(m-CH3-~), -NHCH2(p-CF3-~), -N(CH3)CH2CH2OCH3, -NHCH2CH2~, -NHCH(CH3)~, -NHCH2-(p-F-~), -N(CH3)CH2CH2N(CH3)2, -NHCH2-(tetrahydrofuran-2-yl), -NHCH2(p-trifluoromethylphenyl), -NHCH2C(CH3)=CH2, -NH-[(p-benzyl)pyrid-4-yl], -NH-[(2,6-dimethyl)pyrid-4-yl], -NH-(2-methylcyclohexyl), -NH-(4-methylcyclohexyl), -NH-[N-ethoxycarbonyl]-piperidin-4-yl, -NHOC(CH3)3, -NHCH2CH2CH2CH2-~, -C(O)NH(CH2)3O-(p-CH3)~, -C(O)NH(CH2)6NH2, -NH-(tetrahydrofuran-2-yl), -N(CH3).PHI., -NH(CH2)4NHC(O)-(2-hydroxy-4-azido)-phenyl and -NH(CH2)6-(biotinamidyl).

87. The compound according to Claim 61 wherein X is -C(O)Y and Y
is selected from the group consisting of -CH2CH2CH2CH(CH3)2, -CH2OH, -CH(OH)CH2CH2CH(CH3)2, -CH(OH).PHI., -CH(OH)CH2C(O)OCH3, -C(OH)(CH3)2, -CH2OCH3, -CH2OC(O)OCH3, and -CH2OC(O)C(CH3)3, methyl, ethyl, iso-propyl, n-propyl, iso-butyl, n-butyl, sec-butyl, tert-butyl, -CH2CH2CH(CH3)2, -CH2-pyridy-2-yl, -CH2-pyridy-3-yl, -CH2-pyridy-4-yl, -CH2-fur-2-yl, benzyl, cyclopentyl, phenyl, and -NH-SO2-CH3.

88. The compound according to Claim 61 wherein Z is a covalent bond linking R1 to -CX'X"-.

89. The compound according to Claim 61 wherein the compound of formula I is selected from the group consisting of:
N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-histidine methyl ester N-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-2-(N,N dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-pyridyl)methyl-N'-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(3-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-pyridyl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanoate tert-butyl ester N-[N-(pent-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(dec-4-enoyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[3-(N,N-dimethylamino)propoxy]phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-[(tert-butyloxycarbonyl)methoxy]phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tyrosine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(carboxymethoxy)phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-6-(N,N-dimethylamino)hexanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(3-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-proline methyl ester 1-[N-(3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-pyridyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-2-amino-3-methoxypropionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-morpholinopropionate methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(2-morpholinoethoxy)phenylalaninamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-methoxypropionamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine methyl ester N-(2-methoxyethyl)-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(4-pyridyl)propionamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(2-pyridyl)propionamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl) propionate methyl ester 2-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxylate methyl ester N-(3-methoxybenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(1-naphthyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-naphthyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(2-thienyl)propionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine benzyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-bromo-propyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine 3-iodopropyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetamide N-(N-(3,5-dafluorophenylacetyl)-L-alaninyl]-N~-(tert-butoxycarbonyl)-L-lysine methyl ester methyl N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-4-phenylbutanoate N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine 2-phenylethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine 3-phenylpropyl ester N'-[N-(3,5-difluorophenylacetyi)-L-alaninyl]-2-amino-2-(4-pyridyl)acetamide N-[N-(phenylacetyl)-L-alaninyl]-L-threonine methyl ester N'-(N-(phenylacetyl)-L-alaninyl]-L-leucinamide N'-[N-(phenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N'-[N-(phenylacetyl)-L-alaninyl)-L-valinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-pyridyl)acetate ethyl ester N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-leucinamide N,N dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N,N-dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-leucinamide N,N-dimethyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-valinamide N methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-phenylalaninamide N-methyl-N'-[N-(phenylacetyl)-L-alaninyl]-L-valinamide N methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N,N-dimethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminohexanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-methoxyphenyl)acetate methyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-methoxyphenyl)acetate methyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-pyridyl)acetate ethyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-pyridyl)acetate ethyl ester N-[N-(cyclohexylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(cyclopentylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(cyclohex-1-enylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-1-aminocyclopropane-1-carboxylate methyl ester N-2-(N,N dimethylamino)ethyl-N methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]glycine benzyl ester N-[N-(isovaleryl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-alanine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]glycine ethyl ester N-hydroxy-N'-[N-(3-nitrophenylacetyl)-L-alaninyl]-D,L-threoninamide N-[N-(isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N-(N-(3-nitrophenylacetyl)-L-alaninyl]-2-amino-3-(3-hydroxyphenyl)propionate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-tyrosine ethyl ester N-(N-(isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N-[N-[N-(isovaleryl)-L-valinyl]-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(isovaleryl)-L-phenylalaninyl]-L-alanine iso-butyl ester N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alanine ethyl ester 1-[N-(3-nitrophenylacetyl)-L-alaninyl]-indoline-(S)-2-carboxylate ethyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-methoxy-N methyl-N'-(N-(sovaleryl)-L-phenylglycinyl]-L-alaninamide N-iso-butyl-N'-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N,N di-n-propyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-valinamide N-(4-nitrophenyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-iso-butyl-N'-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninamide N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-(4-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-nitrophenyl)-N'-[N-[N-(isovaleryl)-L-phenylglycinyl]-L-alaninyl]-L-alaninamide N-(4-nitrophenyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-benzyl-N methyl-N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(3,5-difluorobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(3-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-nitrobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophan methyl ester N-(4-methoxybenzyl)-N'-[N-(3,5-diiluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(phenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninyl]-L-phenylglycine methyl ester N-[N-(cyclohexylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine methyl ester N-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]-L-phenylglycine methyl ester N-(2-phenylethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-tryptophanamide N-[N-(3,5-difluorophenylacetyl)-L-alaminyl]-(S)-2-amino-3-cyclohexylpropionate methyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(4-nitrophenyl)propionamide N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-serine ethyl ester N-[(R)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[(S)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-fluorobenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-pyridylmethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-(4-trifluoromethylbenzyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-phenylpropionate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-methylpropionate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-cyclohexylacetate ethyl ester N-(2-methoxyethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(isovaleryl)-2-amino-2-cyclohexylacetyl]-L-alanine ethyl ester N-2-(N,N dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-(2-pyridylmethyl)-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(2-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(4-pyridylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4-fluorophenyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-fluorophenyl)acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alanine ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-phthalimidopropionate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine neopentyl ester N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valinyl]morpholine N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-threonine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-amino-3-tert-butoxybutyryl]morpholine 4-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucinyl]morpholine N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-isoleucine N-[N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-threoninyl]-L-valine ethyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-leucine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-leucine methyl ester N-2-methoxyethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-2-(N,N-dimethylamino)ethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-neopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-2-pyridylmethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide 3-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-L-alaninyl]thiazolidine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-(R)-sec-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide 1-[N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninyl]pyrrolidine N-(S)-sec-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-valine methyl ester N-2-fluoroethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N-[(S)-6-methyl-3-oxohept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-4-nitrobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminobutyramide N-4-nitrobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-aminopentanamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-fluarophenyl)acetate methyl ester N'-[N (3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(5-chlorobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-2-yl) acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-aaninyl]-2-amino-2-(benzothiophen-3-yl) acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-thienyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(benzothiophen-5-yl) acetate ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl) acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetate tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-thienyl)acetic acid N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(1H-tetrazol-5-yl) acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(6-methoxy-2-naphthyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(3-trifluoromethylphenyl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(4,5,6,7-tetrahydrobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(thieno[2,3-b]
thiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(2-methylthiazol-4-yl)acetate methyl ester (3S,4S)-N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-4-amino-3-hydroxy-5-phenylpentanoate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-(S)-2-aminohex-4-enoate methyl ester N-[N-(cyclopropylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-tert-butyl-N'-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(4-phenylphenyl)acetamide N-[N-(3,5-difluorophenylacetyl)-(S)-2-aminobutanoyl]-L-phenylglycine tert-Butyl Ester N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-leucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylalaninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-alanine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-leucine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-isoleucine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-proline methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-phenylalanine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-N-(tert-butoxycarbonyl)-L-lysine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-glycine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-L-valine methyl ester N-[N-(phenylacetyl)-L-alaninyl]-(S)-2-aminobutanoate methyl ester N-[N-(phenylacetyl)-L-alaninyl]-(S)-2-aminopentanoate methyl ester N-[N-(3-nitrophenylacetyl)-L-alaninyl]-L-valine N-[N-(phenylacetyl)-L-alaninyl]-L-N-methylalanine methyl ester N-[N-(isovaleryl)-L-phenylglycinyl]-L-alanine iso-butyl ester N-[N-(isovaleryl)-L-isoleucinyl]-L-alanine iso-butyl ester N-Cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-hydroxyproline ethyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-lysine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-glutamide 1-[N-(3,5-difluorophenylacetyl)-L-alaninyl]piperidine-2-carboxylate methyl ester N-[(S)-3-hydroxy-6-methylhept-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenyl-.alpha.-fluoroacetyl)-L-alaniny]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-2-(S)-aminocyclohexylacetyl]-L-phenylglycine methyl ester N-[(1R,2S)-1-hydroxy-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(1R,2S)-1-hydroxy-1,2-diphenyleth-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(1S,2R)-1-hydroxy-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-2-methoxyethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N-[(S)-.alpha.-hydroxy-.alpha.-phenyl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-1,2-diphenylethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-hydroxyhex-2-yl)-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-hydroxy-.alpha.'-(4-hydroxyphenyl)-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-2-pyridylmethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalaninamide N-[.alpha.-hydroxy-.alpha.'-pyrid-2-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[.alpha.-hydroxy-.alpha.'-pyrid-4-yl-iso-propyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-((S)-1-hydroxy-4-methylpent-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-(.alpha.-methoxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-hydroxy-3-methyl-but-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-2-(6-aminopyrid-2-yl) acetate methyl ester N-[1-hydroxy-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-methoxy-1-phenyleth-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-methoxy-2-phenyl-prop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-1-acetoxyhex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-((S)-1-(tert-butylcarbonyloxy)-hex-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[2-hydroxy-1-(thien-2-yl)ethyl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[(S)-2-hydroxy-2-methyl-1-phenylprop-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-(thien-2-yl)glycinyl]-L-phenylalanine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(cyclopropaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(cyclopentaneacetyl)-L-phenylglycinyl]-L-phenylglycinol N-[N-(3,5-difluorophenylacetyl)-D,L-phenylglycinyl]-D,L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-D,L-valinyl]-D,L-phenylglycinamide N-[N-(2-thienylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(n-caprotyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-norleucinyl]-L-phenylglycine methyl ester N-(N-(3,5-difluorophenylacetyl)-L-norvalinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-tert-leucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-isoleucinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-cyclohexylalaninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(cyclopropyl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-3-yl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-(S)-2-amino-2-(thien-2-yl)acetyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-D-(4-fluorophenyl)glycinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(4-methoxyphenyl)glycinyl]-L-phenylglycine methyl ester N-(N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(cyclopropylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(cyclopentylacetyl)-L-phenylglycinyl]-L-phenylglycine tert-butyl ester N-[N-(tert-butylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butyl-N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(5-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(5-bromothien-2-yl)glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(4-bromothien-2-yl)glycinamide N-tert-butyl-N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-2-yl) glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl) glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(thien-3-yl) glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl) glycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-tert-butyl-N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(5-chlorothien-2-yl)glycinamide N-Cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-4-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenoxy)phenylglycinamide N-(S)-(-)-.alpha.-methylbenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-3-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(ethyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(phenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-(benzyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-bromophenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(cyclohexyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl)-L-4-(4-ethylphenyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(tert-butyl)phenylglycinamide N-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-3-(4-chlorophenoxy)phenylglycinamide N-cyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-(phenyl)phenylglycinamide N-[N-(3,5-difluorophenyl-.alpha.-hydroxyacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-tert-butyl-N'-[N-(3,5-difluorophenyl-.alpha.,.alpha.-difluoroacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine tert-butyl ester N-[(S)-1-oxo-1-phenylprop-2-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(pyrid-3-yl)glycine tert-butyl ester [N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]morpholine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-(2-methoxy)phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N-tert-butoxycarbonyl(hydroxyl amine) ester N-neopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methoxy-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide [N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinyl]azetidine N-iso-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-cyclopropanemethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methoxy-N methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2-methylprop-2-enyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(pyrid-3-yl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(pyrid-4-yl)methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-furfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-cyclopentyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-1-benzylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N,N-dimethyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2,2,6,6-tetramethylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-2-methylcyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-4-methylcyclohexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-1-ethoxycarbonylpiperidin-4-yl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-methyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-tert-butoxy-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide N-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycine N-tert-butyl(hydroxylamine) ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N-(1-ethoxyethen-1-yl)-[N'-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycine hydrazide N-[N-(phenylacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-4-(phenyl)butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-3-(4-iodophenoxy)propyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-6-(amino)hexyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinamide Hydrochloride N-1-(phthalimido)pent-2-yl-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[N-(3,5-difluorophenylacetyl)-L-(3,5-difluorophenyl)glycinyl]-L-(3,5-difluorophenyl)glycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-norleucine N-[N-(cyclopentaneacetyl)-L-alaninyl]-L-phenylglycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine isopropyl ester N-(isopropyl) N'-(N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[N-(cyclopentylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-(N-(cyclopropylacetyl)-L-alaninyl]-L-phenylalanine tert-butyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-phenylglycine iso-butyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-D-phenylglycine methyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-(3-.alpha.-phenyl)proline methyl ester N-[N-(3,5-Difluorophenylacetyl)-L-alaninyl]-L-azetidine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-2-amino-3-(5-chlorobenzothiophen-2-yl)acetate methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-3-(thiazol-4-yl) propionate tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-(thien-2-yl)glycinamide N-[N-(3,4-dichlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-bromophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-fluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(4-fluorophenylacetyi)-L-alaninyl]-D-phenylglycinamide N-[N-(3-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(4-methylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-trifluoromethylphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3-methoxyphenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(2-chlorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(1-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N-(N-(2-naphthylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(phenylacetyl)-L-alaninyl]-D-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycine N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-(S)-2-amino-2-(2-furanyl)acetamide N'-[N-(3,5-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N-(3,4-difluorophenylacetyl)-D-alaninyl]-D-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylalanin-N-methylsulfonamide N"-methyl-N"-phenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-methyl-N"-phenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-phenylglycinamide N"-methyl-N"-benzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-glycinamide N"-4-fluorobenzyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(4-fluoro)phenylglycine neopentyl ester N-[N-(2,3,4,5,6-pentafluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl) glycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(pyrid-3-yl)glycine tert-butyl ester N-[N-(3,5-difluorophenylacetyl)-L-(O-benzyl)serinyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-(O-benzyl)threoninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-threoninyl]-L-phenylglycine methyl ester N-[N-(3,5-difluorophenylacetyl)-L-serinyl]-L-phenylglycine methyl ester N"-4-methylphenyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N"-tetrahydrofurfuryl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenyl-glycinamide N'-[N-(3,5-difluorophenylacetyl)-L-methionyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-2-aminobutanoyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-phenylglycinamide N-[N-(3,5-difluorophenylacetyl)-L-valinyl]-L-phenylglycinamide N-[(R)-.alpha.-methylbenzyl]-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[1-phenyl-2-oxo-3-methylbutan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-pentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[1-phenyl-2-oxo-butan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N-[1-phenyl-2-oxo-4-methylpentan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-.alpha.-hydroxyphenylalanine methyl ester N"-[4-((2-hydroxy-4-azido)-phenyl)-NHC(O)-)butyl] N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N-[(S)-1-phenyl-2-oxo-2-phenyl-ethan-1-yl]-N'-(3,5-difluorophenyl-acetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-fluorophenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-phenylphenylglycine tert-butyl ester [N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-(2,3-benzo[b]proline) methyl ester N"-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-4-n-butylphenylglycinamide N"-tert-butyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-4-(phenylacetenyl)phenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N-[1,3-diphenyl-2-oxo-propan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-2-cyclopentylethan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-(1-phenyl-2-oxo-hexan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N-[1-phenyl-2-oxo-3-methylpentan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N"-n-hexyl-6-biotinamidyl-N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-phenylglycinthioamide N'-[N-(3,5-difluorophenylacetyl)-L-methioninyl]-L-methionine N'-(N-(2-tert-BOC-amino)propionyl)-L-alaninyl]-L-phenylglycine methyl ester N"-tert-butyl N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-L-2-fluorophenylglycinamide N'-[N-(3,5-difluorophenylacetyl)-L-alaninyl]-D,L-2-phenylglycine methyl ester N-[(S)-1-phenyl-2-oxo-3-phenylpropan-1-yl]-N'-(3,5-difluorophenylacetyl)-L-alaninamide N'-[N-(3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl]-D,L-2-phenylglycine N'-[N-(3,5-difluorophenylacetyl)-D,L-thien-3-ylglycinyl)-D,L-2-phenylglycine tert-butyl ester N'-[N-(3,5-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine N'-[N-(3,5-difluorophenylacetyl)-L-thien-3-ylglycinyl]-L-2-phenylglycine tert-butyl ester N-[2-hydroxy-1-(S)phenyleth-1-yl]-N'-[(3,5-difluorophenylacetyl)-L-phenylglycinyl]-L-alaninamide N-[2-hydroxyeth-1-yl]-N'-[(3,5-difluorophenylacetyl)-L-alaninyl]-L-phenylglycinamide N'-[N-(3,5-difluorophenyl-2-oxo-acetyl)-L-alaninyl]-L-2-phenylglycine tert-butyl ester [N-(2,5-dichlorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3,5-difluorophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3,4-dichlorothiophenoxyacetyl)-L-alaninyl]-L-phenylglycine methyl ester [N-(3-aminoproprionyl)-L-alaninyl]-L-phenylglycine tert-butyl ester; and [N-(3-tert-butoxycarbonylamino)propionyl)-L-alaninyl]-L-phenylglycine tert-butyl ester.